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Abstract 
 
Amino acid oxidases (AAOs) are enantioselective flavoenzymes that catalyse the oxidation of 
amino acids into imino acids, which spontaneously hydrolyse in water to form keto acids. AAOs 
have several potential applications, most notably as biocatalysts in the production of 
enantiomerically pure amino acids and keto acids, or in enzymatic biosensors. Therefore, there is a 
demand for a range of AAOs with specific activity against various substrates, encouraging the 
characterisation of less well understood oxidases. 
 
Seven putative oxidases were cloned into the pET-YSBLIC-3C expression vector, expressed in E. 
coli-DE3 expression strains and assayed for activity against all proteinogenic amino acids. Of these 
seven targets, the L-amino acid oxidase from Pseudomonas putida (PpLAAO) was found to be 
highly soluble, had detectable activity against L-aspartate and L-asparagine and had not been 
investigated in depth previously.  
 
The purified PpLAAO protein showed high substrate specificity against L-aspartate and lower 
activity with substrate inhibition against L-asparagine. Very low activity was also detected against 
L-glutamate. The purified protein had optimal activity around pH 7.5 and at temperatures between 
4°C and 30°C. 
 
To investigate the role of residues in the active site area of the PpLAAO protein thirteen active site 
residues, determined by comparison with the structure of the L-aspartate oxidase from E. coli (L-
AspO), were mutated to alanine. Eleven of these mutants were purified and assayed against L-
aspartate, L-asparagine and L-glutamate. Results were largely consistent with knowledge of L-
AspO. 
 
Ingenza Ltd. has an interest in potential applications of L-tyrosine and L-alanine oxidases. Because 
of this iterative combinatorial active site saturation testing, using the active structure of L-AspO 
was performed alongside a small scale epPCR mutagenesis in an attempt to introduce activity 
against L-alanine and L-tyrosine. L-homoserine was also targeted as part of a substrate walking 
approach towards L-alanine; however no novel activity was detected in any transformants. 
 
 2 
Contents 
 
Abstract          1 
 
Contents          2 
 
Figures and Tables         6 
 
List of Abbreviations         11 
 
Acknowledgments         15 
 
Declaration          15  
 
Chapter 1: Introduction        16 
 
1.1 Uses of enantiomerically pure amino acids and amines    16 
1.1.1 Uses of enantiomerically pure L-amino acids     16 
1.1.2 Uses of enantiomerically pure D-amino acids     21 
1.1.3 Uses of enantiomerically pure amines      23 
1.2 Production of enantiomerically pure amino acids     26 
1.2.1 Extraction of L-amino acids       26 
1.2.2 Chemical synthesis of amino acids       26 
1.2.3 Biocatalytic production and racemization of amino acids    29 
1.3 Amino acid oxidases        37 
1.3.1 Structure and Activity of AAOs       37 
1.3.2 Roles of AAOs in Nature        42 
1.3.3 Applications of AAOs        44 
1.4 Objectives of Project        49 
1.4.1 Investigation of target oxidases       49 
1.4.2 Evolution of new substrate activity       51 
1.4.3 Summary          52 
 
Chapter 2: Materials and Methods       53 
 
2.1 General Section         53 
  
3 
2.1.1 Agarose gel electrophoresis       53 
2.1.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)    53 
2.1.3 Transformation of chemically competent E. coli with plasmid   54 
2.1.4 Transformation of electrocompetent E. coli with plasmid    55 
2.1.5 Production of electrocompetent E. coli cells     56 
2.1.6 Polymerase Chain Reaction (PCR)       57 
2.2 Generation of target oxidases       63 
2.2.1 PCR amplification of four target genes      63 
2.2.2 Ligation Independent Cloning (LIC)      64 
2.2.3 Restriction analysis of the plasmids      65 
2.2.4 Analysis of recombinant genes by nucleotide sequencing    65 
2.2.5 Overexpression analysis of target enzymes      66 
2.2.6 Overexpression of target enzymes for assay analysis    67 
2.2.7 Assay of target enzyme substrates       68 
2.2.8 Effects of AIM, L-Glu and L-Arg on solubility of AsAAO and BaAO  69 
2.2.9 Effects of oxygen availability on solubility of AsAAO and BaAO   70 
2.2.10 Solubility screen of BaAO       71 
2.3 Protein Purification and Characterisation      73 
2.3.1 Overexpression of PpLAAO for protein purification    73 
2.3.2 Purification of PpLAAO protein       74 
2.3.3 Liquid phase assay of activity of wild type PpLAAO against substrates  76 
2.3.4 Liquid phase assay of wild type PpLAAO against L-aspartate over pH  78 
2.3.5 Liquid phase assay of WT PpLAAO against L-aspartate over temperature  78 
2.3.6 Overexpression and purification of PpLAAO for crystallisation   79 
2.3.7 Crystallisation screening of PpLAAO      79 
2.3.8 Native gel and Dynamic Light Scattering analysis of wild type PpLAAO  80 
2.3.9 Analysis of effects of different buffers on wild type PpLAAO   81 
2.3.10 Effects of cold purification and G. HCl on PpLAAO quaternary form  83 
2.4 Generation of active site residue mutants of PpLAAO    85 
2.5 Purification and characterisation of active site PpLAAO mutants   87 
2.5.1 Overexpression of active site PpLAAO mutant proteins for purification  87 
2.5.2 Purification of active site PpLAAO mutant protein     87 
2.5.3 Assay of active site PpLAAO mutant proteins against target substrates  88 
2.6 Generation of SDSM CASTing libraries      90 
2.6.1 Building of SDSM CASTing library A      90 
2.6.2 Building of SDSM CASTing library D      93 
2.6.3 Attempts to build SDSM libraries B, C & E using PfUTurbo Polymerase  94 
 4 
2.6.4 PNDTE library SDSM reaction and transformation     95 
2.6.5 Attempts to build SDSM libraries B, C and E using Phusion Polymerase  95 
2.6.6 Attempts to build SDSM libraries B and C using KOD HotStart Polymerase 97 
2.7 Random mutagenesis of wild-type PpLAAO gene sequence   99 
2.8 Screening of epPCR and SDSM CASTing libraries    100 
2.8.1 Solid Phase HRP assay of epPCR and SDSM CASTing libraries A and D  100 
2.8.2 Analysis of potential hits from CASTing library A     102 
2.8.3 Analysis of potential Screening Hits from CASTing library D   103 
2.8.4 Analysis of three error-prone PCR mutants      104 
 
Chapter 3: Cloning, Expression and Assay of Targets     106 
 
3.1 Cloning of targets into pET-YSBLIC3C plasmid     109 
3.2 Expression and solubility of targets      112 
3.3 Activity assay of target oxidases       120 
3.4 Attempts to increase solubility of AsAAO and BaAO    127 
3.5 Conclusions         132 
 
Chapter 4: Characterisation of PpLAAO protein     136 
 
4.1 Purification of PpLAAO protein       136 
4.2 Characterisation of PpLAAO protein      138 
4.3 Attempts to crystallise PpLAAO protein      143 
4.4 Conclusions         147 
 
Chapter 5: Site Directed Mutagenesis of PpLAAO protein    150 
 
5.1 Comparison of PpLAAO and E. coli L-AspO     150 
5.2 Generation of active site mutants of PpLAAO     153 
5.3 Purification of PpLAAO active site mutants     157 
5.4 Activity assay of active site mutants      165 
5.5 Discussion          170 
 
Chapter 6: CASTing and epPCR of PpLAAO      175 
 
6.1 Generation of SDSM CASTing libraries      177 
6.2 Generation of PpLAAO epPCR library      193 
  
5 
6.3 Screening of mutagenesis libraries       195 
6.3.1 Screening of PpLAAO CASTing library A      195 
6.3.2 Screening of PpLAAO CASTing library D      197 
6.3.3 Screening of PpLAAO error-prone PCR mutants     206 
6.4 Conclusions         208 
 
Chapter 7: General Discussion       214 
 
Appendix A: C. glutamicum as an expression strain     217 
 
A.1 Introduction         217 
A.1.1 Physiology of C. glutamicum       217 
A.1.2 History of C. glutamicum in the biochemical industry    217 
A.1.3 Use of C. glutamicum in protein production and biotransformations  218 
A.1.4 Use of C. glutamicum for expression of previous gene targets   218 
A.2 Results          219 
A.2.1 Attempts to clone AsAAO, BaAO & NfOR into pEK-Ex2 shuttle vector  219 
A.2.2 Transformation and expression of pEKEx2-NfOR plasmid    219 
A.3 Discussion          221 
A.4 Materials and Methods        222 
A.4.1 Transformation of electrocompetent E. coli with plasmid    222 
A.4.2 Preparation of pEK-EX2 for cloning      223 
A.4.3 Preparation of gene inserts for cloning into pEKEx2 plasmid   223 
A.4.4 pEKEx2 ligation         225 
A.4.5 Preparation of competent C. glutamicum cells     226 
A.4.6 Transformation of C. glutamicum cells with pEK-Ex2-NfOR plasmid  227 
A.4.7 Gene overexpression of transformed C. glutamicum cells    228 
 
Appendix B: Alignment of Known and Target Oxidases    229 
 
Bibliography          231 
 6 
Figures and Tables 
 
Fig. 1.1: Conversion of D-methionine into L-methionine by animal and adult humans 
Fig. 1.2: Commercial methods for the synthesis of aspartame 
Fig. 1.3: L-homophenylalanine-ethyl ester and ACE inhibitor derivatives 
Fig. 1.4: Synthesis of β-lactam antibiotics from synthetic D-amino acids and 6-APA 
Fig. 1.5: Possible reaction scheme for the production of sweetener Alitame 
Fig. 1.6: Comparison of pyrethroid insecticide Fluvalinate and D-valine 
Fig. 1.7: Racemate resolution of (R,S)-thiazolidinone carboxylic acid 
Fig. 1.8: Example of enantioselective ketone deprotonation using a chiral lithium amide 
Fig. 1.9: Example of enantioselective epoxide rearrangement using a chiral lithium amide 
Fig. 1.10: Example of production of a (S)-4-(1-phenylethylamino)quinazoline 
Fig. 1.11: (S)-1-methoxy-2-aminopropane and its derivative herbicide FRONTIER X2® 
Fig. 1.12: Strecker synthesis method of producing racemic amino acids 
Fig. 1.13: Amidocarbonylation method for production of racemic N-acyl α-amino acids 
Fig. 1.14: Methionine synthesis method developed by Degussa 
Fig. 1.15: Asymmetric Strecker synthesis of an α-aminonitrile 
Fig. 1.16: Production scheme of D-phenylalanine by fermentation in E. coli 
Fig. 1.17: Resolution of an amino acid to its D-form using an L-amino acid oxidase 
Fig. 1.18: Synthesis of L-aspartate from fumarate using L-aspartate ammonia lyase  
Fig. 1.19: Synthesis of L-phenylalanine using L-phenylalanine ammonia lyase 
Fig. 1.20: Synthesis of L-alanine from L-aspartate using L-aspartate β-decarboxylase 
Fig. 1.21: Degussa’s method for production of L-tert-leucine using leucine dehydrogenase 
Fig. 1.22: Great Lakes Chemicals’ production method for L- and D-2-aminobutyric acid 
Fig. 1.23: Method for production of amino acids by racemization of hydantoins 
Fig. 1.24: Fermentation route for the production of D-phenylglycine 
Fig. 1.25: Production of L-cysteine from D,L-ATC 
Fig. 1.26: Resolution of D,L-amino acids using acylases 
Fig. 1.27: Reaction scheme for an L-amino acid oxidase 
Fig. 1.28: Possible reaction mechanisms for the oxidation by amino acid oxidases 
Fig. 1.29: Superimposition of active site area of MAO-N and RoLAAO 
Fig. 1.30: LigPlot+ comaprison of MAO-N-D5, RoLAAO and MAO-B 
Fig. 1.31: Mechanism of oxidation of L-aspartate by the E. coli L-aspO 
Fig. 1.32: Synthesis of Quinolinic acid by L-aspartate oxidase and quinolinate synthase 
Fig. 1.33: Conversion of cephalosporin C into 7-ACA using D-AAO and a glutaryl hydrolase 
 
  
7 
Fig. 2.1: 96 well plate HRP-assay layout 
Fig. 2.2: Standard Bradford calibration 
Fig. 2.3: Layout of well solutions in 24-well crystallisation screen of PpLAAO protein. 
Fig. 2.4: Example of solid phase HRP-based oxidase assay 
 
Fig. 3.1:  Sequence alignment seven targets selected to be cloned into pET-YSBLIC3C  
Fig. 3.2: Cloning region of pET28a and pET-YSBLIC-3C vectors 
Fig. 3.3: Agarose gel of amplified target oxidase gene sequences 
Fig. 3.4: Agarose gel of restriction endonuclease check of cloned targets 
Fig. 3.5: SDS-PAGE of induced cells transformed with non recombinant pET-YSBLIC3C  
Fig. 3.6: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-AsAAO 
Fig. 3.7: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-BaAO 
Fig. 3.8: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-BsGO 
Fig. 3.9: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-NfOR 
Fig. 3.10: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-PpLAAO 
Fig. 3.11: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-RoLAAO 
Fig. 3.12: SDS-PAGE of induced cells transformed with pET-YSBLIC3C-SLAAO 
Fig. 3.13: Example of 96-well HRP-based activity assay 
Fig. 3.14: Activity screen of induced cells transformed with pET-YSBLIC3C plasmid 
Fig. 3.15: Activity screen of induced pET-YSBLIC3C-AsAAO cells  
Fig. 3.16: Activity screen of induced cells transformed with pET-YSBLIC3C-BaAO plasmid 
Fig. 3.17: Activity screen of induced cells transformed with pET-YSBLIC3C-BsGo plasmid 
Fig. 3.18: Activity screen of induced cells transformed with pET-YSBLIC3C-NfOR plasmid 
Fig. 3.19: Activity screen of induced pET-YSBLIC3C-PpLAAO cells  
Fig. 3.20: Activity screen of induced pET-YSBLIC3C-SLAAO cells  
Fig. 3.21: SDS-PAGE of solubilisation attempts of BL21-pET-YSBLIC3C-AsAAO protein 
Fig. 3.22: SDS-PAGE of solubilisation attempts of BL21-pET-YSBLIC3C-BaAO protein 
Fig. 3.23: SDS-PAGE of effects of O2 on BL21-pET-YSBLIC3C-AsAAO/BaAO protein 
Fig. 3.24: SDS-PAGE of Lindwall solubility screen of BL21-pET-YSBLIC3C-BaAO protein 
Fig. 3.25: SDS-PAGE of scaled up BL21-pET-YSBLIC3C-BaAO protein production 
 
Fig. 4.1: SDS-PAGE of protein purified from E. coli BL21-pET-YSBLIC3C-PpLAAO cells 
Fig. 4.2: Elution peak of PpLAAO through 120 mL HiLoad 16/60 Superdex 75 column 
Fig. 4.3: Initial rates of purified PpLAAO against varying concentration of L-aspartate 
Fig. 4.4: Initial rates of purified PpLAAO against varying concentration of L-asparagine 
Fig. 4.5: Initial rates of purified PpLAAO against varying concentration of L-glutamate 
Fig. 4.6: Activity assay of purified PpLAAO against L-aspartate over reaction buffer pH 
 8 
Fig. 4.7: Activity assay of purified PpLAAO against L-aspartate over protein temperature 
Fig. 4.8: 7.5% Native gel separation of purified wild type PpLAAO 
Fig. 4.9: 7.5% native gel separation of wild-type PpLAAO protein in various buffers 
 
Fig. 5.1: Sequence alignment of the L-aspartate oxidases from P. putida and E. coli  
Fig. 5.2: Active site residues of the E. coli L-AspO structure that were targeted for mutation 
Fig. 5.3: SDS-PAGE of protein from induced cells transformed with Q242A1-10 plasmids 
Fig. 5.4: SDS-PAGE of protein from induced H244A1, P245A1-3 and E260A1-2 cells  
Fig. 5.5: SDS-PAGE of protein from L257A1-3, R290A1-3, Y352A1-2 and S391A1-2 cells  
Fig. 5.6: SDS-PAGE of protein from induced cells transformed with T259A1-10 plasmids 
Fig. 5.7: SDS-PAGE of protein from induced V293A1-5 and S389A1-5 cells 
Fig. 5.8: SDS-PAGE of protein from induced H351A1-2 and R386A1-2 cells 
Fig. 5.9: SDS-PAGE of attempted purification of PpLAAO-E260A protein 
Fig. 5.10: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-Q242A protein 
Fig. 5.11: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-H244A protein 
Fig. 5.12: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-P245A protein 
Fig. 5.13: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-L257A protein 
Fig. 5.14: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-T259A protein  
Fig. 5.15: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-R290A protein 
Fig. 5.16: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-H351A protein 
Fig. 5.17: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-Y352A protein 
Fig. 5.18: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-R386A protein 
Fig. 5.19: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-S389A protein 
Fig. 5.20: SDS-PAGE of purified BL21-pET-YSBLIC3C-PpLAAO-S391A protein 
Fig. 5.21: Kinetics plots of activity PpLAAO-based proteins against L-aspartate 
Fig. 5.22: Unfitted kinetics data of PpLAAO-based proteins against L-aspartate 
Fig. 5.23: Unfitted kinetics data of PpLAAO-based proteins against L-asparagine 
Fig. 5.24: Kinetics plots of activity PpLAAO-based proteins against L-glutamate 
 
Fig. 6.1: Substrate walking from L-aspartate to L-alanine using L-homoserine  
Fig. 6.2: Active site of E. coli L-aspartate oxidase showing library CASTing groups 
Fig. 6.3: Agarose gel of PCR amplification of purified pET-YSBLIC-3C-PNDTA plasmids 
Fig. 6.4: Multiple sequence alignment of Wild Type PpLAAO and PNDTA mutants 
Fig. 6.5: SDS-PAGE of induced cells transformed with pET-YSBLIC-3C-PNDTAA-D  
Fig. 6.6: Agarose gel of SDSM reactions using PNDTA primer set 
Fig. 6.7: SDS-PAGE of induced cells transformed pET- YSBLIC-3C-PNDTA70A-I  
  
9 
Fig. 6.8: Agarose gel of PCR amplification of pET-YSBLIC3C-PNDTD plasmid inserts 
Fig. 6.9: Agarose gel of SDSM reactions using PNDTB/C/E primers with PfU Turbo pol 
Fig. 6.10: Agarose gel of SDSM reactions using PNDTB/C/E primers with Phusion pol 
Fig. 6.11: Agarose gel of SDSM reactions using PNDTE primer set 
Fig. 6.12: Agarose gel of PCR amplification of pET-YSBLIC3C-PNDTB plasmid inserts 
Fig. 6.13: Agarose gel of SDSM reactions using PNDTB and C primers with KOD pol 
Fig. 6.14: Agarose gel of PCR amplification of pET-YSBLIC3C-PNDTB plasmid inserts 
Fig. 6.15: Agarose gel of pET-YSBLIC-3C-PpLAAO error-prone PCR products 
Fig. 6.16: End point activity assay of pET-YSBLIC-3C-PNDTA screening hits  
Fig. 6.17: Initial rate activity assay of pET-YSBLIC-3C-PNDTA screening hits 
Fig. 6.18: Solid phase HRP assay of PNDTD libraries against 40 mM LD-aspartate 
Fig. 6.19: Solid phase HRP assay of PNDTD libraries against 100 mM L-homoserine 
Fig. 6.20: Solid phase HRP assay of PNDTD libraries against 100 mM L-alanine 
Fig. 6.21: Solid phase HRP assay of PNDTD libraries against 25 mM L-tyrosine 
Fig. 6.22: SDS-PAGE of induced cells from pET-YSBLIC-3C-PNDTD screening hits 
Fig. 6.23: SDS-PAGE of induced cells from pET-YSBLIC3C-PpLAAO epPCR screening  
Fig. 6.24: PPM2 - 4 mutated residues shown in context of the E. coli L-aspO active site 
 
Fig. A.1: Agarose gel of PCR check of cloned pEK-NfOR and pEK-BaAO 
Fig. A.2: SDS-PAGE of protein from C. glutamicum transformed with pEKEx2 plasmids 
 
Fig. B.1: Alignment of seven target oxidases, L-AspO and CrLAAO 
 
Table 1.1: Summary of seven target oxidases. 
 
Table 2.1: Conditions for PCR cycling methods used for the amplification of DNA by PCR 
Table 2.2: Composition of PCR mix used for the amplification of DNA by PCR  
Table 2.3:  Sequences of primers used for the amplification of DNA by PCR 
Table 2.4: PCR methods, primers and template used for the amplification of target genes 
Table 2.5: Attempted crystallization screens of PpLAAO protein 
Table 2.6: Primers and PCR tubes used to generate PpLAAO active site mutants 
Table 2.7: Optimisation conditions for QuikChange using PfUTurbo and PNDTB/C primers 
Table 2.8: Optimisation conditions for QuikChange using PfUTurbo and PNDTE primers 
Table 2.9: Optimisation conditions for QuikChange using Phusion and PNDTB/E primers 
Table 2.10: Optimisation conditions for QuikChange using Phusion and PNDTC primers 
Table 2.11: Optimisation conditions for QuikChange using KOD and PNDTB/C primers 
 
 10 
Table 3.1: Summary of seven target oxidases 
Table 3.2: Summary of expression conditions of target oxidases 
 
Table 4.1: Kinetic parameters of purified PpLAAO against L-Asp, L-Asn and L-Glu 
Table 4.2: Regularization data from the DLS analysis of wild type PpLAAO at 20°C 
Table 4.3: DLS analysis of purified PpLAAO in Tris/NaCl/AEBSF buffer and 50 mM G. HCl 
Table 4.4: DLS analysis of purified PpLAAO at different temperatures 
 
Table 5.1: Kinetic parameters of wild-type and active site mutants of PpLAAO protein 
Table 5.2: Comparison of the kinetic constants of mutated residues of L-AspO and PpLAAO 
 
Table 6.1: CASTing strategy libraries 
Table 6.2: Summary of changes in mutation site of sequenced PpLAAO mutants PNDTAA-E 
Table 6.3: Changes to target residues in sequenced PNDTD plasmids 
Table 6.4: Concentrations of soluble protein fraction of induced PNDTA screening hits  
Table 6.5: Summary of changes to PPM2-4 mutants 
 
Table A.1: Conditions for PCR cycling methods used for the amplification of DNA by PCR 
Table A.2: Composition of PCR mix used for the amplification of DNA by PCR 
Table A.3:  Sequences of primers used for the amplification of DNA by PCR 
  
11 
List of Abbreviations 
 
(NH4)2SO4 Ammonium sulfate 
4-AAP 4-aminoantipyrine 
6-APA 6-amino penicillic acid 
AA Amino acid 
AAO Amino acid oxidase 
ACE Angiotensin-converting enzyme 
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
AO Amine oxidase 
AIM Auto induction media 
Alitame L-alpha-aspartyl-N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alaninamide 
AMBA α-methylbenzylamine 
APS Ammonium persulfate 
AS Ammonium sulphate 
AsAAO L-amino acid oxidase from Anabaena sp. strain PCC 7120 
Aspartame α-L-aspartyl-L-phenylalanine-methyl ester 
ATC 2-amino-Δ2-thiazoline-4-carboxylic acid 
β-OG β-n-octyl-β-D-glucopyranoside  
BaAO Amine oxidase from Bacillus anthracis  
BHI Brain-heart infusion 
BLAST Basic local alignment search tool 
BSA Bovine serum albumin 
BsGO Glycine oxidase from Bacillus subtilis 
CASTing Combinatorial active site saturation testing 
CaCl2 Calcium chloride 
CHAPS 3[(3-Cholamidopropyl)dimethylammonio]-propanesulfonic acid 
CO2 Carbon dioxide 
CoCl2-6H2O Cobalt chloride hexahydride 
CuCl2-2H2O Copper chloride dihydrate 
DAB 3,3’-diaminobenzidine 
dATP Deoxyadenosine triphosphate 
dNTP Deoxynucleotidetriphosphate 
ddNTP Dideoxynucleotidetriphosphate 
DHAP Dihydroxyacetone phosphate 
DLS Dynamic light scattering 
 12 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Dinucleotide triphosphate 
dsDNA Double stranded deoxyribonucleic acid 
DTT Dithiothreitol 
dTTP Deoxythymidine triphosphate 
EDTA Ethylenediaminetetraacetic acid 
epPCR Error prone polymerase chain reaction 
FAD Flavin adenine dinucleotide 
FDA US Food and Drug Administration 
FeCl3-6H2O Iron chloride hexahydride 
Fluvalinate Cyano-(3-phenoxyphenyl)methyl] 2-[2-chloro-4-(trifluoromethyl)anilino]-
3-methylbutanoate 
G. HCl Guanidine hydrochloride 
GMP Good manufacturing practice 
GnRH Gonadotropin-releasing hormone 
H2O Water 
H2O2 Hydrogen peroxide 
H3BO3 Boric acid 
HCl Hydrogen chloride 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His6 Hexa-histidine 
HRP Horseradish peroxidase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
I.V. Intravenous 
K2HPO4 Dipotassium phosphate 
kcat Catalytic constant 
KCL Potassium chloride 
KH2PO4 Monopotassium phosphate 
Ki Dissociation constant 
KM Substrate concentration at which the reaction rate is half of Vmax 
L-AspO L-aspartate oxidase from E. coli 
LB-agar Luria-Bertani agar 
LB-media Luria-Bertani media 
LDAO Lauryldimethylamine-oxide 
LIC Ligation independent cloning 
  
13 
LiCl Lithium chloride 
MAP Mycolic acid & arabinogalactan-peptidoglycan 
MAO Monoamine oxidase 
MAO-N Monoamine oxidase from Aspergillus niger 
MES 2-(N-morpholino)ethanesulfonic acid 
MgCl2 Magnesium chloride 
MgSO4 Magnesium sulfate 
MnCl2 Manganese chloride 
MRSA Methicillin-resistant Staphylococcus aureus 
MSG Monosodium glutamate 
MWCO Molecular weight cut-off 
Na2HPO4 Sodium phosphate dibasic 
Na2MoO4-5H2O Sodium molybdate pentahydride 
Na2SeO3 Sodium selenite  
NaCl Sodium chloride 
NAD Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide + hydrogen 
NDSB-201 Non detergent sulphobetaines-201 
NEP Neutral endopeptidase 
NfOR Oxidoreductase from Nocardia farcinica 
NiCl2-6H2O Nickel chloride hexahydrate 
NiNTA Nickel-nitriloacetic acid 
NiSO4 Nickel sulfate 
NMDA N-methyl-D-aspartate 
OD Optical density 
P-CHO Wang aldehyde resin 
P-TEA Polymer-supported triethylamine 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
Pd-C Palladium on carbon 
PEG Polyethylene glycol 
PheOMe Phenylalanine-methyl ester 
PpLAAO L-AAO from Pseudomonas putida 
PNDT NDT mutants of PpLAAO 
r.p.m Revolutions per minute 
RoLAAO L-AAO from Rhodococcus opacus 
 14 
(S)-MOIPA (S)-1-methoxy-2-aminopropane 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SDM Site directed mutagenesis 
SDSM Site directed saturation mutagenesis 
SHMT Serine hydroxymethyltransferase 
SLAAO L-AAO from Synechococcus sp. strain ATCC 27144 
SOC media Super optimal broth with catabolite repression 
TAE Tris/acetate buffer 
TBHBA 2-hydroxy-2,4,6-tribromobenzoic acid 
TEMED Tetramethylethylenediamine 
THF Tetrahydrofuran 
TMAO Trimethylamine N-oxide 
Tris  Tris(hydroxymethyl)aminomethane 
UV Ultraviolet 
Vcomponent Volume of component 
Vmax Maximum velocity 
Vtotal Total Volume 
WT Wild type 
YSBL York structural biology laboratory 
Z-Asp N-protected benzoyloxycarbonyl-L-aspartate 
ZnSO4-7H2O Zinc sulfate heptahydrate 
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Chapter 1      Introduction 
 
1.1 Uses of enantiomerically pure amino acids and amines 
 
Enantiomerically pure amino acids and amines are important products for the chemical industry as 
special intermediates for chiral compounds produced by pharmaceutical and agrochemical 
companies, as enantiomerically pure chiral products often require lower doses and have improved 
efficiency over their racemic counterparts.
[1]
 Having enantiomerically pure products also means 
that there is no risk of the other enantiomer of the compound having an unwanted effect, as 
happened the case of the thalidomide drug, where the (S)-form of the drug had a teratogenic effect 
that the (R)-form did not.
[2] 
 
The importance of the market for enantiomerically pure chiral intermediates was increased in 1992, 
when both the US Food and Drug Administration (FDA) and the European Committee for 
Proprietary Medicinal Products both insisted that the physiological effects of each enantiomer of a 
pharmaceutical product must be characterised individually, resulting in longer testing periods for 
racemic chiral compounds. Since 1997, the FDA has also allowed single isomer products to be 
registered in a shorter amount of time, also encouraging the production of enantiomerically pure 
products. 
 
Several proteinogenic amino acids are also used in human and animal nutrition, either as additives 
to foodstuffs that would otherwise be deficient in essential amino acids, e.g. modern animal feeds
[1]
 
or intravenous nutrition solutions
[3]
 or as flavourings for food.
[1]
 
 
1.1.1 Uses of enantiomerically pure L-amino acids 
 
Enantiomerically pure L-amino acids have many industrial uses, and consequently a large market 
for their production- in 1999 the total market for proteinogenic L-amino acids was around 1.5 
million tons, estimated to be worth €3.5 billion. The majority of these amino acids are used in 
human and animal nutrition, with the estimated worldwide consumption of amino acids being 
around 2 million tons in 2001.
[3]
  
 
Animal nutrition accounts for around 55% of the market, with L-lysine, LD-methionine, L-threonine 
and L-tryptophan being added to modern animal feed, as it is usually deficient in these essential 
amino acids.
[1]
 According to an estimate by Ajinomoto Co. Inc. 
(http://www.fao.org/docrep/007/y5019e/y5019e0a.htm accessed 26/04/12), in 2000 between 
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500,000-600,000 tons of both L-lysine and methionine were produced for this purpose. Roughly 
30,000 tons of L-threonine and 1,000 tons of L-tryptophan were also produced for the same reason. 
 
The racemate of methionine can be used in animal feed as D-methionine is converted in animals 
into L-methionine through oxidation of the D-form into α-keto-γ-methiolbutyric acid, followed by a 
transaminase reaction into L-methionine, although some of the α-keto-γ-methiolbutyric acid is lost 
through the spontaneous decarboxylation into β-methylthiopropanoic acid (Figure 1.1).[4] 
 
Figure 1.1 Reaction scheme for the natural conversion of D-methionine into L-methionine by animal and 
adult humans.[4] 
 
Human nutrition and health accounts for a further 40% of the market for proteinogenic amino 
acids. L-glutamate, L-phenylalanine, L-aspartate and glycine are all used as food additives. L-
glutamate is mostly used as the flavouring monosodium glutamate (MSG) and more than 650,000 
tons are produced every year. 
 
Several enantiomerically pure L-amino acids are used as intermediates for chemical synthesis of 
other compounds. L-phenylalanine and L-aspartate are used as the initial substrates in both the 
chemical and chemoenzymatic synthesis of the sweetener aspartame (α-L-aspartyl-L-phenylalanine-
methyl ester).
 [5] 
 
 
In the chemical reaction L-phenylalanine is reacted with methanol to form L-phenylalanine-methyl 
ester (L-PheOMe), which is then reacted with an N-protected anhydride form of L-aspartate to form 
N-protected αβ-L-aspartyl-L-PheOMe. The N-protected αβ-L-aspartyl-L-PheOMe is then treated 
with acid to form a αβ-aspartame. HCl salt, allowing the α-form to be separated by precipitation as 
the α-salt is less soluble in aqueous solution than the β-salt. The α-aspartame. HCl salt is then 
neutralised with a base allowing α-aspartame to be recovered by crystallisation (Figure 1.2a).[5, 6]  
 18 
 
 
Figure 1.2 Commercial methods for the synthesis of aspartame. a. Chemical synthesis method. b. 
chemoenzymatic synthesis method. 
  
19 
The chemoenzymatic reaction is similar, but is catalysed by the enantioselective thermolysin 
enzyme from Bacillus thermoproteolyticus. This enantioselectivity means that DL-phenylalanine 
can be used as a starting substrate. In this case the DL-phenylalanine-methyl ester (DL-PheOMe) is 
reacted with N-protected benzoyloxycarbonyl-L-aspartate (Z-Asp) to form N-Z-Asp-L-PheOMe 
(Figure 1.2b), which then reacts with the remaining D-PheOMe to form an insoluble salt, allowing 
more efficient production of N-Z-Asp-L-PheOMe (not shown), with yields of 95% being described. 
After the reaction the N-Z-Asp-L-PheOMe is separated from the D-PheOMe (which can be 
racemized and reused) and is converted to aspartame through hydrogenolysis (Figure 1.2b).
[5]
 
 
L-aspartate is also one of the starting substrates of the dipeptide sweetener alitame (L-alpha-
aspartyl-N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alaninamide)
[7]
 and L-valine is one of the precursors 
in the fermentation of the immune suppressant drug cyclosporin A, which is used in transplant 
surgeries.
[1, 8]
 The ethyl ester of the synthetic L-homophenylalanine is also used as an intermediate 
in the production of several angiotensin-converting enzyme (ACE) inhibitors, which are used to 
prevent hypertension and congestive heart failure (Figure 1.3).
[9]
 L-homophenylalanine can also be 
used as an intermediate in the production of β-lactam antibiotics, acetylcholinesterase inhibitor 
(used for treatment of Alzheimer’s disease) and neutral endopeptidase (NEP) inhibitor (which 
complement the effects of ACE inhibitors when used simultaneously).
[10]
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Figure 1.3 L-homophenylalanine-ethyl ester and ACE inhibitor derivatives.[9, 10] 
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1.1.2 Uses of enantiomerically pure D-amino acids 
 
Enantiomerically pure, synthetic D-amino acids can also be used as intermediates in the production 
of other pharmaceutical and nutritional compounds. The most well known example is the use of D-
phenylglycine and D-parahydroxyphenylglycine (D-p-hydroxyphenylglycine) in the production of 
the semisynthetic β-lactam antibiotics ampicillin and amoxicillin, respectively. This is performed 
commercially by reacting the D-amino acid with 6-amino penicillic acid (6-APA), catalysed by 
penicillin acylase enzyme from Escherichia coli (Figure 1.4),
[11]
 although work is still being 
performed to increase the activity
[12] 
and stereoselectivity
[13]
 of the enzyme. 
 
Figure 1.4 Synthesis of β-lactam antibiotics from synthetic D-amino acids and 6-APA.[11] a. Synthesis of 
Ampicillin from D-phenylglycine. b. Synthesis of amoxicillin from D-p-hydroxyphenylglycine. 
 
D-alanine is used as another starting point in the synthesis of the sweetener alitame. One possible 
reaction scheme for this starts with a reaction between a N-protected form of D-alanine and 3-
amino-2,2,4,4-tetramethylthietane to form an N-protected N-(2,2,4,4-tetramethyl-3-thietanyl)-D-
alaninamide. This is then deprotected by hydrogenolysis and the resulting N-(2,2,4,4-tetramethyl-3-
thietanyl)-D-alaninamide is reacted with L-aspartate N-thiocarboxyanhydride (Figure 1.5).
[14]
 
 
Another unnatural amino acid, D-valine, is used in the synthesis of the pyrethroid insecticide 
fluvalinate (Cyano-(3-phenoxyphenyl)methyl] 2-[2-chloro-4-(trifluoromethyl)anilino]-3-
methylbutanoate), which is used to control the population of varroa mites in beehives 
(http://www.biosecurity.govt.nz/pests-diseases/animals/varroa/paper/varroa-treatment-
options.htm#4, accessed 25/09/12)  (Figure 1.6).
[8]
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Figure 1.5 Possible reaction scheme for the production of sweetener Alitame starting from a N-protected 
form of D-alanine.[14] 
 
Figure 1.6 Comparison of pyrethroid insecticide Fluvalinate and its amino acid substrate, D-valine. 
 
Similarly to its L-form, D-homophenylalanine can also be used as a precursor to several ACE 
inhibitors, including benazepril (Figure 1.3), as the D-homophenylalanine is converted to (R)-2-
nosyloxy-4-phenylbutyric acid ethyl ester over a three step reaction, and (R)-2-nosyloxy-4-
phenylbutyric acid ethyl ester reacts with a corresponding chiral amine to produce the ACE 
inhibitor.
[15]
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1.1.3 Uses of enantiomerically pure amines 
 
Enantiomerically pure amines are of use as resolving agents for chiral carboxylic acids, as amines 
and carboxylic acids form diastereoisomeric salts, so adding two molar equivalents of an 
enantiomerically pure amine to a racemate of a carboxylic acid will result in one form of the 
carboxylic acid forming a crystal with the amine, and the other staying in solution, allowing the 
two enantiomers of the carboxylic acid to be separated, and the diastereoisomeric salt crystal to be 
separated into the carboxylic acid and the amine using an acid treatment.
[1]
  
 
The commercial production of (R)-mandelic acid uses (R)-phenylethylamine to resolve the racemic 
form of mandelic acid using this method,
[1]
 and a method for the synthesis of a cardioprotective 
calcium antagonist, SP-060-S, involves resolving the racemate form of the substrate thiazolidinone 
carboxylic acid into the S-form through crystallisation with (S)-N-benzyl-1-phenylethylamine 
(Figure 1.7).
[16]
 In this case the amine can be recycled by treatment with NaOH followed by 
extraction and distillation, making it a more environmentally friendly resolving agent. 
 
Figure 1.7 Racemate resolution of (R,S)-thiazolidinone carboxylic acid by crystallisation with 
enantiomerically pure (S)-N-benzyl-1-phenylethylamine for use in synthesis of calcium antagonist SP-060-
SP.[16] 
 
As finding a single, optimal amine to crystallise each carboxylic acid can be quite time consuming, 
a variant of racemic resolution by crystallisation has been developed by Vries et al., which involves 
using a mixture of similar enantiomerically pure amines to form crystals with the carboxylic acid. 
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This “Dutch resolution” has the advantage that the effects of several amines on crystallisation can 
be investigated at the same time, and the enantiomeric excess of the crystallised carboxylic acids 
can be higher when using several amines than with the classical single amine resolution.
[17]
 
 
Enantiomerically pure amines are also of importance as chiral auxiliaries or bases, such as lithium 
amide bases, which can be used for a wide range of enantioselective reactions, including the 
deprotonation of ketones (Figure 1.8), rearrangement of epoxides to allylic alcohols (Figure 1.9) 
and reactions of tricarbonyl (η6-arene)-chromium complexes.[18] Magnesium amide bases may also 
be used for similar purposes, as shown by Henderson et al. using them to deprotonate 
conformationally locked ketones.
[19]
 
 
Figure 1.8 Example of enantioselective ketone deprotonation using a chiral lithium amide.[18] 
 
Figure 1.9 Example of enantioselective epoxide rearrangement using a chiral lithium amide.[18] 
 
Chiral amines can also act as enantioselective catalysts for certain reactions, such as the 
enantioselective epoxidation of alkenes using potassium peroxymonosulfate (Oxone®), which can 
be catalysed by (S)-2-(diphenylmethyl)pyrrolidine.[20] 
 
As chiral amines are chemically active, they are also often used as enantiomerically pure 
intermediates in reactions to produce pharmaceutical compounds. One example is the (S)-4-(1-
phenylethylamino)quinazolines, which are inhibitors of Immunoglobulin E (IgE) synthesis and 
were made by Berger et al.
[21]
 by reacting 4-chloroquinazoline with two molar equivalents of a (S)-
form primary amine, such as (S)-1-phenylethylamine, in tetrahydrofuran (THF) and polymer-
supported triethylamine (P-TEA) to form a mix of the (S)-4-(1-phenylethylamino)quinazoline and 
the primary amine, which was then separated in THF containing 1% acetic acid and Wang 
aldehyde resin (P-CHO) (Figure 1.10).
[21]
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Figure 1.10 Example of production of a (S)-4-(1-phenylethylamino)quinazoline using (S)-1-
phenylethylamine as the amine.[21] 
 
Also, the herbicide FRONTIER X2 ® is commercially synthesized from (S)-1-methoxy-2-
aminopropane ((S)-MOIPA), as only the (S)-enantiomer is biologically active (Figure 1.11).
[22]
 
 
Figure 1.11 (S)-1-methoxy-2-aminopropane and its derivative herbicide FRONTIER X2®.[22] 
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1.2 Production of enantiomerically pure amino acids 
 
1.2.1 Extraction of L-amino acids  
 
As proteins naturally contain L-amino acids, one of the oldest used ways of producing pure amino 
acids is to extract them from protein-rich materials, preferably ones that are produced in large 
quantities and not useful for other reasons, such as hair, meat extracts, plant hydrolysates
[1]
 and 
feathers.
[23]
 The most commonly extracted L-amino acid is cysteine, which is present in the keratin 
found in hair and feathers (cysteine accounts for 14% of the amino acid content of hair keratin),
[24]
 
although L-amino acids serine and proline can also be extracted from keratin.
[23]
  
 
As keratin has a high degree of cross linking disulphide and hydrogen bonds, as well lots of 
hydrophobic interactions, it is a highly stable protein structure that is resistant to traditionally used 
proteases, such as trypsin and pepsin.
[25] 
Due to this stability, the traditional way of extracting 
amino acids from protein-rich materials involves hydrolysing the keratin with strong acids and 
consequently neutralizing the acid with alkalis or buffering it with sodium acetate, which results in 
the amino acids being difficult to separate and leads to the production of unwanted salts as by-
products,
[24]
 which are damaging to the environment.
[1]
 
 
Due to these disadvantages, more recent biocatalytic methods use keratinases to extract the cysteine 
from keratin. Keratinase-like enzymes were traditionally found in mesophilic fungi and 
actinomycetes, however more recently thermophillic bacteria species, which are capable of 
growing on feathers as the only food source, have been discovered. The enzymes responsible for 
the keratin degradation in two of these species; Fervidobacterium pennavorans
[23]
 and 
Thermoanaerobacter keratinophilus sp. nov.,
[23]
 have been purified, in both cases the enzyme is a 
serine-type protease with a molecular mass of 130 kDa and 135 kDa respectively.
[23, 25]
 It is hoped 
that these enzymes can be used to extract amino acids from feathers and other keratin-rich 
materials without producing unnecessary salt as a by-product. 
 
1.2.2 Chemical synthesis of amino acids 
 
Racemic amino acids synthesized for industry can be produced chemically using the Strecker 
synthesis method, first described in 1850, where the respective aldehyde is reacted with ammonia 
and hydrogen cyanide to form an α-amino nitrile. The α-amino nitrile can then be hydrolysed to the 
respective amino acid (Figure 1.12).
[26]
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Figure 1.12 Strecker synthesis method of producing racemic amino acids.[26] 
 
Another chemical method for the production of racemic amino acids is amidocarbonylation, where 
an aldehyde, an amide and carbon monoxide are combined in a single step reaction to form a N-
acyl α-amino acid(Figure 1.13).[27] 
 
Figure 1.13 Amidocarbonylation method for production of racemic N-acyl α-amino acids.[27] 
 
These asymmetric amino acid synthesis methods can be useful in the production of 
enantiomerically pure amino acids as the products can be racemized afterwards using biocatalytic 
methods. There are also two amino acids that can be synthesized asymmetrically for use in 
industry; glycine, due to it being achiral, and methionine, which is converted from its D-form into 
its L-form through a transaminase reaction in animals and human adults, although enantiomerically 
pure L-methionine is still needed when used as a baby food additive.
[1]
 
 
As large-scale synthesis of racemic methionine is commerically viable, Degussa (now Evonik 
Industries) developed a synthesis method that would avoid the formation of large quantities of 
salts. Acrolein and methanethiol are reacted to form 3-methylmercaptopropionaldehyde, which is 
then combined with ammonium hydrogen carbonate and hydrogen cyanide to form 5-(2-
methylthioethyl)hydantoin. The 5-(2-methylthioethyl)hydantoin is then hydrolysed at 170°C with 
an excess of potassium carbonate to form potassium methioninate, which is then acidified under 
CO2 pressure to produce methionine (Figure 1.14).
[1]
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Figure 1.14 Methionine synthesis method developed by Degussa.[1] 
 
Modified versions of the Strecker synthesis method can be used to asymmetrically synthesize 
amino acids, although none are economical enough to be used in an industry scale.
[1]
 One example 
uses a chiral zirconium catalyst to introduce the asymmetrical aspect. This method involves 
reacting an aldehyde with 2-hydroxy-6-methylaniline and ammonia in the presence of a chiral 
zirconium catalyst to form an α-aminonitrile (Figure 1.15). This α-aminonitrile can then be 
converted into a α-amino acid by methylation of the phenolic hydroxyl group, followed by acid or 
base hydrolysis and oxidative cleavage with cerium ammonium nitrate.
[28] 
 
Figure 1.15 Asymmetric Strecker synthesis of a α-aminonitrile.[28] 
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1.2.3 Biocatalytic production and racemization of amino acids 
 
There are several biocatalytic methods of producing enantiomerically pure amino acids, either 
using fermentation, chemoenzymatic methods or biotransformations to synthesize the pure amino 
acids, or using biotransformations to resolve racemates that have already been produced by 
chemical synthesis or other means. 
 
Corynebacterium glutamicum was isolated in 1957 and was discovered to produce and secrete a 
large amount of L-glutamate, making it useful for the production of L-glutamate by fermentation.
[1]
 
C. glutamicum can also produce other amino acids, including L-lysine, L-threonine, L-aspartate and 
L-alanine. However, L-glutamate and L-lysine are the amino acids produced in the greatest 
quantities in industry, due to their large markets
[29]
 and strains of C. glutamicum that increase the 
production efficiency of lysine by overproducing dihydropicolinate synthase, which results in more 
L-lysine production at the expense of L-threonine.
[1]
 
 
L-threonine can also be produced by fermentation of modified strains of E. coli or Serratia 
marcescens. The E. coli strain KY10935 has a deregulated L-threonine biosynthetic pathway and 
blocked L-threonine degradation pathways, allowing it to produce up to 100 g L
-1
 L-threonine after 
77 h fermentation.
[30]
 The S. marcescens strain T-2000 contains a plasmid with deregulated 
versions of aspartokinase and homoserine dehydrogenase, involved in L-threonine production, and 
defective L-threonine degradation enzymes, this strain can produce 100 g L
-1
 after 96 h.
[31]
 The E. 
coli strain is the most commonly used for industrial production of L-threonine,
[32] 
with its high 
growth rate and well-researched physiology being advantages compared to other production 
species.
[33]
  
 
These advantages of E. coli were also an important factor in the optimisation of E. coli for 
producing L-phenylalanine by fermentation by Backman et al.,
[34]
 which is now used as the method 
for producing L-phenylalanine on an industrial scale.
[1]
 
 
Monsanto Co. developed a strain of E coli K12 that produces D-phenylalanine by fermentation. The 
strain uses the 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase and the chorismate 
mutase-prephenate dehydratase enzymes from E. coli to overproduce L-phenylalanine, and an 
alanine racemase from Salmonella typhimurium to convert L-alanine to D-alanine. The L-
phenylalanine is converted to phenylpyruvate by a L-amino acid deaminase from Proteus 
myxofaciens before a D-amino acid aminotransferase from Bacillus sphaericus is used to transfer 
the D-amino group from the D-alanine to the phenylpyruvate, resulting in D-phenylalanine and a 
carboxylic acid. The carboxylic acid is then degraded by natural metabolic pathways from E. coli, 
 30 
which encourages the reaction to work in the direction of D-phenylalanine production (Figure 
1.16).
[35]
 
 
Figure 1.16 Production scheme of D-phenylalanine by fermentation in E. coli.[35] 
 
D-amino acids can also be produced from racemate solutions by chemoenzymatic methods using an 
enantioselective L-amino acid oxidase and a chemical reductant. The enantioselective amino acid 
oxidase only oxidises the L-form of the amino acid, however the reductant will reduce the resulting 
imine into both L- and D-forms of the amino acid. The new L-amino acids are then oxidised again 
and so on until only the D-form remains. 
 
Great Lakes Chemical Corp. developed this method using palladium on carbon (Pd-C) in 
ammonium formate buffer as the reduction agent (Figure 1.17) with yields of 90% with an 
enantiomeric purity of 99% ee being observed.
[1]
 The same method can be used to produce L-amino 
acids from racemate solutions using an appropriate D-amino acid oxidase; however these tend to be 
less common in nature than L-amino acid oxidases, and this method is more commonly used to 
produce unnatural L-amino acids. 
 
L-amino acid oxidases can also be used to resolve amino acids into a D-amino acid and the 
corresponding α-keto acid, which can then be separated using chromatography. Recently an L-
amino acid oxidase from Aspergillus fumigatus has been shown to do this for alanine, 
phenylalanine and tyrosine.
[36] 
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Figure 1.17 Racemisation of an amino acid to its D-form using an enantioselective L-amino acid oxidase and 
Pd-C in ammonia formate as a chemical reductant. 
 
Lyases can also be used as biocatalysts in the synthesis of L-amino acids. Since 1958 L-aspartate 
has been made from fumarate using polyazetidine-immobilised E. coli cells containing L-aspartate 
ammonia lyase activity as a catalyst (Figure 1.18),
[8]
 and this method could be used to produce N-
substituted aspartic acids, as the aspartate ammonia lyase enzyme from Bacillus sp. YM55-1 has 
been shown to incorporate nucleophiles hydroxylamine and hydrazine into the fumarate substrate 
instead of ammonia.
[37]
 Phenylalanine can also be made from E-cinnamic acid using the L-
phenylalanine ammonia lyase from Rhodotorula glutinis as a catalyst (Figure 1.19),
[38]
 however the 
fermentation method mentioned above is more economically viable.
[1]
 
 
Figure 1.18 Synthesis of L-aspartate from fumarate using L-aspartate ammonia lyase.[37] 
 
Figure 1.19 Synthesis of L-phenylalanine from E-cinnamic acid using L-phenylalanine ammonia lyase.[38] 
 
Pseudomonas dacunhae cells immobilised with polyurethane and containing L-aspartate β-
decarboxylase enzyme are also used to covert L-aspartate to L-alanine by removing the acid side 
chain (Figure 1.20),
[39]
 although the release of carbon dioxide means that the reaction has to take 
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place in a pressure reactor in order to stop bubbles of carbon dioxide from disrupting the 
immobilised cell layers.
[1]
 L-aspartate β-decarboxylase can also be used in a single reaction to 
convert fumarate into L-alanine and D-aspartate, which can be used to synthesise semisynthetic 
penicillin aspoxicillin. Fumarate is chemically synthesised into DL-aspartate, and the L-aspartate β-
decarboxylase subsequently converts the L-aspartate into L-alanine, resulting in a mix of D-
aspartate and L-alanine.
[40] 
 
Figure 1.20 Synthesis of L-alanine from L-aspartate using L-aspartate β-decarboxylase.[39] 
 
Amino acid dehydrogenases can be used to convert a 2-oxocarboxylic acid into a Schiff base, 
which is then reduced into an amino acid. This requires a co-substrate like NADH to provide the 
hydride ions, so the reaction has to be run alongside a co-substrate regeneration reaction, such as 
using the formate dehydrogenase from Candia boidinii to oxidise formate and reduce NAD
+
, as 
formate is a cheap substrate (Figure 1.21).
[41]
 The amino acid dehydrogenases do not have much 
substrate specificity, which means that non-proteinogenic amino acids can also be created. Degussa 
used a leucine dehydrogenase to synthesise L-tert-leucine, which is used as a building block for 
anti-cancer and anti-AIDS compounds, from trimethylpyruvic acid (Figure 1.21).
[42]
 
 
Figure 1.21 Degussa’s method for production of L-tert-leucine using leucine dehydrogenase alongside NAD+ 
regeneration reaction using formate dehydrogenase.[42] 
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Aminotransferases can also add an amine group to 2-oxocarboxylic acids, using other amino acids 
as an amine donor instead of needing a co-substrate. Like the dehydrogenases, these can be used to 
make non-proteinogenic amino acids.  
 
One example of their use in industry is the production of L- or D-2-aminobutyric acid by Great 
Lakes Chemicals. Their method uses a genetically modified strain of E. coli as a catalyst in the 
production, which starts with the amine group from L-aspartate or D-aspartate (depending on which 
amino-acid aminotransferase enzyme is built into the strain) being transferred to 2-oxobutyric acid 
to form either L- or D-2-aminobutyric acid, as well as 2-oxalylacetic acid as a by-product. To avoid 
the E. coli cells generating L-alanine from the 2-oxalylacetic acid, the by-product is subsequently 
converted to acetoin, which is removed from the reaction by distillation. This distillation pushes the 
reaction equilibrium in favour of more 2-aminobutyric acid (Figure 1.22).
[1]
 
 
Figure 1.22 Great Lakes Chemicals’ production method for L- and D-2-aminobutyric acid, using E. coli cells 
with amino acid aminotransferase activity as catalysts.[1] 
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Although L-serine can be extracted from keratin, an enzymatic method for its production has been 
developed by Genex Corporation. This method uses a two-step reaction catalysed by serine 
hydroxymethyltransferase (SHMT) enzyme from E. coli. The first step is a non-enzymatic reaction 
between formaldehyde and tetrafolate to form N
5
,N
10
-methylenetetrahydrofolate. SHMT then 
catalyses a reaction between N
5
,N
10
-methyenetetrahydrofolate and glycine that forms L-serine and 
tetrafolate, meaning only the formaldehyde and glycine have to be fed into the reaction.
[8]
 
 
L-and D-amino acids can be produced by racemization of hydantoins (made by chemical synthesis), 
the racemic hydantoins spontaneously racemize at pH higher than 8, and can be treated with 
racemase to increase the rate. This means that the hydantoins can be treated with either a L- or D- 
enantiospecific hydantoinase to form a carbamoyl amino acid, which is subsequently treated with 
either L-or D-carbamoylase to form the respective amino acid with high enantiomeric purity 
(Figure 1.23).
[1]
 
 
Figure 1.23 Method for production of amino acids by racemization of hydantoins. 
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The unnatural amino acids D-phenylglycine and D-hydroxyphenylglycine, used to produce β-lactam 
antibiotics, are usually produced using this method,
[43]
 although a fermentation method for the 
production of D-phenylglycine has been developed by creating a strain of E. coli with the 
hydroxymandelate synthase enzyme from Amycolatopsis orientalis, the hydroxymandelate oxidase 
enzyme from Streptomyces coelicolor, and the D-(4-Hydroxy)phenylglycine aminotransferase 
enzyme from Pseudomonas putida. Phenylpyruvate produced by the cells is converted by the 
hydroxymandelate synthase into mandelate, which is subsequently converted to phenylglyoxylate 
by the hydroxymandelate oxidase. The D-(4-Hydroxy)phenylglycine aminotransferase then adds an 
amino group from L-glutamate to the phenylglyoxylate to make D-phenylglycine (Figure 1.24).
[44] 
 
Figure 1.24 Fermentation route for the production of D-phenylglycine.[44] 
 
As L-cysteine that has been extracted from human hair of animal products cannot be used for 
medical purposes, a method for the synthesis of L-cysteine has been developed that is based on the 
racemization of DL-2-amino-Δ2-thiazoline-4-carboxylic acid (DL-ATC), which can be synthesized 
from α-chloroacrylic acid and thiourea. The DL-ATC is treated with a racemase and an 
enantiospecific L-ATC hydrolase, meaning all the substrate is converted to L-form and 
subsequently to (S)-carbamoyl-L-cysteine. The (S)-carbamoyl-L-cysteine is then hydrolysed to L-
cysteine by a (S)-carbamoyl-L-cysteine hydrolase enzyme (Figure 1.25).  
 
This reaction can be catalysed by cells from strains of Pseudomonas species containing all of these 
activities, as recent example of which is Pseudomonas sp. strain HUT-78 which contains a 
mutation deactivating the L-cysteine desulfhydrase enzyme, which usually decomposes the L-
cysteine product.
[45]
 
 
Enantiospecific L-acylases are also used to resolve D,L-amino acids produced by Strecker synthesis. 
The D,L-amino acids are acylated using the Schotten-Baumann reaction into D,L-N-acetyl-amino 
acids. The L-acylase then catalyses the reaction of L-N-acetyl-amino acids into L-amino acids, 
which are then removed by ion chromatography. The remaining D-N-acetyl-amino acids can then 
be racemized and reused (Figure 1.26). Degussa used this method to produce proteinogenic amino 
acids L-alanine, L-methionine, L-valine and L-tryptophan and some non-proteinogenic amino acids 
O-benzylserine, norleucine and norvaline.
[46]
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Figure 1.25 Production of L-cysteine from D,L-ATC.[45] 
 
Figure 1.26 Resolution of D,L-amino acids using acylases.[46] 
 
Enantiospecific amino acid amidases such as D-amino-peptidase from Ochrobactrum anthropi sp. 
SCRC Cl-38
[47]
 or D-amino acid amide amidohydrolase from Brevibacterium iodinum TPU 5850
[48] 
can also be used to racemize a variety of amino acid amines, which can be prepared by hydrolyzing 
amino nitriles (prepared using Strecker synthesis).
[47] 
One disadvantage of this method is that the 
amino nitriles tend to be unstable substrates and will spontaneously revert back to cyanide, 
hydrogen and ammonia in alkaline solutions,
[49]
 affecting yields unless mild reaction conditions are 
used. 
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1.3 Amino acid oxidases 
 
Amino acid oxidases (AAOs) are enantioselective flavoenzymes that catalyse the oxidation of 
amino acids to imino acids, which in aqueous solutions will spontaneously hydrolyse into keto 
acids, producing hydrogen peroxide and ammonia as by-products (Figure 1.27).
[50]
 They are 
related to amine oxidases (AOs), which are flavoenzymes that catalyse the oxidation of amines to 
imines, and subsequently ketones.
[51]
 AAOs are found in species from bacteria to humans.
[50]
 
 
Figure 1.27 Reaction scheme for an L-amino acid oxidase. 
 
1.3.1 Structure and Activity of AAOs 
 
The monomeric forms of AAOs can range in size from around 39 kDa
[52]
 to 85 kDa,
[53]
 and usually 
contain one molecule of FAD cofactor per monomer. The monomers are usually described as 
having three domains; the FAD binding domain, substrate binding or capping domain and a helical 
domain thought to be involved in dimerisation of the protein.
[54]
  
 
The active enzymes are usually homodimeric
[54]
 although there are exceptions such as the 
homotetrameric aplysianin A enzyme from Aplysia kurodai, which oxidises basic L-amino acids 
arginine and lysine
[53]
 and the tetrameric rat kidney L-AAO, which contains either one or half a 
monomer of flavin mononucleotide per subunit.
[55]
 The effects of the quaternary structures of the 
oxidases on their activity have not been studied in depth, however the aplysianin A enzyme has 
higher binding affinity for its substrates than dimeric L-AAOs with activity against the same 
substrates (KM of 3.34 µM against L-arginine and 2.38 µM against L-lysine,
[53]
 compared with the 
L-AAO from Rhodococcus opacus (RoLAAO) which has KM of 70 µM against L-arginine and 15 
µM against L-lysine).
[56] 
 
The FAD binding domains of AAOs contain a common GR2 motif for binding FAD. The 
secondary structure of the GR2 motif contains the Rossmann fold, which consists of three β-strands 
and 2 α-helices in the pattern β1, α1, β2, α2 and β3 alternating on a parallel sheet. The overall motif 
structure has a parallel β-sheet containing β7, β8, β1, β2, and β3 strands, with the α1 and α2 helices 
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in the correct places to form the Rossmann fold, and an antiparallel other β-sheet containing the β4, 
β5 and β6 strands forming a crossover connection.[57]  
 
There is some controversy as to how the amino acid oxidases catalyse the oxidation reaction. Two 
main mechanisms that have been suggested are a hydride transfer mechanism and the nucleophilic 
mechanism. The hydride transfer mechanism suggests that the role of the enzyme is to hold the 
substrate amino acid in the optimum position for the spontaneous transfer of the α-proton to the 
substrate to the N5 of the flavin (Figure 1.28a).
[51]
  
 
The nucleophilic mechanism was first observed in amine oxidases but could be applicable to amino 
acid oxidases that contain a pair of aromatic residues, which sit at the base of the FAD molecule on 
the re side of the flavin ring, forming an “aromatic cage”. The dipole moment of this aromatic cage 
increases the nucleophilicity of the substrate, allowing it to attack the C4a position of the flavin. 
This causes the N5 of the flavin ring to abstract the α-proton of the substrate, producing a benzylic 
carbanion intermediate that spontaneously rearranges to give the imine and reduced FAD (Figure 
1.28b).
[58]
 
 
Figure 1.28 Possible reaction mechanisms for the oxidation of amino acids by amino acid oxidases. a. 
Hydride transfer mechanism. b. Nucleophilic mechanism.  
 
Since the structure of pig kidney D-AAO was solved, the hydride transfer mechanism has been 
accepted as the mechanism for catalysis by D-AAOs, due to the lack of both an aromatic cage and 
any amino acid side chains that could act as a base for proton abstractions.
[59]
 The structure of the 
D-AAO from Rhodotorula gracilis yeast also supported the hydride transfer mechanism, as the 
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substrates crystallised with the enzyme were held with the α-C-H bond pointing toward the N5 of 
flavin, and again no side chain capable of acting as a base were present in the active site.
[60]
 
 
The mechanism of L-AAOs is more complex as L-AAOs have been considered to be in the 
structural group of monoamine oxidases (MAOs), as opposed to D-AAOs.
[51]
 A mutational analysis 
of the human MAO-A and MAO-B enzymes was in support of the nucleophilic mechanism for 
MAOs. When one of the two residues comprising the aromatic cage (Y444 in MAO-A and Y435 in 
MAO-B) was mutated to aromatic residues with varying dipole moments the kcat/kM of the mutants 
were found to be proportional to the dipole moment of the aromatic cage residue. This suggested 
that the dipole moment of the aromatic cage residues is involved in the oxidation reaction, which 
supports the use of the nucleophilic mechanism for MAO proteins. It is also thought that the 
aromatic cage has a steric role in guiding the substrate towards the active site.
[61]
  
 
The MAO-N protein from Aspergillus niger is also thought to use the nucleophilic mechanism, as it 
has two aromatic residues, Y430 and F466, in the same positions as the aromatic cage residues in 
MAO-A and MAO-B. The dipole effect is less pronounced in MAO-N as tryptophan has a dipole 
moment pointing away from the active site and phenylalanine does not have a permanent dipole 
moment. Interestingly, substrates with their own dipole effect, such as para-nitrobenzylamine, are 
poor substrates for MAO-B, as they cancel out the dipole effect of the aromatic cage. However, a 
N336S/M348K double mutant of MAO-N showed 30-fold higher activity against para-nitro-α-
methylbenzylamine than the wild-type MAO-N, suggesting that a substrate with a dipole effect 
would be able to increase the activity of the MAO-N protein by compensating for the lack of a 
dipole moment in the aromatic cage, supporting the use of the nucleophilic mechanism.
[62]
 
 
Although the possibilty of aromatic cages in L-AAOs has not been investigated, there are some 
structures of L-AAOs that have what appears to be an aromatic cage, and could possibly be using 
the nucleophilic mechanism. One example is the L-AAO from Rhodococcus opacus, which appears 
to have two tryptophan residues (W426 and W467) in the same place as the aromatic cage residues 
of MAO-N (Figures 1.29, 1.30)
[54, 62]
 However there are also some doubts as to whether the MAO 
proteins use the nucleophilic mechanism, due to results of measurements of the oxidation of 
15
N 
benzylamine by MAO-B, which appeared to be more consistent with a hydride transfer mechanism 
than the nucleophilic mechanism.
[51]
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Figure 1.29 Superimposition of active site area of Aspergillus niger Mono Amine Oxidase (MAO-N)
[62]
 
(grey) and Rhodococcus opacus L-AAO (RoLAAO)[54] (coral)  
 
However, there are L-AAOs that do not have aromatic cages and appear to abstract a proton from 
the amino acid substrate before reducing the substrate using the hydride transfer mechanism. One 
example of this is the L-AAO from Calloselasma rhodostoma, where the current understanding is 
that the H223 side chain deprotonates the substrate before it binds G464 at the active site, at which 
point the pair of electrons on the amino nitrogen atoms moves to the α-carbon of the substrate and 
the hydride of the α-carbon is transferred to the N5 of the flavin ring.[63] 
 
The L-aspartate oxidase from E. coli uses a similar mechanism, however in this case the substrate, 
guided into the correct conformation by the E121 side chain,
[64]
 has its a proton abstracted by the 
R290 residue after binding in the active site has occurred. The other proton is also transferred to the 
N5 of the flavin ring (Figure 1.31), although it is unknown if this happens at the same time as the 
proton abstraction or occurs afterwards. There is also some doubt as to which proton is abstracted 
by R290 and which is transferred to the flavin ring, however from the structure of the E. coli L-
AspO solved by Bossi et al.
[65]
 it appears most likely that the α-proton is abstracted by R290 and 
the β-proton is transferred to the flavin ring.[66] 
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Figure 1.30 LigPlot+[67] comparison of the residues interacting with ligand in active site of a mutated form of 
the Aspergillus niger monoamine oxidase (MAO-N-D5)[62], the L-amino acid oxidase from Rhodococcus 
opacus (RoLAAO)[54] and the Human monoamine oxidase B (MAO-B)[61]. Hydrogen bonds are represented 
by dashed green lines, van der Waals contacts are represented by red combs and residues conserved between 
all three structures are circled in red. 
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Figure 1.31 Mechanism of oxidation of L-aspartate by the E. coli L-AspO. The α-proton is abstracted by the 
R290 side chain, allowing the β-proton to transfer to the N5 of the flavin ring.[66] 
 
1.3.2 Roles of AAOs in Nature 
 
In microorganisms, D-AAOs metabolise D-amino acids in the environment to use as carbon and 
nitrogen sources.
[50]
 In eukaryotic species they have a wider range of uses, however D-AAOs in 
some fish species are also involved in the metabolism of D-alanine, as the crustaceans and bivalve 
molluscs that they eat accumulate large concentrations of D-alanine, by racemizing L-alanine using 
an alanine racemize enzyme, to regulate osmotic pressure between cells.
[68]
 
 
In humans D-AAO is involved in a range of neurobiological processes, most notably the regulation 
of D-serine levels. This is important as D-serine can act as an agonist of neuro-modulator N-methyl-
D-aspartate-receptor (NMDA-receptor), and loss of NMDA-receptor activity is implied to be a 
cause of schizophrenia. In support of this, some studies have found that increased expression of D-
AAO and its binding partner G72 can be a risk factor for developing schizophrenia.
[69]
  
 
Brain tissue based D-AAOs are also involved in the regulation of D-alanine, which in the grey 
matter of Alzheimer’s patients is found in 2.2-fold higher concentrations than in control groups and 
D-aspartate, which in the white matter of control groups is found in more than twice the 
concentration as in the white matter of Alzheimer’s patients (although when these figures are 
expressed as a percentage of the total amount of DL-amino acid, the difference between 
Alzheimer’s patients and the control groups are less noticeable).[70] D-alanine (along with D-serine) 
is also found in increased amounts in the ventricular cerebrospinal fluid (where amino acids from 
the brain are deposited) of Alzheimer’s patients compared to control groups.[71]  
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In mammals, D-aspartate is found in the endocrine system as well as the central nervous system, 
and is involved in the regulation of several hormones. In the pineal gland D-aspartate produced by 
other tissues suppresses the secretion of melatonin from parenchyma cells.
[72]
 D-aspartate and its 
derivative, N-methyl-D-aspartate, encourage the release of prolactin by acting on the pituitary and 
adenohypophysis glands respectively.
[73]
 In rats, D-aspartate has been shown to induce testosterone 
synthesis in the testes
[74]
 and the release of gonadotropin-releasing hormone (GnRH) from the 
hypothalamus, which allows D-Asp to induce secretion of luteinizing hormone (involved in 
triggering ovulation and inducing testosterone synthesis) from the pituitary gland.
[75]
 
 
The L-arginine analogue N
G
-nitro-L-arginine acts as a suppressor of nitric oxide synthase, which is 
involved in the regulation of basal blood pressure and peripheral vascular resistance. N
G
-nitro-L-
arginine is originally synthesized as the racemate form N
G
-nitro-DL-arginine, however kidney based 
D-AAOs racemize the product by catalysing the oxidation of the N
G
-nitro-D-arginine (which has no 
effect on nitric oxide synthase) to an α-keto acid, allowing it to be oxidised to the NG-nitro-L-
arginine.
[76]
 
 
L-AAOs have a more diverse range of known roles in nature, as there are examples of L-AAOs that 
have narrow substrate specificity and are used for a more specific role. There are also many broad 
range L-AAOs, although the majority of these are found in snake venoms. The structure of a L-
AAO from Calloselasma rhodostoma venom has a Y-shaped channel than allows oxygen to enter 
the active site and hydrogen peroxide to exit, however hydrogen peroxide is released near to a 
glycan moiety on the enzyme that allows it to bind to a host cell wall. This suggests that the role of 
these L-AAOs is to produce a large concentration of hydrogen peroxide at the host cell wall, 
causing the cell to initiate a stress response and undergo apoptosis.
[63]
 Another toxic, broad range L-
AAO has recently been characterized in the death cap Amanita phalloides mushroom.
[77] 
 
Other broad range L-AAOs can have antibiotic effects through the production of hydrogen 
peroxide. These can be produced by bacteria as a way of competing against other microbes. One 
example is the Streptococcus oligofermentans L-AAO, which is a factor in the inhibition of growth 
of Streptococcus mutans in the oral cavity, which is the primary cause of tooth decay.
[78]
 
Pseudoalteromonas flavipulchra strain C2, a marine bacteria found to associate with coral, can also 
use L-AAO derived H2O2 to disrupt the growth of other bacterial species and has shown anti-
microbial activity against MRSA.
[79] 
 
A broad range L-AAO with anti-bacterial properties has also been found in mouse milk, again with 
the hydrogen peroxide providing the antimicrobial effect.
[80] 
Broad range microbial L-AAOs can 
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also be used to metabolise L-amino acids in the environment, particularly in soils where they are an 
important source of nitrogen, as seen in the fungus Hebeloma cylindrosporum.
[81]
  
 
The L-aspartate oxidase in eubacteria is known to catalyse the first step of the synthesis of 
quinolinic acid (the first substrate in the de novo synthesis of NAD) from L-aspartate and 
dihydroxyacetone phosphate (DHAP). The oxidase reduces L-aspartate to iminoaspartate, which is 
then condensed with DHAP by the quinolate synthase enzyme (Figure 1.32).
[82]
 
 
Figure 1.32 Synthesis of Quinolinic acid by L-aspartate oxidase and quinolinate synthase.[82] 
 
Also, the human Interleukin-4–induced protein is a L-phenylalanine oxidase expressed and secreted 
by dendritic cells, which play a large role in the induction and regulation of the immune response. 
The protein has been shown to suppress the activity of T-lymphocyte cells, with memory T-cells 
being the most sensitive to suppression. The method of suppression appears to be that hydrogen 
peroxide produced by the enzyme down regulates the CD3 ξ-chain of the T-cell receptor at the 
protein level, with a preference for memory T-cells, resulting in reduced T-cell activity.
[83] 
 
1.3.3 Applications of AAOs 
 
 
Several applications for D-AAOs are being developed. Enzymatic biosensors using D-AAOs have 
been developed for the measurement of D-AAs in food and beverages, which can be a sign of 
bacterial infection, and for the analysis of concentrations of D-serine in brain tissue in vivo. For 
food and beverages a graphite electrode with immobilised pig kidney D-AAO coupled with 
Prussian Blue, which acts as an electron mediator from hydrogen peroxide, has been shown to have 
a linear response to D-alanine concentrations between 5 µM and 200 µM.
[84]
  
 
For in vivo detection of D-serine levels in brain tissue, a platinum microelectrode coated with a 
layer of the electron mediator poly-m-phenylenediamine and a layer of yeast Rhodotorula gracilis 
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D-AAO could detect concentrations of D-serine as low as 16 nM with a mean response time of two 
seconds. Unfortunately as the Rhodotorula gracilis D-AAO shows similar levels of activity towards 
D-alanine and D-serine, the microelectrode cannot be used to determine D-serine levels in other 
tissues due to the presence of D-alanine causing false positives.
[85]
 For greater selectivity of these 
biosensors D-AAOs with single substrate specificities would need to be developed or found. In the 
case of the D-serine biosensor a mutant form of the Trigonopsis variabilis D-AAO that shows no 
activity against D-alanine, D-aspartate or D-proline has been created.
[50] 
 
D-AAO enzyme has also been suggested as a possible treatment for cancer, as cancer cells have 
low tolerance for oxidative stress. Polyethylene glycol (PEG) conjugated, recombinant pig kidney 
D-AAO was administered to tumour model mice using I.V. drip and was found to accumulate in 
greater concentrations in tumour cells compared with other organs. Two and four hours after PEG-
D-AAO was administered, 0.5 mmol per mouse of D-proline was injected into the mice, and the 
subsequent hydrogen peroxide production was found to suppress tumour growth with no visible 
side effects.
[86] 
 
A couple of problems with D-AAO as a potential treated for cancer is the high KM of the enzyme 
and the lack of oxygen in solid tumour cells. However Rosini et al. have optimised the D-AAO 
from Rhodotorula gracilis for activity at low oxygen levels, as well as increased activity at low 
levels of D-alanine, which could be used as a substitute for D-proline in this treatment method.
[87]
 
 
D-AAOs can also be used to resolve racemic amino acids into the corresponding L-amino acids 
(using a chemical reductant as discussed in Section 1.2.3) or α-keto acid. One of the first examples 
of this was the use of pig kidney D-AAO to resolve racemic pipecolic acid into L-pipecolic acid, 
which is a component for the production of immunodepressants, and anticancer and 
neuroprotective drugs.
[50] 
 
The yeast Trigonopsis variabilis D-AAO has been used to produce the α-keto acid                          
4-methylthio-2-oxobutyric acid, which can induce apoptosis and is used as an anticancer drug, 
from racemic mixtures of methionine. The D-AAO was immobilised along with catalase enzyme in 
order to prevent the produced hydrogen peroxide from reacting with the 4-methylthio-2-oxobutyric 
acid, and the product was removed from the reaction solution using anion exchange 
chromatography.
[88] 
 
Also, D-AAO can be used alongside a glutaryl hydrolase to convert cephalosporin C into                  
7-aminocephalosporanic acid, which is used as a starting point for the synthesis of many 
cephalosporin based antibiotics. The D-AAO oxidises cephalosporin C into                       
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ketoadipyl-7-aminocephalosporanic acid, which spontaneously decarboxylates into                 
glutaryl-7-aminocephalosporanic acid. The glutaryl hydrolase then removes the glutaryl group to 
produce 7-aminocephalosporanic acid (Figure 1.33).
[50] 
 
Similarly to D-AAOs, L-AAOs can also be used as biosensors for their substrates, as evidenced by 
the development of L-glutamate biosensors using L-glutamate oxidase, which are useful as            
L-glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. A 
recently developed biosensor consists of a platinum microelectrode covered with a permselective 
poly(phenylene diamine) membrane that prevents interference from oxidation of other compounds 
in biological samples such as urate or ascorbate. L-glutamate oxidase, from Streptomyces sp.  
X119-6, was then immobilised in a silica gel around the microelectrode. The resulting platinum 
electrode could then detect the generation of hydrogen peroxide by the L-glutamate oxidase 
specifically, with a linear dependence between 0.5 and 100 μmol of L-glutamate.[89] 
 
L-glutamate oxidase has also been used alongside aspartate aminotransferase and a peroxidase from 
Arthromyces ramosus to form a biosensor for L-aspartate. L-aspartate is converted to L-glutamate 
by the aspartate aminotransferase, which is subsequently oxidised by L-glutamate oxidase to 
produce hydrogen peroxide. The hydrogen peroxide then reacts with the luminol, which produced 
luminescence that can be detected. Unfortunately this sensor requires the removal of any L-
glutamate in the sample in order to determine L-aspartate levels.
[90]
 
 
The L-lysine oxidase from Trichoderma viride has been used to develop biosensors to assay the 
content of essential amino acid L-lysine in nutrition dependant products, such as intravenous 
feeding solutions and cell and tissue culture mediums. A recent example uses L-lysine oxidase 
immobilised in monocrystalline natural diamond paste, which could measure L-lysine 
concentrations as low as 4 pmol L
-1
 and had linear dependence between 1 nmol L
-1 
and               
100 nmol  L
-1
.
[91] 
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Figure 1.33 Method for the conversion of cephalosporin C into 7-aminocephaloporanic acid using D-AAO 
and a glutaryl hydrolase 
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L-lysine oxidase has also been shown to suppress DNA, RNA and protein synthesis in leukaemia 
L-5178Y, human ovary carcinoma, and Burkitt lymphoma tumour cells in vitro. This is thought to 
be due to its removal of L-lysine, which cannot be synthesised by mammals. Mice with grafted 
L1210 tumours survived 34-48% longer than a control group if they were injected with 70 U kg
-1
 of 
L-lysine oxidase, suggesting a possible use as an anti cancer agent.
[92] 
 
A broad range L-AAO from Crotalus adamanteus has been suggested for use as a pre-treatment to 
ready the body for treatment with melphalan, which is an anti-tumour agent designed to travel 
across the blood brain barrier. The disadvantage of melphalan is that it has to compete with large 
neutral L-amino acids like isoleucine, phenylalanine, valine etc. in order to cross the blood brain 
barrier. Moynihan et al. found that pre-treating mice models suffering from intracranial glioma 
with the L-AAO, and allowing time for it to deplete the levels of large neutral amino acids in the 
plasma, before treating the mice with anti-L-AAO serum and subsequently melphalan, increased 
the effectiveness of melphalan against the intracranial glioma.
[93]
 
 
The Crotalus adamanteus L-AAO has also been used to assay the activity of peptide hydrolase 
from the intestinal mucosa. The assay is performed in two steps, the first involved allowing the 
peptide hydrolase to react with peptides, releasing single amino acids if the hydrolase is active. The 
second step involves addition of the L-AAO, horseradish peroxidase, o-dianisidine and sulphuric 
acid. If single peptides are present, the L-AAO releases hydrogen peroxide, causing the peroxidase 
to peroxidise the o-dianisidine into brown dianisidine quinonediimine, which has an absorbance 
around 450nm.
[94]
 The sulphuric acid then reacts with this to form a soluble pink product with 
absorbance around 530nm.
[95] 
 
As mentioned in Section 1.2.3 L-AAOs can also be used in biotransformations producing 
enantiomerically pure D-amino acids and α-keto acids from their L-amino acid substrates. They can 
also be used in other biotransformations, for example the L-amino acid oxidase from Rhodococcus 
sp. AIU Z-35-1 has been shown to convert N
α
-benzyloxycarbonyl-L-lysine into the β-lactam 
antibiotic precursors N
α
-benzyloxycarbonyl-L-aminoadipate-δ-semialdehyde and                           
N
α
-benzyloxycarbonyl-L-aminoadipic acid.
[96]
 
 
Another potential therapeutic use for L-AAOs that has been suggested is that they could be used 
against bacterial infections, as the L-AAO from mouse milk has been found to prevent mastitis by 
killing bacteria
[80]
 and could be used as an anti-bacterial agent outside of milk. It has also been 
suggested that L-AAOs could be added to cleaning products, such as detergent or toothpaste, along 
with a substrate in order to produce hydrogen peroxide as a bleaching agent, however these ideas 
have not been developed at this time.
[55] 
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1.4 Objectives of Project 
 
Amino acid oxidase enzymes could be used for the production of enantiomerically pure amino 
acids or as part of enzymatic biosensors for determining the concentrations of their substrates in 
food or biological samples (Section 1.3.3). This means that a range of amino acid oxidases, 
preferably with strong substrate specificity against various amino acid substrates, would be useful. 
In particular, Ingenza Ltd. has expressed an interest in L-tyrosine or L-alanine oxidases from a 
prokaryotic source, which would be more compatible with GMP guidelines than oxidases from 
other sources. 
 
In the hope of finding an oxidase with natural activity against L-alanine or L-tyrosine, as well as 
increasing the repertoire of available oxidases, seven putative oxidases will be cloned and 
expressed in order to investigate their substrate specificities.  
 
The Turner group has had some success in increasing the substrate range of MAO-N using directed 
evolution, starting with an increase in the enantiospecificity and range of substrates oxidised
[97]
 and 
then creating versions that could oxidise secondary
[98]
 and tertiary
[99]
 amines. This suggests that it 
may be possible to introduce new substrate specificities into the related amino acid oxidases using 
directed evolution if they do not occur naturally.  
 
Therefore, one target will be picked to undergo directed evolution attempts, either to introduce or 
improve activity against L-tyrosine or L-alanine. The choice of target will be based on the 
expression levels, solubility and substrate specificity of the enzyme, and whether the protein in 
question has been studied in depth by other groups. 
 
1.4.1 Investigation of target oxidases 
 
The L-AAO from Synechococcus sp. strain ATCC 27144, (also known as Synechococcus elongatus 
PCC 6301, UniProt code Z48565) (SLAAO) has previously been cloned and expressed in E. coli 
by Ingenza Ltd., who found that it was active against L-arginine and L-lysine, which is consistent 
with previously published data on the enzyme under the species name S. elongates PCC 6301, and 
a 100% identical L-AAO from the related Synechococcus elongatus PCC 7942 (UniProt code 
Q31PP3, now known as UDP-galactopyranose mutase), which were both found to be active 
specifically against basic amino acids, with L-arginine being the best substrate, followed by L-
lysine and then L-histidine.
[100]
 The SLAAO protein (UniProt code P72346) is estimated to be 54 
kDa (estimation using ProtParam: http://web.expasy.org/protparam/ accessed 12/06/12). 
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To select other target proteins to be investigated, a BLAST search of the SLAAO was performed 
and six other putative oxidases were selected. Four of these were classed as putative L-AAOs, one 
as an amine oxidase and one as an oxidoreductase. The seven target proteins are summarized in 
Table 1.1  
 
Table 1.1: Summary of seven target oxidases. 
UniProt Code Classification Species Known substrates Abbreviation 
P72346 
L-amino acid 
oxidase 
Synechococcus sp. 
strain ATCC 27144 
L-arginine, L-lysine SLAAO 
Q8VPD4 
L-amino acid 
oxidase 
Rhodococcus 
opacus 
L-alanine, L-histidine RoLAAO 
Q88MZ2 
L-amino acid 
oxidase 
Pseudomonas 
putida 
L-aspartate PpLAAO 
O31616 
L-amino acid 
oxidase 
Bacillus subtilis Glycine, sarcosine
[101]
 BsGO 
Q8YKW9 
L-amino acid 
oxidase 
Anabaena sp. strain 
PCC 7120  
- AsAAO 
Q5YV66 Oxidoreductase Nocardia farcinica - NfOR 
Q81RW3 Amine Oxidase Bacillus anthracis - BaAO 
 
The L-AAO from Rhodococcus opacus (RoLAAO) (UniProt code Q8VPD4) is a 53 kDa protein 
that has previously been purified and found to have a broad range of substrate activity, with L-
alanine being the best substrate out of the proteinogenic amino acids.
[56]
 The protein has also been 
crystallised previously and forms a homodimeric protein with three subunit domains, an FAD 
binding domain, a substrate binding domain and a helical dimerisation domain. Overall the 
structure is similar to that of many snake venom L-AAOs, and the RoLAAO protein is currently 
thought to use the hydride transfer mechanism to oxidise its substrates.
[54]
 
 
The nadB gene from Pseudomonas putida encodes an L-AAO (PpLAAO) (UniProt code 
Q88MZ2), which is estimated to be around 59 kDa and has shown activity against L-aspartate when 
expressed in E. coli by Ingenza Ltd. Although no papers have been published about the P. putida 
protein, the homologous E. coli L-aspartate oxidase (L-AspO) shares 60% amino acid sequence 
identity and has been previously purified and has had its structure solved by crystallography.
[65]
 
The L-AspO protein is involved in the biosynthesis of NAD (Figure 1.31)
[82]
 so it is possible that 
the PpLAAO protein is also involved in NAD biosynthesis. The L-AspO protein is currently 
thought to abstract a proton from its substrate before oxidising it using the hydride transfer 
mechanism.
[67]
 
 
The glycine oxidase form Bacillus subtilis (BsGO) (UniProt code O31616) is a tetrameric protein 
made of 42 kDa monomers. Glycine oxidase can oxidise neutral D-amino acids such as D-alanine 
and D-proline, as well as glycine and sarcosine. The role of this protein in nature is not currently 
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understood.
[102]
 The mechanism of activity for BsGO has also not been confirmed, although the 
hydride transfer mechanism appears to be the favoured mechanism.
[103]
 
 
The Anabaena sp. strain PCC 7120 putative L-AAO (AsAAO) is a predicted enzyme found in the 
sequenced genome.
[104]
 ProtParam (http://web.expasy.org/protparam/ accessed 12/06/12) estimates 
that the protein will be around 48 kDa in size. The Nocardia farcinica putative oxidoreductase 
(NfOR) (UniProt code Q5YV66) is also a predicted protein from the N. farcinica genome,
[105] 
which is estimated to be around 49 kDa in size by ProtParam (http://web.expasy.org/protparam/ 
accessed 12/06/12). Finally the existence of the putative Bacillus anthracis amine oxidase (BaAO) 
(UniProt code Q81RW3) is predicted from the B. anthracis genome sequence.
[106]
 It is estimated to 
be around 54 kDa (estimation using ProtParam: http://web.expasy.org/protparam/ accessed 
12/06/12). 
 
The amino acid sequence of these seven targets, along with known the known L-AAO from C. 
rhodostoma (CrLAAO) and the L-aspartate oxidase from E. coli are compared in Figure B.1. 
 
The genes encoding these target proteins will be cloned and expressed in E. coli and the resulting 
cells and soluble protein fractions will be screened against potential amino acid and amine 
substrates in an attempt to determine substrate specificity of the enzymes. In order to investigate 
which residues of the proteins are involved in substrate activity and specificity, the target proteins 
will also be subjected to crystallisation screens for the X-ray determination of the protein structure, 
as well as possible mutational analysis of the active site residues. 
 
1.4.2 Evolution of new substrate activity 
 
Ingenza Ltd. has expressed an interest in L-tyrosine and L-alanine oxidases from a prokaryotic 
source, which could be created or developed from naturally occurring enzymes using directed 
evolution techniques. 
 
The Turner group has had success creating variants of the MAO-N, capable of oxidising more 
substrates, using random mutagenesis and screening with a target substrate.
[97, 98]
 However using 
random mutagenesis over the entire length of a gene sequence results in a large number of different 
combinations of mutations, and large numbers of transformants that need to be screened for 
activity. Directed evolution studies generally screen between 1,000-1,000,000 transformants, but 
some go as high as 1,000,000,000.
[107]
 As this lab is not currently designed for high-throughput 
generation and screening of transformants, an approach that would potentially generate changes in 
substrate specificity with fewer transformants may be more efficient. 
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Reetz et al. suggest an iterative combinatorial active site saturation testing (CASTing) method 
where active site residues of the target protein are divided into groups, preferably ones that can be 
mutated using one primer set. The residues in each group are mutated together using site-directed 
saturation mutagenesis (SDSM) and the resulting transformants are screened for desired activity. 
Any transformants showing desired activity then undergo SDSM on the active site residues in one 
of the other groups. This can potentially continue until mutations in all of the groups have been 
covered.
[108] 
 
However, although active site residues do have a large effect on the activity and substrate 
specificity of enzymes, mutations in residues further away from the active site can also have a 
profound effect on the activity of the enzyme.
[109]
 Because of this, a small scale random 
mutagenesis of the entire gene sequence of the target protein will be conducted alongside the 
CASTing procedure, with the intention of developing an amino acid oxidase with activity against 
L-alanine or L-tyrosine. 
 
1.4.3 Summary 
 
In summary, enantiomerically pure amino acids and amines have a variety of uses as substrates for 
the production of other enantiomerically pure chiral products or, in the case of L-amino acids, as 
additives for foodstuffs and nutritional products. Enantiomerically pure amino acids can be 
produced in a variety of ways, one of which uses enantioselective amino acid oxidases to resolve 
their respective substrate into the opposite enantiomer. 
 
AAOs are a group of flavoenzymes, related to amine oxidases, which catalyse the enantiospecific 
oxidation of amino acids into imino acids and generate hydrogen peroxide and ammonia as by-
products. Several possible uses have been suggested for them; however the most common uses are 
the aforementioned substrate deracemisation and their use in enzymatic amino acid biosensors. 
 
Seven putative target oxidases (five L-AAOs, an oxidoreductase and an amine oxidase) were 
selected from a BLAST search of the SLAAO gene sequence to be investigated by cloning 
followed by protein expression and screening of the resulting samples for activity against amino 
acids and amines. Soluble proteins will also be purified and attempts to determine protein structure 
using X-ray crystallography will be initiated. Mutational analysis of the active site residues will 
also be performed, as part of the characterisation of the active site of the protein, if a structure can 
be determined. Directed evolution of one target with the intention of developing an oxidase with 
activity against L-alanine or L-tyrosine will also performed, using both a small scale random 
mutagenesis approach and the iterative CASTing approach. 
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Chapter 2     Materials and Methods 
 
2.1 General Section 
 
This general section describes common procedures such as agarose gel electrophoresis, SDS-
PAGE, the transformation of chemically competent E. coli and Polymerase Chain Reaction (PCR) 
 
2.1.1 Agarose gel electrophoresis 
 
DNA was analysed with agarose gel electrophoresis. Agarose (electrophoresis grade) and SybrSafe 
DNA gel stain were purchased from Invitrogen. 1 kb DNA ladder was purchased from New 
England Biolabs. 
 
A 1% (w/v) agarose gel contained 0.75 g agarose, 75 mL TAE buffer and 1 µL of 10000x SybrSafe 
DNA gel stain. Loading samples consisted of 75% (v/v) DNA solution and 25% (v/v) loading 
buffer. Electrophoreses with 1% agarose gels were conducted at 100 V for 1 h in TAE buffer. “1 kb 
DNA Ladder” was used as a standard to estimate the length of the DNA fragments, this marker 
contains single stranded DNA fragments 10 kb, 8 kb, 6 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1.5 kb, 1 kb and 
0.5 kb in length. The DNA was detected using a SYNGENE-UV-imager. 
 
Loading buffer: 60 mM Tris/HCl, 2% (w/v) SDS, 0.2% (w/v) Bromophenol blue, 10% 
glycerol, 5% (v/v) β-mercaptoethanol, pH 6.8 
TAE buffer:  40 mM Tris/acetate, 2 mM EDTA, pH 7.9 
 
2.1.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein samples were analysed with 12%-SDS-PAGE using Mighty Small gel electrophoresis 
equipment.
[110]
 Acrylamide solution “30% ProtoGel” was purchased from National Diagnostics and 
“Low Molecular Weight Marker” was purchased from BioRad. 
 
A 12%-resolving gel contained 1.6 mL H2O, 1.25 mL buffer (1.5 M Tris/HCl, 0.4 % (w/v) SDS, 
pH 8.8), 2.1 mL acrylamide solution, 25 µL of 10% (w/v) APS and 4 µL of TEMED. 
A stacking gel consisted of 1.6 mL H2O, 0.65 mL buffer (0.5 M Tris/HCl, 0.4% (w/v) SDS, pH 
6.8), 0.25 mL acrylamide solution, 16 µL of 10% APS, 4 µL of TEMED and 4 µL of 1% (w/v) 
Bromophenol Blue. 
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20 µL-loading samples contained 50% (v/v) protein solution and 50% (v/v) loading buffer. 
Loading samples were denatured at 95°C for 5 min. Electrophoreses were carried out at 200 V for 
50 min in running buffer. “Low Molecular Weight Marker” was used as a standard to estimate the 
molecular weights of the proteins in the loading sample. This marker contains phosphorylase B 
(97.4 kDa), serum albumin (66.2 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), trypsin 
inhibitor (21.5 kDa) and lysozyme (14.4 kDa). 
 
After the electrophoresis, the SDS-gel was placed in staining solution and microwaved for 40 s. 
The SDS-gel was then washed with water and placed in destaining solution and microwaved for 40 
s and then left to destain at room temperature. The destaining solution was exchanged several times 
in order to completely destain the SDS-gel. Pictures were taken using a Syngene Gene Genius 
Bioimaging System. 
 
Loading buffer: 0.5 M Tris, 10% (w/v) glycerol, 2% (w/v) SDS, 0.005% Bromophenol 
Blue, 5% (v/v) β-mercaptoethanol, pH 6.8 
Running Buffer: 25 mM Tris, 250 mM glycine, 0.1 % (w/v) SDS, pH 8.4 
Staining Solution: 25% (v/v) propan-2-ol, 10% glacial acetic acid, 0.2% (w/v) Coomassie 
Brilliant BlueR 
Destaining Solution: 5% (v/v) propan-2-ol and 7% (v/v) glacial acetic acid 
 
2.1.3 Transformation of chemically competent E. coli with plasmid 
 
Kanamycin sulphate was purchased from Invitrogen, chloramphenicol from Sigma-Aldrich, 
tetracycline from Merck/Calbiochem, the ingredients for LB-media from Fisher Scientific and agar 
was purchased from LAB M Ltd. Chemically competent E. coli Novablue singles, E. coli BL21-
DE3, E. coli B834-DE3 and E. coli Rosetta2-DE3 were purchased from Merck/Novagen. 
Chemically competent E. coli XL10-Gold and E. coli BL21-Gold-DE3 were purchased from 
Agilent Technologies/Stratagene. 
 
Cell genotypes are as follows: 
Novablue singles: endA1 hsdR17 (rK12
–
 mK12
+
) supE44 thi-1 recA1 gyrA96 relA1 lac F′[proA+B+ 
lacI
q
ZΔM15::Tn10] (TetR) 
BL21-DE3: F
–
 ompT hsdSB (rB
–
 mB
–
) gal dcm (DE3) 
B834-DE3: F
-
 ompT hsdSB(rB
-
 mB
-
) gal dcm met (DE3) 
Rosetta2-DE3: F
-
 ompT hsdSB(rB
-
 mB
-
) gal dcm (DE3) pRARE2 (Cam
R
) 
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XL10-Gold: Tet
R
 Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F  ´proAB lacIqZΔM15 Tn10 (TetR) Amy CamR) 
BL21-Gold-DE3: E. coli B F– ompT hsdS(rB– mB–) dcm+ TetR gal λ(DE3) endA Hte) 
 
Chemically competent E. coli were thawed on ice and rapidly mixed with plasmid DNA under 
sterile conditions. The cells were incubated on ice for 30 min and then heat-shocked at 42°C. E. 
coli Novablue singles; E. coli BL21-DE3, E. coli B834-DE3 and E. coli Rosetta2-DE3 strains were 
heat-shocked for 45 s. E. coli XL10-Gold strains were heat-shocked for 30 s and E. coli BL21-
Gold-DE3 strains were heat-shocked for 20 s. After that, the cells were incubated on ice for 5 min. 
1 mL of sterile LB-media was added to E. coli BL21-DE3, E. coli B834-DE3 and E. coli Rosetta2-
DE3 cells under sterile conditions and 1 mL of LB+ media was added to E. coli XL10-Gold cells. 
The cell suspension was then incubated at 37° for 60 min. 
 
E. coli Novablue singles, E. coli BL21-DE3 and E. coli B834-DE3 strains were plated out onto LB-
agar containing 30 µg/mL of kanamycin. E. coli Rosetta2-DE3 strains were plated out onto LB-
agar containing 30 µg mL
-1
 of kanamycin and 34 µg mL
-1
 chloramphenicol. E. coli XL10-Gold 
strains were plated out onto LB-agar containing 30 µg mL
-1
 of kanamycin, 34 µg mL
-1 
chloramphenicol and 15 µg mL
-1
 tetracycline. E. coli BL21-Gold-DE3 strains were plated out onto 
LB-agar containing 30 µg mL
-1
 of kanamycin and 15 µg mL
-1
 tetracycline. Colonies were obtained 
after incubating the agar plates at 37°C overnight. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, deionised H2O 
LB+ media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, 12.5 mL 1 M MgCl2, 12.5 mL 
1 M MgSO4, 20 mL 20% (w/v) D-glucose, deionised H2O 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, deionised H2O 
 
2.1.4 Transformation of electrocompetent E. coli with plasmid 
 
Kanamycin sulphate, SOC media and electrocompetent E. coli Top10 (genotype F
- 
mcrA Δ(mrr-
hsdRMS-mcrBC) φ80lacZΔM15 ΔlacΧ74 recA1 araD139 Δ(ara-leu) 7697 galU galK rpsL (Str
R
) 
endA1 nupG λ-) cells were purchased from Invitrogen. Electrocompetent E. coli BL21-DE3 cells 
were prepared as in Section 2.1.5. The ingredients for LB-media were purchased from Fisher 
Scientific and agar was purchased from LAB M Ltd. Electrocompetent E. coli BL21-DE3 cells 
were electroporated using a BioRad Gene Pulser electroporation system with pulse controller. 
Electrocompetent E. coli Top10 cells were electroporated using a BioRad E. coli Pulser. 
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Electrocompetent E. coli BL21-DE3 were thawed on ice and rapidly mixed with plasmid DNA 
under sterile conditions. Cells were incubated on ice for 1 min and then transferred to an ice-cold 
0.1 cm electroporation cuvette. Electroporation cuvette was tapped firmly to ensure cells were at 
the bottom of the cuvette and that no bubbles were present. Cells were electroporated in the BioRad 
Gene Pulser at 2.5 kV with resistance set at 200 Ω and capacitance set to 25 µF. 950 µL of SOC 
media was then mixed with the cells and transferred to a fresh 15 mL tube under sterile conditions. 
Cells were incubated at 37°C with shaking at 180 r.p.m for 1 h. Cells were plated out on pre-
warmed LB-agar containing 30 µg mL
-1
 of kanamycin. Colonies were obtained after incubating the 
agar plates at 37°C overnight. 
 
Electrocompetent E. coli Top10 cells were thawed on ice and rapidly mixed with plasmid DNA. 
Cells were incubated on ice for 1 min and then transferred to an ice-cold 0.2 cm electroporation 
cuvette. Cells were electroporated at 2.5 kV in the E. coli Pulser. Cells were mixed with 950 µL 
SOC media and then transferred to a fresh 15 mL tube under sterile conditions. Cells were 
incubated at 37°C with shaking at 180 r.p.m for 90 min. Cells were plated out on pre-warmed LB-
agar containing 30 µg mL
-1
 of kanamycin. Colonies were obtained after incubating the agar plates 
at 37°C overnight. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, deionised H2O 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, deionised H2O 
 
2.1.5 Production of electrocompetent E. coli cells 
 
Chemically competent E. coli BL21-DE3 cells were purchased from Merck/Novagen. Ingredients 
for LB-media and glycerol were purchased from Fisher. Agar was purchased from LAB M Ltd. 
Falcon tubes were spun using a Harrier 18/80 centrifuge. 
 
Chemically competent E. coli BL21-DE3 cells were spread over an LB-agar plate containing no 
antibiotics. The plate was incubated at 37°C overnight. One colony was used to inoculate each of 
two 5 mL starter cultures of LB-media, which were grown at 37°C with shaking at 180 r.p.m 
overnight. 8 mL of starter culture was then used to inoculate 800 mL of LB-media in a 2 L 
Erlenmeyer flask. Cells were grown at 37°C and 180 r.p.m until OD600 was between 0.7 and 0.9. 
 
400 mL of the cells were transferred to eight chilled 50 mL Falcon tubes and kept on ice for 1 h, 
the remaining culture was kept in the flask and chilled on ice for 1 h. The cells in the eight Falcon 
tubes were then spun down by centrifugation at 3850 g and 4°C for 10 min. Supernatant was 
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discarded and the remaining culture was distributed equally between the eight 50 mL Falcon tubes. 
These were then spun down again at 3850 g and 4°C for 10 min. 
 
The cell pellet in each Falcon tube was then resuspended in 5 mL of ice-cold 10% (v/v) glycerol, 
and the Falcon tubes were then filled to 50 mL with ice-cold 10% (v/v) glycerol. Cells were then 
spun down at 3850 g and 4°C for 10 min.  
 
The cell pellet in each Falcon tube was then resuspended in 5 mL of ice-cold 10% glycerol and 
cells were then pooled equally between four of the Falcon tubes. These Falcon tubes were then 
filled up to 50 mL with ice-cold 10% (v/v) glycerol. Cells were then spun down at 3850 g and 4°C 
for 10 min and cell pellets were resuspended with 5 mL of ice-cold 10% (v/v) glycerol, then Falcon 
tubes were filled up to 50 mL with ice-cold 10% (v/v) glycerol.  
 
Cells were then spun down at 3850 g and 4°C for 10 min and cell pellets were resuspended with 5 
mL ice-cold 10% (v/v) glycerol and cells were pooled equally into two of the 50 mL Falcon tubes, 
which were then filled to 50 mL with ice-cold 10% (v/v) glycerol. Cells were then spun down at 
3850 g and 4°C for 10 min.  
 
Each of the two cell pellets was resuspended in 2.5 mL of ice-cold 10% (v/v) glycerol and 
dispensed in 100 µL aliquots into pre-chilled 1.5 mL Eppendorf tubes. These tubes were stored at -
80°C. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, deionised H2O 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, deionised H2O 
 
2.1.6 Polymerase Chain Reaction (PCR) 
 
KOD hot start DNA polymerase kit was purchased from Merck/Novagen, PfUTurbo hot start DNA 
polymerase kit was purchased from Agilent Technologies/Stratagene and Phusion hot start II High-
fidelity DNA polymerase kit was purchased from New England Biolabs. dNTPs were purchased 
from Promega. High-purity salt-free primers were synthesized by Eurofins/MWG Biotech 
(Ebersberg, Germany). PCR cycling using 200 µL thin-walled PCR tubes was carried out with a 
Techne TC312 thermal cycler and PCR cycling using 500 µL thin-walled PCR tubes was carried 
out with a Techne TC312 thermal cycler. Gradient PCRs were carried out using an Eppendorf 
Mastercycler.  
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The conditions for PCR cycling are given in Table 2.1, the compositions of the PCR mixes are 
shown in Table 2.2 and the primer sequences are listed in Table 2.3. 
 
Table 2.1: Conditions for PCR cycling methods used for the amplification of DNA by PCR. 
PCR 
Cycling 
Initial 
denaturation Denaturation Annealing Extension 
Number 
of 
Cycles 
Final 
extension 
A 96°C, 5 min 96°C, 30 s 55°C, 30 s  72°C, 1 min 35 72°C, 5 min 
B 96°C, 5 min 96°C, 30 s 55°C, 30 s  72°C, 90 s 35 72°C, 5 min 
C 95°C, 2 min 95°C, 30 s 72°C, 30 s 72°C, 10 min 35 72°C, 15 min 
D 95°C, 2 min 95°C, 30 s 52°C, 30 s  72°C, 10 min 25 72°C, 15 min 
E 95°C, 2 min 95°C, 30 s 55°C, 30 s  72°C, 90 s 30 72°C, 5 min 
F 95°C, 2 min 95°C, 30 s 64°C ± 
6°C, 30 s 
72°C, 10 min 25 72°C, 15 min 
G 98°C, 2 min 98°C, 20 s None 72°C, 6 min 35 72°C, 10 min 
H 95°C, 2 min 95°C, 1 min 55 °C, 1 
min 
72°C 1.5 min 30 72°C, 10 min 
I 95°C, 1 min 95°C, 50 s 60°C, 50 s 68°C 13min 25 N/A 
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Table 2.2: Composition of PCR mix used for the amplification of DNA by PCR. 
PCR 
mix 
Vtotal in 
µL Vcomponent [Component] in PCR mix 
A 50 33 µL H2O (18.2 Ω
.
 cm) 
5 µL 5 x KOD buffer 
3 µL 25 mM MgSO4 
5 µL 2 mM (each) dNTPs 
1 µL 20 µM forward primer 
1 µL 20 µM reverse Primer 
1 µL Template DNA 
1 µL 1 U µL
-1
 KOD Hot Start DNA 
polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
B 50 28 µL H2O (18.2 Ω
.
 cm) 
5 µL 10 x KOD buffer 
3 µL 25 mM MgSO4 
5 µL 2 mM (each) dNTPs 
1 µL 20 µM forward primer 
1 µL 20 µM reverse Primer 
1 µL Template DNA 
5 µL ≥99.5% DMSO 
1 µL 1 U µL
-1
 KOD Hot Start DNA 
polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
10% DMSO 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
C 25 15.25 µL H2O (18.2 Ω
.
 cm) 
2.5 µL 10 x PfU Turbo buffer 
2.5 µL 2mM (each) dNTPs 
0.5 µL 20 µM forward primer 
0.5 µL 20 µM reverse primer 
2 µL 10 ng µL
-1 
YSBLIC3C-
PpLAAO 
1.25 µL ≥99.5% DMSO 
0.5 µL 2.5 U µL
-1 
PfUTurbo 
HotStart polymerase 
1 x PfU Turbo buffer 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
0.8 ng µL
-1 
YSBLIC3C-PpLAAO 
5% DMSO 
0.05 U µL
-1
 PfUTurbo HotStart 
polymerase 
D 25 14.25 µL H2O (18.2 Ω
.
 cm) 
2.5 µL 5 x PfU Turbo buffer 
2.5 µL 2mM (each) dNTPs 
1 µL 10 µM forward primer 
1 µL 10 µM reverse primer 
2 µL 10 ng µL
-1 
YSBLIC3C-
PpLAAO 
1.25 µL ≥99.5% DMSO 
0.5 µL 2.5 U µL
-1 
PfUTurbo 
HotStart polymerase 
1 x PfU Turbo buffer 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
0.8 ng µL
-1 
YSBLIC3C-PpLAAO 
5% DMSO 
0.05 U µL
-1
 PfUTurbo HotStart 
polymerase 
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Table 2.2: Composition of PCR mix used for the amplification of DNA by PCR. 
PCR 
mix 
Vtotal in 
µL Vcomponent [Component] in PCR mix 
E 25 14 µL H2O (18.2 Ω
.
 cm) 
2.5 µL 10 x KOD buffer 
1.5 µL 25 mM MgSO4 
2.5 µL 2 mM (each) dNTPs 
0.5 µL 20 µM forward primer 
0.5 µL 20 µM reverse Primer 
0.5 µL Template DNA 
2.5 µL ≥99.5% DMSO 
0.5 µL 1 U µL
-1
 KOD Hot Start 
DNA polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
10% DMSO 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
F 25 14.25 µL H2O (18.2 Ω
.
 cm) 
2.5 µL 10 x PfU Turbo buffer 
2.5 µL 2mM (each) dNTPs 
1 µL 10 µM forward primer 
1 µL 10 µM reverse primer 
2 µL 10 ng µL
-1 
YSBLIC3C-
PpLAAO 
1.25 µL ≥99.5% DMSO 
0.5 µL 2.5 U µL
-1 
PfUTurbo 
HotStart polymerase 
1 x PfU Turbo buffer 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
0.8 ng µL
-1 
YSBLIC3C-PpLAAO 
5% DMSO 
0.05 U µL
-1
 PfUTurbo HotStart 
polymerase 
G 20 10.0 µL H2O (18.2 Ω
.
 cm) 
4 µL 5 x Phusion HF buffer 
2 µL 2 mM (each) dNTPs 
0.5 µL 20 µM forward primer 
0.5 µL 20 µM reverse primer 
1 µL 10 ng µL
-1
 YSBLIC3C-
PpLAAO 
1 µL ≥99.5% DMSO 
0.8 µL 5 mM MgSO4  
0.2 µL 2 U µL
-1 
Phusion HotStart II 
polymerase 
1 x Phusion HF buffer 
0.2 mM (each) dNTPs 
0.5 µM forward primer 
0.5 µM forward primer 
0.5 ng µL
-1
 YSBLIC3C-PpLAAO 
5% DMSO 
0.2 mM MgSO4 
0.02 U µL
-1
 Phusion HotStart II 
polymerase 
H 25 13.75 µL H2O (18.2 Ω
.
 cm) 
2.5 µL 10 x KOD buffer 
2.5 µL 2 mM (each) dNTPs 
1.5 µL 25 mM MgSO4 
1 µL 10 µM forward primer 
1 µL 10 µM reverse primer 
1 µL 10 ng µL
 -1
 YSBLIC3C-
PpLAAO 
1.25 µL ≥99.5% DMSO 
0.5 µL 1 U µL
-1 
KOD HotStart 
DNA polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
5% DMSO 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
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Table 2.2: Composition of PCR mix used for the amplification of DNA by PCR. 
PCR 
mix 
Vtotal in 
µL Vcomponent [Component] in PCR mix 
I 50 28.5 µL H2O (18.2 Ω
.
 cm) 
5 µL 5 x PfU Turbo buffer 
5 µL 2mM (each) dNTPs 
1 µL 10 µM forward primer 
1 µL 10 µM reverse primer 
6 µL 10 ng µL
-1 
YSBLIC3C-
PpLAAO 
2.5 µL ≥99.5% DMSO 
1 µL 2.5 U µL
-1 
PfUTurbo HotStart 
polymerase 
1 x PfU Turbo buffer 
0.2 mM of each dNTP 
0.2 µM forward primer 
0.2 µM reverse primer 
1.2 ng µL
-1 
YSBLIC3C-PpLAAO 
5% DMSO 
0.05 U µL
-1
 PfUTurbo HotStart 
polymerase 
J 20 10.8 µL H2O (18.2 Ω
.
 cm) 
4 µL 5 x Phusion HF buffer 
2 µL 2 mM (each) dNTPs 
0.5 µL 20 µM forward primer 
0.5 µL 20 µM reverse primer 
1 µL 10 ng µL
-1
 YSBLIC3C-
PpLAAO 
1 µL ≥99.5% DMSO 
0.2 µL 2 U µL
-1 
Phusion HotStart II 
polymerase 
1 x Phusion HF buffer 
0.2 mM (each) dNTPs 
0.5 µM forward primer 
0.5 µM forward primer 
0.5 ng µL
-1
 YSBLIC3C-PpLAAO 
5% DMSO 
0.02 U µL
-1
 Phusion HotStart II 
polymerase 
K 20 8.8 µL H2O (18.2 Ω
.
 cm) 
4 µL 5 x Phusion HF buffer 
4 µL 2 mM (each) dNTPs 
0.5 µL 20 µM forward primer 
0.5 µL 20 µM reverse primer 
1 µL 10 ng µL
-1
 YSBLIC3C-
PpLAAO 
1 µL ≥99.5% DMSO 
0.2 µL 2 U µL
-1 
Phusion HotStart II 
polymerase 
1 x Phusion HF buffer 
0.4 mM (each) dNTPs 
0.5 µM forward primer 
0.5 µM forward primer 
0.5 ng µL
-1
 YSBLIC3C-PpLAAO 
5% DMSO 
0.02 U µL
-1
 Phusion HotStart II 
polymerase 
L 50 18 µL H2O (18.2 Ω
.
 cm) 
5 µL 10 x Mutazyme
®
 II Reaction 
Buffer 
23 µL 95 ng µL
-1
 pET-YSBLIC3C-
PpLAAO  
1 µL 10 mM (each) dNTP mix 
1 µL 20 µM forward primer 
1 µL 20 µM reverse primer 
1 µL 2.5 U µL
-1
 Mutazyme
® 
II 
DNA polymerase 
1 x Mutazyme
®
 II Reaction Buffer 
43.7 ng µL
-1
 pET-YSBLIC3C-
PpLAAO 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
0.05 U µL
-1
 Mutazyme
® 
II DNA 
polymerase 
M 50 25 µL 2 x EZClone enzyme mix 
0.5 µL 95 ng µL
-1
 pET-
YSBLIC3C-PpLAAO 
500 ng megaprimer 
3 µL EZclone solution 
H2O (18.2 Ω
.
 cm) to 50 µL 
1 x EZClone enzyme mix 
47.5 ng µL
-1 
pET-YSBLIC3C-
PpLAAO 
10 ng µL
-1
 megaprimer 
6% (v/v) EZClone solution 
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Table 2.3: Sequences of primers used for the amplification of DNA by PCR. 
Primer name/ 
Purification 
method Primer sequence (5’ to 3’) 
AsAAO-for/ HPSF CCAGGGACCAGCAATGCAGCACAGGGAATTTACAGGCTGTATTCATAC 
AsAAO-rev/ 
HPSF 
GAGGAGAAGGCGCGTTATTATCGAGGAGCGGTAGAGCCAGCAAAGTG 
BaAO-for/ HPSF CCAGGGACCAGCAATGATGCAGCCATTAACGATGGAAAGAATGCTCC 
BaAO-rev/ HPSF GAGGAGAAGGCGCGTTATCACTTTTCGTTTACTTCATGAGCAACTCG 
BsGO-for/ HPSF CCAGGGACCAGCAATGAAAAGGCATTATGAAGCAGTGGTGATTGGAGG 
BsGO-rev/ HPSF GAGGAGAAGGCGCGTTATCATATCTGAACCGCCTCCTTGCGATCAATTC 
NfOR-for/ HPSF CCAGGGACCAGCAATGGTGGTGGACAGATCGGTGGATGTCGTC 
NfOR-rev/ HPSF GAGGAGAAGGCGCGTTATCACCGGAGGGCGGACGGGCTC 
T7 TAATACGACTCACTATAGGG 
T7-term TATGCTAGTTATTGCTCAGCGGT 
Q242A-for /HPLC GGCGAACCTGGAATTCAACGCGTTCCACCCGACCT 
Q242A-rev /HPLC AGGTCGGGTGGAACGCGTTGAATTCCAGGTTCGCC 
H244A-for /HPLC TGGAATTCAACCAGTTCGCCCCGACCTGCCTGTATC 
H244A-rev /HPLC GATACAGGCAGGTCGGGGCGAACTGGTTGAATTCCA 
P245A-for /HPLC TTCAACCAGTTCCACGCGACCTGCCTGTATC 
P245A-rev /HPLC GATACAGGCAGGTCGCGTGGAACTGGTTGAA 
L257A-for /HPLC CAGGCCAAGAGCTTCGCGATCACCGAAGCCCT 
L257A-rev /HPLC AGGGCTTCGGTGATCGCGAAGCTCTTGGCCTG 
T259A-for /HPLC GAGCTTCCTGATCGCCGAAGCCCTGCG 
T259A-rev /HPLC CGCAGGGCTTCGGCGATCAGGAAGCTC 
E260A-for /HPLC TCCTGATCACCGCAGCCCTGCGCGG 
E260A-rev /HPLC CCGCGCAGGGCTGCGGTGATCAGGA 
R290A-for /HPLC AAGAGCTGGCCCCAGCGGACATCGTGGC 
R290A-rev /HPLC GCCACGATGTCCGCTGGGGCCAGCTCTT 
V293A-for /HPLC ACGGGACATCGCGGCCCGCGCCA 
V293A-rev /HPLC TGGCGCGGGCCGCGATGTCCCGT 
H351A-for /HPLC GGTGCCTGCGGCGGCTTACACCTGCGGC 
H351A-rev /HPLC GCCGCAGGTGTAAGCCGCCGCAGGCACC 
Y352A-for /HPLC TGCCTGCGGCGCATGCCACCTGCGGCGG 
Y352A-rev /HPLC CCGCCGCAGGTGGCATGCGCCGCAGGCA 
R386A-for /HPLC GCACGGCGCCAACGCCATGGCCAGCAAC 
R386A-rev /HPLC GTTGCTGGCCATGGCGTTGGCGCCGTGC 
S389A-for /HPLC CCAACCGCATGGCCGCCAACTCGCTGCTGG 
S389A-rev /HPLC CCAGCAGCGAGTTGGCGGCCATGCGGTTGG 
S391A-for /HPLC GCATGGCCAGCAACGCGCTGCTGGAATGT 
S391A-rev /HPLC ACATTCCAGCAGCGCGTTGCTGGCCATGC 
PpLAAO-for/ 
HPSF 
CCAGGGACCAGCAATGAGCCAACAATTCCAACATGATGTCCTGGTG 
PpLAAO-rev/ 
HPSF 
GAGGAGAAGGCGCGTTATCAGAGCGGGTTAAGGATGGTGTCCTTG 
PNDTA-for/ 
HPLC 
CGGTGGTGCCTGCGGCGNDTNDTACCTGCGGCGGGGTGAT 
PNDTA-rev/ 
HPLC 
ATCACCCCGCCGCAGGTAHNAHNCGCCGCAGGCACCACCG 
PNDTB-for/ 
HPLC 
ACCCACGCGAAGAGCTGGCCCCANDTGACATCNDTGCCCGCGCCATC 
PNDTB-rev/ 
HPLC 
GATGGCGCGGGCAHNGATGTCAHNTGGGGCCAGCTCTTCGCGTGGGT 
PNDTC-for/ 
HPLC 
CCTGCACGGCGCCAACNDTATGGCCNDTAACNDTCTGCTGGAATGTTTTG 
 
PNDTC-rev/ 
HPLC 
CAAAACATTCCAGCAGAHNGTTAHNGGCCATAHNGTTGGCGCCGTGCAGG 
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Table 2.3: Sequences of primers used for the amplification of DNA by PCR. 
Primer name/ 
Purification 
method Primer sequence (5’ to 3’) 
PNDTD-for/ 
HPLC 
GGCGAACCTGGAATTCAACNDTTTCNDTNDTACCTGCCTGTATCACCCAC 
PNDTD-rev/ 
HPLC 
GTGGGTGATACAGGCAGGTAHNAHNGAAAHNGTTGAATTCCAGGTTCGCC 
PNDTE-for/ 
HPLC 
CCCACAGGCCAAGAGCTTCNDTATCNDTNDTGCCCTGCGCGGCGAGGGCG 
PekAsAAO-for/ 
HPSF 
GCAAGTGTGGATCCAAAGGAGATATAGATATATACCATGGGCAGCAGC 
PekAsAAO-rev/ 
HPSF 
TGTGATAAGAATTCTTATTATCGAGGAGCGGTAGAGCCAGCAAAGTGAAT 
PekBaAO-for/ 
HPSF 
GCAAGTGTGGATCCAAAGGAGATATAGATATATACCATGGGCAGCAGC 
PekBaAO-rev/ 
HPSF 
TTATCAGAGGTACCTTATCACTTTTCGTTTACTTCATGAGCAACTCGAAT 
PekNfOR-for/ 
HPSF 
GCAAGTGTGGATCCAAAGGAGATATAGATATATACCATGGGCAGCAGC 
PekNfOR-rev/ 
HPSF 
TCTGATAAGAATTCTTATCACCGGAGGGCGGACGGGCTCGCGGCGTCG 
 
 
2.2 Generation of target oxidases 
 
As three of the seven prokaryotic oxidases (PpLAAO, RoLAAO and SLAAO) within the first 
fifteen BLAST results of an L-amino acid oxidase from Synechococcus sp. strain ATCC 27144 
(Table 3.1) had been cloned previously by Gideon Grogan, The AsAAO, BaAO, BsGO and NfOR 
oxidases were generated by cloning the genes in the pET-YSBLIC-3C vector with ligation 
independent cloning. This section describes the amplification of four genes with polymerase chain 
reaction, cloning of the amplified genes, and analysis of the correct nucleotide sequence and 
overexpression of all seven target genes in E. coli. 
 
2.2.1 PCR amplification of four target genes 
 
The AsAAO, BaAO, BsGO and NfOR genes were amplified with PCR as in Section 2.1. The 
PCRs were separated with 1% agarose gel electrophoresis and purified using Sigma Aldrich’s 
GenElute Gel Extraction kit. Each PCR product was eluted with 50 µL of H2O (18.2 Ω
.
 cm) and its 
concentration was determined using the dsDNA function of an Eppendorf Biophotometer, with an 
absorbance of 0.1 set equal to DNA concentration of 50 ng µL
-1
. The PCR products were stored at -
20°C. 
 
The PCR methods and template DNA used are listed in Table 2.4, the conditions for the PCR 
cycling are given in Table 2.1, the composition of the PCR mix is shown in Table 2.2 and the 
primer sequences are listed in Table 2.3. 
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Table 2.4: PCR methods, primers and template DNA used for the amplification of target genes (Please see 
Table 2.1 for PCR cycling, Table 2.2 for PCR mix and Table 2.3 for primer sequences). 
Gene name PCR method Primers Template DNA 
AsAAO PCR mix A + PCR cycling A 
AsAAO-for, 
AsAAO-rev 
10 ng µL
-1 
Anabaena genomic DNA 
BaAO PCR mix A + PCR cycling A 
BaAO-for, 
BaAO-rev 
35 ng µL
-1 
Genomified Bacillus 
anthracis genomic DNA 
BsGO PCR mix B + PCR cycling B 
BsGO-for, 
BsGO-rev 
10 ng µL
-1
 Bacillus subtilis genomic 
DNA 
NfOR PCR mix B + PCR cycling B 
NfOR-for, 
NfOR-rev 
5 ng µL
-1 
Nocardia farcinica 
genomic DNA 
 
2.2.2 Ligation Independent Cloning (LIC) 
 
Ligation independent cloning was used to ligate the PCR products of target genes AsAAO, BaAO, 
BsGO and NfOR with a modified pET-28a vector, pET-YSBLIC-3C. LIC-qualified T4-DNA 
polymerase and buffer for the T4-DNA polymerase were purchased from Merck/Novagen. dATP 
and dTTP were purchased from Bioline. DTT was purchased from Melford and EDTA was 
purchased from Fisher Scientific. BseRI and NEBuffer 4 were purchased from New England 
Biolabs. The concentration of DNA was determined using an Eppendorf Biophotometer. 
 
9 µg of circular pET-YSBLIC-3C was linearised using the Plasmid Linearisation mix, which was 
incubated at 37°C for 3 h. Linearised vector was separated using 1% agarose gel electrophoresis 
and purified using Sigma Aldrich’s GenElute Gel Extraction kit. Vector was eluted using 50 µL of 
H2O (18.2 Ω
.
 cm), the concentration after extraction was 44 ng µL
-1
. 
 
In order to generate “sticky” single stranded overhangs, 2.2 µg of linear pET-YSBLIC-3C vector 
and 0.2 pmol of each PCR product were treated with T4-DNA polymerase using the Vector T4 
polymerase mix and the Gene T4 polymerase mix, respectively. Vector and Gene T4 polymerase 
mixes were incubated at 22°C for 30 min, followed by incubation at 75°C for 20 min. The vector 
was cleaned up using Sigma Aldrich’s GenElute PCR Clean-up kit, and eluted using 50 µL of H2O 
(18.2 Ω. cm). The concentration after elution was 34 ng µL-1. 
 
2.5 µL of the gene PCR product and 1.5 µL of purified vector were mixed and incubated at room 
temperature for 20 min. 1.5 µL of 25 mM EDTA was added and the reaction was incubated at 
room temperature for another 15 min. 5.5 µL of the reaction was used to transform 25 µL of 
chemically competent E. coli Novablue Singles cells using heat shock. 
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Transformed colonies were used to inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin. 
These starter cultures were incubated at 37°C and shaking at 180 r.p.m overnight. The following 
day, the starter cultures were spun down at 16,000 g in an Eppendorf 5415 C centrifuge. Mutant 
plasmids were isolated using Sigma Aldrich’s GenElute plasmid Miniprep kit, each plasmid was 
eluted using 100 µL of H2O (18.2 Ω
.
 cm) and stored at -20°C. Successful cloning of the genes into 
the pET-YSBLIC-3C vector was confirmed using restriction analysis and nucleotide sequencing. 
 
Plasmid Linearisation mix: 1 x NEBuffer 4, 50 ng µL
-1
 pET-YSBLIC-3C, 0.2 U µL
-1
 BseRI 
Vector T4 polymerase mix: 1 x T4 polymerase buffer, 22 ng µL
-1
 linear pET-YSBLIC-3C,  
2.5 mM dTTP, 5 mM DTT, 0.05 U µL
-1
 T4-DNA polymerase 
Gene T4 polymerase mix: 1 x T4 polymerase buffer, 0.01 pmol µL
-1
 gene PCR product,  
2.5 mM dATP, 5 mM DTT, 0.05 U µL
-1
 T4-DNA polymerase 
LB-media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
 
2.2.3 Restriction analysis of the plasmids 
 
To confirm the cloning of the genes in the pET-YSBLIC-3C vector, the plasmids encoding 
AsAAO, BaAO and NfOR were treated with the restriction endonucleases NdeI and NcoI and the 
plasmids encoding BsGO were treated with the restriction endonucleases SacI and NcoI. The 
restriction endonucleases and the NEBuffer 4 were purchased from New England Biolabs. 
 
500 ng of each purified plasmid encoding AsAAO, BaAO or NfOR was treated using the 
NdeI/NcoI Restriction mix. 500 ng of each purified plasmid encoding BsGO was treated using the 
SacI/NcoI Restriction mix. Restriction mixes were mixed on ice, then incubated at 37°C for 3 h. 
Reactions were analysed using 1% agarose gel electrophoresis. 
 
NdeI/NcoI Restriction mix (v= 10 µL): 1 x NEBuffer 4, 50 ng µL
-1
 plasmid DNA, 1 U µL
-1
 NdeI, 
1 U µL
-1
 NcoI 
SacI/NcoI Restriction mix (v= 10 µL): 1 x NEBuffer 4, 50 ng µL
-1
 plasmid DNA, 1 U µL
-1
 SacI, 
1 U µL
-1
 NcoI 
 
2.2.4 Analysis of recombinant genes by nucleotide sequencing 
 
The correct nucleotide sequence of the plasmids encoding AsAAO, BaAO, BsGO, NfOR and 
PpLAAO was confirmed by nucleotide sequencing. The T7 and T7-term primers (Table 2.3) were 
used as sequencing primers. The sequencing reactions were carried out by the York University 
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Genomics group using an automated form of the Sanger sequencing method, where a PCR reaction 
is run in the presence of both dNTP and a smaller proportion of dideoxyNTPs (ddNTPs). The 
ddNTPs lack the 3’ OH group necessary for the formation of phosphodiester bonds between 
nucleotides, causing the chains to terminate at any point if they incorporate a ddNTP. The different 
size chains are then separated by capillary tube electrophoresis, and as each type of ddNTP is 
labelled with a different fluorescent dye, the base of the ddNTP that caused the chain to terminated 
at each specific point in the sequence can be determined by recording the dye fluorescence of each 
DNA chain, which results in a chromatogram showing the peaks of each wavelength of 
fluorescence at specific points in the sequence (http://www.nature.com/scitable/topicpage/dna-
sequencing-technologies-690). 
 
The sequence chromatograms were analysed with the program Chromas lite, version 2.01 from 
Technelysium (free software). All five of the recombinant genes were found to be free of undesired 
mutations. 
 
2.2.5 Overexpression analysis of target enzymes 
 
The plasmids pET-YSBLIC-3C-AsAAO, pET-YSBLIC-3C-BaAO, pET-YSBLIC-3C-BsGO, pET-
YSBLIC-3C-NfOR, pET-YSBLIC-3C-PpLAAO, pET-YSBLIC-3C-RoLAAO and pET-YSBLIC-
3C-SLAAO, were used to overexpress the seven target genes in E. coli BL21-DE3, E. coli B834-
DE3 and E. coli Rosetta 2-DE3 chemically competent cells. Negative controls using non 
recombinant pET-YSBLIC-3C plasmid were also carried out. AEBSF and IPTG were purchased 
from Melford. OD600 was measured using an Eppendorf Biophotometer. 
 
Transformed E. coli BL21-DE3 and E. coli B834-DE3 cells were grown using 30 µg mL
-1
 
kanamycin as the appropriate antibiotic. Transformed E. coli Rosetta 2-DE3 cells were grown 
using 30 µg mL
-1
 kanamycin and 34 µg mL
-1
 chloramphenicol as the appropriate antibiotics. 
 
1 µL of recombinant plasmid was used to transform 25 µL of chemically competent cells using 
heat shock. Then 5 mL of sterile LB-media containing the appropriate antibiotics were inoculated 
with a single transformed colony. This starter culture was grown overnight at 37°C with shaking at 
180 r.p.m. The next day three 5 mL aliquots of sterile LB-media containing the appropriate 
antibiotics were each inoculated with 100 µL of starter culture. The cells were incubated at 37°C 
with shaking at 180 r.p.m. Overexpression was induced with 1 mM IPTG when OD600 reach 0.5. 
One cell culture was incubated at 37°C for 3 h with shaking at 180 r.p.m, another cell cultures was 
incubated at 30°C for 5 h with shaking at 180 r.p.m and the final cell culture was incubated at 16°C 
overnight with shaking at 180 r.p.m. 
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The cells were harvested by centrifugation for 2 min at 16,000 g using an Eppendorf 5415 C 
centrifuge. The supernatant was discarded and the cell pellet was resuspended in 500 µL H2O (18.2 
Ω. cm). The cell suspension was sonicated on ice for 30 s at 15 microns. Cell debris was pulled 
down by spinning at 16,000 g for 2 min using an Eppendorf 5415 C centrifuge. The soluble 
supernatant was separated from the insoluble cell pellet. The cell pellet was then resuspended in 
500 µL buffer 1. The soluble and insoluble fractions were analysed by SDS-PAGE. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
 
2.2.6 Overexpression of target enzymes for assay analysis 
 
The plasmids pET-YSBLIC-3C-AsAAO, pET-YSBLIC-3C-BaAO, pET-YSBLIC-3C-BsGO and 
pET-YSBLIC-3C-PpLAAO were used to overexpress their respective target genes in E. coli BL21-
DE3 chemically competent cells. The pET-YSBLIC-3C-NfOR plasmid was used to overexpress 
the NfOR protein in E. coli B834-DE3 chemically competent cells and the pET-YSBLIC-3C-
SLAAO plasmid was used to overexpress the SLAAO protein in E. coli Rosetta 2-DE3 chemically 
competent cells. Non recombinant pET-YSBLIC-3C plasmid was also used to transform E. coli 
BL21-DE3 chemically competent cells, for use as negative controls. IPTG was purchased from 
Melford. OD600 and protein concentration were measured using an Eppendorf Biophotometer. 
 
Transformed E. coli BL21-DE3 and E. coli B834-DE3 cells were grown using 30 µg mL
-1
 
kanamycin as the appropriate antibiotic. Transformed E. coli Rosetta 2-DE3 cells were grown 
using 30 µg mL
-1
 kanamycin and 34 µg mL
-1
 chloramphenicol as the appropriate antibiotics. 
 
1 µL of recombinant plasmid was used to transform 25 µL of chemically competent cells using 
heat shock. Then 5 mL of sterile LB-media containing the appropriate antibiotics was inoculated 
with a single transformed colony. This starter culture was grown overnight at 37°C with shaking at 
180 r.p.m. For each starter culture a 10 mL aliquot of sterile LB-media containing the appropriate 
antibiotics was inoculated with 200 µL of starter culture. The cells were incubated at 37°C with 
shaking at 180 r.p.m. Overexpression was induced with 1 mM IPTG when OD600 reach 0.5. Cell 
cultures transformed with non recombinant pET-YSBLIC-3C, pET-YSBLIC-3C-BsGO, pET-
YSBLIC-3C-NfOR and pET-YSBLIC-3C-SLAAO plasmids were left to grown at 37°C with 
shaking at 180 r.p.m for 3 h. Cell cultures transformed with pET-YSBLIC-3C-AsAAO, pET-
YSBLIC-3C-BaAO and pET-YSBLIC-3C-PpLAAO plasmids were left to grown at 16°C with 
shaking at 180 r.p.m overnight. 
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The cells cultures were split into two 5 mL cultures and then harvested by centrifugation for 2 min 
at 16,000 g using an Eppendorf 5415 C centrifuge. The supernatant was discarded and the cell 
pellets were resuspended in 500 µL H2O (18.2 Ω
.
 cm). One cell suspension for each 10 mL culture 
was diluted to OD600 1.5 with H2O (18.2 Ω
.
 cm) and stored at -20°C. 
 
The remaining cell suspension was sonicated on ice for 30 s at 15 microns. Cell debris was pulled 
down by spinning at 16,000 g for 2 min using an Eppendorf 5415 C centrifuge. The soluble 
supernatant was separated from the insoluble cell pellet. The cell pellet was then resuspended in 
500 µL H2O (18.2 Ω
.
 cm). Protein concentration was estimated using an Eppendorf Biophotometer 
and each soluble supernatant was diluted to a protein concentration of 2 mg mL
-1
 and stored at -
20°C. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
 
2.2.7 Assay of target enzyme substrates 
 
In order to determine the natural substrates of the seven target enzymes, a liquid phase horseradish 
peroxidase (HRP)-based assay was used to analyse the activity of the target enzymes against the 
twenty natural amino acids and the amines amylamine, phenylethylamine and AMBA.  
 
TBHBA was purchased from Alfa Aesar. 4-AAP, HRP, L-alanine, L-arginine, L-asparagine, L-
aspartate, L-glutamate, L-glutamine, glycine, L-Isoleucine, L-leucine, L-lysine, L-methionine, L-
proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, amylamine, phenylethylamine and AMBA 
were purchased from Sigma-Aldrich. L-cysteine, L-histidine, L-phenylalanine and L-valine were 
purchased from Sigma/Fluka. KH2PO4 and K2HPO4 were purchased from Fisher, 96-well flat 
bottomed plates were purchased from Corning Costar. A510 was measured on a BMG Labtech 
PolarStar Optima plate reader. 
 
Reactions were repeated twice with each substrate, and two reactions using an assay solution with 
H2O (18.2 Ω
.
 cm) as substrate were used as control reactions. 10 µL of either 2 mg mL
-1
 soluble 
protein fraction or induced cells with OD600 of 1.5 were added to 190 µL of assay solution in an 
Eppendorf tube. Reactions were left to develop for 1 h before being spun down at 16,000 g for 1 
min in an Eppendorf 5415 C centrifuge to remove any protein precipitant or cellular debris. The 
assay solution was then transferred to a 96 well flat-bottomed plate and A510 was measured. The 
mean absorbance of the control reactions was subtracted from all other absorbance readings before 
mean absorbance for each reaction was calculated. Assays were run with the substrate layout 
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shown in Fig. 2.1, positive control wells contained soluble protein fraction from cells transformed 
with pET-YSBLIC-3C-SLAAO plasmid and L-arginine as the substrate. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
- 
- - - - - 
- 
B Glycine L-threonine L-methionine L-tryptophan Positive 
control 
C L-asparagine L-aspartate L-serine L-tyrosine - 
D L-histidine L-valine L-leucine Amylamine - 
E L-arginine L-phenylalanine L-glutamine Phenylethylamine - 
F L-proline L-isoleucine L-cysteine AMBA - 
G L-lysine L-alanine L-glutamate H2O (18.2 Ω
.
 cm) - 
H - - - - - 
Fig. 2.1 Layout of substrates screened using the soluble HRP-based assay in a 96-well plate format. Wells 
marked with a dash were empty. 
 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.5 
Assay solution:    1 x Reaction Buffer, 25 µg mL-1 HRP, 10 mM substrate 
 
2.2.8 Effects of AIM and L-glutamate and L-arginine on solubility of AsAAO and BaAO 
 
The ingredients for LB-media were purchased from Fisher Scientific, Kanamycin sulphate was 
purchased from Invitrogen, IPTG was purchased from Melford. Metal solution for Auto Induction 
Media
[111]
 was prepared by previous YSBL staff. 
 
2 µL of pET-YSBLIC-3C-AsAAO and pET-YSBLIC-3C-BaAO were each used to transform 50 
µL of E. coli BL21-DE3 competent cells using heatshock. One colony of E. coli BL21-DE3-
AsAAO and E. coli BL21-DE3-BaAO were each used to inoculate 5 mL of LB-media containing 
30 µg ml
-1
 of kanamycin. These starter cultures were grown overnight at 37°C with shaking at 180 
r.p.m. For each starter culture, two 10 mL cultures of LB-media containing 30 µg mL
-1
 kanamycin 
were each inoculated with 200 µL of starter culture. Cells were grown at 37°C with shaking at 180 
r.p.m. Overexpression was induced with 1 mM IPTG when OD600 reached 0.5. Cells were left to 
express protein at 16°C with shaking at 180 r.p.m overnight.  
 
For each starter culture, two 10 mL cultures of Auto Induction Media containing 30 µg mL
-1
 
kanamycin were each inoculated with 200 µL of starter culture. These cultures were grown at 30°C 
with shaking at 180 r.p.m for 24 h. 
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Cells were harvested by centrifugation at 16,000 g for 1 min in an Eppendorf 5415 C centrifuge. 
One pellet from each media type was resuspended in 1 mL of buffer 1, and the other pellet was 
resuspended in 1 mL of buffer 2. Cells were lysed by sonication for 30 s and cell debris was spun 
down at 13,700 g for 5 min in an Eppendorf 5415 C centrifuge. Soluble protein supernatant was 
transferred to a fresh tube and insoluble cell pellets were resuspended in the same buffer as 
previously. Insoluble and soluble protein fractions were analysed by 12% SDS-PAGE. 
 
LB-media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Auto induction media: 100 mM MgSO4, 1 x metal mix, 1 x 5052 solution, 1 x NPS 
solution, 92.5 % (v/v) ZY media. 
1000 x Metal mix: 50 mM FeCl3-6H2O (prepared in 0.1 M HCl), 20 mM CaCl2, 10 
mM MnCl2, 10 mM ZnSO4-7H2O, 2 mM CoCl2-6H2O, 4 mM 
CuCl2-2H2O, 2 mM NiCl2-6H2O, 2 mM Na2MoO4-5H2O, 2 mM 
Na2SeO3-5H2O, 2 mM H3BO3 
50 x 5052 solution (V = 1 L): 250 g glycerol, 25 g glucose, 100 g a-lactose, H2O (18.2 Ω
.
 cm) 
20 x NPS solution (V = 1 L): 6.6 g (NH4)2SO4, 13.6 g KH2PO4, 142 g Na2HPO4, H2O (18.2 Ω
.
 
cm), pH 6.75 
ZY media (V = 1 L):  10 g
 
tryptone, 5 g yeast extract, H2O (18.2 Ω
.
 cm) 
Buffer 1:   50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Buffer 2: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 50 mM L-
glutamate, 50 mM L-arginine, pH 7.0 
 
2.2.9 Effects of oxygen availability on solubility of AsAAO and BaAO 
 
The ingredients for LB-media were purchased from Fisher Scientific, Kanamycin sulphate was 
purchased from Invitrogen, AEBSF and IPTG were purchased from Melford. 
 
2 µL of pET-YSBLIC-3C-AsAAO and pET-YSBLIC-3C-BaAO were each used to transform 50 
µL of E. coli BL21-DE3 competent cells using heatshock. Six colonies of E. coli BL21-DE3-
AsAAO and E. coli BL21-DE3-BaAO were each used to inoculate 5 mL of LB-media containing 
30 µg ml
-1
 of kanamycin. These starter cultures were grown overnight at 37°C with shaking at 180 
r.p.m. 
 
For each cell strain, three LB-media cultures of different volumes (0.5 L, 1.0 L, 1.5 L) containing 
30 µg mL
-1
 kanamycin were prepared in 2 L Erlenmeyer flasks. These cultures were inoculated 
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with 1 starter culture per 0.5 L of culture and incubated at 37°C. Gene overexpression was induced 
using 1 mM IPTG once OD600 reached 0.5 and cells were left to grow at 16°C overnight. 
 
10 mL of each culture’s cells was harvested by centrifugation for 1 min at 16,000 g in an 
Eppendorf 5415 C centrifuge. Cell pellets were resuspended in 1 mL of buffer 1 and sonicated for 
30 s at 15 microns. Insoluble material was separated by centrifugation for 5 min at 13,700 g in an 
Eppendorf 5415 C centrifuge. Soluble supernatant was transferred to a fresh tube and the insoluble 
pellet was resuspended in 1 mL buffer 1. Insoluble and soluble protein fractions were analysed by 
12% SDS-PAGE. 
 
LB-media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Buffer 1:   50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
 
2.2.10 Solubility screen of BaAO 
 
The ingredients for LB-media were purchased from Fisher Scientific, Kanamycin sulphate was 
purchased from Invitrogen, AEBSF and IPTG were purchased from Melford. Lindwall solubility 
screen conditions
[112] 
were prepared by previous YSBL staff. 
 
2 µL of pET-YSBLIC-3C-BaAO was used to transform 50 µL of E. coli BL21-DE3 competent 
cells using heat-shock. One colony of E. coli BL21-DE3-BaAO was used to inoculate 5 mL of LB-
media containing 30 µg ml
-1
 of kanamycin. This starter culture was grown overnight at 37°C with 
shaking at 180 r.p.m. 1.2 mL of starter culture was used to inoculate 62 mL of LB-media 
containing 30 µg mL
-1
 kanamycin. Cells were grown at 37°C with shaking at 180 r.p.m. 
Overexpression was induced with 1 mM IPTG when OD600 reached 0.5. Cells were left to express 
protein at 16°C with shaking at 180 r.p.m overnight.  
 
The culture was split into thirty two 2 mL aliquots, which were harvested by centrifugation at 
16,000 g for 1 min in an Eppendorf 5415 C centrifuge. 200 µL of each of the thirty solubilisation 
screen conditions suggested by Lindwall et al.
[112]
 was used to resuspend a single cell pellet, and 
200 µL of H2O (18.2 Ω
.
 cm) was used to resuspend the final cell pellet as a control. Cells were 
sonicated for 20 s at 15 microns and then spun down at 13,700 g for 5 min in an Eppendorf 5415 C 
centrifuge to remove cell debris. Soluble supernatant was transferred to a fresh tube and the 
insoluble cell pellet from the pellet resuspended in H2O was resuspended in 200 µL H2O (18.2 Ω
.
 
cm). This insoluble and the soluble samples were analysed by 12% SDS-PAGE. 
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To determine the effectiveness of the solubilisation screen conditions 4 and 15 at higher volumes of 
culture, 4 colonies of E. coli BL21-DE3-BaAO were each used to inoculate 5 mL of LB-media 
containing 30 µg ml
-1
 of kanamycin. These starter cultures were grown overnight at 37°C with 
shaking at 180 r.p.m. Each 5 mL starter culture was used to inoculate 500 mL of LB-media 
containing 30 µg mL
-1
 kanamycin. Cells were grown at 37°C with shaking at 180 r.p.m. 
Overexpression was induced with 1 mM IPTG when OD600 reached 0.5. Cells were left to express 
protein at 16°C with shaking at 180 r.p.m overnight.  
 
Cells were spun down for 15 min at 5,100 g using the GS3 rotor of a RC-5B Sorvall Centrifuge. 50 
mL of solubilisation screen condition 4, 50 mL of solubilisation screen condition 15, 50 mL of 
buffer 1 and 50 mL of H2O (18.2 Ω
.
 cm) were each used to resuspend one cell pellet. Cells were 
lysed by sonication and cell debris was spun down at 26,900 g for 15 min in the SS34 rotor of a 
RC-5B Sorvall Centrifuge. Soluble supernatant was transferred to a fresh tube and insoluble cell 
pellet was resuspended in the same buffer as previously. Insoluble and soluble samples were 
analysed by 12% SDS-PAGE. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Buffer 1: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
 
Solubility Screen conditions:
[112]
 
1:   100 mM Tris, 10 % glycerol, pH 7.6 
2:   100 mM Tris, 50 mM LiCl, pH 7.6 
3:   100 mM HEPES, 50 mM (NH4)2SO4, 10% glycerol, pH 7.0 
4:   100 mM HEPES, 100 mM KCl, pH 7.0   
5:   100 mM Tris, 50 mM NaCl, 10% isopropanol, pH 8.2 
6:   100 mM K2HPO4/KH2PO4, 50 mM (NH4)2SO4, 1% Triton X-100, pH 6.0 
7:   100 mM triethanolamine, 100 mM KCl, 10 mM DTT, pH 8.5 
8:   100 mM Tris, 100 mM sodium glutamate, 10 mM DTT, pH 8.2 
9:   250 mM K2HPO4/KH2PO4, 0.1% CHAPS, pH 6.0 
10:   100 mM triethanolamine, 50 mM LiCl, 5 mM EDTA, pH 8.5 
11:   100 mM sodium acetate, 100 mM glutamine, 10 mM DTT, pH 5.5 
12: 100 mM sodium acetate, 100 mM KCl, 0.1% n-octyl-β-D-glucoside, pH 
5.5 
13:   100 mM HEPES, 1 M MgSO4, pH 7.0 
14:   100 mM HEPES, 50 mM LiCl, 0.1% CHAPS, pH 7.0 
15:   100 mM K2HPO4/KH2PO4, 2.5 mM ZnCl, pH 4.3 
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16:   100 mM Tris, 50 mM NaCl, 5 mM calcium acetate, pH 7.6 
17:   100 mM triethanolamine, 50 mM (NH4)2SO4, 10 mM MgSO4, pH 8.5 
18:   100 mM Tris, 100 mM KCl, 2 mM EDTA, 1% Triton X-100, pH 8.2 
19:   100 mM sodium acetate, 1 M MgSO4, pH 5.5 
20:   100 mM Tris, 2 M NaCl, 0.1% n-octyl-β-D-glucoside, pH 7.6 
21:   100 mM Tris, 1 M (NH4)2SO4, 10 mM DTT, pH 8.2 
22:   100 mM sodium acetate, 50 mM LiCl, 5 mM calcium acetate, pH 5.5 
23:   100 mM HEPES, 100 mM sodium glutamate, 5 mM DTT, pH 7.0 
24: 100 mM triethanolamine, 100 mM sodium glutamate, 0.02% n-octyl-β-D-
glucoside, 10% glycerol, pH 8.5 
25:   100 mM Tris, 50 mM NaCl, 100 mM urea, pH 8.2 
26:   100 mM triethanolamine, 100 mM KCl, 0.05% dextran sulfate, pH 6.0 
27: 100 mM K2HPO4/KH2PO4, 50 mM (NH4)2SO4, 0.05% dextran sulfate, pH 
6.0 
28:   100 mM HEPES, 50 mM LiCl, 0.1% deoxycholate, pH 7.0 
29:   100 mM Tris, 100 mM KCl, 0.1% deoxycholate, 25% glycerol, pH 7.6 
30: 100 mM potassium acetate, 50 mM NaCl, 0.05% dextran sulfate, 0.1% 
CHAPS, pH 5.5 
 
2.3 Protein Purification and Characterisation 
 
2.3.1 Overexpression of PpLAAO for protein purification 
 
The ingredients for LB-media were purchased from Fisher Scientific, Kanamycin sulphate was 
purchased from Invitrogen, IPTG was purchased from Melford. Transformed cell cultures were 
grown in media containing 30 µg mL
-1
 kanamycin as the appropriate antibiotic. 
 
1 µL of wild type pET-YSBLIC-3C-PpLAAO plasmid was used to transform 25 µL of E. coli 
BL21-DE3 chemically competent cells using heatshock. Four colonies of E. coli BL21-DE3-
PpLAAO were each used to inoculate a 10 mL LB-media starter culture containing appropriate 
antibiotic under sterile conditions. These starter cultures were incubated overnight at 37°C with 
shaking at 180 r.p.m. Two 2 L Erlenmeyer flasks containing 1 L of LB media and appropriate 
antibiotic were each inoculated with 20 mL of starter culture under sterile conditions. The cell 
cultures were incubated at 37°C and shaking at 180 r.p.m until OD600 reached 0.5. Overexpression 
was induced by adding 1 mL of 1 M IPTG to each flask to give a final concentration of 1 mM 
IPTG. The cell culture was incubated at 37°C for 3 h with shaking at 180 r.p.m. The cells were 
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harvested by centrifugation for 15 min at 5,100 g using the GS3 rotor of a RC-5B Sorvall 
Centrifuge. The supernatant was discarded and the cell pellet was stored at -20°C. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
 
2.3.2 Purification of PpLAAO protein 
 
PpLAAO was purified by metal affinity chromatography, followed by gel filtration 
chromatography. Prepacked HiTrap Chelating HP column was purchased from GE Healthcare. 120 
mL HiLoad 16/60 Superdex 75 column was purchased from Pharmacia Biotech. Buffers 1-3, H2O 
(18.2 Ω. cm) and 20% (v/v) ethanol were filtered through a 0.22 µM Whatman filter before use. 
The Prepacked HiTrap Chelating HP Column was loaded using peristaltic pump and gradient was 
run using AKTA Purifier P-900. The 120 mL HiLoad 16/60 Superdex 75 column was operated 
using an AKTA Purifier P-900. 1.6 mL semi-micro cuvettes were purchased from Sarstedt. AEBSF 
was purchased from Melford. 
 
The cell pellets from 2 L of E. coli BL21-DE3-PpLAAO culture were thawed at room temperature 
and resuspended in 100 mL of buffer 1. The cell suspension was cooled on ice for 20 min. The 
cells were then sonicated on ice for 5 x 30 sec at 15 microns. Cell debris was spun down for 15 min 
at 26,900 g at 4°C using a Sorvall RC5B centrifuge and SS34 rotor. The supernatant was decanted 
and filtered through a 0.45 µm ACRODISC filter, followed by 0.2 µm ACRODISC filter. Filtered 
supernatant was then loaded onto a 5 mL HiTrap Chelating HP Column pre-charged with 0.1 M 
NiSO4 using a peristaltic pump, the flow rate was 1 mL min
-1
. After loading, resin was washed with 
25 mL of buffer 1 at 1 mL min
-1
. The column was then transferred to an AKTA Explorer and a 
gradient from buffer 2 to buffer 3 was run starting at 100% buffer 2 to 100% buffer 3 over 100 mL, 
with a flow rate of 1 mL min
-1
. 4 mL fractions were collected. SDS-PAGE showed which sample 
fractions contained the desired protein by approximate monomer molecular weight (~60 kDa). 
 
Sample fractions containing desired protein were combined and protein concentration was 
determined using Coomassie (Bradford) assay. BSA standards were prepared by dissolving BSA 
powder in buffer 1. BSA solutions were used at 0 µg mL
-1
, 25 µg mL
-1
, 125 µg mL
-1
, 250 µg mL
-1
, 
500 µg mL
-1
, 750 µg mL
-1
, 1000 µg mL
-1
, 1500 µg mL
-1
 and 2000 µg mL
-1
 BSA. A protein solution 
dilution was prepared by adding 10 µL of protein solution to 90 µL of buffer 1. Protein solutions 
were used at full concentration and at a 1 in 10 dilution. 
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10 µL of each BSA solution and 10 µL of each protein solution were added to 500 µL of 
Coomassie (Bradford) assay reagent in a 1.6 mL semi-micro cuvette and incubated for 10 min at 
room temperature. The A595 was measured using the Bradford setting of an Eppendorf 
Biophotometer. The absorbance of BSA was plotted against [BSA] as shown in Fig. 2.2, and the 
line of regression was used to determine the concentration of PpLAAO. 
 
Fig. 2.2 Example of a Bradford calibration used to determine the concentration of PpLAAO protein. 
 
The combined protein sample was diluted to a final concentration of 1 mg mL
-1
 using buffer 1. C3 
His tag protease was added to a ratio of 1:100 mg protein. Protein was incubated at 4°C overnight 
and digestion was checked by SDS-PAGE. The digested protein was then loaded onto a 5 mL 
HiTrap Chelating HP column per-charged with 0.1 M NiSO4 using peristaltic pump, flow rate was 
1 ml min
-1
 and flow-through was collected. Resin was washed with 30 mL buffer 1, followed by 30 
mL buffer 2 and then 30 mL buffer 4, flow rate was 1 mL min
-1
 and flow-through was collected. 
Resin was then washed with 30 mL buffer 3, flow rate was 1 mL min
-1
 and flow-through was 
collected. The collected flow-through was analysed on SDS-PAGE to determine protein content. 
Samples containing cleaved protein were then concentrated down to a volume of 4 mL using 
MWCO 30000 Vivaspin 20 tubes, spinning at 4066 g using the GSA rotor .  
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Gel filtration chromatography was then used to purify the protein further: A 2 mL aliquot was 
loaded onto a prepacked and pre-equilibrated 120 mL HiLoad 16/60 Superdex 75 column using a 2 
mL loop on an AKTA Explorer. Resin was washed with 120 mL of buffer 1, flow rate was 1 mL 
min
-1
, and 4 mL fractions were collected. SDS-PAGE showed which sample fractions contained the 
desired protein by approximate monomer molecular weight (~60 kDa). These fractions were then 
pooled and concentrated to 2 mg mL
-1
 using MWCO 30000 Vivaspin 20 tubes. Concentrated 
protein was snap frozen in liquid nitrogen and stored at -80°C. 
 
The approximate purified protein molecular weight was determined using a calibration of the 120 
mL HiLoad 16/60 Superdex 75 column performed by the EMBL 
(http://www.embl.de/pepcore/pepcore_services/protein_purification/chromatography/hiload16-
60_superdex75/ Accessed 17/01/2012),
  
which determined the equation of the calibration curve to 
be: 
 
 
Meaning that molecular weight could be determined using the equation: 
 
 
 
As the elution volume of the purified protein was 52 mL, this makes the molecular weight 116320, 
or 116.32 kDa, which is roughly twice the size of the protein, suggesting that the purified protein is 
in a dimeric form. 
 
Buffer 1: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Buffer 2: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 30 mM Imidazole pH 7.0 
Buffer 3: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 500 mM Imidazole pH 7.0 
Buffer 4: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 70 mM Imidazole pH 7.0 
 
2.3.3 Liquid phase assay of activity of wild type PpLAAO against wild type and target 
substrates 
 
TBHBA was purchased from Alfa Aesar, 4-AAP, HRP, L-aspartate, L-asparagine, L-tyrosine, L-
alanine and L-homoserine were purchased from Sigma-Aldrich, KH2PO4 and K2HPO4 were 
purchased from Fisher, 1 mL cuvettes purchased from Sarstedt. A510 was measured on a GBC 
Cintra 10 spectrophotometer. 
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The Cintra 10 spectrophotometer was programmed to measure A510 every 1 s for 6 min. 950 µL of 
assay solution was pipetted into a 1 mL cuvette. 50 µL of H2O (18.2 Ω
.
 cm) was added and cuvette 
was placed in the background solution position of the Cintra 10. 950 µL of assay solution was 
pipetted into a second 1 mL cuvette. The cuvette was placed in the front position of the Cintra 10. 
The Cintra 10 was set running for 10 s to ensure that the solution absorbance was stable. The front 
cuvette was removed from the Cintra 10 and 50 µL of 2 mg mL
-1 
PpLAAO protein was quickly 
added to the assay solution. The cuvette was mixed by inverting three times before being placed 
back into the Cintra 10. A510 continued to be measured for the remainder of the program.  
 
After the program had finished, the absorbance values at 174 and 226 s were recorded for reactions 
containing L-aspartate. For reactions containing L-asparagine absorbance values at 250 and 300 s 
were recorded.  The absorbance values at 275 s and 325 s were recorded for reactions containing L-
alanine, L-homoserine and L-tyrosine.  
 
Activity was measured in this way with 0.22 mM, 0.43 mM, 0.87 mM, 1.74 mM, 3.48 mM, 6.99 
mM and 13.92 mM L-aspartate; 3.00 mM, 6.00 mM, 12.00 mM, 24.01 mM, 48.02 mM and 96.04 
mM L-asparagine; 50 mM, 100 mM, 150 mM, 200 mM, 250 mM, 300 mM 350 mM, 400 mM, 500 
mM L-glutamate; 1.42 mM, 2.84 mM, 5.68 mM, 11.3 mM, 22.7 mM, 45.5 mM and 91 mM L-
alanine; 0.77 mM, 1.42 mM, 2.84 mM, 5.68 mM, 11.3 mM, 22.7 mM, 45.5 mM and 91 mM L-
homoserine; 1.42 mM, 2.84 mM, 5.68 mM, 11.3 mM and 22.7 mM L-tyrosine in the assay solution. 
Activity was measured three times for each concentration of each substrate. 
 
The rate of change in absorbance, in absorbance unit min
-1
, for each concentration of each substrate 
was determined using the equation:  
 
As the red quinonimine complex product of the HRP reaction has an extinction coefficient of 
29,400 M
-1
 cm
-1
, and the 1 mL cuvettes used have a path length of 1 cm, the Beer Lambert law was 
used to determine the change in concentration of the quinonimine complex, which should be equal 
to the change in concentration of the substrate, using the following calculation: 
 
The SigmaPlot version 12 software with Enzyme Kinetics Module was used to plot Michaelis-
Menten graphs and determine Vmax and KM against L-aspartate and L-asparagine. As the size of the 
PpLAAO protein is 59215 Da, the concentration of protein in mM per mg of protein could be 
determined: 
 78 
 
Therefore, kcat could be determined as follows:  
 
 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.5 
Assay solution: 1 x Reaction Buffer, 25 µg mL
-1
 HRP, and varied 
concentration of substrate 
 
2.3.4 Liquid phase stability assay of wild type PpLAAO against L-aspartate over pH 
 
TBHBA was purchased from Alfa Aesar, 4-AAP, HRP and L-aspartate were purchased from 
Sigma-Aldrich, KH2PO4 and K2HPO4 were purchased from Fisher, 96-well flat bottomed plates 
were purchased from Corning Costar. A510 was measured on a BMG Labtech PolarStar Optima 
plate reader. 
 
Reactions were repeated four times at each pH, and four reactions using an assay solution with pH 
7.4 and H2O (18.2 Ω
.
 cm) as substrate were used as control reactions. 10 µL of 1 mg mL
-1
 PpLAAO 
protein was added to 190 µL of assay solution in an Eppendorf tube. Reactions were left to develop 
for 1 h before being spun down at 16,000 g for 1 min in an Eppendorf 5415 C centrifuge to remove 
any protein precipitant. The assay solution was then transferred to a 96 well flat-bottomed plate and 
A510 was measured. The mean absorbance of the control reactions was subtracted from all other 
absorbance readings before mean absorbance for each reaction was calculated. Assays were run at 
pH 4.7, 5.8, 6.2, 6.6, 7.0, 7.4, 7.8 and 8.2. 
 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, varying pH 
Assay solution:   1 x Reaction Buffer, 25 µg mL
-1
 HRP, 10 mM L-aspartate 
 
2.3.5 Liquid phase stability assay of wild type PpLAAO against L-aspartate over temperature 
 
TBHBA was purchased from Alfa Aesar, 4-AAP, HRP and L-aspartate were purchased from 
Sigma-Aldrich, KH2PO4 and K2HPO4 were purchased from Fisher, 96-well flat bottomed plates 
were purchased from Corning costar. Proteins were incubated at various temperatures in 200 µL 
thin walled PCR tubes purchased from Axygen, using a Techne TC-312 Thermocycler and an 
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Eppendorf Mastercycler gradient PCR machine. A510 was measured on a BMG Labtech PolarStar 
Optima plate reader. 
 
40 µL of protein was kept at 4°C, 10°C, 20°C, 30°C, 40°C, 50°C or 60°C for 5 min, 10 min, 20 
min, 30 min, 45 min or 60 min. Protein was then cooled on ice or 3 h. Three reactions for each 
temperature and time combinations were setup. Three assays using protein kept at 4°C and 
deionised H2O (18.2 Ω
.
 cm) as substrate were setup was control reactions.  
 
10 µL of 1 mg mL
-1
 PpLAAO protein was added to 190 µL of assay solution in an Eppendorf tube. 
Reactions were left to develop for 1 h before being spun down at 16,000 g for 1 min in an 
Eppendorf 5415 C centrifuge to remove any protein precipitant. The assay solution was then 
transferred to a 96 well flat-bottomed plate and A510 was measured. The mean absorbance of the 
control reactions was subtracted from all other absorbance readings before mean absorbance for 
each reaction was calculated. 
 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.4 
Assay solution:   1 x Reaction Buffer, 25 µg mL
-1
 HRP, 10 mM L-aspartate 
 
2.3.6 Overexpression and purification of PpLAAO for crystallisation 
 
PpLAAO protein was overexpressed and purified as in Sections 2.3.1 and 2.3.2. However, after the 
protein was run through the 120 mL HiLoad 16/60 Superdex 75 column, fractions containing the 
protein were pooled together and concentrated to 100 mg mL
-1
 using MWCO 30000 Vivaspin 20 
tubes. Concentrated protein was stored at 4°C. 
 
2.3.7 Crystallisation screening of PpLAAO 
 
Purified and His-tag cleaved PpLAAO protein was subjected to several 96-well crystallisation 
screens, using the sitting drop diffusion method. Screens were transferred from 96-deep-well block 
format to 96-well MRC plates using a Robbins Scientific Hydra
TM
 96. Protein drops were set up 
using a TTP Labtech Mosquito®. Index crystallisation screen was purchased from Hampton. 
PACT crystallisations screen was purchased from Qiagen. AEBSF was purchased from Melford. 
 
For CSS 1+ 2 screens 6 µL of 1 M MES pH 5.6 was added to all wells in columns 1-6 of the MRC 
plate, and 6 µL of Tris pH 8.0 was added to all wells in columns 7-12. For all screens 54 µL of 
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crystallisations screen was transferred from the deep-well blocks to the MRC plate using the 
Hydra
TM
 96. The Mosquito® was then used to create crystallisation drops containing 150 µL of 
well solution and 150 µL of protein solution. 
The combinations of crystal screen and protein solution tried are listed in Table 2.5. 
 
Table 2.5: Combinations of crystallization screens and protein solutions trialled during attempts to 
create crystals of PpLAAO protein. 
Crystallisation Screen Protein Solution 
Index 10 mg mL
-1
 PpLAAO in buffer 1 
Index 30 mg mL
-1
 PpLAAO in buffer 1 
Index 30 mg mL
-1
 PpLAAO in buffer 2 
Index 45 mg mL
-1
 PpLAAO in buffer 1 
Index 60 mg mL
-1
 PpLAAO in buffer 1 
Index 100 mg mL
-1
 PpLAAO in buffer 1 
PACT 30 mg mL
-1
 PpLAAO in buffer 1 
PACT 45 mg mL
-1
 PpLAAO in buffer 1 
PACT 60 mg mL
-1
 PpLAAO in buffer 1 
PACT 100 mg mL
-1
 PpLAAO in buffer 1 
CSS 1 + 2 60 mg mL
-1
 PpLAAO in buffer 1 
 
Buffer 1: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Buffer 2: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 1 mM FAD, pH 7.0 
 
2.3.8 Native gel and Dynamic Light Scattering analysis of wild type PpLAAO 
 
Tris and AEBSF were purchased from Melford. HCl, NaCl, Imidazole, glycerol, propanol and 
glacial acetic acid were purchased from Fisher. Acrylamide solution “30% ProtoGel” was 
purchased from National Diagnostics. APS and TEMED were purchased from Sigma-Aldrich. 
MicroPasteur pipettes were purchased from Alpha laboratories.  
 
Purified wild type PpLAAO was analysed on a 7.5% native-PAGE gel using Mighty Small gel 
electrophoresis equipment.
[110]
  
 
A 7.5%-resolving gel contained 2.45 mL H2O (18.2 Ω
.
 cm), 1.25 mL buffer (1.5 M Tris/HCl, pH 
8.8), 1.25 mL acrylamide solution, 25 µL of 10% (w/v) APS and 4 µL of TEMED. 
A stacking gel consisted of 1.6 mL H2O (18.2 Ω
.
 cm), 0.65 mL buffer (0.5 M Tris/HCl, pH 6.8), 
0.25 mL acrylamide solution, 16 µL of 10% APS, 4 µL of TEMED and 4 µL of 1% (w/v) 
Bromophenol Blue. 20 µL-loading samples contained 50% (v/v) protein solution and 50% (v/v) 
loading buffer. Electrophoreses were carried out at 100 V for 120 min in running buffer, with water 
running through the gel apparatus to ensure that the equipment did not overheat.  
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After the electrophoresis, the native-gel was placed in staining solution and microwaved for 40 s. 
The SDS-gel was then washed with water and placed in destaining solution and microwaved for 40 
s and then left to destain at room temperature. The destaining solution was exchanged several times 
in order to completely destain the native-gel. Pictures of the gel were taken using a Syngene Gene 
Genius Bioimaging System. 
 
Wild type PpLAAO protein was analysed by Dynamic Light Scattering (DLS) using a Protein 
Solutions DynaPro DLS machine with Temperature controlled Microsampler manipulated used the 
Dynamic 5-26 programme. 500 µL of 1 mg ml
-1
 wild type PpLAAO protein and 500 µL of filtered 
buffer 1 were spun down at 16,000 g for 10 min in an Eppendorf 5415 C centrifuge. The DLS 
cuvette was rinsed with H2O (18.2 Ω
.
 cm) for 2 min and left in a beaker of fresh H2O (18.2 Ω
.
 cm) 
for a further 2 min. DLS cuvette was dried with compressed air and cleaned wiped with an optical-
grade cloth. 
 
500 µL of H2O (18.2 Ω
.
 cm) was placed in the DLS cuvette using a micropasteur pipette and the 
cuvette was placed in the DLS machine at 20°C. Counts were measured to ensure that they were 
less than 12,000. H2O was removed from the cuvette and replaced with 500 µL of buffer 1. Counts 
were measured to ensure that they were still below the 12,000 threshold level. Buffer 1 was 
replaced with 500 µL of 1 mg mL
-1
 PpLAAO protein. Counts were measured for 30 s to ensure that 
the levels were stable before data collection was started. Data collection was left to run until at least 
15 statistically accurate blue bars of data had accumulated. 
 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Loading buffer: 0.5 M Tris, 10% (w/v) glycerol, 0.2% (w/v) Bromophenol Blue, pH 6.8 
Running Buffer: 25 mM Tris, 250 mM glycine, pH 8.4 
Staining Solution: 25% (v/v) propan-2-ol, 10% glacial acetic acid, 0.2% (w/v) Coomassie 
Brilliant BlueR 
Destaining Solution: 5% (v/v) propan-2-ol and 7% (v/v) glacial acetic acid 
 
2.3.9 Analysis of effects of different buffers on wild type PpLAAO 
 
Guanidine HCl (G. HCl), Tris and AEBSF were purchased from Melford. Urea, HCl, NaCl, 
Imidazole, glycerol, propanol and glacial acetic acid were purchased from Fisher. Acrylamide 
solution “30% ProtoGel” was purchased from National Diagnostics. SB12, LDAO, TMAO, β-OG, 
APS and TEMED were purchased from Sigma-Aldrich. NSDB-201 was purchased from 
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Calbiochem. Vivaspin 20s with 30,000 MWCO were purchased from Sartorius stedim. 
MicroPasteur pipettes were purchased from Alpha laboratories.  
 
PpLAAO protein purified as in Section 2.3.6 was concentrated to 20 mg mL
-1
 in a Vivaspin 20 
spun at 3,400 g in a Harrier 18/80 centrifuge. 50 µL of protein was mixed with 450 µL of each of 
the following protein buffers: 10 mM LDAO, 10 mM SB12, 0.5% β-OG, 500 mM TMAO, 250 
mM NDSB-201, 50 mM Urea, 100 mM Urea, 200 mM Urea, 50 mM G. HCl, 100 mM G. HCL and 
200 mM G. HCl. 
 
The protein solutions remixed with 500 mM TMAO, 250 mM NDSB-201, 50 mM Urea, 100 mM 
Urea, 200 mM Urea, 50 mM G. HCl, 100 mM G. HCl and 200 mM G. HCl were analysed by 
Dynamic Light Scattering (DLS) using a Protein Solutions DynaPro DLS machine with 
Temperature controlled Microsampler manipulated used the Dynamic 5-26 programme. 500 µL of 
2 mg mL
-1
 PpLAAO protein and 500 µL of filtered protein buffer were spun down at 16,000 g for 
10 min in an Eppendorf 5415 C centrifuge. The DLS cuvette was rinsed with H2O (18.2 Ω
.
 cm) for 
2 min and left in a beaker of fresh H2O (18.2 Ω
.
 cm) for a further 2 min. DLS cuvette was dried 
with compressed air and cleaned wiped with an optical-grade cloth. 
 
500 µL of H2O (18.2 Ω
.
 cm) were placed in the DLS cuvette using a micropasteur pipette and the 
cuvette was placed in the DLS machine at 20°C. Counts were measured to ensure that they were 
less than 12,000. H2O was removed from the cuvette and replaced with 500 µL of protein buffer. 
Counts were measured to ensure that they were still below the 12 k threshold level. Protein buffer 
was replaced with 500 µL of 2 mg mL
-1
 PpLAAO protein. Counts were measured for 30 s to ensure 
that the levels were stable before data collection was started. Data collection was left to run until at 
least 15 statistically accurate blue bars of data had accumulated. The 100 mM and 200 mM G. HCl 
solutions were aborted as protein precipitation was too great for accurate readings to be collected. 
 
PpLAAO protein in buffer 1 was also analysed using DLS as above, but with the temperature at 
4°C, 12°C and 20°C. An analysis at 37°C was attempted but the protein precipitated. 
 
All the remixed protein solutions other than the 100 mM and 200 mM G. HCl solutions were 
analysed on a 7.5% native-PAGE gel using Mighty Small gel electrophoresis equipment.
[110]
  
 
A 7.5%-resolving gel contained 2.45 mL H2O (18.2 Ω
.
 cm), 1.25 mL buffer (1.5 M Tris/HCl, pH 
8.8), 1.25 mL acrylamide solution, 25 µL of 10% (w/v) APS and 4 µL of TEMED. 
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A stacking gel consisted of 1.6 mL H2O (18.2 Ω
.
 cm), 0.65 mL buffer (0.5 M Tris/HCl, pH 6.8), 
0.25 mL acrylamide solution, 16 µL of 10% APS, 4 µL of TEMED and 4 µL of 1% (w/v) 
Bromophenol Blue. 
20 µL-loading samples contained 50% (v/v) protein solution and 50% (v/v) loading buffer. 
Electrophoresis was carried out at 100 V for 120 min in running buffer, with water running through 
the gel apparatus to ensure that the equipment did not overheat. 
 
After the electrophoresis, the native-gel was placed in staining solution and microwaved for 40 s. 
The SDS-gel was then washed with water and placed in destaining solution and microwaved for 40 
s and then left to destain at room temperature. The destaining solution was exchanged several times 
in order to completely destain the native-gel. Pictures of the gel were taken using a Syngene Gene 
Genius Bioimaging System. 
 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Loading buffer: 0.5 M Tris, 10% (w/v) glycerol, 0.2% (w/v) Bromophenol Blue, pH 6.8 
Running Buffer: 25 mM Tris, 250 mM glycine, pH 8.4 
Staining Solution: 25% (v/v) propan-2-ol, 10% glacial acetic acid, 0.2% (w/v) Coomassie 
Brilliant BlueR 
Destaining Solution: 5% (v/v) propan-2-ol and 7% (v/v) glacial acetic acid 
 
2.3.10 Effects of cold purification and G. HCl concentration on PpLAAO quaternary form 
 
G. HCl, Tris and AEBSF were purchased from Melford. NaCl, Imidazole, glycerol, propanol and 
glacial acetic acid were purchased from Fisher. Acrylamide solution “30% ProtoGel” was 
purchased from National Diagnostics. APS and TEMED were purchased from Sigma-Aldrich. 
Vivaspin 20s with 30,000 MWCO were purchased from Sartorius. MicroPasteur pipettes were 
purchased from Alpha Laboratories.  
 
PpLAAO protein was overexpressed and purified as in Sections 2.3.1-2.3.2, however the AKTA 
used was kept in a refrigerator set at 4°C, and extra care was made to ensure that protein was kept 
at ice temperature at all times during purification. Protein was diluted to 1 mg mL
-1
 and 10 µL of 
the purified protein was analysed on a 7.5% native-PAGE gel using Mighty Small gel 
electrophoresis equipment.
[110]
  
 
After purification, the protein was concentrated to 20 mg mL
-1
 in a Vivaspin 20 spun at 3,400 g in a 
Harrier 18/80 centrifuge. 50 µL of protein was mixed with 450 µL of ice-cold, pH 7.0 G. HCl at 
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the following concentrations; 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 
mM. Remixed protein samples were kept at 4°C overnight and amount of precipitation was 
observed visually. Precipitated protein was spun down at 16,000 g for 10 min in an Eppendorf 5415 
C centrifuge and each sample was analysed on a 7.5% native-PAGE gel using Mighty Small gel 
electrophoresis equipment.
[110]
  
 
A 7.5%-resolving gel contained 2.45 mL H2O (18.2 Ω
.
 cm), 1.25 mL buffer (1.5 M Tris/HCl, pH 
8.8), 1.25 mL acrylamide solution, 25 µL of 10% (w/v) APS and 4 µL of TEMED. 
A stacking gel consisted of 1.6 mL H2O (18.2 Ω
.
 cm), 0.65 mL buffer (0.5 M Tris/HCl, pH 6.8), 
0.25 mL acrylamide solution, 16 µL of 10% APS, 4 µL of TEMED and 4 µL of 1% (w/v) 
Bromophenol Blue. 
20 µL-loading samples contained 50% (v/v) protein solution and 50% (v/v) loading buffer. 
Electrophoresis was carried out at 100 V for 120 min in running buffer, with water running through 
the gel apparatus to ensure that the equipment did not overheat. 
 
After the electrophoresis, the native gel was placed in staining solution and microwaved for 40 s. 
The SDS-gel was then washed with water and placed in destaining solution and microwaved for 40 
s and then left to destain at room temperature. The destaining solution was exchanged several times 
in order to completely destain the native gel. Pictures of the gel were taken using a Syngene Gene 
Genius Bioimaging System. 
 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Loading buffer: 0.5 M Tris, 10% (w/v) glycerol, 0.2% (w/v) Bromophenol Blue, pH 6.8 
Running Buffer: 25 mM Tris, 250 mM glycine, pH 8.4 
Staining Solution: 25% (v/v) propan-2-ol, 10% glacial acetic acid, 0.2% (w/v) Coomassie 
Brilliant BlueR 
Destaining Solution: 5% (v/v) propan-2-ol and 7% (v/v) glacial acetic acid 
 
A 24-well crystallisation plate was set up at 4°C using the hanging drop vapour diffusion method, 
with the wells containing the solutions shown in Fig 2.2. The tray was kept at 4°C and checked in 
the microscope periodically to see if crystals had developed. 
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1.0 M AS 1.5 M AS 2.0 M AS 2.5 M AS 3.0 M AS 3.5 M AS 
10% PEG 4K 15% PEG 4K 20% PEG 4K 25% PEG 4K 30% PEG 4K 35% PEG 4K 
15% PEG 3350 
0.2 M AS 
20% PEG 3350 
0.2 M AS 
25% PEG 3350 
0.2 M AS 
30% PEG 3350 
0.2 M AS 
35% PEG 3350 
0.2 M AS 
 
      
Fig 2.3 Layout of well solutions in 24-well crystallisation screen of PpLAAO protein. AS = Ammonium 
sulfate. 
 
2.4 Generation of active site residue mutants of PpLAAO 
 
PfUTurbo HotStart DNA polymerase kit was purchased from Agilent Technologies/Stratagene. 
dNTPs were purchased from Promega. High-purity salt free primers were purchased from 
MWG/Eurofins. PCRs were carried out in either 200 µL or 500 µL thin-walled PCR tubes using a 
Techne TC-312 thermal cycler. DpnI Restriction enzyme was purchased from New England 
Biolabs. Chemically competent E. coli BL21-Gold-DE3 were purchased from Agilent 
Technologies/Stratagene. Electrochemically competent E. coli BL21-DE3 were prepared as in 
Section 2.1.5. Transformed E. coli BL21-DE3 cells were grown using 30 µg mL
-1
 kanamycin as 
the appropriate antibiotic. Transformed E. coli BL21-Gold-DE3 cells were grown using 30 µg mL
-1
 
kanamycin and 15 µg mL
-1
 tetracyclin as the appropriate antibiotic. 
 
Stratagene’s QuikChange method of Site Directed Mutagenesis was used to introduce mutations 
into the YSBLIC3C-PpLAAO plasmid, using PCR cycle C (Table 2.1), PCR mix C (Table 2.2) 
and the primer pairs (Table 2.3) listed in Table 2.6. Each reaction was treated with 1 µL of DpnI 
restriction enzyme and incubated at 37°C for 3 h. 2 µL of the restricted reaction product was used 
to transform 50 µL of the cell strain listed in Table 2.6.  
 
The number of colonies listed in Table 2.6 were each used to inoculate a 5 mL starter culture 
containing appropriate antibiotics. These cultures were grown at 37°C with shaking at 180 r.p.m 
overnight. The next morning 100 µL of starter culture was used to inoculate a fresh 5 mL culture of 
LB-media containing appropriate antibiotics, and the remaining started culture pulled down by 
spinning at 16,000 g for 1 min using an Eppendorf 5415 C centrifuge, the supernatant was 
discarded and cell pellets were stored at -20°C.  
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Table 2.6: Primers and PCR tubes used to generate Alanine substituted mutants of the PpLAAO active site 
residues using the Stratagene QuikChange method and cell strains transformed with resulting plasmid (Please 
see Table 2.3 for primer sequences). 
Mutation Primers 
PCR 
tube size 
Cell Strain 
Number 
of 
colonies 
grown 
Q242A Q242A-for, Q242A-rev 200 µL Electrocompetent E. coli BL21-DE3 10 
H244A H244A-for, H244A-rev 200 µL 
Chemically competent E. coli BL21-
Gold-DE3 
1 
P245A P245A-for, P2425-rev 200 µL 
Chemically competent E. coli BL21-
Gold-DE3 
3 
L257A L257A-for, L257A-rev 200 µL 
Chemically competent E. coli BL21-
Gold-DE3 
3 
T259A T259A-for, T259A-rev 200 µL 
Chemically competent E. coli BL21-
Gold-DE3 
12 
E260A E260A-for, E260A-rev 200 µL 
Chemically competent E. coli BL21-
Gold-DE3 
2 
R290A R290A-for, R290A-rev 500 µL 
Chemically competent E. coli BL21-
Gold-DE3 
3 
V293A V293A-for, V293A-rev 500 µL 
Chemically competent E. coli BL21-
Gold-DE3 
10 
H351A H351A-for, H351A-rev 500 µL Electrocompetent E. coli BL21-DE3 2 
Y352A Y352A-for, Y352A-rev 500 µL 
Chemically competent E. coli BL21-
Gold-DE3 
2 
R386A R386A-for, R386A-rev 500 µL Electrocompetent E. coli BL21-DE3 2 
S389A S389A-for, S389A-rev 500 µL 
Chemically competent E. coli BL21-
Gold-DE3 
10 
S391A S391A-for, S391A-rev 500 µL 
Chemically competent E. coli BL21-
Gold-DE3 
2 
 
The fresh cell cultures were incubated at 37°C with shaking at 180 r.p.m until OD600 was at 0.5. 
Overexpression was induced by adding 5 µL of 1 M IPTG to give a final concentration of 1 mM 
IPTG. The cell culture was incubated at 37°C for 3 h with shaking at 180 r.p.m. The cells were 
harvested by centrifugation for 1 min at 16,000 g using an Eppendorf 5415 C centrifuge. The 
supernatant was discarded and the cell pellet was resuspended in 500 µL buffer 1. The cell 
suspension was sonicated on ice for 30 s at 15 microns. Cell debris was pulled down by spinning at 
16,000 g for 1 min using an Eppendorf 5415 C centrifuge. The soluble supernatant was separated 
from the insoluble cell pellet. The cell pellet was then resuspended in 500 µL buffer 1. The soluble 
and insoluble fractions were analysed by 12.5% SDS-PAGE. 
 
Plasmid DNA from cell strains that appeared to produce correctly sized protein (~60 kDa) was 
purified from the cell pellets stored at -20°C using Sigma-Aldrich’s GenElute DNA Miniprep Kit, 
plasmids were then sent for sequencing by the York University Genomics group (Section 2.2.4) 
using the T7 and T7-term primers (Table 2.3). 
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LB media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, H2O (18.2 Ω
.
 cm) 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
 
2.5 Purification and characterisation of active site PpLAAO mutants 
 
2.5.1 Overexpression of active site PpLAAO mutant proteins for purification 
 
Chemically competent E. coli BL21-DE3 cells were purchased from Merck/Novagen. Ingredients 
for LB-media were purchased from Fisher. Agar was purchased from Lab M Ltd. Kanamycin 
sulfate was purchased from Invitrogen. IPTG was purchased from Melford. OD600 was measured 
using an Eppendorf Biophotometer. Transformed cell cultures were grown in media containing 30 
µg mL
-1
 kanamycin as the appropriate antibiotic. 
 
1 µL of each mutated form of the pET-YSBLIC-3C-PpLAAO plasmid made as in Section 2.4 was 
used to transform 25 µL of E. coli BL21-DE3 chemically competent cells using heatshock. For 
each mutation, two of the resulting colonies were each used to inoculate a 10 mL LB-media starter 
cultures containing appropriate antibiotic under sterile conditions. These starter cultures were 
incubated overnight at 37°C with shaking at 180 r.p.m. A 2 L Erlenmeyer flask containing 1 L of 
LB media and appropriate antibiotic was inoculated with 20 mL of starter culture under sterile 
conditions. The cell cultures were incubated at 37°C and shaking at 180 r.p.m until OD600 reached 
0.5. Overexpression was induced by adding 1 mL of 1 M IPTG to give a final concentration of 1 
mM IPTG. The cell culture was incubated at 37°C for 3 h with shaking at 180 r.p.m. The cells were 
harvested by centrifugation for 15 min at 5,100 g using the GS3 rotor of a RC-5B Sorvall 
Centrifuge. The supernatant was discarded and the cell pellet was stored at -20°C. 
 
LB media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
 
2.5.2 Purification of active site PpLAAO mutant protein 
 
Active site mutants of PpLAAO were purified by anion exchange chromatography, followed by gel 
filtration chromatography. Prepacked HiTrap Chelating HP column was purchased from GE 
Healthcare. 120 mL HiLoad 16/60 Superdex 75 column was purchased from Pharmacia Biotech. 
Buffers 1-3, H2O (18.2 Ω
.
 cm) and 20% (v/v) ethanol were filtered through a 0.22 µM Whatman 
filter before use. The Prepacked HiTrap Chelating HP Column was loaded using peristaltic pump 
and gradient was run using AKTA Purifier P-900. The 120 mL HiLoad 16/60 Superdex 75 column 
was operated using an AKTA Purifier P-900. AEBSF was purchased from Melford. 
 88 
The cell pellets from the 1 L cultures of E. coli BL21-DE3-Active site PpLAAO mutant were 
thawed at room temperature and resuspended in 50 mL of buffer 1. The cell suspension was cooled 
on ice for 20 min. The cells were then sonicated on ice for 5 x 30 sec at 15 microns. Cell debris was 
spun down for 15 min at 26,900 g at 4°C using a Sorvall RC5B centrifuge and SS34 rotor. The 
supernatant was decanted and filtered through a 0.45 µm ACRODISC filter, followed by 0.2 µm 
ACRODISC filter. Filtered supernatant was then loaded onto a 5 mL HiTrap Chelating HP Column 
pre-charged with 0.1 M NiSO4 using a peristaltic pump, the flow rate was 1 mL min
-1
. After 
loading, resin was washed with 25 mL of buffer 1 at 1 mL min
-1
. The column was then transferred 
to an AKTA Explorer and a gradient from buffer 2 to buffer 3 was run starting at 100% buffer 2 to 
100% buffer 3 over 100 mL, with a flow rate of 1 mL min
-1
. 4 mL fractions were collected. SDS-
PAGE showed which sample fractions contained the desired protein by approximate monomer 
molecular weight (~60 kDa). Samples with pure protein were combined and concentrated to 2 mL 
aliquots using a MWCO 30000 Vivaspin 20 tube. 
 
Gel filtration chromatography was then used to purify the protein further: A 2 mL aliquot was 
loaded onto a prepacked and pre-equilibrated 120 mL HiLoad 16/60 Superdex 75 column using a 2 
mL loop on an AKTA Explorer. Resin was washed with 120 mL of buffer 1, flow rate was 1 mL 
min
-1
, and 4 mL fractions were collected. SDS-PAGE showed which sample fractions contained the 
desired protein by approximate monomer molecular weight (~60 kDa). These fractions were then 
pooled and concentrated to 2 mg mL
-1
 using MWCO 30000 Vivaspin 20 tubes. Concentrated 
protein was snap frozen in liquid nitrogen and stored at -80°C. 
 
Buffer 1: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
Buffer 2: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 30 mM Imidazole pH 7.0 
Buffer 3: 50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, 500 mM Imidazole pH 7.0 
 
2.5.3 Activity assay of active site PpLAAO mutant proteins against target substrates 
 
TBHBA was purchased from Alfa Aesar, 4-AAP, HRP, L-aspartate, L-asparagine, L-tyrosine, L-
alanine and L-homoserine were purchased from Sigma-Aldrich, KH2PO4 and K2HPO4 were 
purchased from Fisher, 1 mL cuvettes purchased from Sarstedt. A510 was measured on a GBC 
Cintra 10 spectrophotometer. 
 
The initial rate activity of the purified wild type PpLAAO protein and the purified protein from 
PpLAAO mutants Q242A, H244A, P245A, L257A, T259A, R290A, H351A, Y352A, R386A, 
S389A and S391A were all measured against L-aspartate, L-asparagine, L-homoserine and L-
glutamate as follows:  
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The Cintra 10 spectrophotometer was programmed to measure A510 every 0.1 s for 5 min. 950 µL 
of assay solution was pipetted into a 1 mL cuvette. 50 µL of H2O (18.2 Ω
.
 cm) was added and 
cuvette was placed in the background solution position of the Cintra 10. 950 µL of assay solution 
was pipetted into a second 1 mL cuvette. The cuvette was placed in the front position of the Cintra 
10. The Cintra 10 was set running for 10 s to ensure that the solution absorbance was stable. The 
front cuvette was removed from the Cintra 10 and 50 µL of 2 mg mL
-1 
protein was quickly added to 
the assay solution. The cuvette was mixed by inverting three times before being placed back into 
the Cintra 10. A510 continued to be measured for the remainder of the program.  
 
After the program had finished the absorbance values at 239.9 and 299.9 s were recorded.   
 
Activity was measured in this way with 1.563 mM, 3.125 mM, 6.25 mM, 12.5 mM, 25 mM, 37.5 
mM 50 mM, of each of L-aspartate, L-asparagine, L-homoserine and L-glutamate. Activity was 
measured three times for each concentration of each substrate. 
 
The rate of change in absorbance, in absorbance unit min
-1
, for each concentration of each substrate 
was determined using the equation:  
 
 
As the red quinonimine complex product of the HRP reaction has an extinction coefficient of 
29,400 M
-1
 cm
-1
, and the 1 mL cuvettes used have a path length of 1 cm, the Beer Lambert law was 
used to determine the change in concentration of the quinonimine complex, which should be equal 
to the change in concentration of the substrate, using the following calculation: 
 
Grafit version 7.0 and GraphPad Prism 5 software were used to plot Michaelis-Menten graphs and 
determine Vmax and KM against L-aspartate and L-asparagine. As the size of the PpLAAO protein is 
59215 Da, the concentration of protein in mM per mg of protein could be determined: 
 
Therefore, kcat could be determined as follows:  
 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA) in 1 mL 
DMSO, 15 mg 4-AAP, pH 7.5 
Assay solution: 1 x Reaction Buffer, 25 µg mL
-1
 HRP, and varied 
concentration of substrate 
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2.6 Generation of SDSM CASTing libraries 
 
2.6.1 Building of SDSM CASTing library A 
 
The annealing temperature of the Stratagene QuikChange reaction was optimized in 200 µL thin-
walled PCR tubes using an Eppendorf Mastercycler gradient PCR machine. DpnI restriction 
enzyme was purchased from New England Biolabs. The ingredients for LB-media were purchased 
from Fisher, kanamycin sulphate was purchased from Invitrogen, tetracycline was purchased from 
Merck/Calbiochem. AEBSF and IPTG were purchased from Melford. OD600 was measured using 
an Eppendorf Biophotometer. Other PCRs were carried out in 200 µL thin-walled PCR tubes in a 
Techne TC-312 PCR machine. 
 
The PCR mix was pipetted in 200 µL thin-walled PCR tubes. Stratagene’s QuikChange method of 
SDSM mutagenesis was used to introduce mutations into the YSBLIC3C-PpLAAO plasmid using 
PCR cycle D (Table 2.1) and PCR mix D (Table 2.2) and the PNDTA-for and PNDTA-rev 
primers (Table 2.3). Reactions were performed in duplicate, then mixed together to produce a total 
reaction volume of 50 µL. 25 µL of reaction product was analysed with 1 % agarose gel 
electrophoresis (Section 3.1.1). The remaining 25 µL of the PCR mix was mixed with 1 µL of 
DpnI. The reaction was incubated at 37°C for 3 h. 2 µL of this reaction was cooled down on ice 
and used to transform 25 µL of E. coli XL10-Gold cells using heat shock (Section 2.1.3). 6 single 
colonies were each used to inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin, 34 µg 
mL
-1
 chloramphenicol and 15 µg mL
-1
 tetracycline. These started cultures were incubated at 37°C 
and shaking at 180 r.p.m overnight. 
 
The following day, the starter cultures were spun down at 16,000 g in an Eppendorf 5415 C 
centrifuge. Mutant plasmids were isolated using Sigma Aldrich’s GenElute plasmid Miniprep kit. 
To check size of the gene insert, the inserts of each plasmid was amplified by PCR (Section 3.1.5) 
using PCR cycle E (Table 2.1), PCR mix E (Table 2.2) and the PpLAAO-for and PpLAAO-rev 
primers (b). The reactions were analysed with 1% agarose gel electrophoresis.  
 
The concentration of DNA in the purified plasmids was determined by measuring the absorption at 
280 nm using the dsDNA function on the Eppendorf Biophotometer, with an absorbance of 0.1 
equal to DNA concentration of 50 ng µL
-1
. The plasmids were then concentrated to between 100 
and 150 ng µL
-1
 using a GeneVac miVac DNA concentrator. Each plasmid was then sequenced by 
the York University Genomics group using the T7 and T7-term primers (Table 2.3). Multiple 
sequence alignments were performed using the CLUSTALW2 program version 2.0.12 hosted by 
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the European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/msa/clustalw2/ Accessed 
10/02/2010
 
). 
 
1 µL of each of 4 of the purified mutant plasmids was used to transform E. coli Rosetta2-DE3 
competent cells using heat shock. One colony from each plate was used to inoculate 5 mL of LB-
media containing 30 µg mL
-1
 kanamycin and 34 µg mL
-1 
chloramphenicol. These starter cultures 
were incubated at 37°C and shaking at 180 r.p.m overnight. The following day 100 µL of started 
culture was used to inoculate a fresh 5 mL culture of LB-media containing 30 µg mL
-1
 kanamycin 
and 34 µg mL
-1 
chloramphenicol. These cultures were incubated at 37°C and shaking at 180 r.p.m 
until OD600 was at 0.5. Overexpression was induced by adding 5 µL of 1 M IPTG to give a final 
concentration of 1 mM IPTG. The cell culture was incubated at 37°C for 3 h with shaking at 180 
r.p.m. The cells were harvested by centrifugation for 2 min at 16,000 g using an Eppendorf 5415 C 
centrifuge. The supernatant was discarded and the cell pellet was resuspended in 500 µL buffer 1. 
The cell suspension was sonicated on ice for 30 s at 15 microns. Cell debris was pulled down by 
spinning at 16,000 g for 2 min using the Eppendorf 5415 C centrifuge. The soluble supernatant was 
separated from the insoluble cell pellet. The cell pellet was then resuspended in 500 µL buffer 1. 
The soluble and insoluble fractions were analysed by SDS-PAGE. 
 
PCR mixes were pipetted into 6 200 µL thin-walled PCR tubes. Stratagene’s QuikChange method 
of SDSM mutagenesis was used to introduce mutations into the YSBLIC3C-PpLAAO plasmid 
using PCR cycle F (Table 2.1) and PCR mix F (Table 2.2) with the PNDTA-for and PNDTA-rev 
primers (Table 2.3), with the tubes placed in positions 2, 4, 6, 8, 10 and 12 of the Mastercycler 
gradient PCR machine. PCR products were analysed with 1 % agarose gel electrophoresis. 
 
Based on these results, the Stratagene QuikChange reaction was repeated. PCR mixes were 
pipetted into two 200 µL thin-walled PCR tubes. The pET-YSBLIC3C-PpLAAO plasmid was used 
as a template for the PCR. The PCR was carried out as in section 3.1.5, using PCR cycling C 
(Table 2.1) and PCR mix F (Table 2.2) and the PNDTA-for and PNDTA-rev primers (Table 2.3). 
The two products were mixed together to make a total reaction volume of 50 µL. 25 µL of the PCR 
mix was analysed with 1% agarose gel electrophoresis. The remaining 25 µL of PCR mix was 
mixed with 1 µL of DpnI restriction enzyme. The mixture was incubated at 37°C for 3 h. 2 µL of 
reaction product was cooled and used to transform 25 µL of E. coli BL21-Gold-DE3 competent 
cell using heat shock. 
 
Nine colonies were each used to inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin 
and 15 µg mL
-1 
tetracycline. These starter cultures were incubated at 37°C and shaking at 180 r.p.m 
overnight. The following day 100 µL of started culture was used to inoculate a fresh 5 mL culture 
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of LB-media containing 30 µg mL
-1
 kanamycin and 15 µg mL
-1 
tetracycline. These cultures were 
incubated at 37°C and shaking at 180 r.p.m until OD600 was at 0.5. Overexpression was induced by 
adding 5 µL of 1 M IPTG to give a final concentration of 1 mM IPTG. The cell culture was 
incubated at 37°C for 3 h with shaking at 180 r.p.m. The cells were harvested by centrifugation for 
2 min at 16,000 g using an Eppendorf 5415 C centrifuge. The supernatant was discarded and the 
cell pellet was resuspended in 500 µL buffer 1. The cell suspension was sonicated on ice for 30 s at 
15 microns. Cell debris was pulled down by spinning at 16,000 g for 2 min using an Eppendorf 
5415 C centrifuge. The soluble supernatant was separated from the insoluble cell pellet. The cell 
pellet was then resuspended in 500 µL buffer 1. The soluble and insoluble fractions were analysed 
by 12.5% SDS-PAGE. 
 
Mutant PNDTA plasmids were purified from the remaining 4.9 mL of starter culture using Sigma-
Aldrich’s GenElute Plasmid Miniprep kit. The concentration of DNA in the purified plasmids was 
determined by measuring the absorption at 280 nm using the dsDNA function on the Eppendorf 
BioPhotometer, with an A280 of 1 equal to a DNA concentration of 50 µg mL
-1
. The plasmids were 
then concentrated to between 100 and 150 ng µL
-1
 using a GeneVac miVac DNA concentrator. 
Each plasmid was then sequenced by the University of York Genomics department using the T7 
and T7-term primers (Table 2.3). Sequencing data output was analysed using the Chromas Lite 
programme developed by Technelysium Pty Ltd. Sequence alignments with the wild type-
PpLAAO DNA sequence were performed using the Align program (needle method) hosted by the 
European Bioinformatics Institute (http://www.ebi.ac.uk/Tools/emboss/align/ Accessed 
04/07/2010). 
 
Ten more transformations of E. coli BL21-Gold-DE3 were performed using the PCR product 
mixed with DpnI, resulting in over 430 colonies. Colonies were scrubbed off the plates under 
sterile conditions by pipetting 2 mL of LB-media over each plate and resuspending the colonies by 
wiping the plate with glass spreader. The resuspended cells were the collected with a pipette and 
pooled together. Cells were spun down at 16,000 g for 2 min using the Eppendorf 5415 C 
centrifuge. The mutant plasmid library was then purified using Sigma Aldrich’s GenElute Midiprep 
kit and stored at -20°C until needed. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
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2.6.2 Building of SDSM CASTing library D 
 
DpnI restriction enzyme was purchased from New England Biolabs. The ingredients for LB-media 
were purchased from Fisher, kanamycin sulphate was purchased from Invitrogen, tetracycline was 
purchased from Merck/Calbiochem. AEBSF and IPTG were purchased from Melford. OD600 was 
measured using an Eppendorf Biophotometer.  PCRs were carried out in 200 µL thin-walled PCR 
tubes in a Techne TC-312 PCR machine. 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid twice using PCR cycle G (Table 2.1) and PCR mix G (Table 2.2) 
along with and the PNDTD-for and PNDTD-rev primers (Table 2.3). PCR product was mixed with 
1 µL of DpnI restriction enzyme and incubated at 37°C for 3 h. Duplicate PCRs were mixed to 
make a total reaction volume of 40 µL. 20 µL of product was analysed with 1% agarose gel 
electrophoresis, the remainder was stored at -20°C.  
 
2 µL of DpnI treated PNDTD PCR product was used to transform 75 µL of E. coli Top10 
electrocompetent cells using electroporation. This produced around 400 colonies. Five colonies 
from the transformation were each used to inoculate 5 mL of LB media containing 30 µg mL
-1
 of 
kanamycin. These starter cultures were incubated at 37°C with shaking at 180 r.p.m overnight. 
Plasmid DNA was purified using Sigma-Aldrich’s GenElute Miniprep kit. To determine gene 
insert size, the plasmid DNA was amplified by PCR using PCR cycle condition A (Table 2.1), 
PCR mix H (Table 2.2) and the PpLAAO-for and PpLAAO-rev primers (Table 2.3). Product was 
analysed using 1% agarose gel electrophoresis. 
 
Purified plasmids were sent for nucleotide sequencing (Section 2.2.4). The T7 and T7-term primers 
(Table 2.3) were used as sequencing primers. The sequencing reactions were carried out by the 
York University Genomics group. The sequence chromatograms were analysed with the program 
Chromas lite, version 2.01 from Technelysium (free software). 
 
Transformations of the E. coli Top10 Electrocompetent cells using 2µL of DpnI treated PNDTD 
PCR product were repeated until around 3000 colonies had been produced. Colonies were scrubbed 
off the plates under sterile conditions by pipetting 2 mL of LB-media over each plate and 
resuspending the colonies by wiping the plate with glass spreader. The resuspended cells were the 
collected with a pipette and pooled together. Cells were spun down at 16,000 g for 2 min using the 
Eppendorf 5415 C centrifuge. The mutant plasmid library was then purified using Sigma Aldrich’s 
GenElute Midiprep kit. The concentration of DNA in the purified library was determined to be 87 
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ng µL
-1
 using the dsDNA function of an Eppendorf Biophotometer. The purified PNDTD plasmid 
library was stored at -20°C until needed. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
 cm) 
Buffer 1:  50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
 
2.6.3 Attempts to build SDSM libraries B, C and E using PfUTurbo HotStart Polymerase 
 
PfUTurbo HotStart DNA polymerase kit was purchased from Agilent Technologies/Stratagene. 
dNTPs were purchased from Promega. High-purity salt free primers were purchased from 
MWG/Eurofins. PCRs were carried out in 200 µL thin-walled PCR tubes in a Techne TC-312 PCR 
machine. 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid. The PCR mixes listed in Table 2.7 were used along with PCR 
cycle C (Table 2.1) to amplify the YSBLIC3C-PpLAAO plasmid. This was done using the 
PNDTB-for/PNDTB-rev and the PNDTC-for/PNDTC-rev primer pairs (Table 2.3). The PCR 
mixes listed in Table 2.8 were used along with PCR cycle C (Table 2.1) to amplify the 
YSBLIC3C-PpLAAO plasmid. This was done using the PNDTE-for/PNDTE-rev primer pairs 
(Table 2.3). PCR products were analysed with 1% agarose gel electrophoresis. 
 
Table 2.7: Composition of PCR mix used for the amplification of DNA by PCR using PfU Turbo HotStart 
polymerase with PNDTB-for/PNDTB-rev and PNDTC-for/PNDTC-rev primer pairs. 
 
H2O 
(18.2 
Ω. 
 cm)/ 
µL 
10 * 
PfU 
Buffer/ 
µL 
2 mM 
(each) 
dNTPs/ 
µL 
10 µM 
F 
Primer/ 
µL 
10 µM 
R 
Primer/ 
µL 
10 ng 
µL
-1 
PpLAAO 
Plasmid/ 
µL 
≥99.5% 
DMSO/ 
µL 
PfUTurbo 
HotStart 
Polymerase/ 
µL 
Optimisation 
condition 1 
13.75 2.5 2.5 1.0 1.0 2.0 1.25 0.5 
Optimisation 
condition 2 
10.0 2.5 5.0 1.0 1.0 2.0 1.25 0.5 
Optimisation 
condition 3 
14.25 2.5 2.5 2.0 2.0 2.0 1.25 0.5 
Optimisation 
condition 4 
13.0 2.5 2.5 1.0 1.0 3.0 1.25 0.5 
Optimisation 
condition 5 
12.25 2.5 2.5 1.0 1.0 4.0 1.25 0.5 
Optimisation 
condition 6 
13.25 2.5 2.5 1.0 1.0 2.0 2.5 0.5 
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Table 2.8: Composition of PCR mix used for the amplification of DNA by PCR using PfU Turbo HotStart 
polymerase with PNDTE-for and PNDTE-rev primers. 
 
H2O 
(18.2 
Ω. 
 cm)/ 
µL 
10 * 
PfU 
Buffer/ 
µL 
2 mM 
(each) 
dNTPs/ 
µL 
10 µM 
F 
Primer/ 
µL 
10 µM 
R 
Primer/ 
µL 
10 ng 
µL
-1 
PpLAAO 
Plasmid/ 
µL 
≥99.5% 
DMSO/ 
µL 
PfUTurbo 
HotStart 
Polymerase/ 
µL 
Optimisation 
condition 1 
16.25 2.5 2.5 0.5 0.5 1.0 1.25 0.5 
Optimisation 
condition 2 
13.75 2.5 5.0 0.5 0.5 1.0 1.25 0.5 
Optimisation 
condition 3 
15.25 2.5 2.5 1.0 1.0 1.0 1.25 0.5 
Optimisation 
condition 4 
15.25 2.5 2.5 0.5 0.5 2.0 1.25 0.5 
Optimisation 
condition 5 
14.25 2.5 2.5 0.5 0.5 3.0 1.25 0.5 
Optimisation 
condition 6 
15.00 2.5 2.5 0.5 0.5 1.0 2.5 0.5 
 
2.6.4 PNDTE library SDSM reaction and transformation 
 
PfUTurbo hot start DNA polymerase kit was purchased from Agilent Technologies/Stratagene. 
dNTPs were purchased from Promega. High-purity salt free primers were purchased from 
MWG/Eurofins. DpnI restriction enzyme was purchased from New England Biolabs. PCRs were 
carried out in 200 µL thin-walled PCR tubes in a Techne TC-312 PCR machine. 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid using PCR cycle C (Table 2.1) and PCR mix I (Table 2.2) along 
with the PNDTE-for and PNDTE-rev primers (Table 2.3). PCR product was mixed with 1 µL of 
DpnI restriction enzyme and incubated at 37°C for 3 h. 20 µL of product was analysed with 1% 
agarose gel electrophoresis. 
 
2 µL of the DpnI digested product were used to transform 75 µL of E .coli Top10 electrocompetent 
cells.  
 
2.6.5 Attempts to build SDSM libraries B, C and E using Phusion Polymerase 
 
Phusion hot start II High-fidelity DNA polymerase kit was purchased from New England Biolabs. 
dNTPs were purchased from Promega. High-purity salt free primers were purchased from 
MWG/Eurofins. PCRs were carried out in 200 µL thin-walled PCR tubes in a Techne TC-312 PCR 
machine. 
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Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid. The PCR mixes listed in Table 2.9 were used along with PCR 
cycle G (Table 2.1) to amplify the YSBLIC3C-PpLAAO plasmid. This was done using the 
PNDTB-for/PNDTB-rev and the PNDTE-for/PNDTE-rev primer pairs (Table 2.3). The PCR 
mixes listed in Table 2.10 were used along with PCR cycle G (Table 2.1) to amplify the 
YSBLIC3C-PpLAAO plasmid. This was done using the PNDTC-for/PNDTC-rev primer pairs 
(Table 2.3). PCR products were analysed with 1% agarose gel electrophoresis. 
 
Table 2.9: Composition of PCR mix used for the amplification of DNA by PCR using Phusion HotStart II 
polymerase with PNDTB-for/PNDTB-rev and PNDTE-for/PNDTE-rev primer pairs. 
 
H2O 
(18.2 
Ω. 
 cm)/ 
µL 
5 * 
Phusion 
Buffer/ 
µL 
2 mM 
(each) 
dNTP
s/ µL 
20 µM 
F 
Primer
/ µL 
20 µM 
R 
Primer/ 
µL 
10 ng µL-1 
PpLAAO 
Plasmid/ 
µL 
≥99.5% 
DMSO/ 
µL 
5 mM 
MgSO4/ 
µL 
Phusion 
HotStart II 
Polymerase
/ µL 
Optimisation 
condition 1 
11.2 4.0 2.0 0.5 0.5 1.0 0.6 0 0.2 
Optimisation 
condition 2 
9.2 4.0 4.0 0.5 0.5 1.0 0.6 0 0.2 
Optimisation 
condition 3 
11.7 4.0 2.0 0.25 0.25 1.0 0.6 0 0.2 
Optimisation 
condition 4 
11.7 4.0 2.0 0.5 0.5 0.5 0.6 0 0.2 
Optimisation 
condition 5 
10.8 4.0 2.0 0.5 0.5 1.0 1.0 0 0.2 
Optimisation 
condition 6 
10.4 4.0 2.0 0.5 0.5 1.0 0.6 0.8 0.2 
  
Table 2.10: Composition of PCR mix used for the amplification of DNA by PCR using Phusion HotStart II 
polymerase with the PNDTC-for/PNDTC-rev primer pair. 
 
H2O 
(18.2 
Ω. 
cm)/ 
µL 
5 * 
Phusion 
Buffer/ 
µL 
2 mM 
(each) 
dNTPs/ 
µL 
20 µM 
F 
Primer
/ µL 
20 µM 
R 
Primer/ 
µL 
10 ng µL-1 
PpLAAO 
Plasmid/ 
µL 
≥99.5
% 
DMSO/ 
µL 
5 mM 
MgSO4/ 
µL 
Phusion 
HotStart II 
Polymerase/ 
µL 
Optimisation 
condition 1 
9.2 4.0 4.0 0.5 0.5 1.0 0.6 0 0.2 
Optimisation 
condition 2 
7.2 4.0 6.0 0.5 0.5 1.0 0.6 0 0.2 
Optimisation 
condition 3 
9.7 4.0 4.0 0.25 0.25 1.0 0.6 0 0.2 
Optimisation 
condition 4 
9.7 4.0 4.0 0.5 0.5 0.5 0.6 0 0.2 
Optimisation 
condition 5 
8.8 4.0 4.0 0.5 0.5 1.0 1.0 0 0.2 
Optimisation 
condition 6 
8.4 4.0 4.0 0.5 0.5 1.0 0.6 0.8 0.2 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid using PCR cycle G (Table 2.1) and PCR mix J (Table 2.2) along 
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with the PNDTB-for and PNDTB-rev and the PNDTE-for and PNDTE-rev primers (Table 2.3). 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid using PCR cycle G (Table 2.1) and PCR mix K (Table 2.2) along 
with the PNDTC-for and PNDTC-rev primers (Table 2.3). PCR product was mixed with 1 µL of 
DpnI restriction enzyme and incubated at 37°C for 3 h. 20 µL of product was analysed with 1% 
agarose gel electrophoresis. 2 µL of each of the DpnI digested products from the PNDTB and 
PNDTC reactions was used to transform 75 µL of E. coli Top10 electrocompetent cells.  
 
Four colonies from the PNDTB reactions were each used to inoculate 5 mL of LB media 
containing 30 µg mL
-1
 of kanamycin. These starter cultures were incubated at 37°C with shaking at 
180 r.p.m overnight. Plasmid DNA was purified using Sigma-Aldrich’s GenElute Miniprep kit. To 
determine gene insert size, the plasmid DNA, along with the wild-type YSBLIC-3C-PpLAAO 
plasmid, was amplified by PCR using PCR cycle condition A (Table 2.1), PCR mix H (Table 2.2) 
and the PpLAAO-for and PpLAAO-rev primers (Table 2.3). Product was analysed using 1% 
agarose gel electrophoresis. 
 
LB-media (V=1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
 
2.6.6 Attempts to build SDSM libraries B and C using KOD HotStart Polymerase  
 
KOD HotStart DNA polymerase kit was purchased from Novagen. dNTPs were purchased from 
Promega. High-purity salt free primers were purchased from MWG/Eurofins. PCRs were carried 
out in 200 µL thin-walled PCR tubes in a Techne TC-312 PCR machine. 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid. The PCR mixes listed in Table 2.11 were used along with PCR 
cycle C (Table 2.1) to amplify the YSBLIC3C-PpLAAO plasmid. This was done using the 
PNDTB-for/PNDTB-rev and the PNDTC-for/PNDTC-rev primer pairs (Table 2.3). PCR products 
were analysed with 1% agarose gel electrophoresis. 
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Table 2.11 Composition of PCR mix used for the amplification of DNA by PCR using KOD HotStart 
polymerase with the PNDTB-for/PNDTB-rev and PNDTC-for/PNDTC-rev primer pairs. 
 
H2O 
(18.2 
Ω.cm) 
/ µL 
10 * 
KOD 
Buffer/ 
µL 
25 mM 
MgSO4/ 
µL 
2 mM 
(each) 
dNTPs/ 
µL 
10 µM 
F 
Primer/ 
µL 
10 µM 
R 
Primer/ 
µL 
10 ng µL-1 
PpLAAO 
Plasmid/ µL 
≥99.5% 
DMSO/ 
µL 
K.O.D 
HotStart 
Polymerase/ 
µL 
Optimisation 
condition 1 
13.75 2.5 1.5 2.5 1.0 1.0 1.0 1.25 0.5 
Optimisation 
condition 2 
10.0 2.5 1.0 2.5 2.0 2.0 2.0 2.5 0.5 
Optimisation 
condition 3 
14.25 2.5 1.0 2.5 1.0 1.0 1.0 1.25 0.5 
Optimisation 
condition 4 
13.0 2.5 1.0 2.5 1.0 1.0 1.0 2.5 0.5 
Optimisation 
condition 5 
12.25 2.5 1.0 2.5 2.0 2.0 1.0 1.25 0.5 
Optimisation 
condition 6 
13.25 2.5 1.0 2.5 1.0 1.0 2.0 1.25 0.5 
Optimisation 
condition 7 
12.5 2.5 1.5 2.5 1.0 1.0 1.0 2.5 0.5 
Optimisation 
condition 8 
10.5 2.5 1.5 2.5 2.0 2.0 1.0 2.5 0.5 
Optimisation 
condition 9 
11.5 2.5 1.5 2.5 1.0 1.0 2.0 2.5 0.5 
 
Stratagene’s QuikChange method of SDSM mutagenesis was used to introduce mutations into the 
YSBLIC3C-PpLAAO plasmid in 2x 25 µL reactions using PCR cycle C (Table 2.1) and PCR mix 
H (Table 2.2) with either the PNDTB-for and PNDTB-rev primers (Table 2.3) or the PNDTC-for 
and PNDTC-rev primers (Table 2.3). The 2 products were mixed together to make a total reaction 
volume of 50 µL. 25 µL of the PCR mix were analysed with 1% agarose gel electrophoresis 
(Section 3.1.1). The remaining 25 µL of PCR mix were mixed with 1 µL of DpnI restriction 
enzyme. The mixture was incubated at 37°C for 3 h. 2 µL of reaction product were cooled and used 
to transform 75 µL of E. coli Top10 Electrocompetent cells using electroporation. 
 
Six colonies from the PNDTB reactions were each used to inoculate 5 mL of LB media containing 
30 µg mL
-1
 of kanamycin. These starter cultures were incubated at 37°C with shaking at 180 r.p.m 
overnight. Plasmid DNA was purified using Sigma-Aldrich’s GenElute Miniprep kit. To determine 
gene insert size, the plasmid DNA was amplified by PCR using PCR cycle condition A (Table 
2.1), PCR mix H (Table 2.2) and the PpLAAO-for and PpLAAO-rev primers (Table 2.3). Product 
was analysed using 1% agarose gel electrophoresis. 
 
LB-media (V=1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
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2.7 Random mutagenesis of wild type PpLAAO gene sequence 
 
PpLAAO gene sequence was mutagenized at a low range frequency using the Genemorph® II 
EZClone Domain Mutagenesis Kit, purchased from Stratagene. High-purity salt-free primers were 
synthesized by Eurofins/MWG Biotech (Ebersberg, Germany). Sigma-Aldrich GenElute Gel 
Purification Kit was purchased from Sigma-Aldrich. Materials for LB media were purchased from 
Fisher. PCR cycling was carried out using 500 µL thin-walled PCR tubes and a Techne TC312 
thermal cycler. A control reaction was carried out as according to the Genemorph® II EZClone 
Domain Mutagenesis Kit instructions. 
 
In order to create a target amount of 2-7 mutations in the gene sequence per transformant (1.25- 4.4 
mutation kb
-1
) the Genemorph® II EZClone Domain Mutagenesis Kit instructions recommend 
using an initial target quantity of 500-1000 ng of wild type gene DNA, which equates to 2.2-4.4 µg 
of wild-type pET-YSBLIC3C-PpLAAO plasmid using the following equation: 
 
 
 
 
 
2.2 µg of wild-type pET-YSBLIC3C-PpLAAO was mutagenized using PCR cycle H (Table 2.1), 
PCR mix L (Table 2.2) and the PpLAAO-for and PpLAAO-rev primers (Table 2.3). 2.5 µL of the 
PCR megaprimer product and 2.5 µL (50 ng) of a 1.1 kb gel standard included in the Genemorph® 
II EZClone Domain Mutagenesis Kit were analysed by 1% agarose gel electrophoresis. The 
remaining product was then run on a 1% agarose gel and purified using the Sigma Aldrich 
GenElute Gel purification kit. 
 
The megaprimer product was inserted into the pET-YSBLIC3C plasmid with Stratagene’s 
EZClone reaction, using PCR cycle I (Table 2.1), PCR mix M (Table 2.2) and the megaprimer 
product. Reactions were cooled on ice to below 37°C. 1 µL of DpnI restriction enzyme (included in 
the kit) was added to the reaction product and mixed gently before incubation at 37°C for 2 h. 
 
45 µL of E. coli XL10-Gold supercompetent cells were transformed with 1.5 µL of the DpnI 
treated reaction product as in Section 2.1. Ten 50 µL aliquots of the outgrowth solution were each 
plated onto one LB-agar plates containing 30 µg mL
-1
 of kanamycin, 34 µg mL
-1 
chloramphenicol 
and 15 µg mL
-1
 tetracycline. This resulted in over 4000 colonies. 10 colonies were each used to 
inoculate 5 mL of LB-media containing 30 µg mL
-1
 of kanamycin, 34 µg mL
-1 
chloramphenicol and 
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15 µg mL
-1
 tetracycline and were grown overnight at 37°C with shaking at 180 r.p.m. Cells were 
then spun down at 16,000 g using an Eppendorf 5415 C centrifuge and pellets were stored at -20°C 
until needed. 
 
Colonies were scrubbed off the plates by pipetting 2 mL of LB+ media to each plate and 
resuspending the colonies into the media using a glass spreader under sterile conditions. 
Resuspended colonies were collected using a pipette and spun down at 16,000 g using an 
Eppendorf 5415 C centrifuge. Mutated plasmids were purified using Sigma-Aldrich’s GenElute 
Plasmid Miniprep Kit and stored at -20°C until needed. 
 
LB+ media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, 12.5 mL 1 M MgCl2, 12.5 mL 
1 M MgSO4, 20 mL 20% (w/v) D-glucose, H2O (18.2 Ω
.
cm) 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, H2O (18.2 Ω
.
cm) 
LB media (V= 1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
 
2.8 Screening of Random Mutagenesis and SDSM CASTing libraries 
 
2.8.1 Solid Phase HRP assay of Random Mutagenesis and SDSM CASTing libraries A and D 
 
Colonies lifted using Whatman filter paper. DAB tablets and HRP were purchased from Sigma-
Aldrich, KH2PO4/K2HPO4 buffer solution was provided by Ingenza Ltd. 
 
1 µL of purified PNDTA plasmid library (prepared as in Section 2.6) was used to transform E. coli 
BL21-DE3 Electrocompetent cells using electrophoresis. Cells were diluted by 6 times in LB-
media and 120 µL aliquots of diluted cells were each spread over one LB-agar plate containing 30 
µg mL kanamycin and 100 µM IPTG.  
 
2 µL of purified PNDTD plasmid library (prepared as in Section 2.6) was used to transform 50 µL 
of E. coli Rosetta-2-DE3 competent cells using heat shock. 100 µL aliquots were each spread over 
one LB-agar plate containing 30 µg mL
-1
 kanamycin, 34 µg mL
-1
 chloramphenicol and 100 µM 
IPTG.  
 
2 µL of purified random mutagenesis plasmid library (prepared as in Section 2.7) was used to 
transform 50 µL of E. coli Rosetta-2-DE3 competent cells using heat shock. 100 µL aliquots were 
each spread over one LB-agar plate containing 30 µg mL
-1
 kanamycin, 34 µg mL
-1
 
chloramphenicol and 100 µM IPTG. 
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Resulting colonies were lifted off of the plates onto filter paper under sterile conditions by placing 
an 8 cm disk of filter paper directly onto the LB-agar and rubbing with a glass spreader until wet 
through. Filter paper was lifted off of plate and placed colony side up into a sealable box containing 
damp tissue paper. Boxes were sealed and frozen overnight at -80°C. 
 
The next morning the filter papers containing colonies were thawed at room temperature for one h. 
Fresh 8 cm filter paper disks were placed into 8 cm round petri dishes containing 2 mL of assay 
solution and allowed to soak up assay solution. One thawed filter paper was placed colony side up 
into each petri dish. Petri dishes were then placed with lids on into a sealed box containing damp 
tissue paper. The sealed box was left in the dark to allow assays to develop. Colonies showing 
oxidase activity turned brown compared to colonies containing no active oxidase (Figure 2.4). 
 
Figure 2.4 Example of solid phase HRP-based oxidase assay. a. Wild-type PpLAAO colonies screened with 
20 mM L-aspartate as substrate, brown colour shows presence of H2O2 produced by active oxidase. b Wild-
type PpLAAO colonies screened with H2O (18.2 Ω
.cm) as substrate, no brown colour development seen. 
 
The PNDTA library was screened with 20 mM L-aspartate, 1 mM, 2 mM, 4 mM, 10 mM and 20 
mM LD-asparagine and 40 mM, 60 mM, 80 mM and 100 mM L-homoserine as substrate. Screens 
were left to develop for 4 d. 
 
The PNDTD library was screened with 40 mM LD-aspartate (1 plate), 100 mM L-homoserine (8 
plates), 100 mM L-alanine (10 plates) and 25 mM L-tyrosine (10 plates) as substrate. The screens 
against L-aspartate and L-homoserine were left to develop for 4 d, the screen against L-alanine was 
left to develop for 1 d and the screen against L-tyrosine was left to develop for 2 d. The wild-type 
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control was screened with 40 mM LD-aspartate and H2O (18.2 Ω
.
cm) as substrate. Photos of the 
plate assays were then taken using an Apple iPod Touch Generation 4. 
 
The random mutagenesis library was screened against 20 mM L-aspartate, 20 mM L-tyrosine, 20 
mM L-arginine, 20 mM L-glutamate and 20 mM L-glutamine. Screens were left to develop for 1 d. 
 
Assay solution: 1 DAB tablet per 20 mL, 100 mM KH2PO4/K2HPO4, 25 µg mL
-1 
HRP, 
varied concentration of substrate, pH 7.5 
 
2.8.2 Analysis of potential hits from CASTing library A 
 
BugBuster was purchased from Novagen. Benzonase, TBHBA, Lysozyme and 96-well flat-
bottomed plates were provided by Ingenza Ltd. Bradford reagent was purchased from BioRad. 
HRP and 4-AAP were purchased from Sigma-Aldrich. Protein concentration was determined using 
the Bradford assay setting of an Eppendorf BioPhotometer. 
 
Two colonies from the PNDTA screen against 2 mM LD-asparagine (Referred to as LD-Asn-O1 and 
2) and one colony from the PNDTA screen against 40 mM L-homoserine (Referred to as L-Hse-O) 
deemed to have potential oxidase activity were picked from the filter paper and used to inoculate 5 
mL LB-media contained 30 µg mL
-1
 kanamycin. These starter cultures were incubated at 37°C with 
shaking at 180 r.p.m overnight. 100 µL of starter culture was used to inoculate a fresh 5 mL culture 
of LB-media containing 30 µg mL
-1 
kanamycin. Culture was incubated at 32°C with shaking at 180 
r.p.m until OD600 reached 0.5. Overexpression was induced by adding 5 µL of 1 M IPTG, to give a 
final concentration of 1 mM IPTG. Cells were incubated at 32°C with shaking at 180 r.p.m for 5 h. 
OD600 was measured and a volume of cells equivalent to 1 mL of a culture with OD600 at 5.0 was 
spun down at 16,000 g using a benchtop centrifuge. Cell pellets were stored at -20°C.  
 
Cell pellets were resuspended in 161 µL of resuspension solution. Resuspended cells were 
incubated at 30°C with shaking at 200 r.p.m for 30 min to lyse. Cell debris was spun down at 
16,000 g for 1 min using a benchtop centrifuge. Soluble supernatant was transferred to a fresh 
Eppendorf tube. 20 µL of lysate was diluted with 180 µL of H2O (18.2 Ω
.
cm) three times. 50 µL of 
diluted lysate was mixed with 1450 µL of Bradford reagent. A reagent/lysate mixture was left for 
15 min at room temperature to develop. A595 was measured using the Bradford setting on an 
Eppendorf Biophotometer three times for each dilution. Protein concentration was determined 
using a standard curve for protein concentration that had been set previously. The mean of the three 
readings was calculated and used to determine the mean concentration of protein in each cell lysate. 
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10 µL of lysate was pipetted into a single well of a 96-well plate three times for each substrate 
tested. 190 µL of assay solution was added to each well. Each lysate was tested against 100 mM L-
homoserine, 20 mM LD-asparagine, 20 mM L-aspartate and H2O (18.2 Ω
.
cm). 
 
Abs510 nm over 5 min was measured using Ingenza’s 96-well plate reader. The plate was then left at 
room temperature to develop for 1 h, and A510 was measured using the 96-well plate reader. Rate of 
reaction was determined by subtracting the absorbance at 0 min from the absorption after 5 min. 
The mean rate of reaction of the control reactions using H2O (18.2 Ω
.
cm) as a substrate was 
subtracted from the rates of the other reactions to remove any background absorbance. The mean 
absorption measurement of the control reactions after 1 h was also subtracted from the absorption 
of the other reactions after 1 h. 
 
LB-media (V=1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 
Ω.cm) 
Resuspension solution (V= 161 µL): 150 µL BugBuster, 25 U Benzonase, 0.15 µg Lysozyme  
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.5 
Assay solution: 1 x Reaction Buffer, 25 µg mL
-1
 HRP, and varied 
concentration of substrate 
 
2.8.3 Analysis of potential Screening Hits from CASTing library D 
 
TBHBA was purchased from Alfa Aesar. 4-AAP, HRP, L-alanine, L-asparagine, L-aspartate and L-
tyrosine were purchased from Sigma-Aldrich. KH2PO4 and K2HPO4 were purchased from Fisher, 
AEBSF was purchased from Melford and 96-well flat bottomed plates were purchased from 
Corning Costar. A510 was measured on a BMG Labtech PolarStar Optima plate reader. 
 
Three colonies from the PNDTD screen against L-aspartate (labelled Asp1-3) seven colonies from 
the PNDTD screen against L-homoserine (labelled H1-7), ten colonies from the PNDTD screen 
against L-alanine (labelled Ala1-10) and five colonies from the screen against L-tyrosine (labelled 
Tyr1-5) that had developed a brown colour (Figures 6.16-6.19) were picked from the filter paper 
and used to inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin and 34 µg mL
-1
 
chloramphenicol. These starter cultures were grown overnight at 37°C with shaking at 180 r.p.m. 
(Cultures Asp3, H1, H7 and Tyr4 failed to grow). 
 
The next morning 100 µL of starter culture was used to inoculate 5 mL of fresh LB-media 
containing 30 µg mL
-1
 kanamycin and 34 µg mL
-1
 chloramphenicol. The remaining starter culture 
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was spun down at 16,000 g in an Eppendorf 5415 C centrifuge and stored at -20°C. The fresh 
cultures were grown at 37°C with shaking at 180 r.p.m until OD600 reached 0.5. Gene 
overexpression was induced with 1 mM of IPTG and cells were left to grow at 16°C overnight. 
Cells were spun down at 16,000 g for 1 min using an Eppendorf 5415 C centrifuge. Cell pellets 
were resuspended in 500 µL of buffer 1 and sonicated for 20 s at 15 microns. Cell debris was then 
spun down for 5 min at 13,700 g in the Eppendorf 5415 C centrifuge. Soluble supernatant was 
transferred into a fresh eppendorf tube and the insoluble pellet was resuspended in 500 µL of buffer 
1. Insoluble protein samples were analysed on 12% SDS-PAGE. 
 
Based on those results (Figure 6.20) the Ala3, Ala5 and Ala6 pellets stored earlier were mini-
prepped using the Sigma-Aldrich Gen Elute Plasmid Miniprep kit to purify the plasmids. Plasmids 
were concentrated to between 100-150 ng µL
-1
 and then sent for sequencing (Section 2.2.4) using 
the T7 and T7-term primers (Table 2.3) by the York University Genomics group. The sequence 
chromatograms were analysed with the program Chromas lite, version 2.01 from Technelysium 
(free software). 
 
Buffer 1:    50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.5 
Assay solution: 1 x Reaction Buffer, 25 µg mL
-1
 HRP, and varied 
concentration of substrate 
 
2.8.4 Analysis of three error-prone PCR mutants 
 
TBHBA was purchased from Alfa Aesar. 4-AAP, HRP, L-alanine, L-asparagine, L-aspartate, L-
glutamate, L-glutamine and L-tyrosine were purchased from Sigma-Aldrich. KH2PO4 and K2HPO4 
were purchased from Fisher, AEBSF was purchased from Melford and 96-well flat bottomed plates 
were purchased from Corning Costar. A510 was measured on a BMG Labtech PolarStar Optima 
plate reader. 
 
Five colonies from the epPCR screen against L-aspartate (labelled PPM 1-5) were picked from the 
filter paper and used to inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin and 34 µg 
mL
-1
 chloramphenicol. These starter cultures were grown overnight at 37°C with shaking at 180 
r.p.m. The next morning 100 µL of starter culture was used to inoculate 5 mL of fresh LB-media 
containing 30 µg mL
-1
 kanamycin and 34 µg mL
-1
 chloramphenicol. The remaining starter culture 
was spun down at 16,000 g in an Eppendorf 5415 C centrifuge and stored at -20°C.  
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The fresh cultures were grown at 37°C with shaking at 180 r.p.m until OD600 reached 0.5. Gene 
overexpression was induced with 1 mM of IPTG and cells were left to grow at 16°C overnight. 
Cells were spun down at 16,000 g for 1 min using an Eppendorf 5415 C centrifuge. Cell pellets 
were resuspended in 500 µL of buffer 1 and sonicated for 20 s at 15 microns. Cell debris was then 
spun down for 5 min at 13,700 g in the Eppendorf 5415 C centrifuge. Soluble supernatant was 
transferred into a fresh eppendorf tube and the insoluble pellet was resuspended in 500 µL of buffer 
1. Insoluble and soluble protein samples were analysed on 12% SDS-PAGE. 
 
Soluble protein fractions were tested for activity against 20 mM L-aspartate using the assay 
solution. Assays were prepared in a 1.5 mL Eppendorf tube and left to develop for 1 h. Colour 
development was determined by visual inspection. 
 
The cells pellets stored earlier were mini-prepped using the Sigma-Aldrich Gen Elute Plasmid 
Miniprep kit to purify the plasmids. Plasmids were concentrated to between 100-150 ng µL
-1
 and 
then sent for sequencing (Section 2.2.4) using the T7 and T7-term primers by the York University 
Genomics group. The sequence chromatograms were analysed with the program Chromas lite, 
version 2.01 from Technelysium (free software). Distance of mutated residues from active site of 
the E. coli L-aspartate oxidase structure created by Bossi et al.
[65]
 was calculated using Coot.
[113]
 
 
Buffer 1:    50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0 
2 x Reaction Buffer (V= 50 mL): 100 mM KH2PO4/K2HPO4, 20 mg (TBHBA), 15 mg 4-
AAP, pH 7.5 
Assay solution: 1 x Reaction Buffer, 25 µg mL
-1
 HRP, 20 mM L-aspartate 
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Chapter 3   Cloning, Expression and Assay of Targets 
 
In order to increase the available repertoire of oxidases, particularly ones with activity against L- 
alanine and L-tyrosine, and to determine which oxidase would be worth focusing on, seven target 
oxidases; all within the first fifteen BLAST homology results of the L-amino acid oxidase (L-AAO) 
from Synechococcus ATCC 27144, in organisms for which we had access to genomic DNA and 
described as putative L-AAOs, Oxidoreductases (ORs) or Amine Oxidases (AOs) (Table 3.1) 
(Figure 3.1), were selected to be cloned using Ligation Independent Cloning (LIC) into the 
modified pET28a plasmid, pET-YSBLIC3C.  
 
Table 3.1: Summary of seven target oxidases to be cloned into pET-YSBLIC3C. 
UniProt Code Classification Species Known substrates Abbreviation 
P72346 
L-amino acid 
oxidase 
Synechococcus sp. 
strain ATCC 27144 
L-arginine, L-lysine SLAAO 
Q8VPD4 
L-amino acid 
oxidase 
Rhodococcus 
opacus 
L-alanine, L-histidine RoLAAO 
Q88MZ2 
L-amino acid 
oxidase 
Pseudomonas 
putida 
L-aspartate PpLAAO 
O31616 
L-amino acid 
oxidase 
Bacillus subtilis Glycine, sarcosine
[101]
 BsGO 
Q8YKW9 
L-amino acid 
oxidase 
Anabaena sp. strain 
PCC 7120 
- AsAAO 
Q5YV66 Oxidoreductase Nocardia farcinica - NfOR 
Q81RW3 Amine Oxidase Bacillus anthracis - BaAO 
 
The pET-YSBLIC3C vector was made from Novagen’s pET28a3C plasmid, which contains a 3C 
protease recognition site and hexa-histidine (His6) purification tag (Figure 3.2a), however 
recognition sites AscI and BseRI have been added, and thymine bases in the His6 tag have been 
replaced with cytosines (Figure 3.2b). When the BseRI restriction site is cleaved it causes 
staggered cleavage 8 bp to 10 bp upstream of the site on both strands, which results in the 
linearised plasmid having 2 bp long 3’ overhangs. These overhangs on the plasmids are treated 
with bacteriophage T4 DNA polymerase in the presence of dTTP, which results in the excision of 
the 3’ overhangs up to the first thymine on the 3’ side, leaving a 14-15 bp 5’ overhang on each 
side.
[114]
  
 
The desired gene insert for the pET-YSBLIC3C plasmid can then be amplified using primers with 
LIC-specific additions, which when treated with T4 DNA polymerase in the presence of dATP 
result in 5’ overhangs complementary to those on the pET-YSBLIC3C plasmid, allowing for a 
ligation reaction that is independent of a ligase enzyme to be performed.
[114]
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Q8VPD4_RoLAAO      -----------------------MaFtRRsFmkglgatggAGlaYGaMstlGlApstAaP 
Q5YV66_NfOR        -------------------------mvdRsv----------------------------- 
P72346_SLAAO       -----------------------MrFsRRrFLqsslgaaattglaGtLaAgGqAqtrStP 
Q81RW3_BaAO        -------------------------mmQpltmermlhiinvGlv---------------- 
Q8YKW9_AsAAO       mqhreftgcihtscrlpisfifmfnlnRRqFLlrstlaiaAtvsYdhvqAqkpkspgtlP 
O31616_BsGO        --------------------------mKRhY----------------------------- 
Q88MZ2_PpLAAO      --------------------------msqqF----------------------------- 
 
Q8VPD4_RoLAAO      aRtfqplaagdligKvKgsHsVVVlGgGpAGLcSAfeLqKaGYKVTVLEArtRpGGRVwT 
Q5YV66_NfOR        --------------------DVVVVGAGIAGLvAArdLvRtGHEVlVLEArDRvGGRLln 
P72346_SLAAO       vR----------------krsVlVlGAGMAGLtAAlsLlRrGHQVTViEyqNRiGGRLlS 
Q81RW3_BaAO        --------------KtKnpkqIIiVGAGIsGLvAAslLkEaGHKVTILEAnNRiGGRIyT 
Q8YKW9_AsAAO       --------------KglprrkVIVVGAGIsGLvAAyeLtavGHdVTlLEAskRiGGRVlT 
O31616_BsGO        --------------------EaVVIGgGIiGsaiAyyLaKenkntalfESgt-mGGRttS 
Q88MZ2_PpLAAO      ------------------qHDVlVIGsGaAGLslAlnL-pshlRVaVLskgDlsnGstfw 
 
Q8VPD4_RoLAAO      ARGGseetdlsgetqkctFseGhfynvGatrIpqsH-itldYcRElgVeIqgFgnqnAnt 
Q5YV66_NfOR        A----------------elpgGapiEvGgqwVgpTqhramAlIhElg--LqtFpthdt-- 
P72346_SLAAO       v----------------plkgGqfsEAGgghfranmpyvlSYIRhfkLpLltlndglp-- 
Q81RW3_BaAO        iRe--------------pFsrGlyfnAGpmrIpdTHkltlAYIRkfkLpLnlFinktA-- 
Q8YKW9_AsAAO       lRG--------------aFqgedllElGaarIpsnHhltfgYIKhfgLkLsqFapadg-- 
O31616_BsGO        AaaG---------------------mlGahaeceerdaffdFamhsqrlykglgeel--- 
Q88MZ2_PpLAAO      AqGG-------------vaavldntDtvqshVedTlnaggglchEdaVrftvehsreA-- 
 
Q8VPD4_RoLAAO      fVNyqsdTslsgqsvTyrAakadtFgYmsellkkatdqgaldqvLsREDkdALSEfLsdf 
Q5YV66_NfOR        -------------GraiaeigsSraeY--------------tgaIPKlNplALADVaqa- 
P72346_SLAAO       --------rylfdGkTadAaDlSrWpw---------------dlaPQErrvSVAsLLnt- 
Q81RW3_BaAO        --SdiiyTnnikkrlSifekNpSilgY---------------piLeREkgktaeELMle- 
Q8YKW9_AsAAO       ------------------------------------------kyLtikDgkr-------- 
O31616_BsGO        ---------yalsGvdirqhNggmFkl----------------afseED----------- 
Q88MZ2_PpLAAO      -IqwlieqgvpftrdehySvDdggFeF----------------hLtREgghS-------- 
 
Q8VPD4_RoLAAO      gdlsddgRyLgssrRgyDsEPgaGlNfgt---Ek-----kpfaMqEvIrsgigrNfsfdf 
Q5YV66_NfOR        -----qlRLdrlarRvartDP-----Wra---Er-aEalDaQtfdtwLrrttytaagrsf 
P72346_SLAAO       --------yL--iLnglDtDtvldaNWpd---aQAiQQlDnltLsQlIrq-vggseafiq 
Q81RW3_BaAO        --------VLepiLnyikkDP--nkNWsi---vE--KKykaysLgtfLte-yysDgaidm 
Q8YKW9_AsAAO       --------LLipakvlfqnqP----------------QirpQeIqKl------------- 
O31616_BsGO        ------------vLQlrqmDdldsvsWys---KEevlEkEpyasgdifgasfiqDdvhve 
Q88MZ2_PpLAAO      ------------hrRiihaadatGaaifttllEQArQRpNiQlLeQrVavdlitErrlgl 
 
Q8VPD4_RoLAAO      gydqammmFtp--------------------------vGG--mDRi---yyAfqdrIGtD 
Q5YV66_NfOR        frviteavFaaGpedlsalwascYlgaggGvdtmidVaGGaqqDRvvggtqAiaiALagE 
P72346_SLAAO       lldahggtFtssspalgVipdlaYh---fGdqnlFrIqGG--nDRL---pkAmaaAIGsE 
Q81RW3_BaAO        igvlldmeaymGmslieVlremvff---tsttkyYeITGG--mDaL---pkAflsqLnen 
Q8YKW9_AsAAO       -------------------------------------TdG--fDlL---pkAfaqALtkE 
O31616_BsGO        pyfvcka------------------------------------------yvkaakmLGaE 
Q88MZ2_PpLAAO      pgerclgaYvldrntgeVdt--------fGarftvlaTGG--aaKvylytsnpdgAcGdg 
 
Q8VPD4_RoLAAO      niv---fgaeVtsmknvsegVtVey--taGg--skksItaDyAIcTIP------phLvgR 
Q5YV66_NfOR        lgdrvvlgsPVseVewdeagVrVra--ggG------tVrarrAVVaVP------ppLaaR 
P72346_SLAAO       rfi---ldaPVvaIdqqanratVtv--kdGr-----tfqGDaiIsTIP------ftVlpe 
Q81RW3_BaAO        if----mrykVekIiqenskVmIqv--nheqtIerfmVtGDvAIVTIP------fsalrf 
Q8YKW9_AsAAO       ik----ldePVarIvqtsngVeVsc--lsGq-----rylGDyvlcTVP------ltVlnQ 
O31616_BsGO        if----ehtPVlhVerdgeaLfIkt--psG------dVwanhvVVasg------------ 
Q88MZ2_PpLAAO      iamawragcrVanlefnqfhptclyhpqaksfLiteaLrGEgAlLrLPngerfmprfdpR 
 
Q8VPD4_RoLAAO      Lq----NnLpgdvltal-KaakpssSgKlgieysrrwWEtE-drIYGGasntDkdIsqim 
Q5YV66_NfOR        IrFSP--gLpgdRdQlv-QrMpmgrvvKvnvvydepFWraD-G--FsGqavsDrrplavv 
P72346_SLAAO       VavrP--gwSagKrRmF-aeMeweqtvKviaqtrspvWlaQ-n-VHGwpmagsdrpwerv 
Q81RW3_BaAO        VeiqPyNlfSyyKrRai-ReLnyiaAtKiaiefksrFWEka-G-qYGGksitDlpIrfty 
Q8YKW9_AsAAO       ItFSP--eLSeeKkQaaaggynyraAtRgfvkfpnrFWErE-n-LnGwgffdDeeLwhtt 
O31616_BsGO        -------vwSg----mFfKqLglnnAflpvkgeclsvW------------ndDipLtktl 
Q88MZ2_PpLAAO      eelAPrdiVaraidhem-KrLgvdcvyldithkpadFiKshfptVYerclafgidItrqp 
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Q8VPD4_RoLAAO      FP-YdhynsdrgvVvayYssGKrqEAfeslthrqRlAkaIaEgseihGek-YTrdisssf 
Q5YV66_NfOR        Fd--ntppagspGVLvgFleGRhaDAcsrmdhptRrAqvIdDlagyfGprarTpidyiEk 
P72346_SLAAO       id-itgnegggyGntffYlnGRnkDAmlarPkseRaqaiVdqfrsdlpdl-Fdevvtlad 
Q81RW3_BaAO        YPsYgihtpgaatVLasYtwadealtwdslPdreRiryaLkNlaeiyGeivYSefvtgts 
Q8YKW9_AsAAO       w-----drpektGILhaYlkGekgleidgfegktQqqklLqhwekilpgv--Snysvrsy 
O31616_BsGO        YhdHcyivprksGrLvvgatmKpgD-wsetPdlgglesvMkkaktmlpai---qnmkvDr 
Q88MZ2_PpLAAO      iPvvpaahytcgGVMv--------DdcghtdvpglyAigetsftglhGanrmAsnsllEc 
 
Q8VPD4_RoLAAO      sgSWrRt--------------kYSesAWanwagsGgshggaatpeYek-llEPvdkIy-F 
Q5YV66_NfOR        --dWade--------------eYSrGcy------GaftapgtltrFghalrpPiGplH-w 
P72346_SLAAO       F-AWgeq--------------pwirGSf------Ggpplgga--wmirewttPeGlIH-F 
Q81RW3_BaAO        F-SWsKn--------------pYScGAf------tafepgqElelFpy-itsPsGkVH-F 
Q8YKW9_AsAAO       FhSWtKd--------------iwSkGgW------ayptdeqEkklFpe-lgKseGkIy-F 
O31616_BsGO        F--Wa-----------------------------GlrpgtkDgkpYigrhpEdsrilf-a 
Q88MZ2_PpLAAO      F-vygRaaaadiqahleqvampkalpgWda----sqvtdsdEdviiahnwdElrrfmwdY 
 
Q8VPD4_RoLAAO      AGdHlsna-iaWqhGALt----------SardVvthI----------------------- 
Q5YV66_NfOR        AGteTatrwaGYidGAaE----------SGhRtAREI----------------------- 
P72346_SLAAO       AGdfTTmk-sGWvEGAIE----------SGlRaARqI----------------------- 
Q81RW3_BaAO        AGeHTTlt-hGWmQGAIE----------SGiRVAhEV----------------------- 
Q8YKW9_AsAAO       AGeHTskt-rGWlQGALE----------SGlKaAQEI----------------------- 
O31616_BsGO        AGhfrngillapatGALi----------SdliMnKEV----------------------- 
Q88MZ2_PpLAAO      vGivrTskrlqraQhrIrllldeidefySnyKVSRdlielrnlaqvaelmilsamqrkes 
 
Q8VPD4_RoLAAO      --------hervaqEa----------- 
Q5YV66_NfOR        --------aaaldprhDaaspsalR-- 
P72346_SLAAO       --------dpgaqpEaDtflrQeqRcn 
Q81RW3_BaAO        --------nek---------------- 
Q8YKW9_AsAAO       --------hfagstapr---------- 
O31616_BsGO        --------nqdwlhafridrkEavqi- 
Q88MZ2_PpLAAO      rglhytldypgmldEakdtilnpl--- 
 
Figure 3.1 MUSCLE sequence alignment of the seven targets selected to be cloned into pET-YSBLIC3C. 
Identical residue highlighted in blue, similar residues highlighted in grey. 
 
                           3C Protease 
5’-TATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGGCCCCATATGGCTAGCATGACTGGT-3’ 
3’-ATATGGTACCCGTCGTCGGTAGTAGTAGTAGTAGTGTCGTCGCCGGACCTTCAAGACAAGGTCCCCGGGGTATACCGATCGTACTGACCA-5’ 
         MetGlySerSerHisHisHisHisHisHisSerSerGlyLeuGluValLeuPheGlnGlyProHisMetAlaSerMetThrGly 
 
 
 
            AscI 
5’-TATACCATGGGCAGCAGCCATCATCACCACCACCACAGGCGCGCCTTCTCCTCACTGTTCCAGGGGCCCCATATGGCTAGCATGACTGG-3’ 
3’-TATAGGTACCCGTCGTCGGTAGTAGTGGTGGTGGTGTCCGCGCGGAAGAGGAGTGACAAGGTCCCCGGGGTATACCGATCGTACTGACC-5’ 
         MetGlySerSerHisHisHisHisHisHis           BseRI     
 
Figure 3.2 a. Cloning region of Novagen pET28a derivative pET28a3C, sequences coding for His6 protein 
purification tag and the 3C protease recognition site are underlined. Recognition sequences for NcoI 
(CCATGG) and NdeI (CATATG) are highlighted in bold. b. LIC region of pET-YSBLIC3C. Recognition 
sequences for AscI (GGCGCGCC) and BseRI (GAGGAG) are underlined and labelled. Recognition 
sequences for NcoI (CCATGG) and NdeI (CATATG) are highlighted in bold. 
 
Cloned targets were then used to transform E. coli BL21-DE3, B834-DE3 and Rosetta-2-DE3 
competent protein expression strains to assess expression levels and solubility of each target. 
LIC 
 
a. 
 
b. 
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Whole cells and soluble protein fractions of each target protein were then screened for activity 
against all 20 natural amino acids and three amines, amylamine, phenylethylamine and AMBA. 
 
3.1 Cloning of targets into pET-YSBLIC3C plasmid 
 
The L-AAOs from Synechococcus sp. strain ATCC 27144, Rhodococcus opacus and Pseudomonas 
putida (SLAAO, RoLAAO and PpLAAO, respectively) had already been cloned into the pET-
YSBLIC3C vector by the Technology Facility of the University of York. The L-AAOs from 
Bacillus subtilis and Anabaena sp. strain PCC 7120 (BsGO and AsAAO respectively), the 
oxidoreductase from Nocardia farcinica (NfOR) and the amine oxidase from Bacillus anthracis 
(BaAO) were amplified from genomic DNA via PCR as in Section 2.2.1 (Figure 3.3). 
 
The non recombinant pET-YSBLIC3C vector was cut with restriction endonuclease BseRI, a LIC-
qualified T4 DNA polymerase was used to excise the 3’ strand of the amplified gene insert and the 
restricted pET-YSBLIC3C plasmid up to the first adenine and thymine nucleotide, respectively, 
leaving 5’ overhangs with complementary sequences between the amplified gene insert and the 
restricted pET-YSBLIC3C plasmid.  
 
The gene insert was then annealed to the pET-YSBLIC3C plasmid and transformed into E. coli 
Novablue competent cells as in Section 2.2.2. Several colonies from each target transformation 
were picked for plasmid purification. The size of the insert was checked by restriction analysis 
(Section 2.2.3, Figure 3.4) and plasmids with the correctly sized insert (AsAAO 4, BaAO 4, BsGO 
1 and NfOR 2) were sent for sequencing (Section 2.2.4). All sequences were as expected with no 
undesired mutations. 
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Figure 3.3: 1% agarose gel separations of DNA from PCR amplification of cloning targets. a. Amplification 
of AsAAO from Anabaena genomic DNA: Lane 1, 1 kb DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 
5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Positive reaction (1281 bp); Lane 3, forward primer negative control;  Lane 
4, reverse primer negative control; Lane 5, template negative control. b. Amplification of BaAO from 
Bacillus anthracis genomified DNA: Lane 1, 1 kb DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 
kb, 8 kb, 10 kb); Lane 2, positive reaction in 0% DMSO (1437 bp); Lane 3, positive reaction in 5% DMSO; 
Lane 4, positive reaction in 10% DMSO. c. Amplification of BsGO from Bacillus subtilis genomic DNA: 
Lane 1, 1 kb DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Positive 
reaction (1110 bp); Lane 3, forward primer negative control;  Lane 4, reverse primer negative control; Lane 
5, template negative control. d. Amplification of NfOR from Nocardia genomic DNA: Lane 1, 1 kb DNA 
Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Positive reaction (1392 bp); 
Lane 3, forward primer negative control;  Lane 4, reverse primer negative control; Lane 5, template negative 
control. 
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Figure 3 .4: 1% agarose gel separation of restriction digest of potential AsAAO plasmids: Lane 1, 1kb DNA 
Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Uncut LIC3C vector; Lane 3-
6, digested AsAAO colonies 1-4; Lane 7, Control colony. b. 1% PAGE gel separation of restriction digest of 
potential BaAO plasmids: Lane 1, 1kb DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 
10 kb);  Lane 2-6, digested BaAO colonies 1-5; Lane 7, Uncut LIC3C vector. c. 1% PAGE gel separation of 
restriction digest of potential BsGO plasmids: Lane 1, 1kb DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 
kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Uncut LIC3C vector; Lane 3-4, digested BsGO colonies 1-2; Lane 5, 
Control colony. d. 1% PAGE gel separation of restriction digest of potential NfOR plasmids: Lane 1, 1kb 
DNA Ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, Uncut LIC3C vector; 
Lane 3-4 digested NfOR colonies 1-2. 
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3.2 Expression and solubility of targets 
 
The seven cloned targets and the non recombinant pET-YSBLIC3C vector were each used to 
transform E. coli BL21-DE3, B834-DE3 and Rosetta-2-DE3 competent protein productions strains. 
For each target and strain, gene overexpression was induced at 16°C overnight, 30°C for 5 hours 
and 37°C for 3 hours. Cells were then sonicated and separated into insoluble and soluble protein 
fractions as in Section 2.2.5. Protein fractions were the analysed using 12% SDS-PAGE (Figures 
3.5 - 3.12). 
 
The pET-YSBLIC3C vector was used as a negative control (Figure 3.5). 
 
Figure 3.5: a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with non recombinant 
pET-YSBLIC3C plasmid: Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C 
insoluble fraction 16/30/37°C induction; Lane 5-7, BL21- pET-YSBLIC3C soluble fraction 16/30/37°C 
induction. b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-DE3 transformed with 
non recombinant pET-YSBLIC3C plasmid. Lane 1, low range molecular weight marker; Lane 2-4, B834-
pET-YSBLIC3C insoluble fraction 16/30/37°C induction; Lane 5-7, B834-pET-YSBLIC3C soluble fraction 
16/30/37°C induction; Lane 8-10, Rosetta-2-pET-YSBLIC3C insoluble fraction 16/30/37°C; Lane 11-13 
Rosetta-2-pET-YSBLIC3C soluble fraction 16/30/37°C induction. 
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The pET-YSBLIC3C-AsAAO strains all expressed genes encoding proteins close to the correct 
size (48 kDa), however protein solubility was poor even at lower induction temperatures (Figure 
3.6). 
 
Figure 3.6: a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
AsAAO: Lane 1, low range molecular weight marker; Lane 2-4, BL21- pET-YSBLIC3C-AsAAO insoluble 
fraction 16/30/37°C induction (48 kDa); Lane 5-7, BL21- pET-YSBLIC3C-AsAAO soluble fraction 
16/30/37°C induction (48 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-
DE3 transformed with pET-YSBLIC3C-AsAAO. Lane 1, low range molecular weight marker; Lane 2-4, 
B834- pET-YSBLIC3C-AsAAO insoluble fraction 16/30/37°C induction (48 kDa); Lane 5-7, B834 pET-
YSBLIC3C--AsAAO soluble fraction 16/30/37°C induction (48 kDa); Lane 8-10, Rosetta-2- pET-
YSBLIC3C-AsAAO insoluble fraction 16/30/37°C (48 kDa); Lane 11-13 Rosetta-2- pET-YSBLIC3C-
AsAAO soluble fraction 16/30/37°C induction (48 kDa). 
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The pET-YSBLIC3C-BaAO strains again showed good expression of a protein around the correct 
size (54 kDa) but poor solubility, although solubility showed a slight increase at lower induction 
temperatures (Figure 3.7). 
 
Figure 3.7: a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
BaAO: Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-BaAO insoluble 
fraction 16/30/37°C induction (54 kDa); Lane 5-7, BL21-pET-YSBLIC3C-BaAO soluble fraction 
16/30/37°C induction (54 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-
DE3 transformed with pET-YSBLIC3C-BaAO. Lane 1, low range molecular weight marker; Lane 2-4, 
B834-pET-YSBLIC3C-BaAO insoluble fraction 16/30/37°C induction (54 kDa); Lane 5-7, B834-pET-
YSBLIC3C-BaAO soluble fraction 16/30/37°C induction (54 kDa); Lane 8-10, Rosetta-2-pET-YSBLIC3C-
BaAO insoluble fraction 16/30/37°C (54 kDa); Lane 11-13 Rosetta-2-pET-YSBLIC3C-BaAO soluble 
fraction 16/30/37°C induction (54 kDa). 
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The protein encoded by the pET-YSBLIC3C-BsGO strains appeared to be slightly larger on the 
SDS-PAGE than the expected 42 kDa. All strains showed good expression and reasonable 
solubility at all induction temperatures, although solubility appeared to be highest in the BL21-
pET-YSBLIC3C-BsGO strain (Figure 3.8). 
 
Figure 3.8:  a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
BsGO: Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-BsGO insoluble 
fraction 16/30/37°C induction (42 kDa); Lane 5-7, BL21-pET-YSBLIC3C-BsGO soluble fraction 
16/30/37°C induction (42 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-
DE3 transformed with pET-YSBLIC3C-BsGO: Lane 1, low range molecular weight marker; Lane 2-4, 
B834-pET-YSBLIC3C-BsGO insoluble fraction 16/30/37°C induction (42 kDa); Lane 5-7, B834-pET-
YSBLIC3C-BsGO soluble fraction 16/30/37°C induction (42 kDa); Lane 8-10, Rosetta-2-pET-YSBLIC3C-
BsGO insoluble fraction 16/30/37°C induction (42 kDa); Lane 11-13 Rosetta-2-pET-YSBLIC3C-BsGO 
soluble fraction 16/30/37°C induction (42 kDa). 
 116 
The pET-YSBLIC3C-NfOR protein was not expressed at the correct size (49 kDa) unless induced 
at high temperatures, at lower temperatures a smaller protein around 40 kDa appears to be 
produced instead. The best expression appears to be in Rosetta-2-pET-YSBLIC3C-NfOR strains 
induced at 37°C; however solubility was still poor in all strains (Figure 3.9). 
 
Figure 3.9:  a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
NfOR. Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-NfOR insoluble 
fraction 16/30/37°C induction (49 kDa); Lane 5-7, BL21-pET-YSBLIC3C-NfOR soluble fraction 
16/30/37°C induction (49 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-
DE3 transformed with pET-YSBLIC3C-NfOR. Lane 1, low range molecular weight marker; Lane 2-4, B834-
pET-YSBLIC3C-NfOR insoluble fraction 16/30/37°C induction (49 kDa); Lane 5-7, B834-pET-YSBLIC3C-
NfOR soluble fraction 16/30/37°C induction (49 kDa); Lane 8-10, Rosetta-2-pET-YSBLIC3C-NfOR 
insoluble fraction 16/30/37°C induction (49 kDa); Lane 11-13 Rosetta-2-pET-YSBLIC3C-NfOR soluble 
fraction 16/30/37°C induction (49 kDa). 
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The BL21-pET-YSBLIC3C-PpLAAO strain showed good expression and high solubility of a 
protein around the expected size (59 kDa), particularly when gene overexpression was induced at 
low temperatures. The other pET-YSBLIC3C-PpLAAO strains appeared to produce less protein, 
although soluble protein is still present from the Rosetta-2-pET-YSBLIC3C-PpLAAO strain 
(Figure 3.10). 
 
Figure 3.10: a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
PpLAAO. Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-PpLAAO insoluble 
fraction 16/30/37°C induction (59 kDa); Lane 5-7, BL21-pET-YSBLIC3C-PpLAAO soluble fraction 
16/30/37°C induction (59 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 and Rosetta-2-
DE3 transformed with pET-YSBLIC3C-PpLAAO. Lane 1, low range molecular weight marker; Lane 2-4, 
B834-pET-YSBLIC3C-PpLAAO insoluble fraction 16/30/37°C induction (59 kDa); Lane 5-7, B834-pET-
YSBLIC3C-PpLAAO soluble fraction 16/30/37°C induction (59 kDa); Lane 8-10, Rosetta-2-pET-
YSBLIC3C-PpLAAO insoluble fraction 16/30/37°C induction (59 kDa); Lane 11-13 Rosetta-2-pET-
YSBLIC3C-PpLAAO soluble fraction 16/30/37°C induction (59 kDa). 
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The pET-YSBLIC3C-RoLAAO strains all produced protein at the correct size (53 kDa), although 
the BL21-pET-YSBLIC3C-RoLAAO strain expressed a small (14 kDa) protein when induced at 
16°C and 30°C and the Rosetta-2-YSBLIC3C-RoLAAO strain expressed the small 14 kDa protein 
when induced at 37°C. Despite the apparently high expression none of the strains appeared to 
contain soluble protein (Figure 3.11). Because of this and a preliminary test of the expressed 
proteins activity against its known substrates L-alanine and L-histidine (Table 3.1) that showed no 
activity from the samples, no further work was done using the RoLAAO target. 
 
Figure 3.11:  a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-RoLAAO. Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-
RoLAAO insoluble fraction 16/30/37°C induction (53 kDa); Lane 5-7, BL21-pET-YSBLIC3C-RoLAAO 
soluble fraction 16/30/37°C induction (53 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 
and Rosetta-2-DE3 transformed with pET-YSBLIC3C-RoLAAO. Lane 1, low range molecular weight 
marker; Lane 2-4, B834-pET-YSBLIC3C-RoLAAO insoluble fraction 16/30/37°C induction (53 kDa); Lane 
5-7, B834-pET-YSBLIC3C-RoLAAO soluble fraction 16/30/37°C induction (53 kDa); Lane 8-10, Rosetta-2-
pET-YSBLIC3C-RoLAAO insoluble fraction 16/30/37°C induction (53 kDa); Lane 11-13 Rosetta-2-pET-
YSBLIC3C-RoLAAO soluble fraction 16/30/37°C induction (53 kDa). 
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The pET-YSBLIC3C-SLAAO strains all showed high expression but poor solubility of a protein 
around the expected size of 54 kDa, at all induction temperatures (Figure 3.12). 
 
Figure 3.12:  a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-SLAAO. Lane 1, low range molecular weight marker; Lane 2-4, BL21-pET-YSBLIC3C-
SLAAO insoluble fraction 16/30/37°C induction (54 kDa); Lane 5-7, BL21-pET-YSBLIC3C-SLAAO 
soluble fraction 16/30/37°C induction (54 kDa). b. SDS-PAGE separation of protein from E. coli B834-DE3 
and Rosetta-2-DE3 transformed with pET-YSBLIC3C-SLAAO. Lane 1, low range molecular weight marker; 
Lane 2-4, B834-pET-YSBLIC3C-SLAAO insoluble fraction 16/30/37°C induction (54 kDa); Lane 5-7, 
B834-pET-YSBLIC3C-SLAAO soluble fraction 16/30/37°C induction (54 kDa); Lane 8-10, Rosetta-2-pET-
YSBLIC3C-SLAAO insoluble fraction 16/30/37°C induction (54 kDa); Lane 11-13 Rosetta-2-pET-
YSBLIC3C-SLAAO soluble fraction 16/30/37°C induction (54 kDa). 
 
Based on these results, the optimal expression conditions for each target were chosen (Table 3.2), 
these were used to express protein as in Section 2.2.6. 
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Table 3.2: Summary of expression conditions for six target proteins to be assayed. 
Plasmid E. coli Cell Strain 
Overexpression 
Temperature 
Overexpression 
Time 
Non recombinant pET-YSBLIC-3C BL21-DE3 37°C 3 h 
pET-YSBLIC-3C-AsAAO BL21-DE3 16°C Overnight 
pET-YSBLIC-3C-BaAO BL21-DE3 16°C Overnight 
pET-YSBLIC-3C-BsGO BL21-DE3 37°C 3 h 
pET-YSBLIC-3C-NfOR B834-DE3 37°C 3 h 
pET-YSBLIC-3C-PpLAAO BL21-DE3 16°C Overnight 
pET-YSBLIC-3C-SLAAO Rosetta-2-DE3 37°C 3 h 
 
3.3 Activity assay of target oxidases 
 
The remaining six target enzymes were assayed for activity using a horseradish peroxidase (HRP) 
based assay developed by Ingenza Ltd. to determine the levels of H2O2 being produced as a by-
product of the oxidase activity, as described in Section 2.2.7. The assay contains 4-aminoantipyrine 
(4-AAP) and 2,4,6,tribromo-3-hydroxybenzoic acid (TBHBA), which in the presence of HRP 
combine with the H2O2 to form a soluble red quinoneimine complex. This can be seen visibly and 
qualitative measurement can be performed by reading the absorbance of light at 510 nm. This assay 
was used in a plate format (Figure 3.13) to screen induced whole cells and the induced soluble 
protein fraction of each of the remaining target enzymes against all 20 natural amino acids, 
amylamine, phenylethylamine and AMBA as in Section 2.2.7. 
 
Figure 3.13 Example of horseradish peroxidase assay (active oxidase activity produces pink colour). 
Photograph of soluble SLAAO assay plate, annotation shows the substrate and [average absorbance-control 
absorbance] of a few substrates as an example. 
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The non recombinant pET-YSBLIC-3C was used as a negative control. No significant activity was 
seen against any of the substrates (Figure 3.14), although a very low level of activity was seen in 
all assays against AMBA, regardless of the protein sample used (Figure 3.14-3.20). 
 
Figure 3.14 a. 1 h end point of the activity of induced BL21-pET-YSBLIC3C cells against the natural amino 
acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of induced BL21-
pET-YSBLIC3C soluble cell fraction against the natural amino acids, amylamine, phenylethylamine and α-
methylbenzylamine. 
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The AsAAO cells appeared to show a small level of activity against L-tyrosine, with an A510 
reading of 0.080 (Figure 3.15), however later tests did not show this activity (data not shown). The 
soluble protein fraction did not show any significant activity against any of the substrates (Figure 
3.15); however this may be because there was very little soluble protein produced (Figure 3.6). 
 
Figure 3.15 a. 1 h end point of the activity of induced BL21-pET-YSBLIC3C-AsAAO cells against the 
natural amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of 
induced BL21-pET-YSBLIC3C-AsAAO soluble cell fraction against the natural amino acids, amylamine, 
phenylethylamine and α-methylbenzylamine. 
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Neither the BaAO whole cells or soluble fraction showed any significant activity against any of the 
substrates tested (Figure 3.16), although there was a very small amount of absorbance against the 
three amines in the soluble protein assays (A510 of 0.014, 0.014 and 0.013 for amylamine, 
phenylethylamine and AMBA respectively) (Figure 3.16), this is unlikely to be significant 
compared to more active protein. The low activity may be due to the lack of soluble protein 
produced (figure 3.7). 
 
Figure 3.16 a. 1 h end point of the activity of induced BL21-pET-YSBLIC3C-BaAO cells against the natural 
amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of induced 
BL21-pET-YSBLIC3C-BaAO soluble cell fraction against the natural amino acids, amylamine, 
phenylethylamine and α-methylbenzylamine. 
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The BsGO whole cells showed activity against its known substrate, glycine (Table 3.1) with A510 at 
0.372, as well as lower activity against L-asparagine (A510 was 0.162); however the soluble protein 
fraction did not show any significant activity against any of the substrates (Figure 3.17). The 
activity against L-asparagine is surprising given that BsGO is known to be active against neutral D-
amino acids, rather than L-amino acids.
[102] 
 
Figure 3.17 a. 1 h end point of the activity of induced BL21-pET-YSBLIC3C-BsGO cells against the natural 
amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of induced 
BL21-pET-YSBLIC3C-BsGO soluble cell fraction against the natural amino acids, amylamine, 
phenylethylamine and α-methylbenzylamine. 
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Neither of the NfOR whole cells or soluble protein fractions showed any significant activity against 
the substrates tested (Figure 3.18). Again this may be due to the lack of soluble protein (Figure 
3.9) 
 
Figure 3.18 a. 1 h end point of the activity of induced B834-pET-YSBLIC3C-NfOR cells against the natural 
amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of induced 
B834-pET-YSBLIC3C-NfOR soluble cell fraction against the natural amino acids, amylamine, 
phenylethylamine and α-methylbenzylamine. 
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The PpLAAO cells showed activity against glycine (A510 was 0.578), and a lower amount of 
activity against L-asparagine (A510 was 0.220). The soluble protein fraction showed similar activity 
against glycine and L-asparagine (A510 of 0.478 and 0.098 respectively) and also showed activity 
against L-aspartate with A510 at 0.166 (Figure 3.19). 
 
Figure 3.19 a. 1 h end point of the activity of induced BL21-pET-YSBLIC3C-PpLAAO cells against the 
natural amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of 
induced BL21-pET-YSBLIC3C-PpLAAO soluble cell fraction against the natural amino acids, amylamine, 
phenylethylamine and α-methylbenzylamine. 
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The SLAAO whole cells and soluble protein both showed very high activity against known 
substrate L-arginine (3.712 and  3.643 respectively) and showed high activity against known 
substrate L-lysine (A510 was 2.619 with whole cells and 1.831 with the  soluble protein fraction). 
Both whole cells and soluble protein also showed a lower amount of activity against L-histidine 
(A510 of 0.164 and 0.135 respectively) (Figure 3.20), which is consistent with other Synechococcus 
L-AAOs.
[100] 
 
Figure 3.20 a. 1 h end point of the activity of induced Rosetta-2-pET-YSBLIC3C-SLAAO cells against the 
natural amino acids, amylamine, phenylethylamine and α-methylbenzylamine b. 1 h end point activity of 
induced Rosetta-2-pET-YSBLIC3C-SLAAO soluble cell fraction against the natural amino acids, 
amylamine, phenylethylamine and α-methylbenzylamine. 
 
Based on these results it was decided that PpLAAO would be used as a target for further studies, 
due to its high solubility, activity against L-aspartate and L-asparagine and the fact that the P. 
putida version of the L-aspartate oxidase protein has not previously been purified or characterised 
in depth, although the 60% identical E. coli homologue has a structure solved using 
crystallisation
[65]
 and the effects of some active site residues have been determined through 
mutagenesis studies.
[64, 118] 
 
As both the AsAAO and BaAO targets appeared to potentially show activity against some 
interesting substrates (L-tyrosine for AsAAO and the amines for BaAO) attempts were made to 
increase the solubility of these enzymes so they could be studied further. 
 
3.4 Attempts to increase solubility of AsAAO and BaAO 
 
Both the AsAAO and BaAO targets appear to produce protein, however in both cases the protein is 
insoluble (Figures 3.15 and 3.16). Because of this attempts were made to increase the solubility of 
these two proteins. Auto induction media (AIM)
[111]
 is routinely used to increase the solubility of 
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proteins that are weakly soluble when expressed in colonies grown in LB-media. Golovanov et 
al.
[115]
 also found that adding 50 mM of L-glutamate and 50 mM of L-arginine increased the 
maximum solubility and stability of several proteins, so the effects of these methods were tested on 
each protein as in Section 2.2.8. However no change in solubility was in when using the AIM, the 
50 mM L-glutamate and 50 mM L-arginine, or both in conjunction (Figures 3.21-3.22). 
 
 
 
Figure 3.21 SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
AsAAO, showing effects of auto-induction media (AIM) and adding 50 mM L-glutamate and 50 mM L-
arginine on soluble expression: Lane 1, low range molecular weight marker; Lane 2-3, BL21- pET-
YSBLIC3C-AsAAO insoluble fraction grown in LB without/with 50 mM L-Glu and 50 mM L-Arg (48 kDa); 
Lane 4-5, BL21- pET-YSBLIC3C-AsAAO insoluble fraction grown in AIM without/with 50 mM L-Glu and 
50 mM L-Arg (48 kDa); Lane 6-7, BL21- pET-YSBLIC3C-AsAAO soluble fraction grown in LB 
without/with 50 mM L-Glu and 50 mM L-Arg (48 kDa); Lane 8-9, BL21- pET-YSBLIC3C-AsAAO soluble 
fraction grown in AIM without/with 50 mM L-Glu and 50 mM L-Arg (48 kDa). 
 
97 kDa 
66 kDa 
 
45 kDa 
1      2       3       4      5       6       7        8      
9 
                                   Insoluble                    Soluble 
Media                          LB   LB  AIM AIM LB   LB   
AIM  AIM 
50 mM L-Glu/L-Arg           -       +     -       +     -      +       -      
+ 
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Figure 3.22 SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
BaAO, showing effects of auto-induction media (AIM) and adding 50 mM L-glutamate and 50 mM L-
arginine on soluble expression: Lane 1, low range molecular weight marker; Lane 2-3, BL21- pET-
YSBLIC3C-BaAO insoluble fraction grown in LB without/with 50 mM L-Glu and 50 mM L-Arg (55 kDa); 
Lane 4-5, BL21- pET-YSBLIC3C-BaAO insoluble fraction grown in AIM without/with 50 mM L-Glu and 
50 mM L-Arg (55 kDa); Lane 6-7, BL21- pET-YSBLIC3C-BaAO soluble fraction grown in LB without/with 
50 mM L-Glu and 50 mM L-Arg (55 kDa); Lane 8-9, BL21- pET-YSBLIC3C-BaAO soluble fraction grown 
in AIM without/with 50 mM L-Glu and 50 mM L-Arg (55 kDa). 
 
The level of oxygen available to the culture often has an effect on the solubility of produced 
proteins.
[116]
 To see if this would have any effect on the AsAAO or BaAO targets three different 
volumes of culture (0.5 L, 1.0 L and 1.5 L) were each grown in a 2 L Erlenmeyer flask and protein 
overexpression was induced as normal (Section 2.2.9). To see if this had any effect on solubility 
500 mL of each culture was spun down and analysed using SDS-PAGE, however no improvements 
in solubility were seen in either target. (Figure 3.23). 
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Figure 3.23 a. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
AsAAO, showing effects of changing culture volume in 2L Erlenmeyer flask: Lane 1, BioRad low weight 
molecular marker; Lane 2-4, Lane 2-3, BL21- pET-YSBLIC3C-AsAAO insoluble fractions from 
500/1000/1500 mL culture; Lane 5-7, BL21- pET-YSBLIC3C-AsAAO soluble fractions from 
500/1000/1500 mL culture.  b. SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with 
pET-YSBLIC3C-BaAO, showing effects of changing culture volume in 2L Erlenmeyer flask: Lane 1, 
BioRad low weight molecular marker; Lane 2-4, BL21- pET-YSBLIC3C-BaAO insoluble fractions from 
500/1000/1500 mL culture; Lane 5-7, BL21- pET-YSBLIC3C-BaAO soluble fractions from 500/1000/1500 
mL culture. 
 
A solubility screen developed by Lindwall et al.
[112]
 to screen various resuspension conditions was 
used on the BaAO target protein to determine if the solubility could be increased as in Section 
2.2.10. Conditions 4 (100 mM HEPES, 100 mM KCl, pH 7.0) and 15 (100 mM KH2PO4/K2HPO4, 
2.5 mM ZnCl2, pH 4.3) appeared to increase the solubility of the protein (Figure 3.24).  
 
The production of the BaAO protein was scaled up to two 1 L cultures, which were split into four 
500 mL cultures. Each of these cultures was spun down and resuspended in a different buffer 
condition; H2O, Solubility screen condition 4, Solubility screen condition 15 and a Tris 
resuspension buffer (50 mM Tris/HCl, 300 mM NaCl, 20 µM AEBSF, pH 7.0). The solubility of 
the protein in each condition was analysed using SDS-PAGE. From these results it appeared that 
the Tris based buffer resulted in the most solubility (Figure 3.25). However attempts to purify the 
BaAO protein using NiNTA column failed as no protein bound to the nickel column (data not 
shown).  
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Figure 3.24 SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
BaAO, treated with solubilisation screen conditions: a. Lane 1, BioRad low range molecular weight marker; 
Lane 2-3, BL21- pET-YSBLIC3C-BaAO soluble/insoluble fraction, resuspended in H2O (55 kDa); Lane 4-
15, BL21- pET-YSBLIC3C-BaAO soluble fractions resuspended in solubilisation conditions 1-12 c. b. Lane 
1, BioRad low range molecular weight marker; Lane 2-3, BL21-pET-YSBLIC3C-BaAO soluble/insoluble 
fraction, resuspended in H2O (55 kDa); Lane 4-15, BL21-pET-YSBLIC3C-BaAO soluble fractions 
resuspended in solubilisation conditions 16-24 c. c. Lane 1, BioRad low range molecular weight marker; 
Lane 2-3, BL21- pET-YSBLIC3C-BaAO soluble/insoluble fraction, resuspended in H2O (55 kDa); Lane 4-9, 
BL21-pET-YSBLIC3C-BaAO soluble fractions resuspended in solubilisation conditions 25-30 (55 kDa). 
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Figure 3.25 SDS-PAGE separation of protein from 1 L cultures of E. coli BL21-DE3 transformed with pET-
YSBLIC3C-BaAO, sonicated in different resuspension buffers: Lane 1, BioRad low range molecular weight 
marker; Lane 2-3, BL21- pET-YSBLIC3C-BaAO Insoluble/Soluble fraction, resuspended in H2O (55 kDa); 
Lane 2-3, BL21- pET-YSBLIC3C-BaAO Insoluble/Soluble fraction, resuspended in Tris buffer (55 kDa); 
Lane 2-3, BL21- pET-YSBLIC3C-BaAO Insoluble/Soluble fraction, resuspended in the Solubility Screen 
condition 4 (55 kDa); Lane 2-3, BL21- pET-YSBLIC3C-BaAO Insoluble/Soluble fraction, resuspended in 
the Solubility Screen condition 15 (55 kDa). 
 
3.5 Conclusions 
 
Seven target oxidases were successfully cloned into the pET-YSBLIC-3C expression vector. These 
cloned targets were used to transform the E. coli protein production strains Bl21-DE3, B834-DE3 
and Rosetta-2-DE3 and the genes were overexpressed with different induction temperatures and 
times to determine which combination of strain and induction temperature would result in the 
highest level of soluble protein production for each cloned target. These optimum conditions were 
then used to produce whole cells and soluble protein fractions for each cloned target, which were 
then screened for activity against the twenty proteinogenic amino acids and three amines. 
 
From work done by Ingenza Ltd. and Geueke & Hummel
[56] 
the Rhodococcus opacus L-AAO 
(RoLAAO) is active against a range of proteinogenic substrates, notably L-alanine and L-histidine. 
However, when the gene was overexpressed in the E. coli expression strains no soluble protein was 
produced under any condition (Figure 3.11) and a preliminary test of the induced whole cells and 
soluble fractions against L-alanine and L-histidine did not detect any activity (data not shown), 
suggesting that the protein was not being expressed in an active form in any of the E.coli strains 
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used. In some of the conditions used the E. coli cells appear to be over expressing a protein around 
14 kDa in size, as opposed to the expected 53 kDa RoLAAO protein (Figure 3.11), which might 
suggest that the produced protein is being subjected to protein cleavage by the E. coli expression 
strains used. However it is also possible that the 14 kDa protein is due to overexpression of a non-
specific, native E.coli protein and either DNA fingerprinting or a His-tag based immunoblot of the 
gel would have to be used to determine if this was the case. 
 
Another reason for the insolubility of the protein maybe that it need other factors to help it fold that 
are not present in the E. coli expression strains used, such as chaperone proteins. There is also the 
possibility is that any hydrogen peroxide produced by the RoLAAO protein reacting with L-alanine 
or L-histidine in the cell cytoplasm may be producing reactive oxygen species that would damage 
the DNA and protein inside the cells, resulting in cell death and poor protein expression. As 
looking into these issues would have taken time, and because the RoLAAO protein is already more 
understood than some of the other target proteins, it was decided that this was not a suitable target 
for further work.  
 
The Synechococcus sp. strain ATCC 27144 (aka Synechococcus elongates PCC 6301) L-AAO 
(SLAAO) was known to be active against L-arginine and L-lysine. When expressed in E. coli the 
gene did not appear to produce any soluble protein (Figure 3.13) however when tested for activity 
both the whole cells and soluble protein fractions with the overexpressed gene showed high activity 
against L-arginine and L-lysine, as well as low activity against L-histidine (Figure 3.20). As the 
protein has previously been found to mainly precipitate in cell membrane fractions
[100] 
it may be 
that the protein is folding in an active state in the membrane, although the portion of the protein 
located in the soluble fraction is also highly active. However as the protein has already been 
partially characterised by others
[100]
 and the low solubility would suggest that it may be difficult to 
purify in high quantities, it was decided that it would be worth investigating a less well understood 
or easier to purify target, and no further work was done on this target. 
 
The Bacillus subtilis L-AAO (BsGO) was a known glycine oxidase and has been shown to oxidise 
sarcosine
[101]
 and neutral D-amino acids.
[103]
 When cloned and overexpressed in E. coli BL21-DE3 
cells at 37°C for 3 h gene produced a reasonable amount of soluble protein (Figure 3.8), and 
induced whole cells showed activity against glycine as well as some lower activity against L-
asparagine, although this activity was lost in the soluble protein fraction (Figure 3.17). This might 
suggest that the BsGO protein requires a factor that is present in the E. coli expression strains to 
oxidise its substrates. This would make working with the pure form of the protein difficult, and as 
other groups have already worked on this protein
[101, 102]
 it was disregarded as a target. 
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The putative Nocardia farcinica oxidoreductase (NfOR) did not have any known substrates. 
Unfortunately, when the gene was overexpressed at lower temperatures the produced protein 
appeared to be smaller than expected, at around 40 kDa instead of 49 kDa and although protein 
produced at higher induction temperatures were of the correct size (Figure 3.9) there was no 
soluble protein produced, and neither the induced whole cells or soluble fraction showed any 
activity against the screened substrates (Figure 3.18).  
 
As with the RoLAAO protein, this could be due to proteolysis by the E. coli expression strain, a 
lack of chaperone proteins or damage to the expressing cells by hydrogen peroxide produced by the 
active protein. The NfOR gene sequence is also quite GC rich (74% GC content), which may cause 
poor gene expression in the E. coli, which has a lower overall GC content of 50%.
[117]
 In an attempt 
to counteract this effect, the NfOR gene sequence was cloned into a Corynebacterium glutamicum 
pEKEx2 shuttle expression vector to see if expressing the gene in an organism that had genes with 
a higher GC content than E. coli would help produce more soluble protein. Unfortunately no 
produced protein could be seen from C. glutamicum (Appendix). 
 
The putative L-AAO from Anabaena sp. strain PCC 7120 (AsAAO) also had no known substrates. 
The protein produced in E. coli was of the correct size, however no soluble protein was produced 
(Figure 3.6) and no activity was seen against any of the substrates screened (Figure 3.15). 
Attempts were made to increase the solubility of the produced protein using Auto Induction Media 
(AIM),
[111]
 by adding 50 mM L-glutamate and 50 mM L-arginine
[115]
 to the protein resuspension 
buffer and by adjusting the amount of soluble oxygen available to the bacterial culture,
[116]
 
unfortunately none of these methods resulted in a noticeable increase in the solubility of the 
produced protein (Figures 3.21, 3.23a).  
 
As with the RoLAAO and NfOR genes, the lack of soluble protein could be the lack of chaperone 
proteins available in the expressions trains used or damage to the expressing cells by hydrogen 
peroxide produced by active AsAAO protein. Although the AsAAO gene sequence has a low GC 
content (42%), attempts were made to clone it into the pEKEx2 shuttle vector for expression in C. 
glutamicum, however the cloning was not successful (Appendix) and work on the AsAAO target 
was stopped. 
 
The putative Bacillus anthracis AO (BaAO) has no known substrates. When the gene was cloned 
and expressed in E. coli very little soluble protein was produced, although the protein that was 
produced was all of the expected size (Figure 3.7). Unfortunately no activity was seen from either 
the whole cells or soluble fraction of the induced E. coli cells. As with AsAAO attempts were made 
to solubilise the protein using AIM,
[111]
 by adding 50 mM L-glutamate and 50 mM L-arginine
[115]
 to 
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the protein resuspension buffer and by adjusting the amount of soluble oxygen available to the 
bacterial culture
[116]
 but none of these methods had any noticeable effect on protein solubility 
(Figure 3.22, 3.23b).  
 
A solubilisation screen develop by the Lindwall group
[112]
 was also tested against the BaAO 
produced protein and two of the conditions appeared to increase the solubility of the protein 
(Figure 3.24) however when these were compared with the Tris based buffer in a larger scale 
production the two conditions from the Lindwall screen appeared to have no noticeable effect on 
protein solubility (Figure 3.25). As there appeared to be some soluble protein, an attempt was 
made to purify the protein using a NiNTA column, however no protein bound to the column (data 
not shown) suggesting that the protein that appeared to be the soluble BaAO protein may just have 
been a normal protein produced by the E. coli expression strain. Like the other insoluble proteins, 
the lack of soluble protein could have been caused by a lack of chaperone protein or damage by 
hydrogen peroxide produced by the active protein.  
 
Although the BaAO protein only has a GC content of 35%, attempts were made to clone the gene 
into the pEKEx2 shuttle vector for expression in C. glutamicum, to see if a different expression 
host would help increase solubility of the protein. Unfortunately, cloning was unsuccessful 
(Appendix) the BaAO target was disregarded as a target. 
 
From work done by Ingenza Ltd. the Pseudomonas putida L-AAO (PpLAAO) protein was known 
to have activity against L-aspartate. The gene produced a highly soluble protein when 
overexpressed in E. coli BL21-DE3 cells with an induction temperature of 16°C (Figure 3.10). 
When screened for activity the whole cells and soluble protein fraction of the induced strain both 
showed high activity against glycine and low activity against L-asparagine. The soluble protein 
fraction also showed activity against L-aspartate that was slightly higher than that against L-
asparagine. The loss of activity against L-aspartate in the whole cells is likely to have been due to 
problems transporting the L-aspartate across the bacterial cell membrane. As the PpLAAO protein 
was highly soluble, showed varying activity against three substrates and had not been studied in 
depth previously, it was decided that it was the best target to characterise by purification, 
crystallisation and mutational analysis. These reasons also make it the most optimal target to use as 
a model for directed evolution of an L-alanine or L-tyrosine oxidase, as none of the targets showed 
natural activity against these substrates. 
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Chapter 4    Characterisation of PpLAAO protein 
 
The BL21-DE3-YSBLIC-3C-PpLAAO soluble protein extracts appeared to show activity against 
glycine, L-aspartate and L-asparagine (Figure 3.18). It was also very soluble (Figure 3.9), 
suggesting that it would be easy to purify in large quantities.  It has also not been studied in depth, 
so it is not well understood. For these reasons the PpLAAO protein was selected to be purified and 
characterised using the soluble phase HRP-based assay used in Section 3.3 to determine kinetic 
constants for its activity against glycine, L-aspartate, L-asparagine and target substrates L-glutamate 
L-tyrosine, L-alanine and L-homoserine as well as the pH preference and temperature stability of 
the purified PpLAAO protein. Attempts to crystallise the protein in order to determine the structure 
of the protein by X-ray diffraction were also started. 
 
4.1 Purification of PpLAAO protein 
 
Chemically competent E. coli BL21-DE3 cells were transformed with the YSBLIC-3C-PpLAAO 
plasmid, then grown in a 2 L culture and used to overexpress the gene encoding the PpLAAO 
protein as in Section 2.3.1. This culture was harvested and sonicated, and the PpLAAO protein was 
purified by metal affinity chromatography using a prepacked HiTrap Chelating HP column. The 
His-tag was then cleaved from the protein using C3-protease and cleaved His-tags were removed 
from the protein solution using metal affinity chromatography using the prepacked HiTrap 
Chelating HP column.  The pure protein was then purified further by gel filtration chromatography 
using a 120 mL HiLoad 16/60 Superdex 75 column as in Section 2.3.2, protein from all steps were 
analysed using SDS-PAGE to ensure protein was purified (Figure 4.1).  
 
The protein eluted from the 120 mL HiLoad 16/60 Superdex 75 column after 52 mL (Figure 4.2), 
allowing protein size to be calculated at roughly 116 kDa (Section 2.3), as wild type PpLAAO 
protein is 59 kDa, this suggests that the protein is in a dimeric form. Protein concentration was 
determined by measuring the absorption of the protein solution at 280nm and determining protein 
concentration using the theoretical extinction coefficient as detailed in section 2.3.2. Protein yield 
from 2 L of culture was 20 mg. 
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Figure 4.1: a. SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO using metal affinity based chromatography. Lane 1, low range molecular weight 
marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO  induced culture (60 kDa); 
Lane 3-5, Protein flow-through from column loading of soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO induced culture; Lane 6-10, protein fractions 8-12 from FPLC imidazole gradient of loaded BL21-
pET-YSBLIC3C-PpLAAO protein (60 kDa). b. SDS-PAGE separation of protein from E. coli BL21-DE3 
transformed with pET-YSBLIC3C-PpLAAO, cleaved and purified via gel filtration chromatography. Lane 1, 
low range molecular weight marker; Lane 2-3, BL21-pET-YSBLIC3C-PpLAAO FPLC fractions before/after 
C3-protease cleavage (60 kDa); Lane 4-7, BL21-pET-YSBLIC3C-PpLAAO fractions 11-14 from 1st gel 
filtration chromatography run (60 kDa); Lane 8-10, BL21-pET-YSBLIC3C-PpLAAO fractions 12-14 from 
2nd gel filtration chromatography run (60 kDa). 
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Figure 4.2 Abs280 trace of solution from gel filtration chromatography of purified PpLAAO using 120 mL 
HiLoad 16/60 Superdex 75 column.  
 
4.2 Characterisation of PpLAAO protein 
 
In order to determine the effects that any mutagenesis would have on the activity of the protein, the  
kinetic constants of the purified wild-type PpLAAO protein were tested against glycine, L-
aspartate, L-asparagine and target substrates L-glutamate, L-homoserine, L-alanine and L-tyrosine 
using the HRP-based assay in 1 mL cuvettes in order to record the change in Abs510 over time 
(Section 2.3.3).  
 
The activity against glycine seen previously had been lost in the purified protein, and no significant 
activity was seen against the target substrates L-homoserine, L-alanine and L-tyrosine (data not 
shown); however activity against L-aspartate and L-asparagine was still present and low levels of 
activity were also seen against L-glutamate. (Figures 4.3-5, Table 4.1). Activity against L-aspartate 
was quite high, with a kcat of 10.6 s
-1
 and a kcat/KM of 4684 M
-1
 s
-1
 (Figure 4.3, Table 4.1).  
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Figure 4.3 Rate of H2O2 production of PpLAAO against L-aspartate substrate concentration.  
 
The determination of kinetic constants for the activity against L-asparagine was more difficult, as 
the rates of activity increased steadily over concentration up to 12.5 mM, but then decreased over 
higher concentrations of L-asparagine (Figure 4.4). This meant that the Michaelis Menten 
equations did not really fit the data, causing the calculated KM to be unrealistically low, with an 
apparent kcat of 4.5 s
-1
 and an apparent kcat/KM of 7298 M
-1
 s
-1
 (Table 4.1). Unfortunately there was 
not enough data to model the reaction using a substrate inhibition equation accurately, and an 
attempt to do so resulted in calculated Vmax of 10244 nM
 
min
-1 
mg enzyme
-1
, KM of 6264 mM and Ki 
of 0.01241 mM, which is also unrealistic.  
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Figure 4.4 Rate of H2O2 production of PpLAAO against L-asparagine substrate concentration. 
 
Despite the similarity between the L-aspartate and L-glutamate side chains, the activity against L-
glutamate was very low (Figure 4.5), which is likely the reason the activity was not detected in the 
96-well plate assay screen (Figure 3.19). The KM against L-glutamate of 345 mM was 150-fold 
higher than that of L-aspartate and the kcat against L-glutamate was 10-fold lower than the kcat 
against L-aspartate (Table 4.1). 
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Figure 4.5 Rate of H2O2 production of PpLAAO against L-glutamate substrate concentration. 
 
Table 4.1 Kinetic parameters of PpLAAO enzyme against L-aspartate and L-glutamate and unreliable 
calculated kinetic parameters against L-asparagine. 
Substrate Vmax (nM
 
min
-1 
mg enzyme
-1
)
 
KM (mM) kcat (s
-1
) kcat/KM (M
-1
 s
-1
) 
L-aspartate 10.75 2.263 10.60 4684 
L-asparagine (4.564) (0.6166) (4.50) (7305) 
L-glutamate 1.67 345 1.65 4.77 
 
The pH optimum of the protein was determined using the liquid phase HRP based assay in a 96-
well plate as in Section 2.3.4, with the 60 min end-point of reactions against L-aspartate at pH 4.7, 
5.8, 6.2, 6.6, 7.0, 7.4, 7.8 and 8.2 being measured at A510. From these reactions the optimum pH for 
the wild-type oxidation reaction of PpLAAO appears to be around 7.5 (Figure 4.6), although this 
may be affected by the pH optimum of the HRP enzyme on which the assay is reliant. 
 
The effects of temperature on the protein was measured by incubating the purified protein at 
temperatures of 4°C, 10°C, 20°C, 30°C, 40°C, 50°C and 60°C for 5 min, 10 min, 20 min, 30 min, 
45 min or 60 min. These incubated protein samples were then left on ice for 3 hours and then tested 
for activity against L-aspartate using the liquid phase HRP-based assay as in Section 2.3.5. The 60 
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min end point of these reactions was measured at A510. Visually, the purified protein did not 
precipitate at temperatures of 30°C or lower, but began precipitating after 5 min at temperatures of 
40°C and higher. Despite the protein having precipitated at 40°C, the activity of the protein samples 
treated at 40°C was still at the same levels as protein incubated at lower temperatures (Figure 4.6), 
suggesting any denaturation at 40°C is reversible. Protein activity dropped rapidly when incubated 
at 50°C (Figure 4.6). 
 
Figure 4.6 1 h end point of the activity assay of purified wild-type PpLAAO protein against L-aspartate over 
the pH of the reaction buffer. 
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Figure 4.7 1 h end point of the activity assay of temperature-treated purified wild-type PpLAAO protein 
against L-aspartate over the incubation temperature of the protein, for incubation times of 5 min, 10 min and 
60 min. 
 
4.3 Attempts to crystallise PpLAAO protein 
 
In an attempt to create protein crystals suitable for use in X-ray structure determination, the 
purified PpLAAO protein was concentrated to 10 mg mL
-1
, 30 mg mL
-1
, 45 mg mL
-1
, 60 mg mL
-1
, 
and 100 mg mL
-1 
as in Section 2.3.6. These proteins preparations were added to wells containing 
the 96-well Index crystallisation screen as in Section 3.2.7, along with a sample of the 30 mg ml
-1
 
protein which had 1 mM of FAD added to the protein. However none of these screens produced 
protein crystals. 96 well crystallisation screens were also set up with 30 mg mL
-1
, 45 mg mL
-1
, 60 
mg mL
-1
, and 100 mg mL
-1 
of protein against the PACT crystallisation screen, and 60 mf mL
-1
 
against the CSS 1+2 crystallisation screen, however no protein crystals were produced. 
 
As crystallisation trials were showing large amounts of precipitation but no crystal formation, the 
purified wild type PpLAAO protein was run down a 7.5% native gel and subjected to Dynamic 
Light Scattering (DLS) as in Section 2.3.8 in order to determine if the protein was in a homologous 
form while in solution.  
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Despite the protein eluting from the gel filtration column in a single peak (Figure 4.2) the native 
gel showed the protein separating into at least 5 separate bands (Figure 4.8). This is unlikely to be 
caused by protein aggregation as the protein formed separate bands rather than smearing. It could 
have been caused by different post-translational modifications to the protein changing the 
electronegativity of the protein by different amounts, or the protein could form different quaternary 
structures while in solution. Data from the DLS suggests that the protein is forming different sized 
quaternary structures, as it showed mass readings that are equivalent to both monomer and dimer 
forms of PpLAAO present in the solution, as well as several larger aggregated forms of the protein 
(Table 4.2). 
 
 
 
Figure 4.8 7.5% Native gel separation of wild type PpLAAO protein. Lane 1, 20 µL 1 mg mL-1 wild type 
PpLAAO protein. 
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Table 4.2 Table showing regularization data from the DLS analysis of wild type PpLAAO at 20°C. Possible 
quaternary structure determined by comparing the Radius to the Rh readings from the Results Summary of 
the DLS analysis (data not shown). 
Radius (nm) Possible Quaternary Structure % Intensity % Mass 
2.899  1.61 4.95 
3.841 Monomer 56.8 75.0 
5.090 Dimer 35.3 20.0 
6.744  0.000 0.000 
36.50  3.25 0.00501 
48.36  0.000 0.000 
3295  3.10 2.72 E
-6
 
 
The formation of various different quaternary structures could be due to the protein forming 
disulphide cross-links between cysteine residues after purification. Because of this the purified 
protein was concentrated down and then diluted into several detergents (10 mM LDAO, 10 mM 
SB12, 0.5% β-OG, 500 mM TMAO, 250 mM NDSB-201) and varying concentration of 
precipitates (50 mM Urea, 100 mM Urea, 200 mM Urea, 50 mM G. HCl, 100 mM G. HCL and 200 
mM G. HCl) (Section 2.3.9) in order to see if they could force the protein into a monomeric state 
that would be suitable for crystallisation. 
 
The protein solutions remixed with 500 mM TMAO, 250 mM NDSB-201, 50 mM Urea, 100 mM 
Urea, 200 mM Urea, 50 mM G. HCl, 100 mM G. HCl and 200 mM G. HCl were analysed by DLS 
(Section 2.3.9), although the protein solutions remixed with 100 mM G. HCl and 200 mM G. HCl 
were too precipitated to get a reliable data set. 
 
The solutions remixed with 500 mM TMAO, 250 mM NDSB-201, 50 mM Urea, 100 mM Urea and 
200 mM Urea all still showed various quaternary states, similar to the protein in the original 
Tris/NaCl/AEBSF resuspension buffer (data not shown). However the protein remixed with 50 mM 
G. HCl had precipitated. However after the precipitation had been spun down by centrifugation, the 
remaining protein appeared to be in a mostly monomeric form (Table 4.3), which suggests that 
using a gradient of low concentration of G. HCl may allow the protein to be kept in a monomeric 
state. 
 
Table 4.3 Comparison of the % Intensity and % Mass of the Monomeric and Dimeric forms of the protein 
(determined by comparing Radius in Regularization Data to Rh and MW in Results Summary of DLS 
analysis) in 50 mM Tris, 300 mM NaCl, 20 µM AEBSF and 50 mM G. HCl. 
 Tris/NaCl/AEBSF 50 mM G. HCl 
Quaternary 
Structure 
% Intensity % Mass 
Quaternary 
Structure 
% Intensity 
Monomer 56.8 75.0 2.92 95.0 
Dimer 35.3 20.0 0.00 0.00 
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All of the remixed protein solutions, except for the 100 mM and 200 mM G. HCl, were analysed by 
7.5% native gel as in Section 2.3.9. The 10 mM LDAO, 10 mM SB12, 0.5% β-
octylglucopyranoside and 200 mM Urea all caused a reduction in the larger forms of the protein 
compared to the Tris/NaCl/AEBSF buffer, but there were still at least three different forms of the 
protein in these solutions (Figure 4.9). The 250 mM NDSB-201 appears to have caused an increase 
in the number of forms of the PpLAAO protein compared to the Tris/NaCl/AEBSF buffer and the 
protein remixed in the 500 mM TMAO and the 50 mM and 100 mM Urea appears to have 
aggregated as the protein is smeared in the gel, especially in the 500 mM TMAO solution. 
 
Figure 4.9 7.5% Native-gel analysis of wild-type PpLAAO protein in various buffers. Lane 1, Original 50 
mM Tris, 300 mM NaCl and 20 µM AEBSF buffer; Lane 2, 10 mM LDAO, Lane 3, 10 mM SB12; Lane 4, 
0.5% β-OG; Lane 5, 500 mM TMAO; Lane 6, 250 mM NDSB-201; Lane 7-9, 50 mM, 100 mM and 200 mM 
Urea; Lane 10, 50 mM G. HCl. 
 
The wild type protein in the original Tris/NaCl/AEBSF buffer was also analysed at temperatures of 
4°C, 12°C and 20°C to determine if the temperature of the protein had any effect on the protein 
form in solution (Section 2.3.9). The results suggested that while at cooler temperatures the protein 
was more likely to be in monomeric form (Table 4.4). It’s possible that the preparation and 
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purification steps done at 20°C may have caused the protein to form larger complexes, meaning 
that preparing, purifying and crystallising the protein in a cold room may help the protein stay in 
monomeric form and be more likely to crystallise. 
 
Table 4.4 Comparison of the % Intensity and % Mass of the Monomeric and Dimeric forms of the protein 
(determined by comparing Radius in Regularization Data to Rh and MW in Results Summary of DLS 
analysis) at 20°C, 12°C and 4°C. 
 20°C 12°C 4°C 
Quaternary Structure % Intensity % Mass % Intensity % Mass % Intensity % Mass 
Monomer 56.8 75.0 72.9 90.0 50.3 83.4 
Dimer 35.3 20.0 18.7 9.94 27.8 13.1 
 
Due to these observations, protein was re-purified taking extra care to ensure all steps were done at 
cold temperatures as in Section 2.3.10. This protein prep was analysed on a 7.5% native gel as in 
Section 2.3.10 however the protein still separated into several distinct bands similar to those seen 
in Figure 4.7 (data not shown). 
 
The remaining protein was concentrated down and diluted with ice-cold 5 mM, 10 mM, 15 mM, 20 
mM, 25 mM, 30 mM, 35 mM, 40 mM and 45 mM G. HCl at pH 7.0 as in Section 2.3.10, as the 
protein did not precipitate immediately, the solutions were stored at 4°C overnight. The next 
morning all solutions of protein had precipitated equally. Protein was spun down to remove 
precipitation and samples were analysed using 7.5% native-PAGE gel, however none of the 
samples contained enough free protein to be visible on the gel (data not shown). 
 
A 24-well crystallisation tray was set up at 4°C as in Section 2.3.10, to see if the precipitants 
ammonium sulphate, PEG 4k or PEG 3.5k at a cold temperature could result in production of 
crystals, however no crystals developed from the tray. 
 
4.4 Conclusions 
 
The PpLAAO protein was purified from E. coli BL21-DE3 cells using metal affinity 
chromatography and the attached C terminal His-tag was removed using C3-protease. The cleaved 
protein was then purified further using gel filtration chromatography. The position of the gel 
filtration elution peak (Figure 4.2) suggested that the protein is around 116 kDa in solution, 
roughly corresponding to a dimeric form of the 59 kDa PpLAAO protein. The soluble HRP based 
assay solution used to screen the target oxidases for activity in Section 3.3 was then used to 
determine the rate of activity over substrate concentration of the purified PpLAAO protein against 
glycine, L-aspartate and L-asparagine.  
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The activity seen previously against glycine (Figure 3.19) had been lost in the purified PpLAAO 
protein, with no detectable activity been seen (data not shown). This may be due to another soluble 
protein produced by E. coli that was converting the glycine in the reaction solution into a different 
substrate that could be oxidised by the PpLAAO protein during the previous assays, or possibly the 
PpLAAO protein needs a different cofactor to oxidise glycine that is lost during the protein 
purification. 
 
The protein showed high activity against L-aspartate with a kcat of 10.6 s
-1
 and a kcat/KM of 4684 M
-1
 
s
-1
 (Figure 4.3, Table 4.1), which is roughly ten-fold higher than the kcat/KM of the E. coli L-AspO, 
which is 306 M
-1
 s
-1
.
[118]
 It also showed lower activity against L-asparagine, although a loss of 
activity at the higher concentrations of L-asparagine made it difficult to accurately fit the data to 
either a Michaelis Menten or a substrate inhibition based equation. This meant that the apparent KM 
and Vmax of L-asparagine were calculated to be lower than expected from looking at the data points, 
resulting in an apparent kcat of 4.5 s
-1
 and kcat/KM of 7298 M
-1
 s
-1
. There was also some very low 
activity against L-glutamate, with a kcat of 1.65 s
-1
 and a kcat/KM of 4.77 M
-1
 s
-1
, which had been too 
low to be detected in the screens performed previously (Scetion 3.3). 
 
The effect of pH on the PpLAAO protein was determined by measuring the 1 h end point of 
reactions against L-aspartate at different pH of reaction buffers. PpLAAO was most active around 
pH 7.5 (Figure 4.5), however this may be affected by the pH optimum of the HRP enzyme, which 
is required for the assay. The effects of temperature on the purified protein were determined by 
incubating samples of the purified protein at varying temperatures and varying times, then 
measuring the activity of the protein samples against L-aspartate once the protein had cooled back 
down. The protein activity was unaffected when the sample was incubated between 4°C and 30°C. 
Although protein precipitation could be seen after 5 min at 40°C, the activity of the protein 
incubated at 40°C from 5 min to 1 h was still at the same levels as protein kept at lower 
temperatures, suggesting that the protein is reversibly denatured at 40°C. 
 
Incubation at 50°C caused the protein to lose most of its activity after just 5 min, and protein 
incubation at 60°C for 5 min caused it to lose all activity against L-aspartate, suggesting that the 
protein is irreversibly denatured at temperatures above 50°C (Figure 4.6). 
 
Attempts were then made to crystallise the purified protein for use in X-ray structure determination 
using 96-well crystallisations screens. However the protein showed a large amount of precipitation, 
but no crystals were formed. Because of this the native gel and DLS analysis were used to 
determine if the protein was in a homogenous form in solution, as heterogeneous forms of proteins 
often fail to crystallise. 
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Despite the protein eluting from the gel filtration column in one peak (Figure 4.2), the native gel 
showed the protein forming at least five distinct bands (Figure 4.7). One potential reason for the 
separate bands could either be due to a difference in the protein charge possibly caused by post-
translational modification of the protein.  The separate bands could also the protein grouping into 
several different quaternary forms of the protein in solution, which would have to have happened 
after purification by gel filtration. 
 
The DLS analysis suggested that the protein was forming different sized quaternary structures in 
solution. There were several different protein mass sizes, some of which were equivalent to 
monomeric and dimeric forms of PpLAAO and several larger aggregated forms of the protein. 
Despite the protein apparently purifying as a dimer, the majority of the protein mass in the DLS 
was formed by the monomeric form of the protein (Table 4.2), suggesting the proteins quaternary 
structure partially broke down after the gel filtration. 
 
It is possible that the different quaternary forms of the protein could be caused by cross-links 
formed after the purification. The purified protein was resuspended into several detergents to see if 
these would have any effect on any cross-linking that was occurring. The protein was also 
resuspended into low concentrations of precipitates urea and guanidine hydrochloride (G. HCl) as 
they could have forced the protein into a monomeric form suitable for crystallisation. 
 
Although some detergents and 200 mM Urea reduced the number of bands the protein split into 
when run on a native gel (Figure 4.8) none caused the protein to remain in a single form. A low 
concentration of 50 mM G. HCl caused the majority of the protein to precipitate, however the 
protein that remained in solution was entirely monomeric (Table 4.3). The protein was 
resuspended in lower concentration of G. HCl in an attempt to force the protein into a monomeric 
form without causing larger amounts of it to precipitate, but large amounts of the protein 
precipitated when as little as 5 mM of G. HCl was added. 
 
DLS analysis of the purified PpLAAO protein repeated at 4°C, 12°C and 20°C suggested that the 
protein was more likely to be in a monomeric form at lower temperatures (Table 4.4). Because of 
this the protein purification was repeated, except that the metal affinity chromatography and the gel 
filtration chromatography were both performed at a temperature of 4°C, and extra care was taken to 
ensure the protein was kept ice-cold at all times. However this protein sample still separated into 
several bands when analysed on native gel, indicating that the protein temperature is not the only 
cause of the heterogeneous form of the protein in solution. 
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Chapter 5    Site Directed Mutagenesis of PpLAAO protein 
 
As the activity of the wild-type PpLAAO protein has been characterised, one step towards 
identifying what factors determine the activity and substrate specificity of the PpLAAO enzyme 
and how active it is as a catalyst would be to attempt to rationally mutate the protein based on the 
structure of its active site. As the structure of PpLAAO is still unsolved (Section 4.3) the structure 
of a homologous L-aspartate oxidase (L-AspO) from E. coli
[119, 65]
 was used as a starting point for 
this mutagenesis. 
 
The thirteen active site residues were individually mutated to alanine residues in order to determine 
the effects of each active site residue on the overall efficiency and substrate specificity of the 
PpLAAO protein.  
 
5.1 Comparison of PpLAAO and E. coli L-AspO 
 
As attempts to crystallise the PpLAAO protein for use in structure determination were unsuccessful 
(Section 4.3), a homologous structure of the protein would be useful for use as a starting point 
when deciding what changes to make as part of a rational design approach towards identifying 
what factors determine substrate specificity of the PpLAAO enzyme. 
L-AspO is a 60 kDa monomeric flavoprotein that catalyses the first step of the de novo production 
of NAD.
[119]
 The structure for the R386L mutant of L-AspO in complex with succinate has been 
solved by Bossi et al.
[65]
 and it has 63% sequence homology with the PpLAAO protein (Figure 
5.1). The active site of the E. coli enzyme is divided into a flavin binding domain, comprised of 
residues Q50, G51, G52, E121 (122 in the P. putida enzyme), H351, R386L, S389, S391 and L392 
and a capping domain, including residues H244, L257, L258, T259, E260, S261 and R290.   
Further work by Tedeschi et al.
[118]
 on the role of the active site residues shows that the T259 and 
H244 from the capping domain bind the C1 carboxylate of the succinate ligand and the backbone 
N-H of S389 and H351 are bound to the C2 succinate carboxylate.  The E121 (122 in the P. putida 
enzyme) residue is conserved in L-aspartate oxidases and is thought to be essential for binding the 
amino group of the L-aspartate substrate.
[65]
 The R290 residue from the capping domain is also 
thought to be important in interactions with the amino acid substrate.  
In order to determine if the active site structure of the L-AspO protein is similar enough to that of 
PpLAAO for it to be used as the basis of a site directed mutagenesis strategy, the non-essential 
first-shell active site residues H244, L257, T259, E260, R290, H351, R386, S389 and S391, along 
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with second shell active site residues Q242, P245, V293 and Y352, which are all conserved 
between the E. coli and P. putida L-aspartate oxidases (Figures 5.1-2) were targeted to be 
substituted by alanine in order to disrupt the activity of those residues and investigate the role of 
each residue on the activity of the PpLAAO protein, and determine if these roles are consistent 
with what would be expected from the E. coli active site structure. The kinetic constants for 
H224A, H351A, R290L and R386L mutant forms of the E. coli L-AspO have been determined 
previously by Tedeschi et al.
[118]
 and comparison of these mutants and mutants of the same residues 
in the PpLAAO protein will also show how identical the active sites of the two proteins are. 
 
Q88MZ2_PpLAAO      MSQQFQH--DVLVIGSGAAGLSLALNLPSHLRVAVLSKGDLSNGSTFWAQGGVAAVLDNT 58 
P10902_L-AspO      MNTLPEHSCDVLIIGSGAAGLSLALRLADQHQVIVLSKGPVTEGSTFYAQGGIAAVFDET 60 
                   *.   :*  ***:************.*..: :* ***** :::****:****:***:*:* 
                        ¦β1¦¦ β2 ¦  ¦   α1   ¦     ¦β3¦¦β4¦    ¦α2¦           ¦ 
 
Q88MZ2_PpLAAO      DTVQSHVEDTLNAGGGLCHEDAVRFTVEHSREAIQWLIEQGVPFTRDEHYSVDDGGFEFH 118 
P10902_L-AspO      DSIDSHVEDTLIAGAGICDRHAVEFVASNARSCVQWLIDQGVLFDTHIQPNGEES---YH 117 
                   *:::******* **.*:*...**.*...::*..:****:*** *  . : . ::.   :* 
                        α3     ¦      ¦        α4        ¦          ¦β5¦ 
 
Q88MZ2_PpLAAO      LTREGGHSHRRIIHAADATGAAIFTTLLEQARQRPNIQLLEQRVAVDLITERRLGLPGER 178 
P10902_L-AspO      LTREGGHSHRRILHAADATGREVETTLVSKALNHPNIRVLERSNAVDLIVSDKIGLPGTR 177 
                   ************:*******  : ***:.:* ::***::**:  *****.. ::**** * 
      ¦ α5 ¦   ¦β6 ¦¦   β7   ¦α6¦ 
 
Q88MZ2_PpLAAO      -CLGAYVLDRNTGEVDTFGARFTVLATGGAAKVYLYTSNPDGACGDGIAMAWRAGCRVAN 237 
P10902_L-AspO      RVVGAWVWNRNKETVETCHAKAVVLATGGASKVYQYTTNPDISSGDGIAMAWRAGCRVAN 237 
                     :**:* :**.  *:*  *: .*******:*** **:*** :.**************** 
      ¦  β8   ¦    ¦ β9 ¦ ¦β10¦    ¦α7¦β11¦ ¦α8¦   ¦  α9  ¦ 
 
Q88MZ2_PpLAAO      LEFNQFHPTCLYHPQAKSFLITEALRGEGALLRLPNGERFMPRFDPREELAPRDIVARAI 297 
P10902_L-AspO      LEFNQFHPTALYHPQARNFLLTEALRGEGAYLKRPDGTRFMPDFDERGELAPRDIVARAI 297 
                   *********.******:.**:********* *: *:* **** ** * ************ 
         ¦ β12  ¦           ¦α10¦  ¦β13¦     ¦α11¦  ¦α12¦ ¦    α13 
 
Q88MZ2_PpLAAO      DHEMKRLGVDCVYLDITHKPADFIKSHFPTVYERCLAFGIDITRQPIPVVPAAHYTCGGV 357 
P10902_L-AspO      DHEMKRLGADCMFLDISHKPADFIRQHFPMIYEKLLGLGIDLTQEPVPIVPAAHYTCGGV 357 
                   ********.**::***:*******:.*** :**: *.:***:*::*:*:*********** 
   ¦    ¦β14¦     ¦ α14¦ ¦  α15  ¦      ¦   β15   ¦¦β16 
 
Q88MZ2_PpLAAO      MVDDCGHTDVPGLYAIGETSFTGLHGANRMASNSLLECFVYGRAAAADIQAHLEQVAMPK 417 
P10902_L-AspO      MVDDHGRTDVEGLYAIGEVSYTGLHGANRMASNSLLECLVYGWSAAEDITRRMPYAHDIS 417 
                   **** *:*** *******.*:*****************:*** :** **  ::  .   . 
       ¦    ¦β17¦β18¦¦α16¦¦β19¦       ¦        α17      ¦α18¦ 
 
Q88MZ2_PpLAAO      ALPGWDASQVTDSDEDVIIAHNWDELRRFMWDYVGIVRTSKRLQRAQHRIRLLLDEIDEF 477 
P10902_L-AspO      TLPPWDESRVENPDERVVIQHNWHELRLFMWDYVGIVRTTKRLERALRRITMLQQEIDEY 477 
                   :** ** *:* :.** *:* ***.*** ***********:***:** :** :* :****: 
     ¦        α19        ¦¦β20¦ ¦         α20 
 
Q88MZ2_PpLAAO      YSNYKVSRDLIELRNLAQVAELMILSAMQRKESRGLHYTLDYPGMLDEAKDTILNPL--- 534 
P10902_L-AspO      YAHFRVSNNLLELRNLVQVAELIVRCAMMRKESRGLHFTLDYPELLTHSGPSILSPGNHY 537 
                   *::::**.:*:*****.*****:: .** ********:***** :* .:  :**.*     
                   ¦      ¦         α21         ¦ 
 
Q88MZ2_PpLAAO      --- 
P10902_L-AspO      INR 540 
 
Figure 5.1 ClustalW2 alignment of the L-aspartate oxidases from P. putida (PpLAAO) and E. coli (L-AspO) 
with positions of α-helix and β-sheet structures in L-AspO. * represents conservation of identical residues, : 
represents conservation of strongly similar residues and . represents conservation of weakly similar residues. 
For the L-AspO sequence, FAD-binding domain residues are in red, capping domain residues are in green and 
helical domain residues are in blue. Shared active site residues are highlighted in yellow. 
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Figure 5.2 Active site structure of the E. coli L-AspO solved by Bossi et al..[65] a. The thirteen active site 
residues targeted for mutagenesis. Active site residues in grey, FAD and succinate in yellow. b. LigPlot+[67] 
representation of residues binding to flavin ring of L-AspO. Hydrogen bonds represented by dashed green 
lines and van der Waals forces represented by red combs. c. LigPlot+[67] representation of residues binding 
succinate in active site of of L-AspO. Hydrogen bonds represented by dashed green lines and van der Waals 
forces represented by red combs. 
a. 
b. 
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Figure 5.2 Active site structure of the E. coli L-AspO solved by Bossi et al..[65] a. The thirteen active site 
residues targeted for mutagenesis. Active site residues in grey, FAD and succinate in yellow. b. LigPlot+[67] 
representation of residues binding to flavin ring of L-AspO. Hydrogen bonds represented by dashed green 
lines and van der Waals forces represented by red combs. c. LigPlot+[67] representation of residues binding 
succinate in active site of of L-AspO. Hydrogen bonds represented by dashed green lines and van der Waals 
forces represented by red combs. 
 
5.2 Generation of active site mutants of PpLAAO 
 
To investigate the effect of each of these active site residues on the overall activity and substrate 
specificity of the PpLAAO enzyme, each active site residue was individually mutated to alanine in 
order to disrupt any bonding effects of those residues. 
c. 
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The thirteen SDM mutants were produced from the YSBLIC-3C-PpLAAO plasmid using the 
Stratagene QuikChange method where two complementary, overlapping mutagenic primers are 
used to form a copy of the entire plasmid ring, and the original wild-type plasmid is digested using 
DpnI restriction enzyme, which targets the methylated DNA in plasmids that have been purified by 
Miniprep, but not unmethylated DNA produced by PCR.  
 
The thirteen mutants were produced using Phusion polymerase as in Section 2.4. PCR product was 
treated with DpnI to remove the wild-type plasmid template and was then used to transform 
electrocompetent E.coli Top10 cells or chemically competent E. coli BL21-Gold-DE3 cells 
(Section 2.4, Table 2.6). Depending on the number of colonies produced, a number of colonies 
from each transformation were picked and gene overexpression was induced. Cells were then 
harvested and the insoluble protein fractions were analysed on 12% SDS-PAGE gel in order to 
make sure that the gene inserts in the plasmids were actually capable of expressing protein of the 
correct size before having them sequenced (Figures 5.3-5.8). 
 
 
 
Figure 5.3 SDS-PAGE separation of protein from electrocompetent E. coli BL21-DE3 cells transformed 
with mutated PpLAAO YSBLIC3C plasmids Q242A1-10: Lane 1, BioRad low molecular weight marker; 
Lane 2-11, insoluble protein fraction from Q242A1-10. 
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Figure 5.4 SDS-PAGE separation of protein from E. coli BL21-Gold-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids H244A1, P245A1-3 and E260A1-2. Lane 1, BioRad low molecular weight 
marker; Lane 2, insoluble protein fraction from H244A1; Lane 3-5, insoluble protein fraction from P245A1-
3; Lane 6-7, insoluble protein fraction from E260A1-2. 
 
 
Figure 5.5 SDS-PAGE separation of protein from E. coli BL21-Gold-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids L257A1-3, R290A1-3, Y352A1-2 and S391A1-2. Lane 1, BioRad low 
molecular weight marker; Lane 2-4, insoluble protein fraction from L257A1-3; Lane 4-7, insoluble protein 
fraction from R290A1-3; Lane 8-9, insoluble protein fraction from Y352A1-2; Lane 8-9, insoluble protein 
fraction from Y352A1-2; Lane 10-11, insoluble protein fraction from S391A1-2. 
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Figure 5.6 SDS-PAGE separation of protein from E. coli BL21-Gold-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids T259A1-10: Lane 1, BioRad low molecular weight marker; Lane 2-11, 
insoluble protein fraction from T259A1-10. 
 
Figure 5.7 SDS-PAGE separation of protein from E. coli BL21-Gold-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids V293A1-5 and S389A1-5. Lane 1, BioRad low molecular weight marker; 
Lane 2-6, insoluble protein fraction from V293A1-5; Lane 7-11, insoluble protein fraction from S389A1-5. 
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Figure 5.8 SDS-PAGE separation of protein from electrocompetent E. coli BL21-DE3 cells transformed 
with mutated PpLAAO YSBLIC3C plasmids H351A1-2 and R386A1-2. Lane 1, BioRad low molecular 
weight marker; Lane 2-3, insoluble protein fraction from H351A1-2; Lane 4-5, insoluble protein fraction 
from   R386A1-2. 
 
Based on these results the plasmids from the Q242A1, H244A1, P245A1, L257A1, T259A1, 
E260A2, R290A2, V293A1, H351A1, Y352A1, R386A1, S389A5 and S391A1 strains were 
purified by Miniprep and sent for sequencing at the University of York Genomics department 
(Section 2.4). All thirteen of these plasmids had mutated as expected. 
 
5.3 Purification of PpLAAO active site mutants 
 
The wild type and mutated versions of the pET-YSBLIC-3C-PpLAAO plasmids were used to 
transform E. coli BL21-DE3 cells. A 2 L culture was grown and induced for each strain of the pET-
YSBLIC-3C-PpLAAO plasmid as in Section 2.5.1, these were harvested and the soluble protein 
subjected to nickel affinity chromatography using a Prepacked HiTrap Chelating HP column 
followed by gel filtration chromatography using a 120 mL HiLoad 16/60 Superdex 75 column in 
order to purify the proteins (Section 2.5.2).  
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The E260A mutant did not produce any soluble protein (Figure 5.9) and the V293A mutant protein 
precipitated after the gel filtration chromatography. All the other pET-YSBLIC-3C-PpLAAO 
proteins were purified (Figures 5.10-5.20) with a yield of 15-20 mg from the 2 L culture. As with 
the wild type protein, the mutants eluted from the column after 52 mL. A calibration by the EMBL 
(http://www.embl.de/pepcore/pepcore_services/protein_purification/chromatography/hiload16-
60_superdex75/ Accessed 17/01/2012) of the 120 mL HiLoad 16/60 Superdex 75 column suggests 
that the protein size in solution when purified was roughly 116 kDa. As the PpLAAO protein is 59 
kDa, this suggests that the proteins are found in a dimeric form in solution.  
 
Figure 5.9 SDS-PAGE separation of protein from E. coli BL21-DE3 transformed with pET-YSBLIC3C-
PpLAAO-E260A subjected to metal affinity based chromatography. Lane 1, low range molecular weight 
marker; Lane 2, Total protein fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-E260A  induced culture 
(59 kDa); Lane 3, Soluble fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-E260A  induced culture 
(59 kDa); Lane 4-6, Protein flow-through from column loading of soluble fraction of sonicated BL21-pET-
YSBLIC3C-PpLAAO-E260A induced culture. 
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Figure 5.10 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-Q242A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-Q242A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-Q242A induced culture; Lane 6-12, protein fractions 
7-13 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-Q242A protein (59 kDa); 
Lane 13, low range molecular weight marker; Lane 14-15, Gel filtration fractions 12-13 of BL21-pET-
YSBLIC3C-PpLAAO-Q242A (59 kDa).  
 
Figure 5.11 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-H244A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-H244A  induced culture (59 kDa); Lane 3-4, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-H244A induced culture; Lane 5-9, protein fractions 
8-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-H244A protein (59 kDa); 
Lane 10-12, Gel filtration fractions 17-19 of BL21-pET-YSBLIC3C-PpLAAO-H244A (59 kDa).  
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Figure 5.12 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-P245A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-P245A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-P245A induced culture; Lane 6-7, protein fractions 1-
2 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-P245A protein (59 kDa); Lane 
8-12, protein fractions 8-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
P245A protein (59 kDa); Lane 13-15, Gel filtration fractions 17-19 of BL21-pET-YSBLIC3C-PpLAAO-
P245A (59 kDa). 
 
Figure 5.13 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-L257A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-L257A  induced culture (59 kDa); Lane 3-4, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-L257A induced culture; Lane 5-7, protein fractions 1-
3 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-L257A protein (59 kDa); Lane 
8-12, protein fractions 8-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
L257A protein (59 kDa); Lane 13-15, Gel filtration fractions 17-19 of BL21-pET-YSBLIC3C-PpLAAO-
L257A (59 kDa). 
  
161 
 
Figure 5.14 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-T259A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-T259A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-T259A induced culture; Lane 6-9, protein fractions 8-
11 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-T259A protein (59 kDa); 
Lane 10, combined fractions from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
T259A protein (59 kDa); Lane 11-12, Gel filtration fractions 13-14 of BL21-pET-YSBLIC3C-PpLAAO-
T259A (59 kDa). 
 
Figure 5.15 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-R290A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-R290A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-R290A induced culture; Lane 6-9, protein fractions 
8-11 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-R290A protein (59 kDa); 
Lane 10-11, Gel filtration fractions 13-14 of BL21-pET-YSBLIC3C-PpLAAO-R290A (59 kDa). 
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Figure 5.16 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-H351A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-H351A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-H351A induced culture; Lane 6-10, protein fractions 
8-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-H351A protein (59 kDa); 
Lane 11, combined fractions from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
H351A protein (59 kDa); Lane 12-13, Gel filtration fractions 12-13 of BL21-pET-YSBLIC3C-PpLAAO-
H351A (59 kDa). 
 
Figure 5.17 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-Y352A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-Y352A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-Y352A induced culture; Lane 6-9, protein fractions 
8-11 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-Y352A protein (59 kDa); 
Lane 10, combined fractions from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
Y352A protein (59 kDa); Lane 11-12, Gel filtration fractions 13-14 of BL21-pET-YSBLIC3C-PpLAAO-
Y352A (59 kDa). 
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Figure 5.18 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-R386A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2, Soluble fraction of sonicated BL21-pET-YSBLIC3C-
PpLAAO-R386A  induced culture (59 kDa); Lane 3-5, Protein flow-through from column loading of soluble 
fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-R386A induced culture; Lane 6-10, protein fractions 
8-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-R386A protein (59 kDa); 
Lane 11, combined fractions from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-
R386A protein (59 kDa); Lane 12-13, Gel filtration fractions 12-13 of BL21-pET-YSBLIC3C-PpLAAO-
R386A (59 kDa). 
 
Figure 5.19 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-S389A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2-3, Total/Soluble protein from sonicated BL21-pET-
YSBLIC3C-PpLAAO-S389A  induced culture (59 kDa); Lane 4-6, Protein flow-through from column 
loading of soluble fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-S389A induced culture; Lane 7-10, 
protein fractions 8-11 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-S389A 
protein (59 kDa); Lane 11, combined fractions from FPLC imidazole gradient of loaded BL21-pET-
YSBLIC3C-PpLAAO-S389A protein (59 kDa); Lane 12-13, Gel filtration fractions 13-14 of BL21-pET-
YSBLIC3C-PpLAAO-S389A (59 kDa). 
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Figure 5.20 SDS-PAGE separation of protein purified from E. coli BL21-DE3 transformed with pET-
YSBLIC3C-PpLAAO-S391A using metal affinity based chromatography and gel filtration chromatography. 
Lane 1, low range molecular weight marker; Lane 2-3, Total/Soluble protein from sonicated BL21-pET-
YSBLIC3C-PpLAAO-S391A  induced culture (59 kDa); Lane 4-6, Protein flow-through from column 
loading of soluble fraction of sonicated BL21-pET-YSBLIC3C-PpLAAO-S391A induced culture; Lane 7-10, 
protein fractions 9-12 from FPLC imidazole gradient of loaded BL21-pET-YSBLIC3C-PpLAAO-S391A 
protein (59 kDa); Lane 11, combined fractions from FPLC imidazole gradient of loaded BL21-pET-
YSBLIC3C-PpLAAO-S391A protein (59 kDa); Lane 12-14, Gel filtration fractions 12-14 of BL21-pET-
YSBLIC3C-PpLAAO-S391A (59 kDa). 
 
The purified H351A mutant protein solution was clear in colour, whereas the other PpLAAO 
proteins were yellow due to the presence of the FAD cofactor. This suggests that the H351 residue 
is involved in the binding of FAD, and that the mutation to alanine has disrupted the binding. This 
appears to be consistent with the active site structure of the homologous E. coli L-AspO (Figure 
5.2a) and work by Tedeschi et al..
[118] 
 
5.4 Activity assay of active site mutants 
 
The kinetic parameters of each of the active site mutants were determined against the wild-type 
substrates L-aspartate, L-asparagine and L-glutamate by measuring the initial rate activity of each 
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enzyme against substrate concentrations of 0.781 mM, 1.56 mM, 3.13 mM, 6.25 mM, 12.5 mM, 
25.0 mM, 37.5 and 50.0 mM with a final protein concentration of 0.1 mg mL
-1
, as in Section 2.5.3. 
However, as the wild-type protein only began showing activity against L-glutamate at higher 
concentration, the kinetic parameters against L-glutamate were determined by measuring the initial 
rate activities against concentrations of 50 mM, 100 mM, 150 mM, 200 mM, 250 mM, 300 mM, 
350 mM, 400 mM and 500 mM L-glutamate. 
 
The R386A mutant was inactive against all the substrates tested. All other mutants showed varying 
levels of activity against L-aspartate; however none were more efficient than the wild-type protein 
(Table 5.1a, Figure 5.21). The T259A, H351A and Y352A mutants did show activity against L-
aspartate, (Figures 5.22a, b and c) however as these mutants did not reach Vmax at the substrate 
concentration tested, it was not possible to determine the values of KM and kcat for these mutants, as 
noted in Table 5.1a. 
 
Aside from the wild-type PpLAAO, only the S391A protein showed any activity against L-
asparagine, however both the binding and catalytic efficiency had been reduced compared to the 
wild type protein (Table 5.1a) and the potential substrate inhibition seen in the wild-type protein 
appears to be present in the S391A mutant (Figure 5.23b). 
 
The wild type PpLAAO protein also showed activity against L-glutamate, with a KM of 345 mM 
and a kcat of 1.65 s
-1
 (Table 5.1b). The two mutants that showed activity against L-glutamate, 
Q242A and S389A, both appeared to have higher binding efficiency (roughly a 50-fold decrease in 
KM for Q242A and 35-fold decrease in KM for S389A). However the catalytic efficiency of these 
mutants had been decreased roughly ten-fold and five-fold for Q242A and S389A respectively 
(Table 5.1b). Although, in both of these cases, the standard error of the data points is quite high 
and two data points from each had to be removed as they had negative values (Figure 5.24b and 
c), so the presumed activity may just be due to background noise of the assay. 
 
The effect on the activity that the H244A and H351A mutants have on the activity of PpLAAO is 
consistent with the effect of the same mutations in the L-AspO protein made by Tedeschi et al.
[118]
 
as they all resulted in an increase in the KM of the enzyme against L-aspartate (Table 5.2). Mutation 
of R290 in both cases caused a large loss of activity; however the PpLAAO R290A mutant was not 
completely inactive unlike the L-AspO R290L mutant. Conversely, the PpLAAO R386A mutant 
was inactive, unlike the L-AspO R386L mutant, which had a thousand-fold higher KM against L-
aspartate than the wild type L-AspO (Table 5.2). 
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Table 5.1 a. Kinetic parameters of wild-type and active site mutants of PpLAAO protein against L-aspartate 
and L-asparagine. b. Kinetic parameters of wild-type and active site mutants of PpLAAO protein against L-
glutamate. Parameters determine using Grafit 7.0 software unless otherwise stated. 
a. L-aspartate L-asparagine 
Strain KM / mM kcat/ s
-1
 kcat KM
-1
/ M
-1
 s
-1
 KM / mM kcat/ s
-1
 kcat KM
-1
/ M
-1
 s
-1
 
Wild Type 2.263 10.6 4684.04 (0.6166) (4.5) (7298.09) 
Q242A 63.27 2.28 35.97 No detectable activity 
H244A 75.44 23.69 314.02 No detectable activity 
P245A 158.9
1 
25.62
1
 161.23
1
 No detectable activity 
L257A 599.88 59.28 98.87 No detectable activity 
T259A Couldn’t fit to Michaelis Menten No detectable activity 
R290A 26.11 0.23 8.84 No detectable activity 
H351A Couldn’t fit to Michaelis Menten No detectable activity 
Y352A Couldn’t fit to Michaelis Menten No detectable activity 
R386A No detectable activity No detectable activity 
S389A 14.29 7.837 548.43 No detectable activity 
S391A 3.258 2.501 767.65 (5.98) (0.23) (39.15) 
1
Parameters determined using GraphPad Plus 5 
 
b. L-glutamate 
Strain KM / mM kcat/ s
-1
 kcat KM
-1
/ M
-1
 s
-1
 
Wild Type 345.16 1.65 4.77 
Q242A 6.77 0.13 18.48 
H244A No detectable activity 
P245A No detectable activity 
L257A No detectable activity 
T259A No detectable activity 
R290A No detectable activity 
H351A No detectable activity 
Y352A No detectable activity 
R386A No detectable activity 
S389A 9.20 0.24 26.30 
S391A No detectable activity 
 
Table 5.2 Comparison of the kinetic parameters of mutated forms of the E. coli L-AspO made by Tedeschi et 
al.[118] and mutants of the same residues in PpLAAO. 
E. coli L-AspO
[118] 
PpLAAO 
Form KM / mM kcat/ s
-1
 kcat KM
-1
/ M
-1
 s
-1
 Form KM / mM kcat/ s
-1
 kcat KM
-1
/ M
-1
 s
-1
 
WT 1.6 0.49 306 WT 2.263 10.6 4684.04 
H244A 6.1 0.1 16.4 H244A 75.44 23.69 314.02 
H351A 9.4 0.0024 0.26 H351A KM too high to determine 
R386L 1000 0.0025 0.0025 R386A Inactive mutant 
R290L Inactive mutant R290A 26.11 0.23 8.84 
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Figure 5.21 Kinetics plots of activity PpLAAO-based proteins against L-aspartate. a. Wild type PpLAAO; b. 
Q242A; c. H244A; d. P245A; e. L257A; f. R290A; g. S389A; h. S391A. 
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Figure 5.21 Kinetics plots of activity PpLAAO-based proteins against L-aspartate. a. Wild type PpLAAO; b. 
Q242A; c. H244A; d. P245A; e. L257A; f. R290A; g. S389A; h. S391A. 
 
Figure 5.22 Unfitted kinetics data of PpLAAO-based proteins against L-aspartate. a. T259A; b. H351A; c. 
Y352A. 
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Figure 5.23 Unfitted kinetics data of PpLAAO-based proteins against L-asparagine. a. Wild type PpLAAO. 
b. S391A mutant. 
 
 
Figure 5.24 Kinetics plots of activity PpLAAO-based proteins against L-glutamate. a. Wild type PpLAAO. 
b. Q242A mutant. c. S389A mutant. 
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The activity against target substrates L-homoserine, L-alanine and L-tyrosine was tested in case new 
activity had been introduced by the mutations; however no activity was observed against these 
substrates at substrate concentrations up to 50 mM (data not shown). 
 
5.5 Discussion 
 
As the structure of the PpLAAO protein has yet to be solved, the structure of the E. coli L-AspO, 
which has 60% homology and shares conserved active site residues with the PpLAAO protein, was 
used to form a mutagenesis strategy with the aim of confirming the roles of several active site 
residues and potentially introducing new substrate specificities into the PpLAAO protein. In 
compliance with this strategy, thirteen residues either in or near the active site of the E. coli L-
AspO (Q242, H244, P245, L257, T259, E260, R290, V293, H351, Y352, R386, S389 and S391) 
were individually mutated into alanine, and these mutated genes were subsequently overexpressed, 
and protein was purified using the same method used for the wild-type version of PpLAAO.  
 
The E260 residue appears to form hydrogen bonds with two other residues (R263 and R290) in the 
E. coli L-AspO structure.
[65]
 The disruption of these bonds in the E260A mutant appears to have 
affected the folding of the protein, as the E260A mutant protein was only produced in insoluble 
form (Figure 5.9) and was unable to be purified. The reason for this is unclear, although if the 
E260 residue was anchoring two arginine side chains in place, the loss of this anchor may have 
caused the two arginine residues to move into positions that blocked other side chain interactions 
and resulted in poor folding of the protein.  
 
The V293A mutant could not be purified, as it would spontaneously precipitate after gel filtration 
chromatography. The reason for this is unclear, as in the E. coli L-AspO structure the V293 residue 
does not appear to form any interactions within its immediate environment. It is possible that the 
change to the smaller alanine residue allowed the V293A main chain to move more freely than 
before, causing a loss of protein stability. 
 
The kinetic parameters of the purified wild-type and mutant forms of the PpLAAO protein were 
determined against L-aspartate, L-asparagine and L-glutamate. The wild type protein showed high 
activity against L-aspartate, with a KM of 2.263 mM and a kcat/KM of 4684 M
-1
 s
-1
. The activity 
against L-asparagine was lower, but accurate kinetic parameters were undetermined due to the 
protein showing substrate inhibition at concentrations above 12.5 mM L-asparagine. The protein 
also showed very low activity against L-glutamate, with a KM of 345 mM and a kcat/KM of 4.77 M
-1
 
s
-1 
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Tedeshi et al.
[118]
 have previously investigated the effects of the active site residues on the activity 
of the L-AspO from E. coli on L-aspartate by mutating four of the active site residues into; H244A, 
R290L, H351A and R386L. The results are similar to those found by mutating the PpLAAO 
protein (Table 5.2). In both cases the H244A mutation causes an increase in the KM against L-
aspartate, although it is a larger increase in the PpLAAO protein, as discussed in more detail below. 
Unlike the E. coli L-AspO the H244A mutation appears to cause an increase in kcat, although this 
may be an inaccurate calculation caused by a lack of data for substrate concentrations higher than 
50 mM. 
 
The H351A mutation also causes an increase in the KM against L-aspartate in both proteins (Table 
5.2,
[118]
 Figure 5.21b), it also reduced catalytic efficiency in the E. coli protein, but whether that 
would be true for the PpLAAO protein is undetermined at this point.  
 
The R386L mutant of the E. coli L-AspO protein showed low activity against L-aspartate; however 
no activity was seen in the R386A mutant of PpLAAO. This may either have been due to the 
difference between the effects of a leucine side-chain as opposed to an alanine side chain, or it may 
be that the use of o-dianisidine instead of 4-AAP and TBHBA in the activity assay by Tedeshi et 
al.
[118]
 may have allowed them to detect lower levels of activity, as the lowest value kcat that they 
detected was lower than any of the ones detected for PpLAAO (Tables 5.1, 5.2). 
 
Conversely, the PpLAAO R290A mutant showed a low level of activity, whereas the E. coli R290L 
mutant was completely inactive.
[118]
 This difference may be due to the difference in the mutated 
side chain, so does not necessarily indicate any difference between the E. coli L-AspO and the 
PpLAAO active site structures.  
 
The mutants of the two residues thought to be involved in the binding of the C1 carboxylate of 
succinate in the E. coli L-AspO,
[118]
 H244A and T259A, both show activity against L-aspartate, but 
with lower binding efficiency compared to the wild-type PpLAAO. The H244 residue is thought to 
bind the O2 atom of the C1 carboxylate (Figure 5.2c), and mutation of this residue to alanine in the 
E. coli L-AspO resulted in a 3.8-fold increase in KM,
[118]
 whereas in PpLAAO the same mutation 
has caused a 33-fold increase in KM (Table 5.1a), consistent with the role of the H244 residue in 
the E. coli protein. The T259 residue is thought to bind the O1 atom of the C1 carboxylate (Figure 
5.2c), and its mutation to alanine in PpLAAO resulted in a greatly decreased binding efficiency, as 
the initial rate activities did not begin to plateau over the concentrations of L-aspartate tested 
(Figure 5.21a). This mutation is not reported on by Tedeschi et al.,
[118]
 but the PpLAAO T259A 
mutant points towards a role in substrate binding for the T259 residue. 
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The H351 residue is thought to bind the O4 atom of the C4 carboxylate of the succinate substrate in 
the E. coli L-AspO structure (Figure 5.2c).
[65]
 When this residue was mutated to alanine by 
Tedeschi et al. the resulting protein showed activity against L-aspartate that was three orders of 
magnitude lower than the wild-type activity and a 6.5-fold increase in the dissociation constant for 
the FAD cofactor compared to the wild-type L-AspO.
[118]
 The PpLAAO H351A mutant also 
showed poor binding of FAD, as the purified protein was colourless as opposed to the yellow 
colour of the other purified proteins, and had a lower level of activity than the wild-type protein 
(Figure 5.21b), likely to be due to the loss of the FAD cofactor, although the binding affinity of the 
protein also appears to be lost in the H351A mutant, as the reactions did not appear to be 
approaching Vmax over the substrate concentrations tested (Figure 5.21b). This is also consistent 
with the results of Tedeschi et al.
[118]
 who observed a 5.8-fold increase in KM and a 200-fold 
decrease in catalytic activity against L-aspartate in the H351A mutant compared to the wild-type E. 
coli L-AspO. 
 
The S389 residue is thought to bind the O3 atom of the C4 carboxylate of the succinate substrate in 
the E. coli L-AspO (Figure 5.2c).
[65]
 The PpLAAO S389A mutant showed a 6.3-fold increase in KM 
but only a slight reduction in the catalytic activity against L-aspartate (Table 5.1a), suggesting that 
its role is in substrate binding as opposed to catalysis. Against L-glutamate, the S389A mutant 
showed 38-fold decrease in KM, but a 6.8-fold decrease in activity compared to the wild-type 
PpLAAO. The decrease in KM against L-glutamate could suggest that this residue may be a 
potential point for saturation mutagenesis when attempting to change substrate specificity, as the 
increased binding against L-glutamate at the expense of L-aspartate suggests it has a role in 
substrate specificity. 
 
Of the arginines in the active site, mutation of R386, which is suggested to have a role in binding 
the α-carboxylate of the actual substrate L-aspartate, gave a mutant with no detectable activity. 
Mutation of the same residue to leucine in the E. coli L-AspO resulted in a mutant with a 196-fold 
decrease in activity and a 625-fold increase in the KM for L-aspartate compared to the wild-type 
form. 
 
Mutation of R290 to alanine, which is thought to have a role in abstracting the proton from the Cα 
of the L-aspartate substrate in the E. coli L-AspO, resulted in a 50-fold decrease in kcat against L-
aspartate, although the mutation of the same residue to leucine in the E. coli L-AspO resulted in a 
completely inactive protein.
[118]
 In a related note, the mutation of Q242 side chain, which forms a 
H-bond with the R290 residue in the L-AspO structure (Figure 5.2a),
[65]
 resulted in a mutant with a 
30-fold increase in KM and a 4.6-fold decrease in kcat compared to the wild-type PpLAAO, 
suggesting that the Q242 residue may have a role in fixing the essential R290 residue in place to 
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allow for effective proton abstraction. The Q242A mutant also showed increase binding efficiency, 
but lower catalytic activity against L-glutamate than the wild-type PpLAAO (Table 5.1b). 
 
In the E. coli L-AspO structure, the S391 residue appears to form H-bonds with the N1 of the FAD 
flavin ring (Figure 5.2b). When mutated to alanine the resulting protein showed a slight reduction 
in binding efficiency, with a KM of 3.25 mM compared to the wild-type 2.26 mM, but a 4 fold 
decrease in catalytic activity (Table 5.1a). This suggests that the exact positioning of the flavin 
ring in conjunction with the positioning of the substrate in the active site is important to the 
catalytic efficiency of the PpLAAO enzyme, which is consistent with its suggested hydride transfer 
mechanism.
[64]
 The S391A mutant also showed activity against L-asparagine, although with lower 
binding efficiency and catalytic efficiency than the wild-type PpLAAO (Table 5.1a, Figure 5.22). 
 
The Y352 residue has some van der Waals interactions with the FAD molecule (Figure 5.2a-b), as 
well as forming hydrogen bonds with two residues outside the active site, H382 and E394, shown 
on the E. coli L-AspO structure.
[65]
 When this residue is mutated to alanine, the resulting protein 
had a reduced binding affinity and catalytic activity against L-aspartate compared to the wild-type 
PpLAAO (Figure 5.21c). This could be due to the loss of the steric interaction with the ribitol 
chain resulting in a shift of position of the flavin ring, resulting in less efficient proton abstraction 
from the substrate. Otherwise the loss of the H-bonds to the H382 and E394 residues may result in 
a shift some of the substrate binding residues, causing a loss of binding affinity. 
 
The remaining two residues P245 and L257, which are both close to the H244 residue that binds 
the C1 carboxylate of succinate in the E. coli L-aspO structure 
[65]
 (P245 is adjacent to H244 and 
L257 sites beneath it (Figure 5.2a)), each gave mutants with a greatly increased KM and increased 
kcat, which indicates roles in substrate binding which had not been recognised previously.  
 
Overall, this mutagenesis strategy has increased the understanding of the role of the active site 
residues in PpLAAO and possibly other L-aspartate oxidases. Activity against target substrates L-
alanine and L-tyrosine was tested, just in case the changes to the active site had resulted in proteins 
with activity against different substrates, however no new activity was observed. This is likely to 
be because the changes to the active site were not large enough to result in a large change in 
substrate specificity. It may also be because of the hydride transfer mechanism that this protein 
uses, which requires a specific angle between the substrate and the flavin ring of FAD in order for 
effective proton abstraction from the substrate, meaning that changes to the active site area a more 
likely to have a negative effect on overall activity than they would in an enzyme where the 
positioning of the substrate was not as crucial to the activity of the enzyme. This effect can possibly 
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be seen with the Q242A and S389A mutants, which both showed better binding efficiency, but far 
lower catalytic activity against L-glutamate than the wild-type PpLAAO protein. 
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Chapter 6    CASTing and epPCR of PpLAAO 
 
The site directed mutagenesis (SDM) of the PpLAAO active site residues performed in Chapter 5 
has developed a greater understanding of the roles of the active site residues, with results that are 
consistent with the active site structure of the E. coli L-aspartate oxidase (L-aspO) solved by Bossi 
et al.
[65]
 Now that a highly soluble and active amino acid oxidase (AAO) has been identified, it 
would be of interest to try and evolve activity towards other amino acid substrates, particularly our 
targets L-alanine and L-tyrosine. 
 
However, there is a large difference between the side-chains of L-aspartate and those of the target 
substrates, so one round of directed evolution may not be enough to introduce activity against these 
two substrates. Because of this the directed evolution libraries will be screened against L-
homoserine, as part of a substrate walking approach towards L-alanine (Figure 6.1). If any mutants 
show activity against L-homoserine after one round of directed evolution these could then be used 
as a basis for evolution of an L-alanine oxidase. 
 
Figure 6.1 Substrate walking from L-aspartate to L-alanine, using L-homoserine as a mid-way point. 
 
As a strategy for this directed evolution, thirteen active site residues from the structure of the E. 
coli L-aspartate oxidase built by Bossi et al.
[65] 
(Section 5.1) were split into 5 groups as in Figure 
6.2 and Table 6.1. Each of these 5 groups contained residues that were sequentially close enough 
to each other that they were all able to be mutated using one primer set. This would allow for 
directed evolution using an iterative CASTing approach used by Reetz et al,
[108]
 where each group 
of residues is mutated using site directed saturation mutagenesis (SDSM) and then screened for 
activity against target substrates, then any strains showing activity are mutated at a different group 
of residues, and so on. 
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Figure 6.2 Structure of E. coli L-aspartate oxidase[65] showing library CASTing designation groups A (red), 
B (green), C (blue), D (magenta) and E (grey) along with succinate substrate and FAD (yellow). 
 
Table 6.1 CASTing strategy libraries- grouped in order to minimise the distance between amino acids in the 
DNA sequence for primer design. 
Library Amino acids 
A (red) H351, Y352 
B (green) R290, V293 
C (blue) L386, S389, S391 
D (magenta) Q242, H244, P245 
E (grey) L257, T259, E260 
 
In order to keep the number of transformants needed to cover at least 95% of all possible 
combinations of mutations at a low enough number for screening at the lab bench level, the codon 
degeneracy used for the SDSM reactions was the NDT degeneracy (N: 
adenine/cytosine/guanine/thymine; D: adenine/guanine/thymine; T: thymine), which forms codons 
for 12 chemically diverse amino acid side chains (L-phenylalanine, L-leucine, L-isoleucine, L-
valine, L-tyrosine, L-histidine, L-asparagine, L-aspartate, L-cysteine, L-arginine, L-serine and 
glycine).  
 
This was instead of using the standard NNK (K: guanine/thymine) degeneracy, which results in 32 
codons for all 20 natural amino acid side chains. As discussed by Reetz et al.,
[107]
 using the NDT 
degeneracy means that 430 transformants need to be screen in a library where 2 residues are 
mutated in order to cover 95% of all possible mutations, and 5175 transformants are needed for a 
library with 3 residue mutations. For the NNK degeneracy the numbers of transformants needed are 
3066 and 98163 for libraries with 2 and 3 residue mutations respectively. 
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Although, in most cases, changes in residues that are closer to the active site will have more effect 
on enzyme activity than mutation in residues further away from the active site, mutating residues 
throughout the enzyme structure could have a beneficial effect on enzyme activity, as discussed by 
Morley & Kazlauskas.
[109] 
For this reason the wild type PpLAAO gene sequence was subjected to 
random mutagenesis using the Stratagene MutaZyme II error prone PCR polymerase, which 
contains a combination of Stratagene’s reduced fidelity MutaZyme I, and a reduced fidelity Taq 
polymerase to reduce mutational bias between A and T and G and C mutations,
[120]
 resulting in a 
larger number of possible codon mutations. 
 
6.1 Generation of SDSM CASTing libraries 
 
The SDSM CASTing libraries were produced from the YSBLIC-3C-PpLAAO plasmid using the 
Stratagene QuikChange method where two complementary, overlapping mutagenic primers are 
used to form a copy of the entire plasmid ring, and the original wild-type plasmid is digested using 
DpnI restriction enzyme, which targets the methylated DNA in plasmids that have been purified by 
Miniprep, but not unmethylated DNA produced by PCR.  
 
The PpLAAO CASTing library A was produced using Pfu Turbo HotStart polymerase and primers 
designed to induce mutations into the sites His351 and Tyr352, with a PCR annealing temperature 
of 52°C. The PCR reaction was digested with DpnI and then used to transform chemically 
competent E.coli XL10-Gold cells, as in Section 2.6.1. Plasmid DNA was purified from six of the 
resulting colonies, named PNDTA A-F, and the length of the gene insert was checked by PCR 
amplification using primers that bound to each end of the PpLAAO gene sequence. However the 
size of the insert appeared to vary between the different plasmids (Figure 6.3). 
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Figure 6.3 1% agarose gel separation of DNA from PCR amplification of plasmid inserts using: Lane 1, 1 kb 
DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb), Lane 2-7, PCR amplification of 
insert sequence in pET-YSBLIC3C PNDTAA-F plasmids (Expected- 1605 bp). 
 
PNDTAA-E were sent for sequencing by the York University Genomics department and all five 
strains had mutations in the expected base pairs (Table 6.2). However PNDTAA, PNDTAB and 
PNDTAD also had 283, 169 and 207 bp (respectively) sections of partial and whole primer insert 
sequences (Figure 6.4), possibly caused by a 9 base pair repeat found on either side of the 
mutagenic sequence of the primers (Table 2.3) which allowed the complementary primers to bind 
to each other and form chains, which were then incorporated into the new sequence around the 
primer binding site. 
 
Table 6.2 Summary of changes in mutation site of sequenced PpLAAO mutants (PNDTAA-E) 
Plasmid 
Nucleotide sequence of mutation 
site 
Amino acid changes from Wild-Type 
Wild-type PpLAAO CATTAC N/A 
PNDTAA GTTCGT His351Val, Tyr352Arg 
PNDTAB TATTAT His351Tyr 
PNDTAC TATCAT His351Tyr, Tyr352His 
PNDTAD TTTTAT His351Phe 
PNDTAE CTTGAT His351Leu, Tyr352Asp 
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WTPpLAAO        ------------------------------------------------------------ 
PNDTAC          CGGGTTCAATTCCCC-TCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG 59 
PNDTAE          -GGGAAAATTTCCCC-TCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG 58 
PNDTAB          --GGGCAACATTCCA-TCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG 57 
PNDTAD          -GGGCGGAACATTCC-TCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG 58 
PNDTAA          --TGCGGGTCATTCCCTCTAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGG 58 
                                                                             
 
WTPpLAAO        ------------------------------------------------------------ 
PNDTAC          GCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAG 119 
PNDTAE          GCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAG 118 
PNDTAB          GCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAG 117 
PNDTAD          GCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAG 118 
PNDTAA          GCAGCAGCCATAAACATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAGGGACCAG 118 
                                                                             
 
WTPpLAAO        --ATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 58 
PNDTAC          CAATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 179 
PNDTAE          CAATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 178 
PNDTAB          CAATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 177 
PNDTAD          CAATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 178 
PNDTAA          CAATGAGCCAACAATTCCAACATGATGTCCTGGTGATCGGCAGCGGTGCCGCCGGTCTCA 178 
                  ********************************************************** 
 
WTPpLAAO        GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 118 
PNDTAC          GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 239 
PNDTAE          GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 238 
PNDTAB          GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 237 
PNDTAD          GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 238 
PNDTAA          GCCTGGCACTTAACCTCCCCAGCCACCTTCGCGTTGCCGTATTGAGCAAGGGCGACCTGT 238 
                ************************************************************ 
 
WTPpLAAO        CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 178 
PNDTAC          CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 299 
PNDTAE          CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 298 
PNDTAB          CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 297 
PNDTAD          CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 298 
PNDTAA          CCAACGGCTCGACCTTCTGGGCCCAGGGCGGCGTCGCTGCAGTGCTGGACAACACCGATA 298 
                ************************************************************ 
 
WTPpLAAO        CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 238 
PNDTAC          CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 359 
PNDTAE          CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 358 
PNDTAB          CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 357 
PNDTAD          CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 358 
PNDTAA          CTGTGCAGTCGCATGTCGAGGACACCCTCAATGCCGGCGGCGGGCTGTGCCATGAAGACG 358 
                ************************************************************ 
 
WTPpLAAO        CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 298 
PNDTAC          CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 419 
PNDTAE          CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 418 
PNDTAB          CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 417 
PNDTAD          CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 418 
PNDTAA          CAGTGCGCTTTACCGTCGAGCACAGCCGCGAAGCGATCCAATGGCTGATCGAGCAAGGCG 418 
                ************************************************************ 
 
WTPpLAAO        TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 358 
PNDTAC          TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 479 
PNDTAE          TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 478 
PNDTAB          TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 477 
PNDTAD          TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 478 
PNDTAA          TGCCCTTCACCCGCGATGAGCACTACAGCGTCGACGATGGCGGCTTCGAGTTCCACCTCA 478 
                ************************************************************ 
 
WTPpLAAO        CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 418 
PNDTAC          CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 539 
PNDTAE          CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 538 
PNDTAB          CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 537 
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PNDTAD          CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 538 
PNDTAA          CCCGTGAAGGGGGCCATAGCCACCGGCGCATCATCCACGCCGCCGACGCTACCGGCGCGG 538 
                ************************************************************ 
 
WTPpLAAO        CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 478 
PNDTAC          CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 599 
PNDTAE          CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 598 
PNDTAB          CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 597 
PNDTAD          CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 598 
PNDTAA          CAATCTTCACCACGCTGCTGGAACAGGCTCGCCAGCGCCCGAACATCCAGCTGCTGGAGC 598 
                ************************************************************ 
 
WTPpLAAO        AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 538 
PNDTAC          AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 659 
PNDTAE          AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 658 
PNDTAB          AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 657 
PNDTAD          AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 658 
PNDTAA          AGCGGGTGGCGGTCGACCTGATCACTGAACGCCGCCTGGGCCTGCCCGGCGAACGCTGCC 658 
                ************************************************************ 
 
WTPpLAAO        TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 598 
PNDTAC          TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 719 
PNDTAE          TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 718 
PNDTAB          TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 717 
PNDTAD          TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 718 
PNDTAA          TGGGCGCCTACGTGCTCGACCGCAACACCGGCGAGGTGGACACCTTCGGCGCGCGCTTCA 718 
                ************************************************************ 
 
WTPpLAAO        CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 658 
PNDTAC          CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 779 
PNDTAE          CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 778 
PNDTAB          CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 777 
PNDTAD          CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 778 
PNDTAA          CCGTGCTGGCCACGGGCGGTGCGGCCAAGGTCTATCTCTACACCAGCAACCCCGATGGTG 778 
                ************************************************************ 
 
WTPpLAAO        CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 718 
PNDTAC          CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 839 
PNDTAE          CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 838 
PNDTAB          CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 837 
PNDTAD          CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 838 
PNDTAA          CCTGCGGCGACGGTATCGCCATGGCCTGGCGGGCCGGCTGCCGAGTGGCGAACCTGGAAT 838 
                ************************************************************ 
 
WTPpLAAO        TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 778 
PNDTAC          TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 899 
PNDTAE          TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 898 
PNDTAB          TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 897 
PNDTAD          TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 898 
PNDTAA          TCAACCAGTTCCACCCGACCTGCCTGTATCACCCACAGGCCAAGAGCTTCCTGATCACCG 898 
                ************************************************************ 
 
WTPpLAAO        AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 838 
PNDTAC          AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 959 
PNDTAE          AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 958 
PNDTAB          AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 957 
PNDTAD          AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 958 
PNDTAA          AAGCCCTGCGCGGCGAGGGCGCCCTGCTGCGCCTGCCCAACGGCGAACGTTTCATGCCAC 958 
                ************************************************************ 
 
WTPpLAAO        GCTTCGACCCACGCGAAGAGCTGGCCCCACGG-------GACA-------TCGTGGCCCG 884 
PNDTAC          GCTTCGACCCACGCGAAGAGCTGGCCCCACGG-------GACA-------TCGTGGCCCG 1005 
PNDTAE          GCTTCGACCCACGCGAAGAGCTGGCCCCACGG-------GACA-------TCGTGGCCCG 1004 
PNDTAB          GCTTCGACCCACGCGAAGAGCTGGCCCCACGG-------GACA-------TCGTGGCCCG 1003 
PNDTAD          GCTTCGACCCACGCGAAGAGCTGGCCCCACGG-------GACA-------TCGTGGCCCG 1004 
PNDTAA          GCTTCGACCCACGCGAAGAGCTGGACCTGCGGCCGGGGTGATGGTGGTGCCTGCGGCGCG 1018 
                ************************ **  ***       **           * *** ** 
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WTPpLAAO        CGCCATCGACCACGAGATGAA--GCGC--CTG-GGCG---TGGA----CTGCG------T 926 
PNDTAC          CGCCATCGACCACGAGATGAA--GCGC--CTG-GGCG---TGGA----CTGCG------T 1047 
PNDTAE          CGCCATCGACCACGAGATGAA--GCGC--CTG-GGCG---TGGA----CTGCG------T 1046 
PNDTAB          CGCCATCGACCACGAGATGAA--GCGC--CTG-GGCG---TGGA----CTGCG------T 1045 
PNDTAD          CGCCATCGACCACGAGATGAA--GCGCTGCTGCGGCGATTTATA----CTGCGGCGGGGT 1058 
PNDTAA          TATTACCTGCGGCGGGGTGAGTGGTGC--CTGCGGCG---TGTATTACCTGCGGCGGGGT 1073 
                    * *  *  ** * ***   * **  *** ****   *  *    *****      * 
 
WTPpLAAO        A----------------------TAC---CTG-GAC--ATCACTC-ACAAGC-------- 949 
PNDTAC          A----------------------TAC---CTG-GAC--ATCACTC-ACAAGC-------- 1070 
PNDTAE          A----------------------TAC---CTG-GAC--ATCACTC-ACAAGC-------- 1069 
PNDTAB          A----------------------TAC---CTG-GAC--ATCACTC-ACAAGC-------- 1068 
PNDTAD          G----------------------TGGTG-CTGCGGCGAATCATAC-TGCGGCGGGGTG-- 1092 
PNDTAA          GATACCCGTCAGCCGATCCCCGGTGGTGCCTGCGGCGTGTATTACCTGCGGCGGGGTGAC 1133 
                                       *     *** * *   *    *     **         
 
WTPpLAAO        --------CTGCAG--------AT-TTCATCAAGA--GCCAC-TTCCCCACCGTGTAC-- 987 
PNDTAC          --------CTGCAG--------AT-TTCATCAAGA--GCCAC-TTCCCCACCGTGTAC-- 1108 
PNDTAE          --------CTGCAG--------AT-TTCATCAAGA--GCCAC-TTCCCCACCGTGTAC-- 1107 
PNDTAB          --------CTGCAG--------AT-TTCATCAAGA--GCCAC-TTCCCCACCGTGTAC-- 1106 
PNDTAD          GGTGGTG-CTGCGGCGTATCGTAC-TGCGGCGGGGTGGGTGC-TGCGGCGCGTTATACTG 1149 
PNDTAA          GGTGGTGCCTGCGGCGGATAATACCTGCGGCGGGGGTGGTGCCTGCGGCGGGTGTTAC-- 1191 
                        **** *        *  * *  *  *   *   * * *  *      ***   
 
WTPpLAAO        --GAGCGCTGCCTGGC--CTTTGGCA-TCGATAT-CACCCGTCAGCCGATCCCGGTGGTG 1041 
PNDTAC          --GAGCGCTGCCTGGC--CTTTGGCA-TCGATAT-CACCCGTCAGCCGATCCCGGTGGTG 1162 
PNDTAE          --GAGCGCTGCCTGGC--CTTTGGCA-TCGATAT-CACCCGTCAGCCGATCCCGGTGGTG 1161 
PNDTAB          --GAGCGCTGCCTGGC--CTTTGGCA-TCGATAT-CACCCGTCAGCCGATCCCGGTGGTG 1160 
PNDTAD          CGGCGGGGTGATTGGTG-CTGCGGCGGTTAGTAC-TGCG-GCGGGGTGAT--CGGTGGTG 1204 
PNDTAA          CTGCGGCG-----GGTGCCTGCGGCGGATTTTACCTGCG-GCGGGGTG----CGGTGGTG 1241 
                  * *        **   **  ***      **    *  *   *  *    ******** 
 
WTPpLAAO        C----------------------------------------------------------- 1042 
PNDTAC          C----------------------------------------------------------- 1163 
PNDTAE          C----------------------------------------------------------- 1162 
PNDTAB          CTGCGGCGTATCGTACTGCGGCGGGGTGATACTGCGGCGTTTTTTACGTGCGGCGGGTGG 1220 
PNDTAD          CG---------------------------------------------------------- 1206 
PNDTAA          CC---------------------------------------------------------- 1243 
                *                                                            
 
WTPpLAAO        ------------------------------------------------------------ 
PNDTAC          ------------------------------------------------------------ 
PNDTAE          ------------------------------------------------------------ 
PNDTAB          TGCGTGCGGCGATTTTTACCTGCGGCGGGTGCCTGCGGCGCTTTATACCTGCGGCGGGGT 1280 
PNDTAD          ------------------------------------------------------------ 
PNDTAA          ------------------------------------------------------------ 
                                                                             
 
WTPpLAAO        --------------------------------------------------CTGCGGCGCA 1052 
PNDTAC          --------------------------------------------------CTGCGGCGTA 1173 
PNDTAE          --------------------------------------------------CTGCGGCGCT 1172 
PNDTAB          GATGGTGGTGCCTGCGGCGGTTGATACCTGCGGCGGGGTGACGGTGGTGCCTGCGGCGTA 1340 
PNDTAD          ------------TGCGGCGCGTTGTACCTGCGGCGGGGTGATGGTGGTGCCTGCGGCGTT 1254 
PNDTAA          ------------TGCGGCGTTTGATACCTGCGGCGG-----------TGCCTGCGGCGGT 1280 
                                                                  ********   
 
WTPpLAAO        TTACACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1112 
PNDTAC          TCATACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1233 
PNDTAE          TGATACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1232 
PNDTAB          TTATACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1400 
PNDTAD          TTATACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1314 
PNDTAA          TCGTACCTGCGGCGGGGTGATGGTCGACGACTGCGGCCACACCGATGTGCCTGGCTTGTA 1340 
                *   ******************************************************** 
 
WTPpLAAO        TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1172 
PNDTAC          TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1293 
PNDTAE          TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1292 
PNDTAB          TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1460 
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PNDTAD          TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1374 
PNDTAA          TGCCATCGGCGAAACCAGTTTCACCGGCCTGCACGGCGCCAACCGCATGGCCAGCAACTC 1400 
                ************************************************************ 
 
WTPpLAAO        GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1232 
PNDTAC          GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1353 
PNDTAE          GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1352 
PNDTAB          GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1520 
PNDTAD          GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1434 
PNDTAA          GCTGCTGGAATGTTTTGTGTACGGTCGCGCCGCCGCTGCCGACATCCAGGCGCACCTGGA 1460 
                ************************************************************ 
 
WTPpLAAO        GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1292 
PNDTAC          GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1413 
PNDTAE          GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1412 
PNDTAB          GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1580 
PNDTAD          GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1494 
PNDTAA          GCAAGTGGCCATGCCCAAGGCCTTGCCCGGCTGGGACGCCAGCCAGGTGACCGACTCGGA 1520 
                ************************************************************ 
 
WTPpLAAO        CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1352 
PNDTAC          CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1473 
PNDTAE          CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1472 
PNDTAB          CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1640 
PNDTAD          CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1554 
PNDTAA          CGAGGACGTGATCATTGCGCACAACTGGGACGAACTGCGGCGCTTCATGTGGGACTACGT 1580 
                ************************************************************ 
 
WTPpLAAO        CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1412 
PNDTAC          CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1533 
PNDTAE          CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1532 
PNDTAB          CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1700 
PNDTAD          CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1614 
PNDTAA          CGGCATCGTGCGCACCAGCAAGCGCCTGCAGCGGGCCCAGCACCGCATTCGCCTGCTGCT 1640 
                ************************************************************ 
 
WTPpLAAO        GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1472 
PNDTAC          GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1593 
PNDTAE          GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1592 
PNDTAB          GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1760 
PNDTAD          GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1674 
PNDTAA          GGATGAAATCGACGAGTTCTACAGCAACTACAAGGTCAGCCGTGACCTGATCGAGCTGCG 1700 
                ************************************************************ 
 
WTPpLAAO        CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1532 
PNDTAC          CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1653 
PNDTAE          CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1652 
PNDTAB          CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1820 
PNDTAD          CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1734 
PNDTAA          CAACCTGGCGCAAGTGGCCGAGCTGATGATCCTGTCAGCCATGCAGCGCAAGGAAAGCCG 1760 
                ************************************************************ 
 
WTPpLAAO        AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1592 
PNDTAC          AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1713 
PNDTAE          AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1712 
PNDTAB          AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1880 
PNDTAD          AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1794 
PNDTAA          AGGGTTGCATTACACACTGGATTATCCAGGGATGCTGGACGAGGCCAAGGACACCATCCT 1820 
                ************************************************************ 
 
WTPpLAAO        TAACCCGCTCTGA----------------------------------------------- 1605 
PNDTAC          TAACCCGCTCTGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAAT 1773 
PNDTAE          TAACCCGCTCTGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAAT 1772 
PNDTAB          TAACCCGCTCTGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAAT 1940 
PNDTAD          TAACCCGCTCTGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAAT 1854 
PNDTAA          TAACCCGCTCTGACGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAAAT 1880 
                *************                                                
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WTPpLAAO        ------------------------------------------------------------ 
PNDTAC          GGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACC 1833 
PNDTAE          GGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACC 1832 
PNDTAB          GGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACC 2000 
PNDTAD          GGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACC 1914 
PNDTAA          GGGTCGCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACC 1940 
                                                                             
 
WTPpLAAO        ---------------------------------------------------------- 
PNDTAC          ACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTAG--GTGGCCC 1889 
PNDTAE          ACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTAGTGGCGGC-- 1888 
PNDTAB          ACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAG-AAGCTAGTGCT----- 2052 
PNDTAD          ACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAG-AAGCTGA-GTTGCCCC 1970 
PNDTAA          ACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAG-AAGCTA---CTGCCC- 1993 
 
Figure 6.4 CLUSTAL 2.0.12 multiple sequence alignment of Wild Type PpLAAO, and PNDTA A-E, insert 
sequences, with extra oligo sequences in orange text and mutated residues highlighted in yellow. 
 
The PNDTAA-D purified plasmids were also used to transform competent E.coli BL21-DE3 cells 
in order to analyse the protein expression (Section 2.6.1). The PNDTAC strain produced protein 
that was the same size as the wild-type PpLAAO protein (59 kDa), however the PNDTAA strain 
did not produce any protein and the PNDTAB and PNDTAD strains produced truncated protein 
that was around 45 kDa in size (Figure 6.5), probably due to the extra base pairs causing a stop 
codon to be formed. 
 
 
Figure 6.5 SDS-PAGE separation of protein from E. coli BL21-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids PNDTAA-D: Lane 1, BioRad low molecular weight marker; Lane 2-5, 
insoluble protein fraction from PNDTAA-D; Lane 6-9, soluble protein fraction from PNDTAA-D. 
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As the extra insertions were potentially being caused by the primer pairs self annealing, an increase 
in the annealing temperature of the PCR reaction was attempted. The PCR annealing temperature 
was optimised using a Eppendorf Mastercycler gradient PCR machine to run the PCR with 
annealing temperatures of 59.1°C, 61.3°C, 63.5°C, 65.7°C, 67.9°C and 70.5°C. PCR product was 
visible in all reactions (Figure 6.6), so the library was produced with an annealing temperature of 
72°C as in Section 2.6.1. 
 
The resulting PCR reaction was digested with DpnI and then transformed into E.coli BL21-Gold-
DE3 competent cells. Nine colonies were picked and protein overexpression was induced as in 
Section 2.6.1. As seven of the nine strains produced proteins that were the expected 59 kDa in size 
(Figure 6.7), ten more transformations were performed, resulting in a total of over 400 colonies. 
These colonies were pooled together and then Midiprepped to form a pure plasmid library as in 
Section 2.6.1. 
 
Figure 6.6 1% agarose gel separation of DNA product of SDSM reactions using PNDTA primer set with 
varying annealing temperatures: Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 
kb, 10 kb); Lane 2-7, DNA product of SDSM QuikChange of pET-YSBLIC3C PpLAAO plasmid with 
annealing temperature of 59- 70°C (6974 bp). 
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Figure 6.7 SDS-PAGE separation of protein from E. coli BL21-Gold-DE3 cells transformed with mutated 
PpLAAO YSBLIC3C plasmids PNDTA70 A-I: Lane 1, BioRad low molecular weight marker; Lane 2-10, 
insoluble protein fraction from PNDTA70A-I. 
 
The PpLAAO CASTing library D was produced using Phusion polymerase and a primer set 
designed to induce mutations in the Gln242, His244 and Pro245 base pairs, as in Section 2.6.2. 
PCR product was treated with DpnI to remove the wild-type plasmid template and was then used to 
transform electrocompetent E.coli Top10 cells. Plasmid was purified from five of the resulting 
colonies, named PNDTD1-5, by Miniprep. The sizes of the gene insert in the purified plasmids 
were checked using PCR as with the CASTing library A. As the plasmids all appeared to have the 
same size insert (Figure 6.8), the plasmids were sent for sequencing by the York University 
Genomics department. 
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Figure 6.8 1 % agarose gel separation of DNA product of PCR amplification of pET-YSBLIC3C-PNDTD 
plasmids using PpLAAO-for and PpLAAO-rev primer set to determine gene insert size. Lane 1, 1 kb DNA 
ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, DNA amplification of wild 
type pET-YSBLIC3C-PpLAAO plasmid gene insert, Lane 3-7, DNA amplification of pET-YSBLIC3C-
PNDTD1-5 plasmid gene insert. 
 
Plasmids PNDTD2-3 and PNDTD5 had mutated as expected, with only the three target residues 
showing any mutation (Table 6.3). PNDTD1 had mutations at the Gln 242 and His 244 sites but 
the Pro 245 site (CCG) was unchanged, which should not have been possible under the NDT 
degeneracy, possibly caused by an error in primer synthesis. All other parts of the protein were as 
in the wild type. PNDTD4 contained a long primer insert around at primer-binding site, similar to 
those seen previously when building the PNDTA library. 
 
Table 6.3 Changes to target residues in sequenced PNDTD plasmids 
Plasmid ID Target Nucleotide Sequence Target Amino Acids 
pET-YSBLIC3C-PpLAAO CAGTTCCACCCG Gln 242, His 244, Pro 245 
pET-YSBLIC3C-PNDTD1 CGTTTCAGCCCG Arg 242, Ser 244, Pro 245 
pET-YSBLIC3C-PNDTD2 GTTTTCAGTGAT Val 242, Ser 244, Asp 245 
pET-YSBLIC3C-PNDTD3 CGTTTCTGTAGT Arg 242, Cys 244, Ser 245 
pET-YSBLIC3C-PNDTD5 ATTTCCATATTA Iso 242, Iso 244, Leu 245 
 
As most of the colonies appeared to be capable of expressing untruncated mutated protein, 
transformations were repeated until around 4000 colonies had been produced. These colonies were 
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scrubbed off the plates and combined, then midi-prepped to form a plasmid library with a 
concentration of 87 ng µL
-1
, as in Section 2.6.2. 
 
Attempts were made to create the PpLAAO CASTing libraries B, C and E (Figure 6.1, Table 6.1) 
using Pfu Turbo HotStart polymerase and primers sets designed to induce mutations in the Arg 290 
and Val 293 positions for library B, the Lys 386, Ser 389 and Ser 391 positions for library C and 
the Lys 257, Thr 259 and Glu 260 positions for library E. However even when varying the PCR 
reactions conditions for libraries C and B (Section 2.6.3), the reactions failed to produce any 
visible product that was around the expected 7 kb in size when analysed on agarose gel 
electrophoresis (Figure 6.9 a and b) and although the library E did show some product when PCR 
conditions were varied as in section 2.6.3 (Figure 6.9 c), only 50 colonies were obtained when the 
digested product was used to transform electrocompetent E. coli Top10 cells as in Section 2.6.4, 
whereas around 4000 would be needed to cover 95% of all possible mutation combinations, so a 
product that would result in a greater number of transformants would be ideal. 
 
Because of this, the reaction conditions were optimised for each library using the Phusion 
polymerase, as in Section 2.6.5. These optimisations resulted in a PCR product that was the 
expected size for all three of the libraries (Figure 6.10). For each library, the condition that resulted 
in the most visible product on agarose electrophoresis was repeated and digested with DpnI, and 
levels of product was checked by agarose gel electrophoresis. Unfortunately there appeared to be 
far less PCR product form the library E reaction after DpnI digestion (Figure 6.11).  
 
The library B and library C reactions were used to transform electrocompetent E. coli Top10 cells, 
resulting in 30 colonies from the library B reaction but only 5 from the library C reaction, which 
was not a good enough transformation efficiency compared to the 4000 colonies needed for 95% 
coverage of all possible mutation combinations.  
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Figure 6.9 1% agarose gel separation of DNA product of SDSM reactions of pET-YSBLIC3C PpLAAO 
plasmid (6974 bp) using PfU Turbo HotStart polymerase with varying PCR mix conditions. a. SDSM 
QuikChange using PNDTB primer set. Lane 1-6, DNA product of SDSM using PfU optimisation mix 1-6. b. 
SDSM QuikChange using PNDTC primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 
kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2-7, DNA product of SDSM using PfU optimisation mix 1-6. c. SDSM 
QuikChange using PNDTE primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 
6 kb, 8 kb, 10 kb); Lane 2-7, DNA product of SDSM using PfU optimisation mix 1-6. 
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Figure 6.10 1% agarose gel separation of DNA product of SDSM reactions of pET-YSBLIC3C PpLAAO 
plasmid (6974 bp) using Phusion HotStart polymerase with varying PCR mix conditions. a. SDSM 
QuikChange using PNDTB primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 
6 kb, 8 kb, 10 kb); Lane 2-7, DNA product of SDSM using Phusion optimisation mix 1-6. b. SDSM 
QuikChange using PNDTC primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 
6 kb, 8 kb, 10 kb); Lane 2-7, DNA product of SDSM using Phusion optimisation mix 1-6. c. SDSM 
QuikChange using PNDTE primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 
6 kb, 8 kb, 10 kb); Lane 2-7, DNA product of SDSM using Phusion optimisation mix 1-6. 
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Figure 6.11 1% agarose gel separation of DNA product of SDSM reactions of pET-YSBLIC3C PpLAAO 
plasmid (6974 bp) using Phusion II HotStart polymerase and PNDTE primer set. Lane 1, 1 kb DNA ladder 
(0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, DNA product of SDSM using PCR 
mix C (Table 2.3) after digestion with DpnI. 
 
Plasmid was purified from four of colonies from the library B transformation and the length of the 
gene insert was checked using PCR as in Section 2.6.5, using the wild-type pET-YSBLIC-3C-
PpLAAO plasmid as a positive control. The PCR reaction to check the first plasmid failed to make 
any visible product. However, two of the remaining three plasmids had gene inserts that were 
longer than the wild-type plasmid (Figure 6.12), suggesting that the primer had been inserted into 
the new gene sequences, as had happened before with the library A reactions.  
 
As the primer insertions could have been being caused by the polymerase incorporating sub-
optimal primer pairings, the library B and C reactions were optimised using KOD HotStart 
polymerase as it is less efficient at staying bound to DNA than the Phusion polymerase is,            
due to a dsDNA binding domain that is fused to Phusion polymerases 
(http://www.finnzymes.com/pcr/phusion_products.html accessed 04/10/12), which may be 
allowing the Phusion polymerase bind to suboptimal primer pairing 
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. The optimisations were done as described in Section 2.6.6 and both resulted in visible product at 
the expected 7 kb, but also a shorter product around 3 kb long (Figure 6.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.12 1% agarose gel separation of DNA from PCR amplification of plasmid inserts: Lane 1, 1 kb 
DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2-5, PCR amplification of 
insert sequence in pET-YSBLIC3C PNDTB Phsuion plasmids 1-4; Lane 6, PCR amplification of insert 
sequence in pET-YSBLIC3C PpLAAO plasmid (1605 bp). 
 
Reaction condition 1 (Section 2.6.6, Figure 6.13) was repeated for both library B and C reactions, 
and the resulting product was digested using DpnI and used to transform electrocompetent E. coli 
Top10 cells. Unfortunately transformation with the library C PCR product did not result in any 
colonies. The library B product resulted in around 80 colonies, six of which were picked to have 
their plasmids purified as in Section 2.6.6. The length of the gene insert of these plasmids was 
checked using PCR as in Section 2.6.6, along with the wild-type pET-YSBLIC-3C-PpLAAO 
plasmid as a control. 
 
Unfortunately, four of the six plasmids purified had inserts that were longer than that of the wild-
type plasmid (Figure 6.14), with plasmids 1 and 2 appearing to have a roughly 2 kb long insert, 
which was larger than any of the plasmids made using the Phusion polymerase, which had roughly 
1.7 kb long inserts at most. (Figures 6.12, 6.14). 
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Figure 6.13 1% agarose gel separation of DNA product of SDSM reactions of pET-YSBLIC3C PpLAAO 
plasmid (6974 bp) using KOD HotStart polymerase with varying PCR mix conditions. a. SDSM QuikChange 
using PNDTB primer set. Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 
10 kb); Lane 2-9, DNA product of SDSM using KOD optimisation mix 1-9. b. SDSM QuikChange using 
PNDTC primer set. Lane 1, 1 kb DNA ladder (0.5kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); 
Lane 2, DNA product of SDSM using KOD optimisation mix 1; Lane 3, Blank lane containing overspill; 
Lane 4-10, DNA product of SDSM using KOD optimisation mix 3-9. 
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Figure 6.14 1% agarose gel separation of DNA from PCR amplification of plasmid inserts: Lane 1, 1 kb 
DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, PCR amplification of 
insert sequence in pET-YSBLIC3C PpLAAO plasmid (1605 bp); Lane 3-8, PCR amplification of insert 
sequence in pET-YSBLIC3C PNDTB KOD plasmids 1-6. 
 
6.2 Generation of PpLAAO epPCR library 
 
In order to determine if mutations further away from the active site of the PpLAAO protein could 
have any effect on the substrate specificity of the enzyme, the pET-YSBLIC-3C-PpLAAO gene 
sequence was mutated using error prone PCR (epPCR), with a goal of between 2 and 7 mutations 
per gene sequence. This was done using the GeneMorph® II EZClone domain mutagenesis kit 
from Stratagene as in Section 2.7. 
 
The PpLAAO gene sequence was amplified from the wild-type pET-YSBLIC-3C-PpLAAO 
plasmid using the error-prone polymerase MutaZyme II. 2.5 µL of the amplified megaprimer 
product was analysed on 1% agarose gel along with a 2.5 µL of a 20 ng µL
-1
, 1.1 kb DNA standard 
provided in the kit. From observing the bands intensity, the megaprimer product was determined to 
be at least 50 ng µL
-1
 (Figure 6.15a), which was enough to necessitate using gel purification to 
obtain the megaprimer product. After analysis, the remaining epPCR product was run on a 1% 
agarose gel (Figure 6.15b) and the megaprimer band was cut out and purified used Sigma-
Aldrich’s GenElute Gel Purification kit (Section 2.7). 
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Figure 6.15 1% agarose gel electrophoresis of error-prone PCR products. a. 2.5 µL analysis of epPCR 
product: Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, 20 
ng µL-1 DNA standard (1.1 kb); Lane 3, 2.5 µL of epPCR amplification of pET-YSBLIC-3C-PpLAAO gene 
sequence (1605 bp); Lane 4, epPCR amplification of positive control plasmid. b. Gel purification of epPCR 
product: Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 kb, 10 kb); Lane 2, 
epPCR amplification of pET-YSBLIC-3C-PpLAAO gene sequence (1605 bp). 
 
The mutated megaprimer product was incorporated into the pET-YSBLIC-3C-PpLAAO plasmid 
using the EZClone reaction mix and Stratagene’s QuikChange method. The wild-type plasmid was 
digested with DpnI and the product was used to transform super-competent E. coli XL10-Gold 
cells. This resulted in over 4000 colonies. The colonies were scrubbed off the plates and pooled 
together, then mini-prepped to form a plasmid library, as in Section 2.7. 
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6.3 Screening of mutagenesis libraries 
 
In order to screen them for activity, the mutagenesis libraries were used to transform competent E. 
coli DE3 cells, which were spread over plates containing 100 µM IPTG to induce gene 
overexpression. The resulting colonies were then transferred onto filter paper, which was frozen at 
-80°C overnight to lyse the cells and release the overexpressed protein. The cells were then allowed 
to soak up a HRP-based assay solution containing the target substrate and 3-diaminobenzidine, 
which in the presence of H2O2 is converted by HRP into an insoluble brown polymer, causing any 
colonies that produce enzymes with activity against the target substrate turn brown (Section 2.8.1, 
Figure 2.4). 
 
6.3.1 Screening of PpLAAO CASTing library A 
 
The PNDTA library was screened for activity against 20 mM L-aspartate, 1 mM, 2 mM, 4 mM, 10 
mM and 20 mM LD-asparagine and 40 mM, 60 mM, 80 mM and 100 mM L-homoserine using the 
solid-phase HRP assay, as in Section 2.8.1, with screens being left to develop in the dark for 4 
days. 
 
No activity against L-aspartate was seen in any colonies, which was unsurprising as both the 
H351A and Y352A mutants showed very little activity against L-aspartate (Section 5.4), suggesting 
that these residues are important to the activity of the PpLAAO enzyme. One colony on the plate 
with 40 mM L-homoserine and two colonies on the plate with 2 mM LD-asparagine as substrate 
appeared to be slightly browner in colour than the other colonies on their plates. These colonies 
were named L-Hse-O, L-Asn-O1 and L-Asn-O2 and were picked and had plasmids purified and 
gene overexpression induced as in Section 2.8.2. The cells were lysed with BugBuster and the 
soluble fraction was separated by centrifugation, then the concentration of protein in the soluble 
cell fractions was measured using Bradford reagent as in Section 2.8.2 (Table 6.4). 
 
The activity of the soluble protein fractions was then tested against 20 mM L-aspartate, 20 mM LD-
asparagine and 100 mM L-homoserine using the soluble HRP based plate assay as in Section 2.8.2, 
with the rate of change in absorbance and the end point of the assay after 1 hour being measured. 
Unfortunately no significant activity was seen from any of the soluble protein fractions (Figure 
6.16, Figure 6.17), with the highest end point absorbance being the L-Hse-O fraction against L-
aspartate with an absorbance of 0.0150 (Figure 6.16), which is less than 10% of the end-point 
absorbance of the wild-type PpLAAO soluble fraction against L-aspartate (Figure 3.18), 
suggesting that the brown colour seen in the solid phase assay was a false positive. 
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Table 6.4 Measured protein concentrations of soluble fractions of E. coli BL21-DE3 cells over expressing 
protein from PNDTA70 plasmids with potential target activity. 
Sample 
Name 
 
Reading 
1/ ng 
mL
-1
 
Reading 
2/ ng 
mL
-1
 
Reading 
3/ ng 
mL
-1
 
Replica 
Average/ 
ng mL
-1
 
Sample 
Average/ 
ng mL
-1
 
Concentration 
of undiluted 
sample/ mg 
mL
-1 
L-Hse-O / 
1:10 
dilution 
Replica 1 471 481 480 477 
499 4.9 Replica 2 533 532 543 536 
Replica 3 483 481 485 483 
LD-Asn-
O1/ 1:10 
dilution 
Replica 1 471 471 489 477 
402 4.0 Replica 2 364 364 372 367 
Replica 3 357 363 363 361 
LD-Asn-
O2 / 1:10 
dilution 
Replica 1 311 308 314 311 
326 3.2 Replica 2 226 229 238 231 
Replica 3 437 439 433 436 
 
 
Figure 6.16 Graph of the 1 h end-point activity of L-Hse-O, LD-Asn-O1 and LD-Asn O2 soluble protein 
fraction against 100 mM L-homoserine (blue), 20 mM LD-asparagine (red) and 20 mM L-aspartate (green).  
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Figure 6.17 Graph of the rate of reaction of L-Hse-O, LD-Asn-O1 and LD-Asn O2 soluble protein fraction 
against 100 mM L-homoserine (blue), 20 mM LD-asparagine (red) and 20 mM L-aspartate (green) over 5 
minutes. 
 
6.3.2 Screening of PpLAAO CASTing library D 
 
The PNDTD plasmid library was screened against 40 mM LD-aspartate, 100 mM L-homoserine, 
100 mM L-alanine and 25 mM L-tyrosine using the solid-phase HRP assay, as in Section 2.8.1. 
Several colonies in each screen appeared to show activity against the substrates. Three colonies 
from the screen against LD-aspartate (Figure 6.18), seven colonies from the screen against L-
homoserine (Figure 6.19), ten colonies from the screen against L-alanine (Figure 6.20) and five 
colonies from the screen against L-tyrosine (Figure 6.21) were picked and and had plasmids 
purified and gene overexpression induced as in Section 2.8.3, however the starter cultures for 
Asp3, H1, H7 and Tyr4 failed to grow. 
 
  
 
 
 
 198 
 
Figure 6.18. Solid phase HRP assay of PNDTD libraries against 40 mM LD-aspartate after 4 days 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.19. Solid phase HRP assay of PNDTD libraries against 100 mM L-homoserine after 4 days 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.19. Solid phase HRP assay of PNDTD libraries against 100 mM L-homoserine after 4 days 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.20 Solid phase HRP assay of PNDTD libraries against 100 mM L-alanine after 1 day of 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.20 Solid phase HRP assay of PNDTD libraries against 100 mM L-alanine after 1 day of 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.21. Solid phase HRP assay of PNDTD libraries against 25 mM L-tyrosine after 3 days of 
development. Colonies that were picked for protein analysis are labelled. 
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Figure 6.21. Solid phase HRP assay of PNDTD libraries against 25 mM L-tyrosine after 3 days of 
development. Colonies that were picked for protein analysis are labelled. 
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The induced cell pellets were lysed by sonication and analysed using 12% SDS-PAGE as in 
Section 2.8.3. Of all the strains only the Ala 3, Ala 5 and Ala 6 strains produced protein of the 
same size as the wild type PpLAAO protein. Ala 7 and Ala 9 appeared to produce a smaller 
protein, and the remaining strains failed to produce any proteins (Figure 6.22). 
 
Figure 6.22. 12% SDS-PAGE separation of insoluble protein fractions of hits from the pET-YSBLIC3C-
PNDTD library screening. a. Lane 1, low range molecular weight marker; Lane 2-3, pET-YSBLIC3C-
PNDTD-Asp1-2 insoluble protein fractions; Lane 4-8, pET-YSBLIC3C-PNDTD-H2-6 insoluble protein 
fractions; Lane 9-12, pET-YSBLIC3C-PNDTD-Tyr1-3 and 5 insoluble protein fractions. b. Lane 1, low 
range molecular weight marker; Lane 2-11, pET-YSBLIC3C-PNDTD-Alal1-10 insoluble protein fractions. 
 
The Ala3, Ala5 and Ala6 plasmids were purified by Miniprep and sent for sequencing, however 
none of the three had any changes from the wild-type PpLAAO, and further screening using the 
liquid phase assay showed no noticeable activity against L-alanine. 
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6.3.3 Screening of PpLAAO error-prone PCR mutants  
 
The PpLAAO epPCR library was screened against 20 mM L-aspartate, 20 mM L-tyrosine, 20 mM 
L-alanine, 20 mM L-glutamate and 20 mM L-glutamine using the solid-phase HRP assay, as in 
Section 2.8.1. Screens were left to develop in the dark for 1 day. Roughly half of the colonies 
screened against L-aspartate developed a brown colour; however no colonies in the remaining 
screens showed any activity. 
 
Five colonies from the screen against L-aspartate (referred to as PPM1-5) were picked and had 
plasmids purified and gene overexpression induced as in Section 2.8.4. Protein expression was 
analysed using 12% SDS-PAGE. PPM 3 produced a large amount of soluble protein. PPM 1 and 4 
produced less soluble protein, PPM 2 produced very little soluble protein and PPM5 produced no 
soluble protein (Figure 6.23).  
 
The purified plasmids were sent for sequencing, however only the pET-YSBLIC-3C-PPM2-4 
plasmids sequenced successfully. There were 4 mutations in all and the distance of each mutated 
residue from the succinate occupying the active site of the E. coli L-aspartate oxidase structure 
solved by Bossi et al
[65]
 was determined using the Coot Crystallographic model building software 
(Section 2.8.4).
[113]
   
 
PPM2 had mutations in two residues, N216K and A504V. N216 is roughly 11.5 Å from the 
succinate C2 (Table 6.5) and is also quite close (3.5 Å) to the flavin part of the FAD molecule, 
with the mutated form potentially occupying the space that the flavin is in (Figure 6.24). This may 
account for the poor solubility of the protein. A504 is 24.15 Å from the succinate and does not 
appear to be affecting anything in the active site (Table 6.5, Figure 6.24), although the mutation 
could still be causing the enzyme to fold poorly, causing a drop in solubility. 
 
PPM3 had a change in one residue- R121C, which is equivalent to the R120 residue in the E. coli 
L-aspartate oxidase structure. This residue is only 10.6 Å from the active site succinate (Table 6.5) 
and is next to the E121 residue, which is thought to form an ionic interaction with the α-amino 
group of the L-aspartate substrate in the E. coli LASPO.
[64]
 
  
207 
 
Figure 6.23. 12% SDS-PAGE separation of colonies from E. coli BL21-DE3 cells transformed with the error 
prone PCR products of the pET-YSBLIC3C-PpLAAO plasmid. Lane 1, low range molecular weight marker; 
Lane 2-6, pET-YSBLIC3C-PPM1-5 insoluble protein fractions; Lane 7-11, pET-YSBLIC3C-PPM1-5 
soluble protein fractions. 
 
Table 6.5 Summary of changes to PPM2-4 mutants and distance of affected residues from the succinate 
occupying the active site in the E. coli L-aspartate oxidase structure solved by Bossi et al.[65] 
Mutant 
strain 
Mutations 
Equivalent 
residue in E. 
coli 
Distance from 
succinate C2 in E. 
coli L-AspO (Å) 
Solubility 
(Figure 6.21) 
Activity vs. 
L-Asp 
PPM2 
(Blue) 
N216K N216 11.3 
Low None 
A504V A504 24.1 
PPM3 
(Red) 
R121C R120 10.6 High 
Equivalent to 
wild type 
PPM4 
(Magenta) 
R491H R491 27.9 Medium 
Lower than wild 
type 
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Figure 6.24 PPM2 (Blue), PPM 3 (Red) and PPM 4 (Magenta) mutated residues shown in context of the E. 
coli L-aspartate oxidase active site structure solved by Bossi et al.[65] Wild type residues are in grey, FAD and 
succinate are yellow. 
 
The PPM4 strain had one mutation roughly 28 Å from the active site succinate, R491H. As 
arginine has a large side chain that is usually involved in several bonding interactions, it is likely 
that the change to the more compact histidine side chain has affected these bonds and caused the 
protein to be less soluble. 
 
A quick test of the activity of each of the soluble protein fractions of PPM2-4 against L-aspartate 
was performed using the soluble HRP-based assay and visual inspection to roughly determine the 
level of assay development, as in Section 2.8.4. The levels of activity were proportional to the 
solubility of the strains, with PPM2 showing no activity, PPM4 showing lower levels of activity 
than the wild type protein and PPM3 showing levels of activity equivalent to the wild type 
PpLAAO soluble protein fraction (Table 6.5). 
 
6.4 Conclusions 
 
With the intention of introducing new substrate activities to the PpLAAO protein, particularly L-
tyrosine and L-alanine via L-homoserine, attempts were made to mutate the PpLAAO gene 
sequence using an iterative CASTing approach
[108]
 and error-prone PCR (epPCR).  
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For the iterative CASTing, the thirteen active site residues that were mutated into alanine in 
Chapter 5 were split into five groups, each of which contained residues sequentially close enough 
to be mutated using one primer set. These residues were then mutated in groups using the NDT 
codon degeneracy, which codes for twelve chemically diverse side chains residues. 
 
Group A contained H351 from the flavin binding domain and Y352, both of which caused a loss of 
activity when mutated into alanine (Section 5.4). A library of around 400 mutated PNDTA 
colonies was made despite some earlier problems with the mutagenic primers being incorporated 
into the newly formed plasmids and causing protein truncation. These problems were possibly 
caused by a 9 bp sequence that was repeated either side of the two residues that were to be mutated 
(Table 2.3) which possibly caused the complementary primers to bind to each other in long chains 
before being incorporated into the mutagenic primers. In order to discourage this mismatched 
binding, the annealing temperature was increased to 72°C, which appeared to resolve the problem. 
 
When screened, no activity against L-aspartate was found in any of the PNDTA mutants, and 
although some colonies appeared to show a small amount of activity against L-asparagine and L-
homoserine during the solid-phase screen, no activity could be seen in the liquid phase screen of 
the induced protein fractions of these strains.  
 
This is not unexpected, as the H351A mutant lost the ability to bind FAD and showed no activity 
against L-aspartate (Section 5.3) and the Y352A mutant had drastically increased KM against L-
aspartate, although as both L-histidine and L-tyrosine were both possible side residues resulting 
from the NDT degeneracy, there should have been some transformants that had retained the wild-
type residues. The lack of this activity shows that not all of the possible mutations had been 
covered by the PNDTA library. This could be due to chance, as the number of colonies made only 
guarantees 95% coverage of the all the potential mutations, however it could also mean that the 
problem with the primer insertions had not been resolved, and that some mutants were inactive due 
to the protein being truncated or insoluble. 
 
The CASTing group B contained R290 from the capping domain, which showed no activity when 
mutated into alanine (Section 5.4), and V293, which caused a loss of protein stability when 
mutated into alanine (Section 5.3). Attempts to make a PNDTB library were started using PfU 
Turbo, Phusion and KOD HotStart polymerases. The PfU Turbo polymerase failed to produce any 
PCR product; however the Phusion and KOD polymerases products both produced a reasonable 
number of transformants after treatment with DpnI. Unfortunately, the transformants from the 
reactions using both Phusion and KOD polymerases contained plasmids with larger inserts than the 
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wild-type PpLAAO plasmid, most likely caused by the mutagenic primers being inserted into the 
newly formed plasmids as was seen in the PNDTA library.  
 
In this case the PNDTB primers do not appear to have a particularly large repeated sequence, 
however the short sequence GCCC does appear on both sides of the mutagenic sequence of the 
forward primer, and another CCC sequence is found at the beginning of the forward primer, so 
these could be causing the primer to form long chains that are then incorporated into the newly 
formed primers. The longest difference between the PpLAAO wild-type and the PNDTB plasmids 
appeared to be higher on the plasmids produced using KOD polymerase that those produced using 
Phusion polymerase (Figures 6.12, 6.14) this could be because the higher fidelity Phusion 
polymerase was not allowing the primers to bind to each other quite as badly as the KOD 
polymerase was, so the inserted sections weren’t able to grow as long as in the products made with 
KOD polymerase. 
 
The CASTing group C contained R386, S389 and S391, all of which are part of the flavin binding 
domain of the E. coli L-AspO. The mutation of the R386 residue resulted in a loss of activity 
against L-aspartate. The mutation of S389 caused a slight decrease in catalytic activity and a six-
fold increase in the KM of L-aspartate and the mutation of S391 into alanine caused a slight increase 
in KM and a five-fold decrease in the catalytic activity against L-aspartate. Unfortunately, despite 
attempts to produce a library using PfU Turbo, Phusion and KOD HotStart polymerases, the 
products of the QuikChange PCR reactions did not result in enough transformants to collect the 
4000 transformants needed to ensure 95% coverage of all the potential combinations of mutations 
of the three targeted residues. 
 
Group D contained Q242 from the flavin binding domain, H244 from the capping domain and 
P245, all of which resulted in an increase in the KM of L-aspartate when mutated into alanine 
residues. Despite there being no obvious repeated or complementary sequences in the PNDTD 
primer set, some of the PCR products produced using Phusion polymerase still contained inserted 
primer sequences around the mutation site, however they appeared to be few in number so around 
4000 mutated transformants were collected to form the PNDTD library.  
 
This library was the screened against 20 mM L-aspartate, L-alanine, L-homoserine and L-tyrosine. 
For each substrate there were several colonies that developed positive results for activity against all 
of these substrates (Figures 6.18-6.21). However, when these colonies were grown and the 
insoluble and soluble protein fractions were analysed on SDS-PAGE, the strains that had shown 
activity against L-aspartate, L-homoserine and L-tyrosine all failed to produce any protein. Two of 
the strains that showed activity against L-alanine had produced truncated protein and another four 
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strains did not produce any protein, however sequencing of the plasmids from the three strains that 
expressed the correctly sized protein showed that they were expressing the wild-type PpLAAO 
protein, which did not show any activity detectable against L-alanine.  
 
The reason that these colonies appeared to show activity in the solid phase screen is unclear. There 
may have been another protein expressed the E. coli cells in some cases that was causing a reaction 
against the targeted substrates, or causing a build-up of H2O2 for another reason. It is also possible 
that these colonies had been exposed to extra oxygen through air bubbles under the filter paper 
used to soak the colonies in the assay solution, which would cause the reaction buffer to develop 
more quickly, although care was taken not to allow air bubbles to form when the assay was being 
carried out. 
 
Group E contained L257, T259 and E260, all from the capping domain of the E. coli L-AspO. The 
mutation of L257 into alanine caused a large increase in the KM against L-aspartate and the 
mutation of T259 into alanine resulted in the loss of activity against L-aspartate. The E260A mutant 
was insoluble when expressed in E. coli BL21-DE3 cells. Unfortunately, despite attempts to 
produce a library using PfU Turbo and Phusion polymerases, the products of the QuikChange PCR 
reactions did not result in enough transformants to collect the 4000 transformants needed to ensure 
95% coverage of all the potential combinations of mutations of the three targeted residues. 
 
As the iterative CASTing approach was being hindered by the issues with primer insertions in the 
mutated plasmids and difficulty producing enough PCR product to generate large enough numbers 
of transformants to ensure effective coverage of all possible combinations of mutations for the 
groups targeting three active site residues, attempts to introduce new substrate activity to the 
PpLAAO protein using epPCR were started. 
 
The epPCR was setup with a goal of between two and seven base pair substitutions per gene 
sequence. Over 4000 transformants were collected and used to prepare a plasmid library. When this 
library was screened roughly half of the colonies screened showed activity against 20 mM L-
aspartate; however no colonies showed activity against 20 mM L-tyrosine, L-arginine, L-glutamate 
or L-glutamine. It is likely that the number of transformants collected for the library was far too low 
to stand a significant chance of containing a mutant that would show significant activity against a 
new substrate, however collecting the number of transformants needed (generally between 1,000-
1,000,000, but possibly as high as 1,000,000,000)
[107]
 was beyond the scope of what would be 
practical to do on benchtop without a greater amount of automation available. 
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Five of the colonies from the screen against L-aspartate were picked and the plasmids were purified 
and sequenced to determine how effective the mutation had been, however only three of these 
plasmids (PPM2-4) were sequenced successfully. The PPM2 mutant had mutations in two amino 
acid residues, N216K and A504V, and had poor solubility and showed no detectable activity 
against L-aspartate. This lack of activity is consistent with the E. coli L-aspartate structure, as the 
N216 residue is close to the flavin ring of FAD (roughly 3.5 Å) and as lysine is a larger residue 
than asparagine, the mutation is likely to disrupt the positioning of the flavin ring, which is 
important to the catalytic activity of the oxidase (Chapter 5).
[121]
 
 
PPM3 had one mutation, R121C, which is equivalent to the R120 residue in the E. coli L-AspO 
structure. Despite it being next to the E122 (E121 in E. coli) residue, which is thought to form an 
ionic interaction with the α-amino group of the L-aspartate substrate,[64] the R121C mutation does 
not appear to have affected the solubility or the activity of the protein against L-aspartate. This may 
be due to the fact that the R121 residue side chain extends away from the L-aspartate substrate in 
the E. coli L-AspO structure (Figure 6.24).
[65]
 
 
PPM4 also had one mutation, R491H. The R491 residue is situated away from the active site area, 
roughly 27 Å from the succinate substrate in the E. coli L-AspO structure.
[65]
 The mutant appears to 
cause a slight drop in solubility and the soluble protein fraction shows less activity than the wild-
type PpLAAO protein, however this may be due to the reduction in soluble protein available in the 
solution as opposed to a reduction in catalytic efficiency. The cause for the lack of solubility is 
unclear; however it may be due to the replacement of the relatively long and thin arginine side 
chain with the shorter and wider histidine, which may affect the interactions of the residues around 
the mutation and cause a disruption in the folding of the protein. 
 
Unfortunately, the attempts to introduce new substrate specificities to the PpLAAO protein using 
the less labour-intensive CASTing method were hindered by problems caused by unwanted copies 
of the primer sequences being inserted into the newly generated mutants, causing an unknown 
proportion of the generated mutants to be inactive. Although the epPCR worked, despite there 
being fewer mutations per gene sequence than expected (1-2 mutations per gene sequence, as 
opposed to 2-7), the number of mutants that would have to be generated in order to find one that 
showed detectable activity against a new substrate would be too large to consider preparing on a 
benchtop laboratory setup, particularly as the colony screen would be difficult to perform in an 
automated fashion.  
 
If it was possible to reduce the amount of the primer insertions, the SDSM CASTing method would 
be a useful way to attempt directed evolution against the PpLAAO protein, and more work would 
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be useful in determining the cause of the primer insertions. It is possible that the use of DMSO in 
the PCR reaction to increase the amount of PCR product was also facilitating the poor binding of 
the primers that was causing them to be incorporated into the mutagenic primers, so attempting to 
optimize the PCR reaction without using DMSO, possibly by using betaine instead, may be a 
useful place to start investigating this issue. 
 
Another issue may be that the disruption to the active site caused by mutating several active site 
residues at one time may knocking out the enzymes activity completely, rather than just changing 
it. It may be more effective to either use SDSM on one residue at a time, or to target residues 
further away from the active site in order to fine tune the structure of the enzyme, rather than 
disrupting it. 
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Chapter 7 General Discussion 
 
Amino acid oxidases have a variety of roles in Nature and several potential uses as biocatalysts, 
enzymatic biosensors and potential medical therapies. For use as biocatalysts, it would be useful to 
find or develop amino acid oxidases with activity against a variety of different amino acids. 
However, for use in biosensors for amino acids it would be optimal to develop a variety of different 
amino acid oxidases, each with strong substrate specificity for a different amino acid to minimise 
the amount of false readings caused by other amino acids in the sample. 
 
Seven target oxidases were selected from the results of a BLAST search using the sequence of the 
L-amino acid oxidase from Synechococcus sp. strain ATCC 27144. These were cloned into the 
pET-YSBLIC-3C expression vector for expression in E. coli expression cell strains and screened 
against L-amino acid substrates (Chapter 3). The L-amino acid oxidase from Pseudomonas putida 
(PpLAAO) was highly soluble, easily purified and showed strong substrate specificity against L-
aspartate and L-asparagine, with a very low level of activity against L-glutamate (Chapter 4). 
 
A greater understanding of the structure of the active site area of the protein would be beneficial for 
determining a strategy for directed evolution of the protein using site-directed mutagenesis. 
However, attempts to solve the structure of the PpLAAO protein by X-ray crystallography were 
unsuccessful due to the protein appearing to form several different quaternary structures in 
solution. Because of this the solved structure of a homologous L-aspartate oxidase from E. coli (L-
AspO) was used to identify potential active site residues of the PpLAAO protein. These active site 
residues were analysed by alanine scanning in Chapter 5, as the residues were each mutated to 
alanine in turn and the resulting purified protein was assayed for activity against L-aspartate, L-
asparagine and L-glutamate. 
 
The results of this mutational analysis were largely consistent with the knowledge of the active site 
structure of the L-AspO protein. Mutation of residues involved in the binding of the C1 carboxylate 
(H244 and T259) and the C4 carboxylate (H351 and S389) resulted in an increase in the KM against 
L-aspartate. Mutation of P245 and L257 residues, found close to the H244 side chain, also caused a 
decrease in the binding efficiency of the protein against L-aspartate. Interestingly, the S389A 
mutant showed higher binding efficiency against L-glutamate than the wild-type protein, although 
the catalytic activity of the protein was decreased. This may suggest that this residue could be a 
potential target for site directed mutagenesis when attempting to change substrate specificity. 
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Mutation of the R290 residue, thought to be involved in abstraction of the α-proton from L-
aspartate, caused a decrease in the kcat of the protein against L-aspartate, as did mutation of the 
Q242 residue, which appears to hold the R290 side chain in place. The S391A mutation also caused 
a greater decrease in catalytic activity than in binding efficiency, probably because the S391 side 
chain forms bonds with the flavin ring of FAD, so mutation is likely to cause a disruption in 
cofactor binding. The binding of FAD was also disrupted by the H351A mutation in both the L-
AspO and PpLAAO proteins. 
 
As the PpLAAO protein appeared to be consistent with the active site structure of the L-AspO 
protein, the L-AspO structure was used to develop an iterative CASTing strategy around the active 
site residues for the directed evolution of the PpLAAO protein, unfortunately only two of the five 
initially planned libraries was created, due to problems caused by primer insertions described in 
Chapter 6.  
 
A small scale random mutagenesis attempt was performed using epPCR to introduce mutations into 
the gene. This library and the successful CASTing libraries were screened for activity against target 
substrates L-homoserine, L-alanine and L-tyrosine. However, none of the transformants from either 
mutagenesis attempt showed any novel substrate activity. 
 
The PpLAAO protein could potentially have practical use as part of an enzymatic biosensor for L-
aspartate, as current L-aspartate biosensors use a combination of L-glutamate oxidase and an 
aspartate aminotransferase and require L-glutamate in the sample to be removed prior to use, 
whereas the PpLAAO protein has very poor activity against L-glutamate. 
 
For future work on this protein, a greater and more conclusive understanding of its structure would 
be of use. Because of this generating crystals for X-ray diffraction would be useful. As seen in 
Chapter 4 it may be possible to force the protein into a single monomer form using protein 
precipitates like guanidine hydrochloride, therefore a screen of the effects of a variety of 
precipitates against the purified protein, both in pure form or as part of the crystal screen, may help 
towards the crystallisation of the PpLAAO protein.  
 
Directed evolution of novel substrate specificity into PpLAAO would also be a priority. A larger 
scale random mutagenesis library may produce mutants with activity against target substrates, or 
maybe greater activity against L-asparagine or L-glutamate. Alternatively, production of the 
CASTing libraries using a different mutagenesis method, such as the In-fusion method developed 
by Clontech, may result in more reliable libraries without the proportion of truncated mutants 
found when screening in Chapter 6. 
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Otherwise site-directed saturation mutagenesis could be used to investigate the effects of single 
active site residues in greater detail. As the S389A mutation appeared to increase the binding 
efficiency of L-glutamate compared to the wild-type, a library of S389 mutants may also house 
novel substrate activity, screening of these mutants could also be done using a more sensitive 
oxidase assay, such as the o-dianisidine assay used by Tedeschi et al., in order to determine less 
drastic changes in catalytic activity and substrate binding.  
 
An assay based on using HPLC of the reaction to determine the levels of product produced directly 
or using fluorescence of the FAD to determine cofactor turnover would have been useful in 
determining kinetic constants and the optimal temperature and pH of the protein, as they would not 
be reliant on a separate enzyme that may be affecting the results of the assay.  
 
Other work towards identifying an L-AAO with activity against either L-alanine or L-tyrosine could 
include cloning more potential L-AAOs in the hope of finding more soluble targets, or using 8M 
Urea to unfold some of the more insoluble products in order to purify and then refold and 
investigate them in more detail. 
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Appendix A   C. glutamicum as an expression strain 
 
A.1 Introduction 
 
A.1.1 Physiology of C. glutamicum 
 
Corynebacterium glutamicum is a non-pathogenic and non-spore-forming
[122]
 member of the 
Corynebacterineae, a Gram-positive group of bacteria that are defined by the presence of mycolic 
acids in their cell envelope structures. This group also includes the Mycobacterium and Nocardia 
genera.
[123]
  
 
The unique Corynebacterineae cell envelope structural organisation is close to that of a Gram-
negative bacteria. This cell envelope consists of an arabinogalactan-peptidoglycan polymer, which 
is covalently linked to an outer lipid layer that mostly contains mycolic acids, which are 
collectively known as the MAP polymer complex.
[123]
 C. glutamicum also has a crystalline single-
protein surface layer consisting of hexameric cores of PS2, a 52 kDa protein coded by the cspB 
gene.
[124]
 This PS2 S-layer is anchored to the cell wall by a hydrophobic C-terminal domain and is 
very resistant to treatment with proteases and detergent,
[125]
 although how much of the cell is 
covered by the S-layer is dependent on the carbon source and growth conditions of the bacteria.
[126]
  
 
C. glutamicum, like other Corynebacterineae members, has a GC-rich codon content compared to 
another model bacteria E. coli (67% and 51% respectively), and the GC-wobble-position content is 
much higher in C. glutamicum than in E. coli (88% and 55% respectively).
[127]
  
 
A.1.2 History of C. glutamicum in the biochemical industry 
 
The first industrial application using the soil bacterium Corynebacterium glutamicum was the 
production of the amino acid L-glutamic acid by fermentation. This process originated in Japan in 
1957 after Kinoshita et al. discovered that in certain conditions the bacterium could be made to 
secrete large quantities of L-glutamic acid, which is used as an important food additive and had 
previously been produced by hydrolysis of soy or other plant proteins.
[128] 
 
Later, in the 1970s, random mutagenesis was used to create variant strains of C. glutamicum that 
were capable of efficiently producing L-lysine and L-threonine, and further advances in molecular 
biology allowed more efficient L-lysine and L-threonine producing strains, as well as strains used to 
produce other amino acids and vitamins such as diaminopentane.
[129] 
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A.1.3 Use of C. glutamicum in protein production and biotransformations 
 
C. glutamicum is considered an attractive microorganism for biocatalysis reactions, due to its high 
cofactor regeneration rate,
[130]
 as well as the S-layer and mycomembranes of the cell envelope 
structures, which allows the bacterium to be stable in organic compounds.
[123]
 C. glutamicum is also 
non-pathogenic, has no spore forming abilities and its products can be considered to be food-
grade,
[128]
 making it more convenient for use in industry and GMP applications than other, less 
safe, microorganisms. The GC-rich codon usage compared to E. coli
[127]
 may also make it a better 
producer of proteins from related GC-rich bacteria such as those in the Nocardia and 
Mycobacterium genera.
[128]
 
 
Because of this, there have been many genetic tools and methods developed for C. glutamicum 
transformation and protein production, such as plasmid vectors
[131]
 and methods for the 
transformation of C. glutamicum by electroporation,
[132]
 as it has no natural DNA uptake 
system.
[128]
 And although C. glutamicum is often grown in media containing animal based brain-
heart infusion media (BHI),
[130, 132]
 growth and transformations have been shown using LB-
media,
[133, 134]
 which is cheaper and more acceptable in industry and GMP applications which 
discourage the use of animal-based products.  
 
A.1.4 Use of C. glutamicum for expression of previous gene targets 
 
As three of the unstudied target gene sequences originally cloned into pET-YSBLIC-3C; the 
Anabeana sp. strain PCC 7120 (AsAAO), the Bacillus anthracis Amine Oxidase (BaAO) and the 
Nocardia farcinica oxidoreductase (NfOR); failed to produce soluble protein when expressed in 
several E. coli expression strains (Chapter 3), it was thought that expressing the genes in a 
different expression species, like C. glutamicum, may result in more soluble protein production, 
especially with in the case of NfOR, which is from a genus related to C. glutamicum.
[123]
 
 
To allow for easier cloning procedures, the pEKEx2 shuttle vector
[131]
 was selected as the vector for 
the target gene sequences, as it is accepted and replicated in both E. coli and C. glutamicum, 
allowing for the cloning of the vector to be carried out using high transformation efficiency E. coli 
strains, which were more simple to transform than the C. glutamicum strain. 
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A.2 Results 
 
A.2.1 Attempts to clone AsAAO, BaAO and NfOR sequences into pEK-Ex2 shuttle vector  
 
The pEK-Ex2 E. coli/ C. glutamicum shuttle vector was prepared using Miniprep and digested with 
relevant restriction endonucleases as in Section A.4.2. Due to the lack of a ribosome binding site in 
the pEKEx2 plasmid, amplification primers for the AsAAO, BaAO and NfOR gene sequences 
were all designed to contain the ribosome binding sequence AAGGAGATATAGAT seven bases 
upstream of the starting codon ATG, as done by Doo et al..
[130]
 The AsAAO, BaAO and NfOR 
gene sequences were amplified from the pET-YSBLIC3C-AsAAO, pET-YSBLIC3C-BaAO and 
pET-YSBLIC3C-NfOR plasmids, respectively, using KOD polymerase as in Section A.4.3. 
Attempts to ligate the amplified gene sequences to the pEK-EX2 shuttle vector were carried out as 
in Section A.4.4. Transformation of E. coli Top10 electrocompetent cells with the ligation mixed 
resulted in 5 colonies from the pEK-Ex2-BaAO reaction and 2 from the pEK-Ex2-NfOR reaction. 
The pEK-Ex2-AsAAO reaction did not result in any colonies. 
 
Plasmid was purified from each of the colonies using Sigma-Aldrich’s GenElute plasmid Miniprep 
kit, and the size of the gene inserts was checked by PCR as in Section A.4.4 (Figure A.1). Based 
on the results of this gel, pEK-NfOR-2 and pEK-BaAO-5 were sent for sequencing at the 
University of York Genomics department. pEK-NfOR-2 had ligated successfully with the correct 
gene sequence, however the pEK-BaAO-5 plasmid contained a different gene sequence from the 
BaAO gene. 
 
A.2.2 Transformation and expression of pEKEx2-NfOR plasmid 
 
Following a protocol used by Liebl et al.,
[132]
 competent C.glutamicum cells were prepared by 
growth at a low temperature, followed by several washes using ice-cold 10% glycerol as in Section 
A.4.5 and both the non recombinant pEKEX2 and the pEKEx2-NfOR plasmid was used to 
transform these competent cells using electroporation followed by heat shock, as in Section A.4.6. 
Translucent colonies grew after 2-3 days and were then used to innoculate a 5 mL LB culture, 
which was grown and had gene overexpression induced as in Section A.4.7. The induced cells 
were harvested by centrifugation and sonicated in an attempt to split open the C. glutamicum cells 
and analyse the resulting protein. Soluble and insoluble fractions were analysed using 12% SDS-
PAGE, however very little protein was seen in either the insoluble or soluble fractions of the 
induced cells, and there was no noticeable protein production in the cells transformed with the 
pEKEx2-NfOR plasmid compared to the cells transformed with non recombinant pEKEx2 plasmid 
(Figure A.2).  
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Figure A.1 1% agarose gel separation of DNA from PCR amplification of potential pEKEx2-NfOR and 
pEKEx2-BaAO plasmid inserts: Lane 1, 1 kb DNA ladder (0.5 kb, 1 kb, 1.5 kb, 2 kb, 3 kb, 4 kb, 5 kb, 6 kb, 8 
kb, 10 kb); Lane 2, PCR amplification of pET-YSBLIC-3C-NfOR insert; Lanes 3-4, PCR amplification of 
pEKEx2-NfOR 1-2 plasmids; Lane 5, PCR amplification of pET-YSBLIC-3C-BaAO insert; Lanes 6-10, 
PCR amplification of pEKEx2-BaAO-1-5 plasmids. 
 
Figure A.2 SDS-PAGE separation of protein from competent C. glutamicum ATCC 13032 cells 
transformed with pEKEx2 plasmid variants: Lane 1, low range molecular weight marker; Lane 2, ATCC 
13032-pEKEx2 insoluble fraction; Lanes 3-4, ATCC 13032-pEKEx2-NfOR1-2 insoluble fractions; Lane 5 
ATCC 13032-pEKEx2 soluble fraction; Lanes 6-7, ATCC 13032-pEKEx2-NfOR1-2 soluble fractions. 
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A.3 Discussion 
 
Attempts were made to clone the AsAAO, BaAO and NfOR gene sequences into the pEK-Ex2 
shuttle vector for expression in C. glutamicum, however, only the NfOR sequence was successfully 
cloned.  
 
The AsAAO and BaAO gene inserts were amplified sucessfully (data not shown) and the activity 
of the restriction enzymes had all been checked by performing single enzyme restrictions on the 
non recombinant pEK-Ex2 plasmid (data not shown), meaning that problems may have been 
caused by the digestion of the gene insert or during the ligation step. If more time had been 
available attempts to address these problems would have included using alternative primer designs 
for the insert PCR amplification and redoing the ligation step with a different batch of ligase and 
varying plasmid:insert ratios. 
 
Both the non recombinant pEK-Ex2 and the pEK-Ex2 NfOR plasmids were used to transform 
comptetent C. glutamicum cells that had been prepared using a method proposed by Liebl et al..
[132]
 
Small translucent colonies took 2-3 days to appear, which was expected based on work by Takano 
et al..
[135]
 These colonies were picked and gene overexpression was induced in a similar manner to 
the E. coli expression strains, although the time taken for the culture to reach OD600 was longer in 
C. glutamicum compared to E. coli expression strains (around 5-6 h as opposed to 2-3 h), so the 
culture was left at 30°C overnight to produce protein, whereas E. coli would be left for around 5 h. 
 
Cells were then harvested by centrifugation and sonicated in an attempt to disrupt the C. 
glutamicum cell envelope. However, when analysed on SDS-PAGE there was very little protein 
found in the insoluble fraction of the sonicated cell cultures, and almost none in the soluble 
fractions (Figure A.2). The lack of protein in the insoluble fractions suggests that there is little cell 
volume in the cultures, this may either be due to the cells not having had enough time to grow or 
possibly the C. glutamicum being unable to reach higher cell density in LB media. 
 
The lack of soluble protein may just be due to the lack of protein overall, or may suggest that the 
soniciation was not enough to disrupt the C. glutamicum cells. Although Doo et al.
[130]
 disrupted 
their cells using an ultrasonic processor, they were using different growth conditions, which may 
have affected the variable level of coverage of the protective crystalline protein surface-layer.
[126]
 
 
Either way, there does not appear to have been any production of the NfOR protein, as both the 
pEK-Ex2 and pEK-Ex2-NfOR strains have the same protein expression pattern (Figure A.2). As 
the amount of IPTG used to induce gene induction was the same as used successfully by Doo et 
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al.,
[130]
 who were also using the same plasmid vector and ribosomal binding site, it could be 
possible that the antibiotic selection did not work or C. glutamicum was unable to produce the 
NfOR protein due to another reason (e.g. oxidases potentially causing a toxic build-up of H2O2 if a 
compatible substrate is present in the cell cytoplasm.).  
 
If more time had been available to address these issues, transformation and the culture growth 
could both be repeated with a higher concentration of kanamycin to ensure that the cells had been 
transformed and the plasmid was being retained during growth. Re-cloning the sequence using a 
different ribosomal binding site, or potentially a different plasmid vector, could also been have 
tried. Cloning in a protein that had been expressed successfully in E. coli, such as the PpLAAO 
protein, could also have acted as a useful comparision of how well protein expression was working 
in the C. glutamicum system and cloning in a protein known to be successfully expressed in C. 
glutamicum previously and attempting to overexpress it would determine if the method I was using 
was suitable for protein expression. 
 
A.4 Materials and Methods 
 
A.4.1 Transformation of electrocompetent E. coli with plasmid 
 
Kanamycin sulfate, SOC media and electrocompetent E. coli Top10 cells were purchased from 
Invitrogen. The ingredients for LB-media were purchased from Fisher Scientific and agar was 
purchased from LAB M Ltd. Electrocompetent E. coli Top10 cells were electroporated using a 
BioRad E. coli Pulser. 
 
Electrocompetent E. coli Top10 cells were thawed on ice and rapidly mixed with plasmid DNA. 
Cells were incubated on ice for 1 min and then transferred to an ice-cold 0.2 cm electroporation 
cuvette. Cells were electroporated at 2.5 kV in the E. coli Pulser. Cells were mixed with 950 µL 
SOC media and then transferred to a fresh 15 mL tube under sterile conditions. Cells were 
incubated at 37°C with shaking at 180 r.p.m for 90 min. Cells were plated out on pre-warmed LB-
agar containing 30 µg mL
-1
 of kanamycin. Colonies were obtained after incubating the agar plates 
at 37°C overnight. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, H2O (18.2 Ω
.
cm) 
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A.4.2 Preparation of pEK-EX2 for cloning 
 
pEK-Ex2 plasmid pellet was provided by Prof. Sun-Yang Park. BamHI restriction enzyme, EcoRI 
restriction enzyme, KpnI restriction enzyme, 100 x BSA, NEBuffer 1 and NEBuffer 3 were 
purchased from New England Biolabs. UV-cuvettes for Eppendorf Biophotometer were purchased 
from Sarstedt. 
 
pEKEx2 plasmid pellet was resuspended in 10 µL of H2O (18.2 Ω
.
cm). 1 µL pEKEx2 plasmid was 
used to transform E. coli Top10 electrocompetent cells as in Section A.4.1. One colony was used to 
inoculate 5 mL of LB-media containing 30 µg mL
-1
 kanamycin. This starter culture was grown 
overnight at 37°C with shaking at 180 r.p.m. Plasmid was purified using Sigma-Aldrich’s GenElute 
Plasmid Miniprep kit. Plasmid concentration was measured using the dsDNA function of an 
Eppendorf Biophotometer, with an A280 nm of 1 set equal to 50 µg mL
-1
 DNA. 
 
2 µg of purified pEKEx2 plasmid was digested using the KpnI/BamHI Restriction mix. 2 µg of 
purified pEKEx2 plasmid was digested using the EcoRI/BamHI Restriction mix. Restriction mixes 
were incubated at 37°C for 3 hours. Restriction digests were separated using 1 % agarose gel 
electrophoresis, along with a lane of undigested plasmid as a control. Digested gel bands were 
visualized using an Invitrogen SafeImager system and excised using a scalpel. DNA was purified 
from the gel bands using Sigma-Aldrich’s GenElute Gel Extraction kit. DNA concentration was 
measured using the dsDNA function of an Eppendorf Biophotometer, with an A280 nm of 1 set equal 
to 50 µg mL
-1
 DNA. Digested plasmid was stored at -20°C until needed. 
 
LB-media (V=1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O 
(18.2 Ω.cm) 
KpnI/BamHI Restriction mix (v=30 µL): 1 x NEBuffer 1, 1 x BSA, 333.3 U µL
-1
 KpnI, 
1000 U µL
-1
 BamHI, 2 µg DNA 
EcoRI/BamHI Restriction mix (v=30 µL): 1 x NEBuffer 3, 1 x BSA, 666.7 U µL
-1
 KpnI, 
666.7 U µL
-1
 BamHI, 2 µg DNA 
 
A.4.3 Preparation of gene inserts for cloning into pEKEx2 plasmid 
 
KOD HotStart polymerase kit was purchased from Novagen. YSBLIC3C-AsAAO, YSBLIC3C-
BaAO, and YSBLIC3C-NfOR plasmids were prepared previously (Sections 2.2.1-2.2.4). BamHI 
restriction enzyme, EcoRI restriction enzyme, KpnI restriction enzyme, 100 x BSA, NEBuffer 1 
and NEBuffer 3 were purchased from New England Biolabs. UV-cuvettes for Eppendorf 
Biophotometer were purchased from Sarstedt. 
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AsAAO gene insert was amplified from YSBLIC3C-AsAAO plasmid by PCR using PCR Cycle A 
(Table A.1), PCR mix A (Table A.2) and the PekNfOR-for and PekAsAAO-rev primers (Table 
A.3). BaAO gene insert was amplified from YSBLIC3C-BaAO plasmid by PCR using PCR Cycle 
A (Table A.1), PCR mix A (Table A.2) and the PekNfOR-for and PekBaAO-rev primers (Table 
A.3). NfOR gene insert was amplified from YSBLIC3C-NfOR plasmid by PCR using PCR Cycle 
A (Table A.1), PCR mix A (Table A.2) and the PekNfOR-for and PekNfOR-rev primers (Table 
A.3). 
 
PCR reactions were separated by 1 % agarose gel electrophoresis. Appropriately sized gel bands 
were visualized using an Invitrogen SafeImager system and excised using a scalpel. DNA was 
purified from the gel bands using Sigma-Aldrich’s GenElute Gel Extraction kit. DNA 
concentration was measured using the dsDNA function of an Eppendorf Biophotometer, with an 
A280 of 1 set equal to 50 µg mL
-1
 DNA. 
 
Table A.1: Conditions for PCR cycling methods used for the amplification of DNA by PCR. 
PCR 
Cycling 
Initial 
denaturation 
Denaturation Annealing Extension 
Number 
of 
Cycles 
Final extension 
A 95°C, 2 min 95°C, 30 sec 
55°C, 30 
sec 
72°C, 90 
sec 
30 72°C, 5 min 
 
Table A.2: Composition of PCR mix used for the amplification of DNA by PCR. 
PCR 
mix 
Vtotal in 
µL 
Vcomponent [Component] in PCR mix 
A 50 27 µL H2O (18.2 Ω
.
cm) 
5 µL 5 x KOD buffer 
3 µL 25 mM MgSO4 
5 µL 2 mM (each) dNTPs 
1 µL 20 µM forward primer 
1 µL 20 µM reverse Primer 
1 µL Template DNA 
2.5 µL ≥99.5% DMSO 
1 µL 1 U µL
-1
 KOD Hot Start DNA 
polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
5% DMSO 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
B 25 13.75 µL H2O (18.2 Ω
.
cm) 
2.5 µL 10 x KOD buffer 
2.5 µL 2 mM (each) dNTPs 
1.5 µL 25 mM MgSO4 
1 µL 10 µM forward primer 
1 µL 10 µM reverse primer 
1 µL 10 ng µL
 -1
 YSBLIC3C-
PpLAAO 
1.25 µL ≥99.5% DMSO 
0.5 µL 1 U µL
-1 
KOD HotStart 
DNA polymerase 
1 x KOD buffer 
1.5 mM MgSO4 
0.2 mM of each dNTP 
0.4 µM forward primer 
0.4 µM reverse primer 
2% (v/v) template DNA 
5% DMSO 
0.02 U µL
-1
 KOD Hot Start DNA 
polymerase 
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Table A.3: Sequences of primers used for the amplification of DNA by PCR. 
Primer name/ 
Purification 
method 
Primer sequence 
PekAsAAO-
rev/ HPSF 
TGTGATAAGAATTCTTATTATCGAGGAGCGGTAGAGCCAGCAAAGTGAAT 
PekBaAO-
rev/ HPSF 
TTATCAGAGGTACCTTATCACTTTTCGTTTACTTCATGAGCAACTCGAAT 
PekNfOR-for/ 
HPSF 
GCAAGTGTGGATCCAAAGGAGATATAGATATATACCATGGGCAGCAGC 
PekNfOR-rev/ 
HPSF 
TCTGATAAGAATTCTTATCACCGGAGGGCGGACGGGCTCGCGGCGTCG 
PekSeq-for/ 
HPSF 
ATCATCGGCTCGTATAATGTGTGGAATTGTGAGC 
PekSeq-rev/ 
HPSF 
ATTTGATGCCTGGCAGTTCCCTACTCTCG 
 
2 µg of purified BaAO insert was digested using the KpnI/BamHI Restriction mix. 2 µg of purified 
AsAAO insert and NfOR insert were both digested using the EcoRI/BamHI Restriction mix. 
Restriction mixes were incubated at 37°C for 3 hours. Restriction digests were separated using 1 % 
agarose gel electrophoresis. Digested gel bands were visualized using an Invitrogen SafeImager 
system and excised using a scalpel. DNA was purified from the gel bands using Sigma-Aldrich’s 
GenElute Gel Extraction kit. DNA concentration was measured using the dsDNA function of an 
Eppendorf Biophotometer, with an A280 of 1 set equal to 50 µg mL
-1
 DNA. Insert DNA was stored 
at -20°C until needed. 
 
KpnI/BamHI Restriction mix (v= 30 µL): 1 x NEBuffer 1, 1 x BSA, 333.3 U µL
-1
 KpnI, 
1000 U µL
-1
 BamHI, 2 µg DNA 
EcoRI/BamHI Restriction mix (v= 30 µL): 1 x NEBuffer 3, 1 x BSA, 666.7 U µL
-1
 KpnI, 
666.7 U µL
-1
 BamHI, 2 µg DNA 
 
A.4.4 pEKEx2 ligation 
 
T4 qualified DNA ligase kit was purchased from New England Biolabs. ATP was purchased from 
Sigma-Aldrich. Ligation mix was incubated using a Techne TC-312 Thermocycler machine. 
 
T4 DNA Ligation mix was prepared using pEK-EX2 plasmid digested with EcoRI and BamHI 
(Section A.4.2) and AsAAO insert digested with EcoRI and BamHI, (Section A.4.3) as well as 
NfOR insert digested with EcoRI and BamHI (Section A.4.2). T4 DNA Ligation mix was prepared 
using pEKEX2 plasmid digested with KpnI and BamHI (Section A.4.2) and AsAAO insert 
digested with KpnI and BamHI, (Section A.4.3). Ligation mix was incubated at 16°C with shaking 
at 180 r.p.m overnight. Ligation mixes were stored at -20°C until needed. 
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1 µL of ligation mix was used to transform 75 µL of E. coli electrocompetent Top10 Cells as in 
Section A.4.1. This resulted in 5 colonies from the pEK-Ex2-BaAO reaction and 2 colonies from 
the pEK-Ex2-NfOR reaction. Colonies were each used to inoculate 5 mL of LB-media containing 
30 µg mL
-1
 kanamycin. Starter culture was grown overnight at 37°C with shaking at 180 r.p.m. 
Plasmid was purified using Sigma-Aldrich’s GenElute Plasmid Miniprep kit. Plasmid DNA 
concentration was measured using the dsDNA functions of an Eppendorf Biophotometer. 
 
The gene insert of the purified pEK-Ex2-BaAO plasmids, along with the insert from the 
YSBLIC3C-BaAO plasmid, were amplified via PCR using PCR cycle A (Table A.1), PCR mix B 
(Table A.2) and the PekNfOR-for and PekBaAO-rev primers (Table A.3).The gene insert of the 
purified pEK-Ex2-NfOR plasmids, along with the insert from the YSBLIC3C-NfOR plasmid, were 
amplified using PCR using PCR cycle A (Table A.1), PCR mix B (Table A.2) and the PekNfOR-
for and PekNfOR-rev primers (Table A.3). Products were analysed on 1% agarose electrophoresis 
gel. 
 
Based on these results, the pEK-Ex2-BaAO5 and pEK-Ex2-NfOR1 plasmids were concentrated to 
100-150 ng µl
-1
 and sent for sequencing using the PekSeq-for and PekSeq-rev primers (Table A.3) 
by the York University Genomics group. The sequence chromatograms were analysed with the 
program Chromas lite, version 2.01 from Technelysium (free software). The pEK-Ex2-NfOR1 
plasmid had ligated and contained no undesired mutations, however the pEK-Ex2-BaAO5 plasmid 
had failed to ligate. 
 
T4 DNA Ligation mix (V= 10 µL): 1 x T4 DNA ligase buffer, 1 mM ATP, 3 µL 
digested PekEx2 plasmid, 4 µL digested gene 
inserts, 40 cohesive end units µL
-1
 T4 qualified 
DNA ligase. 
LB-media (V=1 L):  10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O 
(18.2 Ω.cm) 
EcoRI/BamHI Restriction mix (v= 30 µL): 1 x NEBuffer 3, 1 x BSA, 666.7 U µL
-1
 KpnI, 
666.7 U µL
-1
 BamHI, 500 ng DNA 
 
A.4.5 Preparation of competent C. glutamicum cells 
 
C. glutamicum ATCC 13032 cells were brought in ampoule form. Ingredients for LB-media and 
glycerol were purchased from Fisher Scientific and agar was purchased from LAB M Ltd, D-
glucose was purchased from Sigma-Aldrich. 
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1 mL of LB-media was used to resuspend purchased C. glutamicum cells. Resuspended cells were 
used to inoculate LB-agar plates and 100 mL of LB-media. Plates were grown overnight at 30°C 
and the LB-culture was grown overnight at 30°C with shaking at 180 r.p.m. Both plates and the 
culture grew. 700 µL of C. glutamicum culture was mixed with 300 µL of 50% glycerol and stored 
at -80°C. 
 
Two colonies of C. glutamicum ATCC 13032 were each used to inoculate 10 mL of LB-media 
containing 2% (v/v) filter-sterilized D-glucose in a 50 mL conical flask. These were grown 
overnight at 30°C and 180 r.p.m. The next morning 100 mL of LB-media in a 1 L conical flask 
were inoculated with the overnight culture to an optical density of 0.3 at 600 nm. This culture was 
then grown at 18°C and 120 r.p.m for 28 h. 
 
The culture was chilled on ice for 10 min before cells were spun down by centrifugation for 10 min 
at 4,000 g in a Harrier 18/80 benchtop centrifuge. The cells were washed with 50 mL of ice-cold 
10% (v/v) glycerol four times and were finally resuspended in 0.5 mL of ice-cold 10% (v/v) 
glycerol. 100 µL aliquots were transferred to ice-cold 1.5 mL Eppendorf tubes and were snap 
frozen in liquid nitrogen, before storing at -80°C. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
LB-agar (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar, H2O (18.2 Ω
.
cm) 
 
A.4.6 Transformation of C. glutamicum cells with pEK-Ex2-NfOR plasmid 
 
C. glutamicum ATCC 13032 cells were brought in ampoule form. Ingredients for LB-media were 
purchased from Fisher Scientific and agar was purchased from LAB M Ltd, D-sorbitol and 0.2 cm 
gap Electroporation cuvettes were purchased from Sigma-Aldrich. Cells were electroporated in a 
BioRad Gene Pulser electroporation system with pulse controller. 
 
C. glutamicum was transformed with pEK-Ex2-NfOR plasmid. Non recombinant pEK-Ex2 plasmid 
and H2O (18.2 Ω
.
cm) were also used instead as control reactions. 
 
100 µL of competent C. glutamicum ATCC 13032 (Section A.4.5) was thawed on ice and 1 µL of 
plasmid was added and mixed gently with the pipette tip. Cells were transferred to an ice-cold 0.2 
cm Electroporation cuvette and tapped firmly on the benchtop to remove any bubbles from the mix. 
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Cuvettes were wiped with a tissue to remove moisture and then electroporated at 2.5 kV with 
capacitance of 25 µF and resistance at 200 Ω. 
Cells were then added to 1 mL of LB media containing 0.5 M D-sorbitol, which was heatshocked at 
46°C for 6 min and then grown at 30°C for 90 min. 200 µL aliquots were then spread on LB agar 
plates containing 25 µg mL
-1
 kanamycin and 0.5 M D-sorbitol. Plates were grown at 30°C for 3 d. 
 
A.4.7 Gene overexpression of transformed C. glutamicum cells 
 
C. glutamicum ATCC 13032 cells were brought in ampoule form. Ingredients for LB-media were 
purchased from Fisher Scientific. Kanamycin was purchased from Invitrogen and IPTG was 
purchased from Melford. 
 
One colony of transformed C. glutamicum was used to inoculate a 5 mL culture of LB media 
containing 25 µg mL
-1
 kanamycin; this starter culture was grown overnight at 30°C with shaking at 
180 r.p.m. 100 µL of starter culture was then used to inoculate a fresh 5 mL culture of LB media 
containing 25 µg mL
-1
 kanamycin. This culture was grown at 30°C with shaking at 180 r.p.m until 
the OD600 of the culture was roughly 0.5. Gene overexpression was induced by adding 1 mM IPTG 
and cells were left to overexpress overnight at 30°C with shaking at 180 r.p.m. 
 
The cells were harvested by centrifugation for 1 min at 16,000 g using an Eppendorf 5415 C 
centrifuge. The supernatant was discarded and the cell pellet was resuspended in 500 µL buffer 1. 
The cell suspension was sonicated on ice for 30 s at 15 microns. Cell debris was pulled down by 
spinning at 16,000 g for 1 min using an Eppendorf 5415 C centrifuge. The soluble supernatant was 
separated from the insoluble cell pellet. The cell pellet was then resuspended in 500 µL buffer 1. 
The soluble and insoluble fractions were analysed by 12.5% SDS-PAGE. 
 
LB-media (V= 1 L): 10 g tryptone, 5 g yeast extract, 10 g NaCl, H2O (18.2 Ω
.
cm) 
 
  
229 
Appendix B  Alignment of known and target oxidases  
 
The seven target oxidases expressed in Chapter 3, along with the known L-AAO from 
Calloselasma rhodostoma (CrLAAO) and the L-aspartate oxidase from E. coli were aligned using 
the CLUSTAL W2 program from the European Bioinformatics Institute website. 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/)  
 
Q81RW3_BaAO        --------------------------------------MMQPLTMERMLHIINVGLVKTK 22 
P81382_CrLAAO      -----------MNVFFMFSLLFLAALGSCADDRNPLAECFQENDYEEFLEIARNGLKATS 49 
Q88MZ2_PpLAAO      -----------MSQQFQH--DVLVIG-------SGAAGLSLALNLPSHLRVAVLSKGDLS 40 
P10902_L-AspO      -----------MNTLPEHSCDVLIIG-------SGAAGLSLALRLADQHQVIVLSKGPVT 42 
Q8YKW9_AsAAO       MQHREFTGCIHTSCRLPISFIFMFNLNRRQFLLRSTLAIAATVSYDHVQAQKPKSPGTLP 60 
P72346_SLAAO       ------------------------MRFSRRRFLQSSLGAAATTGLAGTLAAGGQAQTRST 36 
Q5YV66_NfOR        ---------------------------------------------------------MVD 3 
Q8VPD4_RoLAAO      ---------MAFTRRSFMKGLGATGGAGLAYGAMSTLGLAPSTAAPARTFQPLAAGDLIG 51 
O31616_BsGO        ------------------------------------------------------MKR--- 3 
                                                                                
 
Q81RW3_BaAO        N---PKQIIIVGAGISGLVAASLLKEAGHKVTILEANNRIGGRIYTIREP---------- 69 
P81382_CrLAAO      N---PKHVVIVGAGMAGLSAAYVLAGAGHQVTVLEASERPGGRVRTYRN----------- 95 
Q88MZ2_PpLAAO      N---GSTFWAQGGVAAVLDNTDTVQSHVEDTLNAGGGLCHEDAVRFTVEH---------- 87 
P10902_L-AspO      E---GSTFYAQGGIAAVFDETDSIDSHVEDTLIAGAGICDRHAVEFVASN---------- 89 
Q8YKW9_AsAAO       KGLPRRKVIVVGAGISGLVAAYELTAVGHDVTLLEASKRIGGRVLTLRGA---------- 110 
P72346_SLAAO       PVR-KRSVLVLGAGMAGLTAALSLLRRGHQVTVIEYQNRIGG--RLLSVP---------- 83 
Q5YV66_NfOR        R---SVDVVVVGAGIAGLVAARDLVRTGHEVLVLEARDRVGG--RLLNAE---------- 48 
Q8VPD4_RoLAAO      KVKGSHSVVVLGGGPAGLCSAFELQKAGYKVTVLEARTRPGGRVWTARGGSEETDLSGET 111 
O31616_BsGO        ----HYEAVVIGGGIIGSAIAYYLAKENKNTALFESG-TMGGRTTSAAAG---------- 48 
                              *.       :  :     ..                              
 
Q81RW3_BaAO        ----FSRGLYFNAGPMRIPDTHKLTLAYIRKFKLPLNLFINKTASDIIYTNNIKKRLSIF 125 
P81382_CrLAAO      ----EEAGWYANLGPMRLPEKHRIVREYIRKFDLRLNEFSQENDNAWYFIKNIRKKVGEV 151 
Q88MZ2_PpLAAO      ----SREAIQWLIEQGVPFTRDEHYSVDDGGFEFHLTREGGHSHRRIIHAADATGAAIFT 143 
P10902_L-AspO      ----ARSCVQWLIDQGVLFDTHIQPNGEES---YHLTREGGHSHRRILHAADATGREVET 142 
Q8YKW9_AsAAO       ----FQGEDLLELGAARIPSNHHLTFGYIKHFGLKLSQFAPADG---KYLTIKDGKRLLI 163 
P72346_SLAAO       ----LKGGQFSEAGGGHFRANMPYVLSYIRHFKLPLLTLNDGLPR--YLFDGKTADAADL 137 
Q5YV66_NfOR        ----LPGGAPIEVGGQWVGPTQHRAMALIHELGLQTFPTHDTGRAIAEIGSSRAEYTGAI 104 
Q8VPD4_RoLAAO      QKCTFSEGHFYNVGATRIPQS-HITLDYCRELGVEIQGFGNQNANTFVNYQSDTSLSGQS 170 
O31616_BsGO        ----MLGAHAECEERDAFFDFAMHSQRLYKGLGEELYALSGVDIR--QHNGGMFKLAFSE 102 
                                                                                
 
Q81RW3_BaAO        EKNPSILGYPILEREKGKTAEELMLEV----------LEPILNYIKKDPNKNWSIVEKKY 175 
P81382_CrLAAO      KKDPGLLKYPVKPSEAGKSAGQLYEES----------LGKVVEELKR---TNCSYILNKY 198 
Q88MZ2_PpLAAO      TLLEQARQRPNIQLLEQRVAVDLITERRLGLPGER-CLGAYVLDRNTGEVDTFGARFTVL 202 
P10902_L-AspO      TLVSKALNHPNIRVLERSNAVDLIVSDKIGLPGTRRVVGAWVWNRNKETVETCHAKAVVL 202 
Q8YKW9_AsAAO       PAKVLFQNQPQIRPQE-------------------------------------------- 179 
P72346_SLAAO       SRWPWDLAPQERRVSVASLLNTYLILN--------------GLDTDTVLDANWPDAQAIQ 183 
Q5YV66_NfOR        PKLNPLALADVAQAQLRLDRLARRVAR----------TDPWRAERAEALDAQTFDTWLRR 154 
Q8VPD4_RoLAAO      VTYRAAKADTFGYMSELLKKATDQGALD-------QVLSREDKDALSEFLSDFGDLSDDG 223 
O31616_BsGO        EDVLQLRQMDDLDSVSWYSKEEVLEKE--------------------------------- 129 
                                                                                
 
Q81RW3_BaAO        KAYSLGTFLTEY--YSDGAIDMIGVLLDMEAYMGMSLIEVLREMVFFTSTTKYYEITGGM 233 
P81382_CrLAAO      DTYSTKEYLIKEGDLSPGAVDMIGDLLNEDSGYYVSFIESLKHDDIFAYEKRFDEIVDGM 258 
Q88MZ2_PpLAAO      ATGGAAKVYLYTSNPDGACGDGIAMAWRAGCRVANLEFNQFHPTCLYHPQAKSFLITEAL 262 
P10902_L-AspO      ATGGASKVYQYTTNPDISSGDGIAMAWRAGCRVANLEFNQFHPTALYHPQARNFLLTEAL 262 
Q8YKW9_AsAAO       ----------------------------------------------------IQKLTDGF 187 
P72346_SLAAO       QLDNLTLSQLIRQVGGSEAFIQLLDAHGGTFTSSSPALGVIPDLAYHFGDQNLFRIQGGN 243 
Q5YV66_NfOR        TTYTAAGRSFFRVITEAVFAAGPEDLSALWASCYLGAGGGVDTMIDVAGGAQQDRVVGGT 214 
Q8VPD4_RoLAAO      RYLGSSRRGYDSEPGAGLNFGTEKKPFAMQEVIRSGIGRNFSFDFGYDQAMMMFTPVGGM 283 
O31616_BsGO        ------------------------------------------------PYASGDIFGASF 141 
                                                                             .  
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Q81RW3_BaAO        DALPKAFLSQL-NENIFMRYKVEKIIQENSKVMIQVNHEQT--------IERFMVTGDVA 284 
P81382_CrLAAO      DKLPTAMYRDI-QDKVHFNAQVIKIQQNDQKVTV-VYETLS--------KETPSVTADYV 308 
Q88MZ2_PpLAAO      RGEGALLRLPN-GERFMPRFDPREELAPRDIVARAIDHEMKRLGVDCVYLDITHKPADFI 321 
P10902_L-AspO      RGEGAYLKRPD-GTRFMPDFDERGELAPRDIVARAIDHEMKRLGADCMFLDISHKPADFI 321 
Q8YKW9_AsAAO       DLLPKAFAQAL-TKEIKLDEPVARIVQTSNGVEVSCLSGQR-------------YLGDYV 233 
P72346_SLAAO       DRLPKAMAAAIGSERFILDAPVVAIDQQANRATVTVKDGRT-------------FQGDAI 290 
Q5YV66_NfOR        QAIAIALAGEL-GDRVVLGSPVSEVEWDEAGVRVRAGGGTVR--------------ARRA 259 
Q8VPD4_RoLAAO      DRIYYAFQDRIGTDNIVFGAEVTSMKNVSEGVTVEYTAGGSK----------KSITADYA 333 
O31616_BsGO        IQDDVHVEPYFVCKAYVKAAKMLGAEIFEHTPVLHVERDGE---------------ALFI 186 
                         .                                                 .    
 
Q81RW3_BaAO        IVTIPFSALRFVEIQPYNLFSYYKRRAIRELNYIAATKIAIEFKSRFWEKAG-QYGGKSI 343 
P81382_CrLAAO      IVCTTSRAVRLIKFNPPLLP--KKAHALRSVHYRSGTKIFLTCTTKFWEDDG-IHGGKST 365 
Q88MZ2_PpLAAO      KSHFPTVYERCLAFGIDITR--QPIPVVPAAHYTCGGVMVDDCGHTDVPGLY-AIGETSF 378 
P10902_L-AspO      RQHFPMIYEKLLGLGIDLTQ--EPVPIVPAAHYTCGGVMVDDHGRTDVEGLY-AIGEVSY 378 
Q8YKW9_AsAAO       LCTVPLTVLNQITFSPELSEE-KKQAAAGGYNYRAATRGFVKFPNRFWEREN-LNGWGFF 291 
P72346_SLAAO       ISTIPFTVLPEVAVRPGWSAG--KRRMFAEMEWEQTVKVIAQTRSPVWLAQN-VHGWPMA 347 
Q5YV66_NfOR        VVAVPPPLAARIRFSPGLPGD--RDQLVQRMPMGRVVKVNVVYDEPFWRADG-FSGQAVS 316 
Q8VPD4_RoLAAO      ICTIPPHLVGRLQNNLPGDVL----TALKAAKPSSSGKLGIEYSRRWWETEDRIYGGASN 389 
O31616_BsGO        KTPSGDVWANHVVVASGVWSG----MFFKQLGLNNAFLPVKGECLSVWNDDIPLTKTLYH 242 
                              :                                                 
 
Q81RW3_BaAO        TDLP--IRFTYYPSYGIHTPGAATVLASYTWADEALTWDSLPDRERIRYALKNLAEIYG- 400 
P81382_CrLAAO      TDLP--SRFIYYPNHNFTN--GVGVIIAYGIGDDANFFQALDFKDCADIVFNDLSLIHQL 421 
Q88MZ2_PpLAAO      TGLHGANRMASNSLLECFVYGRAAAADIQAHLEQVAMPKALPGWDASQVTDSDEDVIIAH 438 
P10902_L-AspO      TGLHGANRMASNSLLECLVYGWSAAEDITRRMPYAHDISTLPPWDESRVENPDERVVIQH 438 
Q8YKW9_AsAAO       DDEE-----LWHTTWDRPE--KTGILHAYLKGEKGLEIDGFEGKTQQQKLLQHWEKILP- 343 
P72346_SLAAO       GSDR---PWERVIDITGNEGGGYGNTFFYLNGRNKDAMLARPKSERAQAIVDQFRSDLP- 403 
Q5YV66_NfOR        DRRP-----LAVVFDNTPPAGSPGVLVGFLEGRHADACSRMDHPTRRAQVIDDLAGYFG- 370 
Q8VPD4_RoLAAO      TDKD---ISQIMFPYDHYNSDRGVVVAYYSSGKRQEAFESLTHRQRLAKAIAEGSEIHG- 445 
O31616_BsGO        DHCY--------------IVPRKSGRLVVGATMKPGDWSETPDLGGLESVMKKAKTMLP- 287 
                                                                       .        
 
Q81RW3_BaAO        --EIVYSEFVTGTSFSWSKNPYSCGAFTAFEPGQELE------LFPYITSPSGKVHFAG- 451 
P81382_CrLAAO      PKKDIQSFCYPSVIQKWSLDKYAMGGITTFTPYQFQH------FSDPLTASQGRIYFAG- 474 
Q88MZ2_PpLAAO      NWDELRRFMWDYVGIVRTSKRLQRAQHRIRLLLDEID------EFYSNYKVSRDLIELR- 491 
P10902_L-AspO      NWHELRLFMWDYVGIVRTTKRLERALRRITMLQQEID------EYYAHFRVSNNLLELR- 491 
Q8YKW9_AsAAO       ---GVSNYSVRSYFHSWTKDIWSKGGWAYPTDEQEKK------LFPELGKSEGKIYFAG- 393 
P72346_SLAAO       ---DLFDEVVTLADFAWGEQPWIRGSFGGP-PLGGAW------MIREWTTPEGLIHFAG- 452 
Q5YV66_NfOR        ---PRARTPIDYIEKDWADEEYSRGCYGAFTAPGTLTR-----FGHALRPPIGPLHWAGT 422 
Q8VPD4_RoLAAO      --EKYTRDISSSFSGSWRRTKYSESAWANWAGSGGSHGGAATPEYEKLLEPVDKIYFAG- 502 
O31616_BsGO        ---AIQNMKVDRFWAGLRPGTKDGKPYIGRHPEDSRI-------LFAAGHFRNGILLAPA 337 
                                                                         :      
 
Q81RW3_BaAO        EHTTLTHGWMQGAIESGIRVAHEVNEK------------------------ 478 
P81382_CrLAAO      EYTAQAHGWIDSTIKSGLRAARDVNLASENPSGIHLSNDNEL--------- 516 
Q88MZ2_PpLAAO      NLAQVAELMILSAMQR--KESRGLHYTLDYPGMLDEAKDTILNPL------ 534 
P10902_L-AspO      NLVQVAELIVRCAMMR--KESRGLHFTLDYPELLTHSGPSILSPGNHYINR 540 
Q8YKW9_AsAAO       EHTSKTRGWLQGALESGLKAAQEIHFAGSTAPR------------------ 426 
P72346_SLAAO       DFTTMKSGWVEGAIESGLRAARQIDPGAQPEADTFLRQEQRCN-------- 495 
Q5YV66_NfOR        ETATRWAGYIDGAAESGHRTAREIAAALDPRHDAASPSALR---------- 463 
Q8VPD4_RoLAAO      DHLSNAIAWQHGALTSARDVVTHIHERVAQEA------------------- 534 
O31616_BsGO        TGALISDLIMNKEVNQDWLHAFRIDRKEAVQI------------------- 369 
                                          :                            
 
Figure B.1: ClustalW2 alignment of target oxidases along with two L-AAOs that have known structures, the 
L-AAO from C. rhodostoma (CrLAAO) and the L-aspartate oxidase from E. coli (L-AspO). * represents 
conservation of identical residues, : represents conservation of strongly similar residues and . represents 
conservation of weakly similar residues. For oxidases with known structures, FAD-binding domain residues 
are in red, substrate/capping domain residues are in green and helical/dimerisation domain residues are in 
blue. For the α-helix and β-sheet positions of the L-AspO protein, see Figure 5.1.
  
231 
Bibliography 
 
1. Breuer, M., Ditrich K., Habicher T., Hauer B., Kesseler M., Stürmer R. & Zelinski T. 
Industrial methods for the production of optically active intermediates. Angewandte 
Chemie International Edition, English 43, 788–824 (2004). 
 
2. Stephens, T. D., Bunde, C. J. . & Fillmore, B. J. Mechanism of action in thalidomide 
teratogenesis. Biochemical Pharmacology 59, 1489–1499 (2000). 
 
3. Kusumoto, I. Industrial Production of L-Glutamine. The Journal of Nutrition 131, 2552S–
2555S (2001). 
 
4. Hasegawa, H., Shinohara, Y., Akahane, K. & Hashimoto, T. Direct Detection and 
Evaluation of Conversion of D-Methionine into L-Methionine in Rats by Stable Isotope 
Methodology. The Journal of Nutrition 135, 2001–2005 (2005). 
 
5. Yagasaki, M. & Hashimoto, S. Synthesis and application of dipeptides; current status and 
perspectives. Applied Microbiology and Biotechnology 81, 13–22 (2008). 
 
6. Hill, J. B. et al. One-pot process for the preparation of .alpha.-L-aspartyl-L-phenylalanine 
methyl ester from a mixture containing both .alpha. and .beta. isomers thereof, which 
comprises admixing with said isomeric mixture hydrogen peroxide and an organic acid. 
(1991).at <http://www.google.com/patents/US5053532> 
 
7. Kim, C. & Shin, C. S. Solvent-free enzymatic synthesis of alitame precursor using eutectic 
substrate mixtures. Enzyme and Microbial Technology 28, 611–616 (2001). 
 
8. Rozzell, D. & Wagner, F. Biocatalytic Production of Amino Acids and Derivatives. 
(Hanser Publishers: 1992). 
 
9. Chang, C.-Y. & Yang, T.-K. Asymmetric synthesis of ACE inhibitor-Benazepril HCl via a 
bioreductive reaction. Tetrahedron: Asymmetry 14, 2239–2245 (2003). 
 
10. Ahmad, A. L., Oh, P. C. & Abd Shukor, S. R. Sustainable biocatalytic synthesis of L-
homophenylalanine as pharmaceutical drug precursor. Biotechnology Advances 27, 286–
296 (2009). 
 232 
 
11. Drauz, K. Enzyme Catalysis in Organic Synthesis. (John Wiley & Sons: 2012). 
 
12. Liu, B., Wu, Q., Lv, D. & Lin, X. Modulating the synthetase activity of penicillin G 
acylase in organic media by addition of N-methylimidazole: Using vinyl acetate as 
activated acyl donor. Journal of Biotechnology 153, 111–115 (2011). 
 
13. Deaguero, A. L., Blum, J. K. & Bommarius, A. S. Improving the Diastereoselectivity of 
Penicillin G Acylase for Ampicillin Synthesis from Racemic Substrates. Protein 
Engineering, Design and Selection 25, 135–144 (2012). 
 
14. Brennan, T. M. & Hendrick, M. E. Branched amides of L-aspartyl-d-amino acid 
dipeptides. (1983).at <http://www.google.com/patents?id=5AY2AAAAEBAJ> 
 
15. Regla, I., Luna H., Pérez, HI., Demare, P., Bustos-Jaimes, I. , V. & 
Calcagno, ML. Enzymatic resolution of N-acetyl-homophenylalanine with mammalian 
kidney acetone powders. Tetrahedron: Asymmetry 15, 1285–1288 (2004). 
 
16. Kato, T., Ozaki, T., Tsuzuki, K. & Ohi, N. Practical Synthesis of Novel Cardioprotective 
Drug, CP-060S. Organic Process Research & Development 5, 122–126 (2000). 
 
17. Vries, T., Wynberg, H., Echten, E., Koek, J., Hoeve, W., Kellogg, R., Broxterman,Q.,  
Minnaard, A., Kaptein, B., Sluis, S., Hulshof, L., & Kooistra J. The Family Approach to 
the Resolution of Racemates. Angewandte Chemie International Edition 37, 2349–2354 
(1998). 
 
18. O’Brien, P. Recent advances in asymmetric synthesis using chiral lithium amide bases. 
Journal of the Chemical Society, Perkin Transactions 1 8, 1439-1458 (1998) 
 
19. Henderson, K. W., Kerr, W. J. & Moir, J. H. Enantioselective deprotonation reactions 
using a novel homochiral magnesium amide base. Chemical Communications 6, 479–480 
(2000). 
 
20. Adamo, M. F. A., Aggarwal, V. K. & Sage, M. A. Epoxidation of Alkenes by Amine 
Catalyst Precursors:  Implication of Aminium Ion and Radical Cation Intermediates. 
Journal of the American Chemical Society 122, 8317–8318 (2000). 
  
233 
21. Berger, M., Albrecht, B., Berces, A., Ettmayer, P., Neruda, W. & Woisetschläger, M. S(+)-
4-(1-Phenylethylamino)quinazolines as Inhibitors of Human Immunoglobuline E 
Synthesis:  Potency Is Dictated by Stereochemistry and Atomic Point Charges at N-1. 
Journal of Medical Chemistry 44, 3031–3038 (2001). 
 
22. Schulze, B. & Wubbolts, M. G. Biocatalysis for industrial production of fine chemicals. 
Current Opinion in Biotechnology 10, 609–615 (1999). 
 
23. Friedrich, A. B. & Antranikian, G. Keratin Degradation by Fervidobacterium pennavorans, 
a Novel Thermophilic Anaerobic Species of the Order Thermotogales. Applied 
Environmental Microbiology 62, 2875–2882 (1996). 
 
24. Lucas, C. & Beveridge, J. The analysis of hair keratin. Biochemical Journal 34, 1356–1366 
(1940). 
 
25. Riessen, S. & Antranikian, G. Isolation of Thermoanaerobacter keratinophilus sp. nov., a 
novel thermophilic, anaerobic bacterium with keratinolytic activity. Extremophiles 5, 399–
408 (2001). 
 
26. Yet, L. Recent Developments in Catalytic Asymmetric Strecker‐Type Reactions. 
Angewandte Chemie International Edition 40, 875–877 (2001). 
 
27. Beller, M. & Eckert, M. Amidocarbonylation—An Efficient Route to Amino Acid 
Derivatives. Angewandte Chemie International Edition 39, 1010–1027 (2000). 
 
28. Ishitani, H., Komiyama, S., Hasegawa, Y. & Kobayashi, S. Catalytic Asymmetric Strecker 
Synthesis. Preparation of Enantiomerically Pure α-Amino Acid Derivatives from 
Aldimines and Tributyltin Cyanide or Achiral Aldehydes, Amines, and Hydrogen Cyanide 
Using a Chiral Zirconium Catalyst. Journal of the American Chemical Society 122, 762–
766 (2000). 
 
29. Hermann, T. Industrial production of amino acids by coryneform bacteria. Journal of 
Biotechnology 104, 155–172 (2003). 
 
30. Okamoto, K., Kino, K. & Ikeda, M. Hyperproduction of L-Threonine by an Escherichia 
coli Mutant with Impaired L-Threonine Uptake. Bioscience, Biotechnology, and 
Biochemistry 61, 1877–1882 (1997). 
 234 
31. Masuda, M., Takamatsu, S., Nishimura, N., Komatsubara, S. & Tosa, T. Improvement of 
Nitrogen Supply for L-Threonine Production by a Recombinant Strain of Serratia 
marcescens. Applied Biochemistry and Biotechnology 37, 255–265 (1992). 
 
32. Faurie, R. & Thommel, J. Microbial Production of L-Amino Acids. (Springer: 2003). 
 
33. Lee, M.-H., Lee H.-W., Park J.-H., Ahn J.-O., Jung J.-K. & Hwang Y.-I. Improved L-
threonine production of Escherichia coli mutant by optimization of culture conditions. 
Journal of Bioscience and Bioengineering 101, 127–130 (2006). 
 
34. Backman, K. O'Connor, M.J., Maruya, A., Rudd, E., McKay, D., Balakrishnan, R., Radjai, 
M., DiPasquantonio, V., Shoda, D., Hatch, R. & Venkatasubramanian, K. Genetic 
Engineering of Metabolic Pathways Applied to the Production of Phenylalanine. Annals of 
the New York Academy of Sciences 589, 16–24 (2006). 
 
35. Taylor, P., Grinter, N., McCarthy, S., Pantaleone, D., Ton, J., Yoshida, R. & 
Fotheringham, I. D-Phenylalanine Biosynthesis Using Escherichia Coli: Creation of a New 
Metabolic Pathway. Applied Biocatalysis in Specialty Chemicals and Pharmaceuticals 
Chapter 5, 65–75 (2001). 
 
36. Singh, S., Gogoi, B. K. & Bezbaruah, R. L. Racemic resolution of some DL-amino acids 
using Aspergillus fumigatus L-amino acid oxidase. Current Microbiology 63, 94–99 
(2011). 
 
37. Weiner, B., Poelarends, G. J., Janssen, D. B. & Feringa, B. L. Biocatalytic Enantioselective 
Synthesis of N‐Substituted Aspartic Acids by Aspartate Ammonia Lyase. Chemistry - A 
European Journal 14, 10094–10100 (2008). 
 
38. Yamada, S., Nabe, K., Izuo, N., Nakamichi, K. & Chibata, I. Production of L-
Phenylalanine from Trans-Cinnamic Acid with Rhodotorula Glutinis Containing L-
Phenylalanine Ammonia-Lyase Activity. Applied Environmental Microbiology 42, 773–
778 (1981). 
 
39. Fusee, M. C. & Weber, J. E. Immobilization by Polyurethane of Pseudomonas dacunhae 
Cells Containing L-Aspartate β-Decarboxylase Activity and Application to L-Alanine 
Production. Applied and Environmental Microbiology 48, 694–698 (1984). 
 
  
235 
40. Tosa, T., Senuma, M., Nakagawa, Y. & Morimoto, T. Industrial Application of Microbial 
Sensors for Bioprocess Control. Annals of the New York Academy of Sciences 672, 184–
194 (1992). 
 
41. Wichmann, R., Wandrey, C., Bückmann, A. F. & Kula, M.-R. Continuous enzymatic 
transformation in an enzyme membrane reactor with simultaneous NAD(H) regeneration. 
Biotechnology and Bioengineering 67, 791–804 (2000). 
 
42. Bommarius, A. S. Schwarm, M.,  Stingl, K., Kottenhahn, M., Huthmacher, K. & Drauz, K. 
Synthesis and use of enantiomerically pure tert-leucine. Tetrahedron: Asymmetry 6, 2851–
2888 (1995). 
 
43. Wegman, M. A., Janssen, M. H. A., van Rantwijk, F. & Sheldon, R. A. Towards 
Biocatalytic Synthesis of β‐Lactam Antibiotics. Advanced Synthesis & Catalysis 343, 559–
576 (2001). 
 
44. Müller, U. Assema, F., Gunsior, M., Orf, S., Kremer, S., Schipper, D., Wagemans, A., 
Townsend, A., Sonke, T., Bovenberg, R. & Wubbolts, M. Metabolic engineering of the E. 
coli L-phenylalanine pathway for the production of D-phenylglycine (D-Phg). Metabolic 
Engineering 8, 196–208 (2006). 
 
45. Yang, B., Liu, Z., Deng, B., Zeng, Y., Hu, J., Li, W. & Hu, Z. Isolation and genetic 
improvement of Pseudomonas sp. strain HUT-78, capable of enzymatic production of L-
cysteine from DL-2-amino-Δ2-thiazoline-4-carboxylic acid. The Journal of General and 
Applied Microbiology 57, 379–386 (2011). 
 
46. Wöltinger, J., Karau, A., Leuchtenberger, W. & Drauz, K. Membrane Reactors at Degussa. 
Technology Transfer in Biotechnology 92, 289–316 (2005). 
 
47. Asano, Y. & Lübbehüsen, T. L. Enzymes acting on peptides containing d-amino acid. 
Journal of Bioscience and Bioengineering 89, 295–306 (2000). 
 
48. Komeda, H. & Asano, Y. A novel d-stereoselective amino acid amidase from 
Brevibacterium iodinum: Gene cloning, expression and characterization. Enzyme and 
Microbial Technology 43, 276–283 (2008). 
 
 236 
49. Moser, R. & Matthews, C. Hydrolysis of aminoacetonitrile: Peptide formation. Cellular 
and Molecular Life Sciences 24, 658–659 (1968). 
 
50. Khoronenkova, S. V. & Tishkov, V. I. D-amino acid oxidase: physiological role and 
applications. Biochemistry (Moscow) 73, 1511–1518 (2008). 
 
51. Fitzpatrick, P. F. Oxidation of Amines by Flavoproteins. The Archives of Biochemistry and 
Biophysics 493, 13–25 (2010). 
 
52. Pilone, M. S. D-Amino acid oxidase: new findings. Cellular and Molecular Life Sciences 
57, 1732–1747 (2000). 
 
53. Jimbo, M., Nakanishi, F., Sakai, R., Muramoto, K. & Kamiya, H. Characterization of 
L‐amino acid oxidase and antimicrobial activity of aplysianin A, a sea hare‐derived 
antitumor‐antimicrobial protein. Fisheries Science 69, 1240–1246 (2003). 
 
54. Faust, A., Niefind, K., Hummel, W. & Schomburg, D. The structure of a bacterial L-amino 
acid oxidase from Rhodococcus opacus gives new evidence for the hydride mechanism for 
dehydrogenation. Journal of Molecular Biology 367, 234–248 (2007). 
 
55. Yu, Z. & Qiao, H. Advances in Non-snake Venom L-Amino Acid Oxidase. Applied 
Biochemistry and Biotechnology 167, 1–13 (2012). 
 
56. Geueke, B. & Hummel, W. A new bacterial L-amino acid oxidase with a broad substrate 
specificity: purification and characterization. Enzyme and Microbial Technology 31, 77–87 
(2002). 
 
57. Dym, O. & Eisenberg, D. Sequence-structure analysis of FAD-containing proteins. Protein 
Science 10, 1712–1728 (2001). 
 
58. Edmondson, D. E., Binda, C. & Mattevi, A. Structural insights into the mechanism of 
amine oxidation by monoamine oxidases A and B. The Archives of Biochemistry and 
Biophysics 464, 269–276 (2007). 
 
59. Mizutani, H., Miyahara, I., Hirotsu, K., Nishina, Y., Shiga, K., Setoyama, C. & Miura, R. 
Three-dimensional structure of porcine kidney D-amino acid oxidase at 3.0 A resolution. 
Journal of Biochemistry 120, 14–17 (1996). 
  
237 
60. Umhau, S., Pollegioni, L., Molla, G., Diederichs, K., Welte, W., Pilone, M. S. & Ghisla, S. 
The x-ray structure of D-amino acid oxidase at very high resolution identifies the chemical 
mechanism of flavin-dependent substrate dehydrogenation. Proceedings of the National 
Academy of Sciences United States of America 97, 12463–12468 (2000). 
 
61. Li, M., Binda, C., Mattevi, A. & Edmondson, D. E. Functional role of the ‘aromatic cage’ 
in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant 
proteins. Biochemistry 45, 4775–4784 (2006). 
 
62. Atkin, K. E. et al. The structure of monoamine oxidase from Aspergillus niger provides a 
molecular context for improvements in activity obtained by directed evolution. Journal of 
Molecular Biology 384, 1218–1231 (2008). 
 
63. Moustafa, I. M., Foster, S., Lyubimov, A. Y. & Vrielink, A. Crystal structure of L-AAO 
from Calloselasma rhodostoma with an L-phenylalanine substrate: insights into structure 
and mechanism. Journal of Molecular Biology 364, 991–1002 (2006). 
 
64. Tedeschi, G., Nonnis, S., Strumbo, B., Cruciani, G., Carosati, E. & Negri, A. On the 
catalytic role of the active site residue E121 of E. coli L-aspartate oxidase. Biochimie 92, 
1335–1342 (2010). 
 
65. Bossi, R. T., Negri, A., Tedeschi, G. & Mattevi, A. Structure of FAD-bound L-aspartate 
oxidase: insight into substrate specificity and catalysis. Biochemistry 41, 3018–3024 
(2002). 
 
66. Guillén Schlippe,, Y. V. & Hedstrom, L. A twisted base? The role of arginine in enzyme-
catalyzed proton abstractions. The Archives of Biochemistry and Biophysics 433, 266–278 
(2005). 
 
67. Laskowski R A, Swindells M B (2011). LigPlot+: multiple ligand-protein interaction 
diagrams for drug discovery. J. Chem. Inf. Model., 51, 2778-2786 
 
68. Abe, H., Yoshikawa, N., Sarower, M. G. & Okada, S. Physiological Function and 
Metabolism of Free D-Alanine in Aquatic Animals. Biological and Pharmaceutical 
Bulletin 28, 1571–1577 (2005). 
 
 238 
69. Verrall, L., Burnet, P., Betts, J. & Harrison, P. The neurobiology of D-amino acid oxidase 
(DAO) and its involvement in schizophrenia. Molecular Psychiatry 15, 122–137 (2010). 
 
70. Fisher, G. H., D'Aniello, A., Vetere, A., Padula, L., Cusano, G. P. & Man, E. H. Free D-
aspartate and D-alanine in normal and Alzheimer brain. Brain Research Bulletin 26, 983–
985 (1991). 
 
71. Fisher, G., Lorenzo, N., Abe, H., Fujita, E., Frey, W. H., Emory, C., Di Fiore, M. M. & D' 
Aniello, A. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer 
and normal subjects. Amino Acids 15, 263–269 (1998). 
 
72. Furuchi, T. & Homma, H. Free D-aspartate in mammals. Biological and Pharmaceutical 
Bulletin 28, 1566–1570 (2005). 
 
73. D’Aniello, G., Tolino, A., D'Aniello, A., Errico, F., Fisher, G. H. & Di Fiore, M. M. The 
Role of D-Aspartic Acid and N-Methyl-D-Aspartic Acid in the Regulation of Prolactin 
Release. Endocrinology 141, 3862–3870 (2000). 
 
74. D’Aniello, A., Di Cosmo, A., Di Cristo, C., Annunziato, L., Petrucelli, L. & Fisher, G. 
Involvement of D-Aspartic acid in the synthesis of testosterone in rat testes. Life Sciences 
59, 97–104 (1996). 
 
75. D’aniello, A., Di Fiore, M. M., Fisher, G. H., Milone, A., Seleni, A., D'Aniello, S., Perna, 
A. F. & Ingrosso, D. Occurrence of D-Aspartic Acid and N-Methyl-D-Aspartic Acid in Rat 
Neuroendocrine Tissues and Their Role in the Modulation of Luteinizing Hormone and 
Growth Hormone Release. FASEB Journal 14, 699–714 (2000). 
 
76. Wang, Y.-X., Gong, N., Xin, Y.-F., Hao, B., Zhou, X.-J. & Pang, C. C. Biological 
implications of oxidation and unidirectional chiral inversion of D-amino acids. Current 
Drug Metabolism 13, 321–331 (2012). 
 
77. Stasyk, T., Lutsik-Kordovsky, M., Wernstedt, C., Antonyuk, V., Klyuchivska, O., 
Souchelnytskyi, S., Hellman, U. & Stoika, R. A new highly toxic protein isolated from the 
death cap Amanita phalloides is an L-amino acid oxidase. FEBS Journal 277, 1260–1269 
(2010). 
 
  
239 
78. Tong, H., Chen, W., Shi, W., Qi, F. & Dong, X. SO-LAAO, a Novel L-Amino Acid 
Oxidase That Enables Streptococcus Oligofermentans To Outcompete Streptococcus 
Mutans by Generating H2O2 from Peptone. Journal of Bacteriology 190, 4716–4721 
(2008). 
 
79. Chen, W. M., Lin, C. Y., Chen, C. A., Wang, J. T. & Sheu, S. Y. Involvement of an L-
amino acid oxidase in the activity of the marine bacterium Pseudoalteromonas flavipulchra 
against methicillin-resistant Staphylococcus aureus. Enzyme and Microbial Technology 47, 
52–58 (2010). 
 
80. Nagaoka, K., Aoki, F., Hayashi, M., Muroi, Y., Sakurai, T., Itoh, K., Ikawa, M., Okabe, 
M., Imakawa, K. & Sakai, S. L-Amino Acid Oxidase Plays a Crucial Role in Host Defense 
in the Mammary Glands. FASEB J 23, 2514–2520 (2009). 
 
81. Nuutinen, J. T., Marttinen, E., Soliymani, R., Hildén, K. & Timonen, S. L-Amino Acid 
Oxidase of the Fungus Hebeloma Cylindrosporum Displays Substrate Preference Towards 
Glutamate. Microbiology 158, 272–283 (2012). 
 
82. Marinoni, I., Nonnis, S., Monteferrante, C., Heathcote, P., Härtig, E., Böttger, L. H., 
Trautwein, A. X., Negri, A., Albertini, A. M. & Tedeschi, G. Characterization of L-
aspartate oxidase and quinolinate synthase from Bacillus subtilis. FEBS Journal 275, 
5090–5107 (2008). 
 
83. Boulland, M.-L., Marquet, J., Molinier-Frenkel, V., Möller, P., Guiter, C., Lasoudris, F., 
Copie-Bergman, C., Baia, M., Gaulard, P., Leroy, K. & Castellano, F. Human IL4I1 is a 
secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-
lymphocyte proliferation. Blood 110, 220–227 (2007). 
 
84. Wcisło, M., Compagnone, D. & Trojanowicz, M. Enantioselective screen-printed 
amperometric biosensor for the determination of D-amino acids. Bioelectrochemistry 71, 
91–98 (2007). 
 
85. Pernot, P., Mothet, J. P., Schuvailo, O., Soldatkin, A., Pollegioni, L., Pilone, M., Adeline, 
M. T., Cespuglio, R. & Marinesco, S. Characterization of a Yeast d-Amino Acid Oxidase 
Microbiosensor for D-Serine Detection in the Central Nervous System. Analytical 
Chemistry 80, 1589–1597 (2008). 
 
 240 
86. Fang, J., Deng, D., Nakamura, H., Akuta, T., Qin, H., Iyer, A. K., Greish, K. & Maeda, H. 
Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated 
D-amino acid oxidase. Internation Journal of Cancer 122, 1135–1144 (2008). 
 
87. Rosini, E., Pollegioni, L., Ghisla, S., Orru, R. & Molla, G. Optimization of D-amino acid 
oxidase for low substrate concentrations – towards a cancer enzyme therapy. FEBS Journal 
276, 4921–4932 (2009). 
 
88. García-García, M., Martínez-Martínez, I., Sánchez-Ferrer, Á. & García-Carmona, F. 
Production of the Apoptotic Cellular Mediator 4-Methylthio-2-oxobutyric Acid by Using 
an Enzymatic Stirred Tank Reactor with in Situ Product Removal. Biotechnology Progress 
24, 187–191 (2008). 
 
89. Tian, F., Gourine, A. V., Huckstepp, R. T. R. & Dale, N. A microelectrode biosensor for 
real time monitoring of L-glutamate release. Analytica Chimica Acta 645, 86–91 (2009). 
 
90. Janasek, D. & Spohn, U. A chemiluminometric FIA procedure for the enzymatic 
determination of L-aspartate. Sensors and Actuators B: Chemical 74, 163–167 (2001). 
 
91. Stefan-van Staden, R.-I., Nejem, R. M., van Staden, J. F. & Aboul-Enein, H. Y. 
Amperometric biosensor based on diamond paste for the enantioanalysis of L-lysine. 
Biosens Bioelectron 35, 439–442 (2012). 
 
92. Lukasheva, E. V. & Berezov, T. T. L-lysine α-oxidase: physicochemical and biological 
properties. Biochemistry (Moscow). 67, 1152–1158 (2002). 
 
93. Moynihan, K., Elion, G. B., Pegram, C., Reist, C. J., Wellner, D., Bigner, D. D., Griffith, 
O. W. & Friedman, H. S. L-Amino acid oxidase (LOX) modulation of melphalan activity 
against intracranial glioma. Cancer Chemotherapy and Pharmacology 39, 179–186 (1996). 
 
94. Claiborne, A. & Fridovich, I. Chemical and enzymic intermediates in the peroxidation of 
o-dianisidine by horseradish peroxidase. 1. Spectral properties of the products of 
dianisidine oxidation. Biochemistry 18, 2324–2329 (1979). 
 
95. Shoaf, C. R., Isselbacher, K. J. & Heizer, W. D. Rapid colorimetric assay for intestinal 
peptide hydrolases. Analytical Biochemistry 61, 72–85 (1974). 
 
  
241 
96. Isobe, K., Fukuda, N. & Nagasawa, S. Analysis of selective production of N
α
-
benzyloxycarbonyl-L-aminoadipate-δ-semialdehyde and Nα-benzyloxycarbonyl-L-
aminoadipic acid by Rhodococcus sp. AIU Z-35-1. Journal of Bioscience and 
Bioengineering 105, 152–156 (2008). 
 
97. Carr, R., Alexeeva, M., Enright, A., Eve, T. S., Dawson, M. J. & Turner, N. J. Directed 
Evolution of an Amine Oxidase Possessing both Broad Substrate Specificity and High 
Enantioselectivity. Angewandte Chemie International Edition 42, 4807–4810 (2003). 
 
98. Carr, R., Alexeeva, M., Dawson, M. J., Gotor-Fernándezm V., Humphrey, C. E., Turner, 
N. J. Directed Evolution of an Amine Oxidase for the Preparative Deracemisation of 
Cyclic Secondary Amines. ChemBioChem 6, 637–639 (2005). 
 
99. Dunsmore, C. J., Carr, R., Fleming, T. & Turner, N. J. A Chemo-Enzymatic Route to 
Enantiomerically Pure Cyclic Tertiary Amines. Journal of the American Chemical Society 
128, 2224–2225 (2006). 
 
100. Gau, A. E., Heindl, A., Nodop, A., Kahmann, U. & Pistorius, E. K. L-amino acid oxidases 
with specificity for basic L-amino acids in cyanobacteria. Zeitschrift für Naturforschung, C, 
Journal of Biosciences 62, 273–284 (2007). 
 
101. Nishiya, Y. & Imanaka, T. Purification and characterization of a novel glycine oxidase 
from Bacillus subtilis. FEBS Letters 438, 263–266 (1998). 
 
102. Mörtl, M., Diederichs, K., Welte, W., Molla, G., Motteran, L., Andriolo, G., Pilone, M. S., 
Pollegioni, L. Structure-function correlation in glycine oxidase from Bacillus subtilis. 
Journal of Biological Chemistry 279, 29718–29727 (2004). 
 
103. Jamil, F., Afza Gardner, Q.-A., Bashir, Q., Rashid, N. & Akhtar, M. Mechanistic and 
Stereochemical Studies of Glycine Oxidase from Bacillus subtilis Strain R5. Biochemistry 
49, 7377–7383 (2010). 
 
 
 
 
 
 242 
104. Kaneko, T., Nakamura, Y., Wolk, C. P., Kuritz, T., Sasamoto, S., Watanabe, A., Iriguchi, 
M., Ishikawa, A., Kawashima, K., Kimura, T., Kishida, Y., Kohara, M., Matsumoto, M., 
Matsuno, A., Muraki, A., Nakazaki, N., Shimpo, S., Sugimoto, M., Takazawa, M., 
Yamada, M., Yasuda, M. & Tabata, S. Complete genomic sequence of the filamentous 
nitrogen-fixing cyanobacterium Anabaena sp. strain PCC 7120. DNA Research 8, 205–
213; 227–253 (2001). 
 
105. Ishikawa, J., Yamashita. A., Mikami, Y., Hoshino, Y., Kurita, H., Hotta, K., Shiba, T. & 
Hattori, M. The Complete Genomic Sequence of Nocardia Farcinica IFM 10152. PNAS 
101, 14925–14930 (2004). 
 
106. Read, T. D. et al. The genome sequence of Bacillus anthracis Ames and comparison to 
closely related bacteria. Nature 423, 81–86 (2003). 
 
107. Reetz, M.T., Kahakeaw, D. & Lohmer, R. Addressing the numbers problem in directed 
evolution. Chembiochem 9, 1797-1804 (2008). 
 
108. Reetz, M.T., Wang, L.-W. & Bocola, M. Directed evolution of enantioselective enzymes: 
iterative cycles of CASTing for probing protein-sequence space. Angewandte Chemie 
International Edition 45, 1236-1241 (2006). 
 
109. Morley, K.L. & Kazlauskas, R.J. Improving enzyme properties: when are closer mutations 
better? Trends In Biotechnology 23, 231-237 (2005). 
 
110. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-685 (1970). 
 
111.  Studier, F.W. Protein production by auto-induction in high-density shaking cultures. 
Protein Expression and Purification 41, 207-234 (2005). 
 
112. Lindwall, G., Chau, M.-F., Gardner, S.R. & Kohlstaedt, L.A. A sparse matrix approach to 
the solubilization of overexpressed proteins. Protein Engineering 13, 67-71 (2000). 
 
113. Emsley, P. & Cowtan, K. Coot: model building tools for molecular graphics Acta 
Crystallographica Section D- Biological Crystallography 60, 2126-2132 (2004) 
 
  
243 
114. Fogg, M. J. & Wilkinson, A. J. Higher-throughput approaches to crystallization and crystal 
structure determination. Biochemical Society Transactions 36, 771–775 (2008). 
 
115.   Golovanov, A.P., Hautbergue, G.M., Wilson, S.A. & Lian, L.-Y. A simple method for 
improving protein solubility and long-term stability. Journal Of The American Chemical 
Society 126, 8933-8939 (2004). 
 
116.  Weickert, M.J., Doherty, D.H., Best, E.A. & Olins, P.O. Optimization of heterologous 
protein production in Escherichia coli. Current Opinion in Biotechnology 7, 494-499 
(1996). 
 
117. Hildebrand, F., Meyer, A. & Eyre-Walker, A. Evidence of Selection upon Genomic GC-
Content in Bacteria. PLoS Genetics 6, (2010). 
 
118. Tedeschi, G., Ronchi, S., Simonic, T., Treu, C., Mattevi, A. and Negri, A. (2001) Probing 
the Active Site of L-aspartate oxidase by Site-Directed Mutagenesis: Role of Basic 
Residues in Fumarate Reduction. Biochemistry, 40, 4738-4744. 
 
119. Mortarino, M., Negri, A., Tedeschi, G., Simonic, T., Duga, S., Gassen, H. G. & Ronchi, S. 
L-aspartate oxidase from Escherichia coli. I. Characterization of coenzyme binding and 
product inhibition. European Journal of Biochemistry 239, 418–426 (1996). 
 
120. Stratagene GeneMorph® II EXClone domain mutagenesis kit instruction manual, Revision 
B, catalogue #200552. 
 
121.  Bacchella, L., Lina, C., Todone, F., Negri, A., Tedeschi, G., Ronchi, S. & Mattevi, A. 
Crystallization of L-aspartate oxidase, the first enzyme in the bacterial de novo biosynthesis 
of NAD. Acta Crystallographica Section D: Biological Crystallography 55, 549-551 
(1999). 
 
122. Mateos, L. M., Ordóñez, E., Letek, M. & Gil, J. A. Corynebacterium glutamicum as a 
model bacterium for the bioremediation of arsenic. International Microbiology 9, 207–215 
(2010). 
 
123. Bayan, N., Houssin, C., Chami, M. & Leblon, G. Mycomembrane and S-layer: two 
important structures of Corynebacterium glutamicum cell envelope with promising 
biotechnology applications. Journal of Biotechnology 104, 55–67 (2003). 
 244 
124. Scheuring, S., Stahlberg, H., Chami, M., Houssin, C., Rigaud, J.L. & Engel, A. Charting 
and unzipping the surface layer of Corynebacterium glutamicum with the atomic force 
microscope. Molecular Microbiology 44, 675–684 (2002). 
 
125. Chami, M., Bayan, N., Peyret, J.L., Gulik-Krzywicki, T., Leblon, G. & Shechter, E. The 
S‐layer protein of Corynebacterium glutamicum is anchored to the cell wall by its 
C‐terminal hydrophobic domain. Molecular Microbiology 23, 483–492 (1997). 
 
126. Soual-Hoebeke, E., de Sousa-D’Auria, C., Chami, M., Baucher, M.F., Guyonvarch, A., 
Bayan, N., Salim, K. & Leblon, G. S-Layer Protein Production by Corynebacterium Strains 
Is Dependent on the Carbon Source. Microbiology 145, 3399–3408 (1999). 
 
127. Sanli, G., Blaber, S. I. & Blaber, M. Reduction of wobble-position GC bases in 
Corynebacteria genes and enhancement of PCR and heterologous expression. Journal of 
Molecular Microbiology and Biotechnology 3, 123–126 (2001). 
 
128. Vertès, A. A., Inui, M. & Yukawa, H. Manipulating Corynebacteria, from Individual 
Genes to Chromosomes. Applied Environmental Microbiology 71, 7633–7642 (2005). 
 
129. Kind, S., Jeong, W. K., Schröder, H. & Wittmann, C. Systems-wide metabolic pathway 
engineering in Corynebacterium glutamicum for bio-based production of diaminopentane. 
Metabolic Engineering 12, 341–351 (2010). 
 
130. Doo, E.-H., Lee, W.-H., Seo, H.-S., Seo, J.-H. & Park, J.-B. Productivity of cyclohexanone 
oxidation of the recombinant Corynebacterium glutamicum expressing chnB of 
Acinetobacter calcoaceticus. Journal of Biotechnology 142, 164–169 (2009). 
 
131. Eikmanns, B. J., Kleinertz, E., Liebl, W. & Sahm, H. A family of Corynebacterium 
glutamicum/Escherichia coli shuttle vectors for cloning, controlled gene expression, and 
promoter probing. Gene 102, 93–98 (1991). 
 
132. Liebl, W., Bayerl, A., Schein, B., Stillner, U. & Schleifer, K. H. High efficiency 
electroporation of intact Corynebacterium glutamicum cells. FEMS Microbiology Letters 
65, 299–303 (1989). 
 
  
245 
133. Haynes, J. A. & Britz, M. L. The Effect of Growth Conditions of Corynebacterium 
Glutamicum on the Transformation Frequency Obtained by Electroporation. Journal of 
General Microbiology 136, 255–263 (1990). 
 
134. Park, J.-U., Jo J.-H., Kim Y.-J., Chung S.-S., Lee J.-H. & Lee H.-H. Construction of heat-
inducible expression vector of Corynebacterium glutamicum and C. ammoniagenes: fusion 
of lambda operator with promoters isolated from C. ammoniagenes. Journal of 
Microbiology and Biotechnology 18, 639–647 (2008). 
 
135. Takano, H., Shimizu A., Shibosawa R., Sasaki R., Iwagaki S., Minagawa O., Yamanaka 
K., Miwa K., Beppu T. & Ueda K. Characterization of developmental colony formation in 
Corynebacterium glutamicum. Applied Microbiology and Biotechnology 81, 127–134 
(2008). 
 
 
  
 
 
 
 
 
